MICHAEL A TEITELL

UNIVERSITY OF CALIFORNIA LOS ANGELES, LOS ANGELES, CA

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$5,317,547

FY 2026

Project Title

Cancer Center Support Grant

Grant Number:

5P30CA016042-50

Activity Code:

P30

Mechanism:

Research Centers

Agency:

NIH

Start Date:

12/1/1996

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The NCI-designated UCLA Jonsson Comprehensive Cancer Center (JCCC) resides in the most populous county in the US, with a mission to accelerate discoveries to prevent and cure cancer. The Center provides infrastructure, administration, resources, and mechanisms to foster collaborative, high impact, t...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Judy Lieberman

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$733,069

FY 2026

Project Title

Activating gasdermin pores to induce pyroptosis and stimulate anti-tumor immunity

Grant Number:

5R01CA287076-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/4/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Cancer immunotherapy using checkpoint blockade (CPB) has revolutionized cancer treatment, providing durable cures with acceptable toxicity in some cancer patients. However, only a few cancer types respond and even in responding tumor types, response is often limited to a minority of these cancers, w...

Research Terms

<3-D><3-Dimensional><3D><Adaptive Immune System><Agonist><Alkynes><Amphoterin><Amphoterin Gene><Anti-Cancer Agents><Antigen Presentation><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Caspase 1><Azides><Beta Proprotein Interleukin 1><Binding Proteins><Biochemical><Biotinylation><Breast Cancer><Breast Cancer Model><Breast tumor model><CAR T cell therapy><CAR T therapy><CASP-1><CASP1><CASP1 gene><Cancer Drug><Cancer Induction><Cancer Patient><Cancer Treatment><Cancers><Caspase><Caspase Gene><Caspase-1><Caspase-1 Gene><Cell Body><Cell Communication and Signaling><Cell Death><Cell Signaling><Cell membrane><Cell-Death Protease><Cells><Chemistry><Chromosomal Protein, Nonhistone, HMG1><Chromosomal Protein, Nonhistone, HMG1 Gene><Colorectal Cancer><Combined Modality Therapy><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><Cytoplasmic Membrane><Data><Drugs><Electron Cryomicroscopy><Engineering><FM1 Gene Product><Family><GEM model><GEMM model><Genetically Engineered Mouse><HMG-1><HMG-1 Gene><HMG-1 Protein><HMG1><HMG1 Gene><HMG3><HMG3 Gene><HMGB1><HMGB1 Protein><HMGB1 gene><Heparin-Binding Protein p30><High Mobility Group Box Protein 1><High Mobility Group Protein 1><High Mobility Group Protein 1 Gene><High-Mobility Group (Nonhistone Chromosomal) Protein 1><High-Mobility Group (Nonhistone Chromosomal) Protein 1 Gene><High-Mobility Group Box 1><High-Mobility Group Box 1 Gene><Human><ICE Protease><ICE-like protease><IL-1><IL-1 beta><IL-1 beta Convertase><IL-1 beta-Converting Enzyme><IL-1 β><IL-1-b><IL-1BC><IL-1b Converting Enzyme><IL-1β><IL1><IL1-Beta><IL1-β><IL1B Protein><IL1B-Convertase><IL1BC><IL1BCE><IL1F2><IL1β><Immune><Immune Regulators><Immune Surveillance><Immune response><Immune system><Immunes><Immunity><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic Surveillance><Immunomodulators><Immunosuppressed Host><Immunosurveillance><Implant><Inflammasome><Inflammation><Inflammation Mediators><Inflammatory><Innate Immunity><Interleukin 1-B Converting Enzyme><Interleukin 1-Beta Convertase><Interleukin 1beta><Interleukin I><Interleukin-1><Interleukin-1 Beta Converting Enzyme><Interleukin-1 Converting Enzyme><Interleukin-1 beta><Interleukin-1β><Intracellular Communication and Signaling><Knock-out><Knockout><Laboratories><Ligand Binding Protein><Ligand Binding Protein Gene><Lymphocyte-Stimulating Hormone><Macrophage Cell Factor><Malignant Breast Neoplasm><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Medication><Medicinal Chemistry><Mice><Mice Mammals><Microfluidics><Minority><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Murine><Mus><N-terminal><NH2-terminal><Native Immunity><Natural Immunity><Neoplastic Disease Chemotherapeutic Agents><Non-Specific Immunity><Nonhistone Chromosomal Protein HGM1><Nonhistone Chromosomal Protein HGM1 Gene><Nonspecific Immunity><Normal Tissue><Normal tissue morphology><Outcome><PD-1 antibody><PD1 antibody><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Physiologic pulse><Plasma Membrane><Preinterleukin 1 Beta><Process><Programmed Cell Death><Property><Propidium Diiodide><Propidium Iodide><Protein Binding><Pulse><SBP-1><SBP-1 Gene><Sampling><Sepsis><Series><Signal Transduction><Signal Transduction Systems><Signaling><Staining method><Stains><Strepavidin><Streptavidin><Structure><Sulfoglucuronyl Carbohydrate Binding Protein><Sulfoglucuronyl Carbohydrate Binding Protein Gene><System><T Helper Factor><T cell response><T-Cells><T-Lymphocyte><Testing><Therapeutic><Toxic effect><Toxicities><Tumor Cell><Tumor Immunity><Tumor-Infiltrating Lymphocytes><Tumor-Specific Treatment Agents><Vaccination><aPD-1><aPD1><acquired immune system><adaptive immunity><analog><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer drug><anti-cancer immunotherapy><anti-cancer therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><anticancer immunotherapy><antitumor immunity><biological signal transduction><bound protein><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cancer therapy><cancer type><cancer-directed therapy><carcinogenesis><cell imaging><cell killing><cellular imaging><check point blockade><checkpoint blockade><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor T cell therapy><chimeric antigen receptor T therapy><combination therapy><combined modality treatment><combined treatment><cryo-EM><cryoEM><cryogenic electron microscopy><cystein protease><cystein proteinase><cysteine endopeptidase><cytokine><drug/agent><genetically engineered mouse model><genetically engineered murine model><host response><human disease><immune check point blockade><immune checkpoint blockade><immune competent><immune modulators><immune system response><immune-based cancer therapies><immunogenic><immunogenic apoptosis><immunogenic cell death><immunomodulatory molecules><immunoregulator><immunoregulatory molecules><immunoresponse><immunosuppressed patient><immunotherapy for cancer><immunotherapy of cancer><in vivo><inflammatory mediator><lymphocyte activating factor><malignancy><malignant breast tumor><mammary cancer model><mammary tumor model><meter><mouse model><multi-modal therapy><multi-modal treatment><murine model><necrocytosis><neoplasm/cancer><neoplastic cell><pathogen><plasmalemma><response><screening><screenings><spheroids><subcutaneous><subdermal><synergism><three dimensional><thymus derived lymphocyte><tool><tumor><tumor growth><tumor microenvironment><µfluidic><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hao Wu

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$733,069

FY 2026

Project Title

Activating gasdermin pores to induce pyroptosis and stimulate anti-tumor immunity

Grant Number:

5R01CA287076-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/4/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Cancer immunotherapy using checkpoint blockade (CPB) has revolutionized cancer treatment, providing durable cures with acceptable toxicity in some cancer patients. However, only a few cancer types respond and even in responding tumor types, response is often limited to a minority of these cancers, w...

Research Terms

<3-D><3-Dimensional><3D><Adaptive Immune System><Agonist><Alkynes><Amphoterin><Amphoterin Gene><Anti-Cancer Agents><Antigen Presentation><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Caspase 1><Azides><Beta Proprotein Interleukin 1><Binding Proteins><Biochemical><Biotinylation><Breast Cancer><Breast Cancer Model><Breast tumor model><CAR T cell therapy><CAR T therapy><CASP-1><CASP1><CASP1 gene><Cancer Drug><Cancer Induction><Cancer Patient><Cancer Treatment><Cancers><Caspase><Caspase Gene><Caspase-1><Caspase-1 Gene><Cell Body><Cell Communication and Signaling><Cell Death><Cell Signaling><Cell membrane><Cell-Death Protease><Cells><Chemistry><Chromosomal Protein, Nonhistone, HMG1><Chromosomal Protein, Nonhistone, HMG1 Gene><Colorectal Cancer><Combined Modality Therapy><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><Cytoplasmic Membrane><Data><Drugs><Electron Cryomicroscopy><Engineering><FM1 Gene Product><Family><GEM model><GEMM model><Genetically Engineered Mouse><HMG-1><HMG-1 Gene><HMG-1 Protein><HMG1><HMG1 Gene><HMG3><HMG3 Gene><HMGB1><HMGB1 Protein><HMGB1 gene><Heparin-Binding Protein p30><High Mobility Group Box Protein 1><High Mobility Group Protein 1><High Mobility Group Protein 1 Gene><High-Mobility Group (Nonhistone Chromosomal) Protein 1><High-Mobility Group (Nonhistone Chromosomal) Protein 1 Gene><High-Mobility Group Box 1><High-Mobility Group Box 1 Gene><Human><ICE Protease><ICE-like protease><IL-1><IL-1 beta><IL-1 beta Convertase><IL-1 beta-Converting Enzyme><IL-1 β><IL-1-b><IL-1BC><IL-1b Converting Enzyme><IL-1β><IL1><IL1-Beta><IL1-β><IL1B Protein><IL1B-Convertase><IL1BC><IL1BCE><IL1F2><IL1β><Immune><Immune Regulators><Immune Surveillance><Immune response><Immune system><Immunes><Immunity><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic Surveillance><Immunomodulators><Immunosuppressed Host><Immunosurveillance><Implant><Inflammasome><Inflammation><Inflammation Mediators><Inflammatory><Innate Immunity><Interleukin 1-B Converting Enzyme><Interleukin 1-Beta Convertase><Interleukin 1beta><Interleukin I><Interleukin-1><Interleukin-1 Beta Converting Enzyme><Interleukin-1 Converting Enzyme><Interleukin-1 beta><Interleukin-1β><Intracellular Communication and Signaling><Knock-out><Knockout><Laboratories><Ligand Binding Protein><Ligand Binding Protein Gene><Lymphocyte-Stimulating Hormone><Macrophage Cell Factor><Malignant Breast Neoplasm><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Medication><Medicinal Chemistry><Mice><Mice Mammals><Microfluidics><Minority><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Murine><Mus><N-terminal><NH2-terminal><Native Immunity><Natural Immunity><Neoplastic Disease Chemotherapeutic Agents><Non-Specific Immunity><Nonhistone Chromosomal Protein HGM1><Nonhistone Chromosomal Protein HGM1 Gene><Nonspecific Immunity><Normal Tissue><Normal tissue morphology><Outcome><PD-1 antibody><PD1 antibody><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Physiologic pulse><Plasma Membrane><Preinterleukin 1 Beta><Process><Programmed Cell Death><Property><Propidium Diiodide><Propidium Iodide><Protein Binding><Pulse><SBP-1><SBP-1 Gene><Sampling><Sepsis><Series><Signal Transduction><Signal Transduction Systems><Signaling><Staining method><Stains><Strepavidin><Streptavidin><Structure><Sulfoglucuronyl Carbohydrate Binding Protein><Sulfoglucuronyl Carbohydrate Binding Protein Gene><System><T Helper Factor><T cell response><T-Cells><T-Lymphocyte><Testing><Therapeutic><Toxic effect><Toxicities><Tumor Cell><Tumor Immunity><Tumor-Infiltrating Lymphocytes><Tumor-Specific Treatment Agents><Vaccination><aPD-1><aPD1><acquired immune system><adaptive immunity><analog><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer drug><anti-cancer immunotherapy><anti-cancer therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><anticancer immunotherapy><antitumor immunity><biological signal transduction><bound protein><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cancer therapy><cancer type><cancer-directed therapy><carcinogenesis><cell imaging><cell killing><cellular imaging><check point blockade><checkpoint blockade><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor T cell therapy><chimeric antigen receptor T therapy><combination therapy><combined modality treatment><combined treatment><cryo-EM><cryoEM><cryogenic electron microscopy><cystein protease><cystein proteinase><cysteine endopeptidase><cytokine><drug/agent><genetically engineered mouse model><genetically engineered murine model><host response><human disease><immune check point blockade><immune checkpoint blockade><immune competent><immune modulators><immune system response><immune-based cancer therapies><immunogenic><immunogenic apoptosis><immunogenic cell death><immunomodulatory molecules><immunoregulator><immunoregulatory molecules><immunoresponse><immunosuppressed patient><immunotherapy for cancer><immunotherapy of cancer><in vivo><inflammatory mediator><lymphocyte activating factor><malignancy><malignant breast tumor><mammary cancer model><mammary tumor model><meter><mouse model><multi-modal therapy><multi-modal treatment><murine model><necrocytosis><neoplasm/cancer><neoplastic cell><pathogen><plasmalemma><response><screening><screenings><spheroids><subcutaneous><subdermal><synergism><three dimensional><thymus derived lymphocyte><tool><tumor><tumor growth><tumor microenvironment><µfluidic><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David E. Avigan

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$728,501

FY 2026

Project Title

Personalized Adoptive T-cell Therapy for AML

Grant Number:

5R01CA262629-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2021

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract/Project Summary The development of strategies to expand and activate AML specific T cells is of critical importance. We have developed a personalized cancer vaccine in which patient derived tumor cells are fused with autologous dendritic cells (DCs), presenting a broad array of antigens tha...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jacalyn Rosenblatt

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$728,501

FY 2026

Project Title

Personalized Adoptive T-cell Therapy for AML

Grant Number:

5R01CA262629-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2021

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract/Project Summary The development of strategies to expand and activate AML specific T cells is of critical importance. We have developed a personalized cancer vaccine in which patient derived tumor cells are fused with autologous dendritic cells (DCs), presenting a broad array of antigens tha...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Goutam Chakraborty

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$722,198

FY 2026

Project Title

Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer

Grant Number:

5R01CA274967-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract A leading contributor to the significant mortality burden of prostate cancer, the second cause of cancer death among U.S. men, is the short-lived efficacy of androgen deprivation therapy (ADT), the mainstay of care for advanced and symptomatic disease. Increasingly alterations in DNA damage...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nagavarakishore Pillarsetty

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$722,198

FY 2026

Project Title

Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer

Grant Number:

5R01CA274967-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract A leading contributor to the significant mortality burden of prostate cancer, the second cause of cancer death among U.S. men, is the short-lived efficacy of androgen deprivation therapy (ADT), the mainstay of care for advanced and symptomatic disease. Increasingly alterations in DNA damage...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vladimir Ponomarev

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$722,198

FY 2026

Project Title

Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer

Grant Number:

5R01CA274967-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract A leading contributor to the significant mortality burden of prostate cancer, the second cause of cancer death among U.S. men, is the short-lived efficacy of androgen deprivation therapy (ADT), the mainstay of care for advanced and symptomatic disease. Increasingly alterations in DNA damage...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ALBERT FOLCH

UNIVERSITY OF WASHINGTON, SEATTLE, WA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$660,987

FY 2026

Project Title

Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors

Grant Number:

5R01CA272677-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT: The integration of electrochemical biosensors with microelectronics offers a unique avenue for miniaturized, low-cost systems that merge biomolecular sensing with digital computing, programming, and communication. Here we propose to integrate electrochemical aptamer-based sensors (“aptasen...

Research Terms

<(TNF)-α><3-D Imaging><3D imaging><After Care><After-Treatment><Aftercare><Animals><Anti-Cancer Agents><Anti-Cancer Drug Screens><Anticancer Drug Sensitivity Tests><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Antitumor Drug Screening Assays><Antitumor Drug Screens><Architecture><Assay><Bioassay><Biologic Models><Biological Assay><Biological Models><Biopsy><Biosensor><Body Tissues><Cachectin><Cancer Drug><Cancer Drug Tests><Cancer Patient><Cancers><Cell Body><Cell Culture Techniques><Cell Death><Cell Death Induction><Cells><Checkpoint inhibitor><Clinical Trials><Colorectal Cancer><Combination immunotherapy><Combined Modality Therapy><Communication><Complement><Complement Proteins><Computer Models><Computerized Models><Data><Data Collection><Development><Devices><Dissociation><Drug Combinations><Drug Evaluation><Drug Evaluation Studies><Drug Screening><Drug Targeting><Drug Therapy><Drug resistance><Drugs><Engineering / Architecture><Failure><Ferricytochrome c><Ferrocytochrome c><Genomics><Hepatic Neoplasm Secondary><Hepatic metastasis><Hour><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><Image><Immune><Immune Interferon><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Inflammatory><Interferon Gamma><Interferon Type II><Intratumoral heterogeneity><Kinases><Liver secondaries><Liver secondary cancer><MC-38><MC38><Machine Learning><Macrophage-Derived TNF><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Marketing><Mechanics><Medication><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Liver><Metastatic Tumor><Metastatic Tumor to the Liver><Metastatic malignant neoplasm to liver><Methodology><Mice><Mice Mammals><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Model System><Modern Man><Molecular><Monitor><Monocyte-Derived TNF><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Neoplasm Metastasis><Neoplastic Disease Chemotherapeutic Agents><Oncology><Oncology Cancer><Optics><Organoids><PD-1 antibody><PD1 antibody><Pathway interactions><Patients><Periodicals><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phase><Phosphotransferase Gene><Phosphotransferases><Play><Price><Process><Protein Array><Proteins><Role><Sampling><Secondary Neoplasm><Secondary Tumor><Shapes><Solid Neoplasm><Solid Tumor><System><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Techniques><Technology><Testing><Three-Dimensional Imaging><Time><Tissues><Transphosphorylases><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Specific Drug Screening Tests><Tumor-Specific Treatment Agents><Vascular Endothelium><Work><aPD-1><aPD1><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer drug><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><aptamer><biological sensor><cancer cell><cancer metastasis><cancer microenvironment><cell culture><cell cultures><check point inhibition><check point modulation><checkpoint inhibition><checkpoint modulation><chemotherapy><colon cancer patients><colorectal cancer patients><combination therapy><combinatorial immunotherapy><combined modality treatment><combined treatment><complementation><computational modeling><computational models><computer based models><computerized modeling><cost><cytochrome c><cytokine><developmental><digital><digital computing><drug detection><drug development><drug intervention><drug resistant><drug testing><drug treatment><drug/agent><dual immunotherapy><efficacy testing><heterogeneity in tumors><human data><human tissue><imaging><immune check point inhibition><immune check point inhibitor><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><individualized cancer care><individualized oncology><insight><intra-tumoral heterogeneity><intratumor heterogeneity><kinase inhibitor><lFN-Gamma><liver metastases><machine based learning><malignancy><malignant liver neoplasm, specified as secondary><mechanic><mechanical><metastasis in the liver><metastasis to the liver><metastasize to the liver><metastatic cancer to liver><metastatic liver><metastatic liver neoplasm><meter><microelectronics><microfluidic chip><miniaturize><miniaturized><mouse model><multi-modal therapy><multi-modal treatment><murine model><necrocytosis><neoplasm/cancer><optical><organ chip><organ on a chip><organ on chip><parallelization><pathway><periodic><periodical><personalization of treatment><personalized medicine><personalized oncology><personalized therapy><personalized treatment><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><post treatment><precision cancer care><precision cancer medicine><precision oncology><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><preservation><pricing><protein kinase inhibitor><resistance to Drug><resistant to Drug><response><response to therapy><response to treatment><safety testing><screening><screenings><secondary liver malignancy><secondary malignant liver neoplasm><sensor><social role><therapeutic response><therapy response><treatment response><treatment responsiveness><tumor><tumor cell metastasis><tumor heterogeneity><tumor microenvironment><user-friendly><virtual><µfluidic><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Tyler J. Curiel

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$660,030

FY 2026

Project Title

Adipocyte PD-L1 in the Breast Tumor Microenvironment

Grant Number:

5R01CA279566-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death protein 1 (PD-1), modulate anti-tumor immunity and are major targets of current checkpoint blockade immunotherapies. However, clinical trials of αPD-L1/αPD-1 antibodies in breast cancer to date have demonstrated only...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

YANFEN HU

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$660,030

FY 2026

Project Title

Adipocyte PD-L1 in the Breast Tumor Microenvironment

Grant Number:

5R01CA279566-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death protein 1 (PD-1), modulate anti-tumor immunity and are major targets of current checkpoint blockade immunotherapies. However, clinical trials of αPD-L1/αPD-1 antibodies in breast cancer to date have demonstrated only...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rong Li

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$660,030

FY 2026

Project Title

Adipocyte PD-L1 in the Breast Tumor Microenvironment

Grant Number:

5R01CA279566-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death protein 1 (PD-1), modulate anti-tumor immunity and are major targets of current checkpoint blockade immunotherapies. However, clinical trials of αPD-L1/αPD-1 antibodies in breast cancer to date have demonstrated only...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Phuoc T. Tran

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$658,606

FY 2026

Project Title

Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC

Grant Number:

7R01CA271540-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Cancer immunotherapy (IMT) can produce robust and durable anti-tumor immune responses in some cases. However, many cancers are non-responsive to IMT and combination approaches need to be actively investigated, particularly in lethal tumors such as IMT-insensitive non-small cell lung cancer (NSCLC). ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Andrew B. Sharabi

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$650,597

FY 2026

Project Title

Investigating the Role of B-cells in Durable Complete Responses to Immunotherapy in Head and Neck Cancer

Grant Number:

1R01CA292622-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary While response rates to Checkpoint Blockade Immunotherapy (CBI) in Head and Neck Squamous Cell Carcinoma (HNSCC) are generally low, approximately 3-5% of patients show durable complete responses (dCR) and remain disease-free for at least two years following treatment. The mechanisms ...

Research Terms

<19S Gamma Globulin><7S Gamma Globulin><Ab response><Ab-dependent cellular cytotoxicity><Agonist><Antibodies><Antibody Formation><Antibody Production><Antibody Repertoire><Antibody Response><Antigen Presentation><Antigen-Presenting Cells><Antigens><B-Cell Activation><B-Cell Development><B-Cell Lymphocytic Neoplasm><B-Cell Neoplasm><B-Cells><B-Lymphocytes><B-cell><B-lineage tumor><Blood Plasma Cell><CD19><CD19 gene><CTLA-4 blockade><CTLA4 blockade><Cell Body><Cells><Class Switching><Class Switchings><Clinical Evaluation><Clinical Testing><Clinical Treatment Moab><Clone Cells><Development><Disease><Disorder><Drugs><Extraordinary responder><Future><Goals><HNSCC><HPV><Head and Neck Cancer><Head and Neck Carcinoma><Head and Neck Squamous Cell Carcinoma><Human Papilloma Virus><Human Papillomavirus><IgA><IgG><IgM><Immune mediated therapy><Immune response><Immunoglobulin A><Immunoglobulin Class Switching><Immunoglobulin Class Switchings><Immunoglobulin G><Immunoglobulin M><Immunologically Directed Therapy><Immunotherapeutic agent><Immunotherapy><In complete remission><Infectious Human Wart Virus><Innate Immunity><Isotype Switching><Isotype Switchings><Knowledge><Malignant Head and Neck Neoplasm><Mediating><Medication><Memory><Memory B Cell><Memory B-Lymphocyte><Mission><Modeling><Monoclonal Antibodies><Native Immunity><Natural Immunity><Neoplasm Antibodies><No Evidence of Disease><Non-Specific Immunity><Nonspecific Immunity><Outcome><PD 1><PD-1><PD1><Pathway interactions><Patients><Persons><Pharmaceutical Preparations><Phase><Plasma Cells><Plasmacytes><Play><Public Health><Radiation><Reporting><Research><Role><SCCHN><Scientific Advances and Accomplishments><Specificity><T-Cells><T-Lymphocyte><Testing><Translating><Tumor Antibodies><Tumor Antigens><Tumor Cell><Tumor Immunity><Tumor-Associated Antigen><Virus><Work><accessory cell><activated B cells><adaptive immunity><adoptive B cell therapy><adoptive B cell transfer><anti-IgM><anti-cancer immunotherapy><anti-cancer research><anti-tumor antibody><anti-tumor immune response><anti-tumor immunity><antibody biosynthesis><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><anticancer immunotherapy><antitumor antibody><antitumor immunity><cancer antigens><cancer immunity><cancer immunotherapy><cancer research><cell type><check point blockade><checkpoint blockade><clinical test><complete response><determine efficacy><developmental><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><exceptional responders><extreme responders><head and neck squamous carcinoma><head and neck squamous cell cancer><head/neck cancer><host response><immune check point blockade><immune checkpoint blockade><immune drugs><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunoglobulin biosynthesis><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><immunotherapy trials><improved><improved outcome><innovate><innovation><innovative><insight><mAbs><malignant head and neck tumor><monoclonal Abs><neoplastic cell><novel><pathway><patient profile><plasmocyte><positive responders><profiles in patients><programmed cell death 1><programmed cell death protein 1><programmed death 1><research clinical testing><response><response to therapy><response to treatment><scientific accomplishments><scientific advances><sle2><social role><systemic lupus erythematosus susceptibility 2><therapeutic response><therapy response><thymus derived lymphocyte><translational opportunities><translational potential><treatment response><treatment responsiveness><tumor><tumor-specific antigen><wart virus>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Francesco Marangoni

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$648,626

FY 2026

Project Title

Mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy

Grant Number:

1R01CA287116-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Checkpoint blockade immunotherapy (CBI) by inhibiting PD1 has provided durable benefits in ~40% of patients with metastatic melanoma and several patients with Merkel cell, non-small cell lung, squamous head and neck, and clear cell kidney cancer. However, PD1 blockade alone and in combinat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Janghee Woo

EMORY UNIVERSITY, ATLANTA, GA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$646,181

FY 2026

Project Title

The Role of Clonal Hematopoiesis in Lung Cancer: Immune Dysregulation and Therapeutic Targeting

Grant Number:

1R01CA300078-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Clonal hematopoiesis (CH) is an age-related condition affecting over 20% of individuals aged 70 and older. While CH mutations are known to increase the risk of myeloid malignancies, growing evidence suggests they also contribute to lung cancer development by promoting immune...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Keiran Smalley

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$645,631

FY 2026

Project Title

Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy

Grant Number:

5R01CA290792-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary-Abstract Tumor microenvironment (TME) consists of many cell types that co-exist to promote tumor progression. Most cancer therapeutics are designed to target one molecule in one defined cell type. For example, vemurafenib (BRAF inhibitor) kills melanoma cells through targeting mutate...

Research Terms

<3,3'-diindolylmethane><Agonist><B-Cells><B-Lymphocytes><B-cell><B-raf-1><BRAF><BRAF gene><Beta Cadherin-Associated Protein><Beta-1 Catenin><Binding><Blood monocyte><Breast Cancer><CD152><CD152 Antigen><CD152 Gene><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><CUL-2><Cancers><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Checkpoint inhibitor><Clonal Expansion><Critical Paths><Critical Pathways><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic cell><Data><Data Set><Development><Drug Kinetics><Drug Synthesis and Chemistry><Drugs><E3 Ligase><E3 Ubiquitin Ligase><Endometrial Cancer><Endometrial Carcinoma><Endometrium Cancer><Endometrium Carcinoma><Environment><Eragrostis><Exhibits><Family member><Future><Generalized Growth><Goals><Growth><Immune><Immune checkpoint inhibitor><Immunes><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Indoles><Infiltration><K Cells><K lymphocyte><Keytruda><Kidney Cancer><Kidney Carcinoma><Killer Cells><LYT3><Lead><Ligands><Literature><MEKs><Malignant Breast Neoplasm><Malignant Cell><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Marrow monocyte><Mediating><Medication><Melanoma><Melanoma Cell><Metabolic><Mice><Mice Mammals><Modeling><Modification><Molecular><Molecular Interaction><Murine><Mus><Mutate><Myeloid-derived suppressor cells><NK Cells><Natural Killer Cells><Nature><Nuclear Orphan Receptor><Nuclear Receptors><Outcome><PD 1><PD-1><PD-1 antibody><PD-1/PD-L1><PD-1/PDL1><PD1><PD1 antibody><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PRO2286><Pathway interactions><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Property><Protac><Proteins><Proteolysis targeting chimeric><Protocol><Protocols documentation><Publishing><RAFB1><Regulatory T-Lymphocyte><Rejuvenation><Renal Cancer><Renal Carcinoma><Reporting><Research><Research Specimen><Resistance><Role><Safety><Specimen><Subcellular Process><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Technology><Teff><Teff cell><Therapeutic><Tissue Growth><Treg><Tumor Immunity><Tumor Promotion><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Work><aPD-1><aPD1><analog><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><anticancer immunotherapy><antitumor immunity><beta cat><beta catenin><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cancer progression><cancer type><celastrol><cell type><clinical translation><clinically translatable><cytotoxic T-lymphocyte antigen 4><design><designing><developmental><diindolylmethane><drug synthesis><drug/agent><effector T cell><exhaust><exhaustion><fatty acid oxidation><heavy metal Pb><heavy metal lead><immune check point inhibitor><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune-based cancer therapies><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive myeloid cells><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><in vivo><in vivo Model><inhibitor><innovate><innovation><innovative><malignancy><malignant breast tumor><meeting><meetings><monocyte><mutational status><myeloid suppressor cells><myeloid-derived suppressive cells><nano-molar><nanomolar><neoplasm progression><neoplasm/cancer><neoplastic progression><novel><ontogeny><pathway><pembrolizumab><pharmacophore><programmed cell death 1><programmed cell death protein 1><programmed death 1><proteolysis targeting chimaera><proteolysis targeting chimera><rational design><recruit><regulatory T-cells><resistant><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><therapeutic response><therapeutic target><therapy response><thymus derived lymphocyte><tool><treatment response><treatment responsiveness><tripterine><tumor><tumor growth><tumor microenvironment><tumor progression><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase><v-raf Murine Sarcoma Viral Oncogene Homolog B1><αPD-1><αPD1><β-catenin>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Weizhou Zhang

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$645,631

FY 2026

Project Title

Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy

Grant Number:

5R01CA290792-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary-Abstract Tumor microenvironment (TME) consists of many cell types that co-exist to promote tumor progression. Most cancer therapeutics are designed to target one molecule in one defined cell type. For example, vemurafenib (BRAF inhibitor) kills melanoma cells through targeting mutate...

Research Terms

<3,3'-diindolylmethane><Agonist><B-Cells><B-Lymphocytes><B-cell><B-raf-1><BRAF><BRAF gene><Beta Cadherin-Associated Protein><Beta-1 Catenin><Binding><Blood monocyte><Breast Cancer><CD152><CD152 Antigen><CD152 Gene><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><CUL-2><Cancers><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Checkpoint inhibitor><Clonal Expansion><Critical Paths><Critical Pathways><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic cell><Data><Data Set><Development><Drug Kinetics><Drug Synthesis and Chemistry><Drugs><E3 Ligase><E3 Ubiquitin Ligase><Endometrial Cancer><Endometrial Carcinoma><Endometrium Cancer><Endometrium Carcinoma><Environment><Eragrostis><Exhibits><Family member><Future><Generalized Growth><Goals><Growth><Immune><Immune checkpoint inhibitor><Immunes><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Indoles><Infiltration><K Cells><K lymphocyte><Keytruda><Kidney Cancer><Kidney Carcinoma><Killer Cells><LYT3><Lead><Ligands><Literature><MEKs><Malignant Breast Neoplasm><Malignant Cell><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Marrow monocyte><Mediating><Medication><Melanoma><Melanoma Cell><Metabolic><Mice><Mice Mammals><Modeling><Modification><Molecular><Molecular Interaction><Murine><Mus><Mutate><Myeloid-derived suppressor cells><NK Cells><Natural Killer Cells><Nature><Nuclear Orphan Receptor><Nuclear Receptors><Outcome><PD 1><PD-1><PD-1 antibody><PD-1/PD-L1><PD-1/PDL1><PD1><PD1 antibody><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PRO2286><Pathway interactions><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Property><Protac><Proteins><Proteolysis targeting chimeric><Protocol><Protocols documentation><Publishing><RAFB1><Regulatory T-Lymphocyte><Rejuvenation><Renal Cancer><Renal Carcinoma><Reporting><Research><Research Specimen><Resistance><Role><Safety><Specimen><Subcellular Process><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Technology><Teff><Teff cell><Therapeutic><Tissue Growth><Treg><Tumor Immunity><Tumor Promotion><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Work><aPD-1><aPD1><analog><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><anticancer immunotherapy><antitumor immunity><beta cat><beta catenin><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cancer progression><cancer type><celastrol><cell type><clinical translation><clinically translatable><cytotoxic T-lymphocyte antigen 4><design><designing><developmental><diindolylmethane><drug synthesis><drug/agent><effector T cell><exhaust><exhaustion><fatty acid oxidation><heavy metal Pb><heavy metal lead><immune check point inhibitor><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune-based cancer therapies><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive myeloid cells><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><in vivo><in vivo Model><inhibitor><innovate><innovation><innovative><malignancy><malignant breast tumor><meeting><meetings><monocyte><mutational status><myeloid suppressor cells><myeloid-derived suppressive cells><nano-molar><nanomolar><neoplasm progression><neoplasm/cancer><neoplastic progression><novel><ontogeny><pathway><pembrolizumab><pharmacophore><programmed cell death 1><programmed cell death protein 1><programmed death 1><proteolysis targeting chimaera><proteolysis targeting chimera><rational design><recruit><regulatory T-cells><resistant><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><therapeutic response><therapeutic target><therapy response><thymus derived lymphocyte><tool><treatment response><treatment responsiveness><tripterine><tumor><tumor growth><tumor microenvironment><tumor progression><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase><v-raf Murine Sarcoma Viral Oncogene Homolog B1><αPD-1><αPD1><β-catenin>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Guangrong Zheng

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$645,631

FY 2026

Project Title

Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy

Grant Number:

5R01CA290792-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary-Abstract Tumor microenvironment (TME) consists of many cell types that co-exist to promote tumor progression. Most cancer therapeutics are designed to target one molecule in one defined cell type. For example, vemurafenib (BRAF inhibitor) kills melanoma cells through targeting mutate...

Research Terms

<3,3'-diindolylmethane><Agonist><B-Cells><B-Lymphocytes><B-cell><B-raf-1><BRAF><BRAF gene><Beta Cadherin-Associated Protein><Beta-1 Catenin><Binding><Blood monocyte><Breast Cancer><CD152><CD152 Antigen><CD152 Gene><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><CUL-2><Cancers><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Checkpoint inhibitor><Clonal Expansion><Critical Paths><Critical Pathways><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic cell><Data><Data Set><Development><Drug Kinetics><Drug Synthesis and Chemistry><Drugs><E3 Ligase><E3 Ubiquitin Ligase><Endometrial Cancer><Endometrial Carcinoma><Endometrium Cancer><Endometrium Carcinoma><Environment><Eragrostis><Exhibits><Family member><Future><Generalized Growth><Goals><Growth><Immune><Immune checkpoint inhibitor><Immunes><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Indoles><Infiltration><K Cells><K lymphocyte><Keytruda><Kidney Cancer><Kidney Carcinoma><Killer Cells><LYT3><Lead><Ligands><Literature><MEKs><Malignant Breast Neoplasm><Malignant Cell><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Marrow monocyte><Mediating><Medication><Melanoma><Melanoma Cell><Metabolic><Mice><Mice Mammals><Modeling><Modification><Molecular><Molecular Interaction><Murine><Mus><Mutate><Myeloid-derived suppressor cells><NK Cells><Natural Killer Cells><Nature><Nuclear Orphan Receptor><Nuclear Receptors><Outcome><PD 1><PD-1><PD-1 antibody><PD-1/PD-L1><PD-1/PDL1><PD1><PD1 antibody><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PRO2286><Pathway interactions><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Property><Protac><Proteins><Proteolysis targeting chimeric><Protocol><Protocols documentation><Publishing><RAFB1><Regulatory T-Lymphocyte><Rejuvenation><Renal Cancer><Renal Carcinoma><Reporting><Research><Research Specimen><Resistance><Role><Safety><Specimen><Subcellular Process><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Technology><Teff><Teff cell><Therapeutic><Tissue Growth><Treg><Tumor Immunity><Tumor Promotion><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Work><aPD-1><aPD1><analog><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><anticancer immunotherapy><antitumor immunity><beta cat><beta catenin><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cancer progression><cancer type><celastrol><cell type><clinical translation><clinically translatable><cytotoxic T-lymphocyte antigen 4><design><designing><developmental><diindolylmethane><drug synthesis><drug/agent><effector T cell><exhaust><exhaustion><fatty acid oxidation><heavy metal Pb><heavy metal lead><immune check point inhibitor><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune-based cancer therapies><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive myeloid cells><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><in vivo><in vivo Model><inhibitor><innovate><innovation><innovative><malignancy><malignant breast tumor><meeting><meetings><monocyte><mutational status><myeloid suppressor cells><myeloid-derived suppressive cells><nano-molar><nanomolar><neoplasm progression><neoplasm/cancer><neoplastic progression><novel><ontogeny><pathway><pembrolizumab><pharmacophore><programmed cell death 1><programmed cell death protein 1><programmed death 1><proteolysis targeting chimaera><proteolysis targeting chimera><rational design><recruit><regulatory T-cells><resistant><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><therapeutic response><therapeutic target><therapy response><thymus derived lymphocyte><tool><treatment response><treatment responsiveness><tripterine><tumor><tumor growth><tumor microenvironment><tumor progression><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase><v-raf Murine Sarcoma Viral Oncogene Homolog B1><αPD-1><αPD1><β-catenin>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xiaoping Bao

PURDUE UNIVERSITY, WEST LAFAYETTE, IN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$641,936

FY 2026

Project Title

CAR neutrophils produced in vivo to remodel tumor microenvironment and treat glioblastoma

Grant Number:

5R01CA293514-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/21/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Glioblastoma (GBM) is the most aggressive type of cancer that occurs in the brain. While functional anti- cancer therapeutics, such as emerging chimeric antigen receptor (CAR)-T and natural killer (NK) cell therapies, have been developed to treat various cancers, their therapeutic a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Qing Deng

PURDUE UNIVERSITY, WEST LAFAYETTE, IN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$641,936

FY 2026

Project Title

CAR neutrophils produced in vivo to remodel tumor microenvironment and treat glioblastoma

Grant Number:

5R01CA293514-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/21/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Glioblastoma (GBM) is the most aggressive type of cancer that occurs in the brain. While functional anti- cancer therapeutics, such as emerging chimeric antigen receptor (CAR)-T and natural killer (NK) cell therapies, have been developed to treat various cancers, their therapeutic a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Isabelle Francoise Vanhaezebrouck

PURDUE UNIVERSITY, WEST LAFAYETTE, IN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$641,936

FY 2026

Project Title

CAR neutrophils produced in vivo to remodel tumor microenvironment and treat glioblastoma

Grant Number:

5R01CA293514-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/21/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Glioblastoma (GBM) is the most aggressive type of cancer that occurs in the brain. While functional anti- cancer therapeutics, such as emerging chimeric antigen receptor (CAR)-T and natural killer (NK) cell therapies, have been developed to treat various cancers, their therapeutic a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MICHELLE KROGSGAARD

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$635,940

FY 2026

Project Title

Optimizing TCR-CD3 signaling for immunotherapy of cancer

Grant Number:

5R01CA284604-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The recent development of T cell-based cancer immunotherapies, including checkpoint blockade (anti-PD-1, anti-CTLA-4 and others) or adoptive T cell therapy (ACT) using modified patient T cells, has led to improved patient outcomes for a variety of cancers. However, durable responses are obs...

Research Terms

<70 kDa zeta-associated protein><ARAM><Affinity><Ag Recognition Activation Motif><Amino Acids><Antigen Targeting><Antigens><Antitumor Response><Assay><Avidity><Binding><Binding Sites><Bioassay><Biological Assay><Biosensor><CD152><CD152 Antigen><CD152 Gene><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Detection><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell surface><Cells><Clone Cells><Closure by Ligation><Co-Stimulator><Combining Site><Complex><Costimulator><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DNA mutation><Data><Development><Effectiveness><Electron Cryomicroscopy><Epidermal Thymocyte Activating Factor><Event><FRET><Fluorescence Resonance Energy Transfer><Förster Resonance Energy Transfer><GP100><Genetic Change><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Goals><Human><IL-2><IL2 Protein><ITAM><Immune><Immune mediated therapy><Immune system><Immunes><Immunity><Immunologically Directed Therapy><Immunoreceptor Tyr-Based Activation Motif><Immunoreceptor Tyrosine-Based Activation Motif><Immunotherapeutic agent><Immunotherapy><In Vitro><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intracellular Communication and Signaling><Kinases><Kinetics><Libraries><Ligation><Lymphocyte Mitogenic Factor><Lytotoxicity><ME20><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mediating><Melanocyte Protein 17><Melanoma><Membrane><Methodology><Methods><Mitogenic Factor><Modern Man><Molecular Interaction><Mouse Homolog of SILVER><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><Mutation Analysis><Names><OKT3 antigen><PD 1><PD-1><PD-1 antibody><PD1><PD1 antibody><PMEL gene><PMEL protein><PMEL17><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pattern><Peptide Vaccines><Peptide-MHC><Peptide-Major Histocompatibility Protein Complex><Peptide/MHC Complex><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Play><Premelanosomal Protein><Production><Protein Phosphorylation><Protein Tyrosine Kinase Zap70><Proteins><Publishing><Reactive Site><Receptor Signaling><Regimen><Regulatory T-Lymphocyte><Research><Role><SILV gene><SILV protein><SRK><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Structure><Syk-related tyrosine kinase><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell differentiation><T cell directed therapies><T cell growth factor><T cell immune therapy><T cell immunotherapy><T cell response><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Activation><T-Cell Antigen Receptors><T-Cell Development><T-Cell Growth Factor><T-Cell Ontogeny><T-Cell Receptor><T-Cell Stimulating Factor><T-Cells><T-Lymphocyte><T-Lymphocyte Development><T-cell therapeutics><T-cell transfer therapy><T3 Antigens><T3 Complex><T3 molecule><Testing><Thymocyte Stimulating Factor><Time><Toxic effect><Toxicities><Transfection><Transphosphorylases><Treg><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Work><ZAP-70><ZAP-70 Gene><ZAP-70 Kinase><ZAP-70 protein><ZAP70><Zeta-Chain Associated Protein Kinase><aCTLA-4><aCTLA-4 antibodies><aCTLA4><aPD-1><aPD1><activate T cells><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><aminoacid><anti programmed cell death 1><anti-CTLA-4><anti-CTLA-4 antibodies><anti-CTLA4><anti-CTLA4 antibodies><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor response><antiPD-1><anticancer immunotherapy><biological sensor><biological signal transduction><cancer antigens><cancer immunotherapy><cancer microenvironment><cell killing><check point blockade><checkpoint blockade><cryo-EM><cryoEM><cryogenic electron microscopy><cytokine><cytotoxic T-lymphocyte antigen 4><cytotoxicity><design><designing><developmental><efficacy testing><engineered T cells><exhaustion><experiment><experimental research><experimental study><experiments><extracellular><fighting><functional outcomes><genetically engineered T-cells><genome mutation><immune check point blockade><immune checkpoint blockade><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in silico><in vivo><malignancy><melanoma cancer model><melanoma model><melanoma tumor model><membrane structure><meter><mouse model><murine model><mutant><name><named><naming><neoplasm/cancer><neoplastic cell><new approaches><novel><novel approaches><novel strategies><novel strategy><pMHC><patient oriented outcomes><programmed cell death 1><programmed cell death protein 1><programmed death 1><protein complex><regulatory T-cells><resistance to therapy><resistant to therapy><response><sle2><social role><systemic lupus erythematosus susceptibility 2><therapeutic T-cell platform><therapeutic resistance><therapy resistant><thymus derived lymphocyte><transgenic T- cells><treatment resistance><tumor><tumor initiation><tumor microenvironment><tumor-specific antigen><α-CTLA-4><α-CTLA4><αCTLA-4><αCTLA4><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Cheng Zhu

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$635,940

FY 2026

Project Title

Optimizing TCR-CD3 signaling for immunotherapy of cancer

Grant Number:

5R01CA284604-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The recent development of T cell-based cancer immunotherapies, including checkpoint blockade (anti-PD-1, anti-CTLA-4 and others) or adoptive T cell therapy (ACT) using modified patient T cells, has led to improved patient outcomes for a variety of cancers. However, durable responses are obs...

Research Terms

<70 kDa zeta-associated protein><ARAM><Affinity><Ag Recognition Activation Motif><Amino Acids><Antigen Targeting><Antigens><Antitumor Response><Assay><Avidity><Binding><Binding Sites><Bioassay><Biological Assay><Biosensor><CD152><CD152 Antigen><CD152 Gene><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Detection><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell surface><Cells><Clone Cells><Closure by Ligation><Co-Stimulator><Combining Site><Complex><Costimulator><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DNA mutation><Data><Development><Effectiveness><Electron Cryomicroscopy><Epidermal Thymocyte Activating Factor><Event><FRET><Fluorescence Resonance Energy Transfer><Förster Resonance Energy Transfer><GP100><Genetic Change><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Goals><Human><IL-2><IL2 Protein><ITAM><Immune><Immune mediated therapy><Immune system><Immunes><Immunity><Immunologically Directed Therapy><Immunoreceptor Tyr-Based Activation Motif><Immunoreceptor Tyrosine-Based Activation Motif><Immunotherapeutic agent><Immunotherapy><In Vitro><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intracellular Communication and Signaling><Kinases><Kinetics><Libraries><Ligation><Lymphocyte Mitogenic Factor><Lytotoxicity><ME20><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mediating><Melanocyte Protein 17><Melanoma><Membrane><Methodology><Methods><Mitogenic Factor><Modern Man><Molecular Interaction><Mouse Homolog of SILVER><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><Mutation Analysis><Names><OKT3 antigen><PD 1><PD-1><PD-1 antibody><PD1><PD1 antibody><PMEL gene><PMEL protein><PMEL17><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pattern><Peptide Vaccines><Peptide-MHC><Peptide-Major Histocompatibility Protein Complex><Peptide/MHC Complex><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Play><Premelanosomal Protein><Production><Protein Phosphorylation><Protein Tyrosine Kinase Zap70><Proteins><Publishing><Reactive Site><Receptor Signaling><Regimen><Regulatory T-Lymphocyte><Research><Role><SILV gene><SILV protein><SRK><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Structure><Syk-related tyrosine kinase><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell differentiation><T cell directed therapies><T cell growth factor><T cell immune therapy><T cell immunotherapy><T cell response><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Activation><T-Cell Antigen Receptors><T-Cell Development><T-Cell Growth Factor><T-Cell Ontogeny><T-Cell Receptor><T-Cell Stimulating Factor><T-Cells><T-Lymphocyte><T-Lymphocyte Development><T-cell therapeutics><T-cell transfer therapy><T3 Antigens><T3 Complex><T3 molecule><Testing><Thymocyte Stimulating Factor><Time><Toxic effect><Toxicities><Transfection><Transphosphorylases><Treg><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Work><ZAP-70><ZAP-70 Gene><ZAP-70 Kinase><ZAP-70 protein><ZAP70><Zeta-Chain Associated Protein Kinase><aCTLA-4><aCTLA-4 antibodies><aCTLA4><aPD-1><aPD1><activate T cells><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><aminoacid><anti programmed cell death 1><anti-CTLA-4><anti-CTLA-4 antibodies><anti-CTLA4><anti-CTLA4 antibodies><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor response><antiPD-1><anticancer immunotherapy><biological sensor><biological signal transduction><cancer antigens><cancer immunotherapy><cancer microenvironment><cell killing><check point blockade><checkpoint blockade><cryo-EM><cryoEM><cryogenic electron microscopy><cytokine><cytotoxic T-lymphocyte antigen 4><cytotoxicity><design><designing><developmental><efficacy testing><engineered T cells><exhaustion><experiment><experimental research><experimental study><experiments><extracellular><fighting><functional outcomes><genetically engineered T-cells><genome mutation><immune check point blockade><immune checkpoint blockade><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in silico><in vivo><malignancy><melanoma cancer model><melanoma model><melanoma tumor model><membrane structure><meter><mouse model><murine model><mutant><name><named><naming><neoplasm/cancer><neoplastic cell><new approaches><novel><novel approaches><novel strategies><novel strategy><pMHC><patient oriented outcomes><programmed cell death 1><programmed cell death protein 1><programmed death 1><protein complex><regulatory T-cells><resistance to therapy><resistant to therapy><response><sle2><social role><systemic lupus erythematosus susceptibility 2><therapeutic T-cell platform><therapeutic resistance><therapy resistant><thymus derived lymphocyte><transgenic T- cells><treatment resistance><tumor><tumor initiation><tumor microenvironment><tumor-specific antigen><α-CTLA-4><α-CTLA4><αCTLA-4><αCTLA4><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DONG M SHIN

EMORY UNIVERSITY, ATLANTA, GA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$619,091

FY 2026

Project Title

Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck

Grant Number:

5R01CA262123-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/18/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immune checkpoint inhibitors (ICI) such as anti-PD-1 antibodies, have improved the survival of patients with metastatic head and neck squamous cell carcinoma (HNSCC). However, only a subset (<20%) of patients responds to single agent ICI. Since ICI acts by blocking the negat...

Research Terms

<21+ years old><Address><Adjuvant><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Antigen Targeting><Antigenic Determinants><Antigens><Antineoplastic Vaccine><Antitumor Response><Applications Grants><Autologous><Binding Determinants><Biological><Blood><Blood Reticuloendothelial System><Cancer Cause><Cancer Etiology><Cancer Model><Cancer Vaccines><CancerModel><Cancers><Carbohydrates><Cell Body><Cells><Cessation of life><Checkpoint inhibitor><Clinical><Clinical Treatment Moab><Clinical Trials><Clinical Trials Design><Data><Death><Dependence><Dose><Drugs><Epitopes><Exhibits><Gene Alteration><Gene Mutation><Gene Targeting><Grant Proposals><HNSCC><Head and Neck Cancer><Head and Neck Carcinoma><Head and Neck Squamous Cell Carcinoma><Heterogeneity><Histocompatibility Complex><Histocompatibility Complices><Human><Immune><Immune Markers><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunity><Immunologic Markers><Immunologic Stimulation><Immunological Stimulation><Immunologically Directed Therapy><Immunostimulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Intratumoral heterogeneity><Keytruda><Lead><Link><Logistics><Major Histocompatibility Complex><Major Histocompatibility Complices><Malignant Cell><Malignant Head and Neck Neoplasm><Malignant Neoplasms><Malignant Oral Cavity Neoplasm><Malignant Oral Cavity Tumor><Malignant Oral Neoplasm><Malignant Tumor><Medication><Membrane><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Squamous Cell Carcinoma><Metastatic Tumor><Mice><Mice Mammals><Modern Man><Monoclonal Antibodies><Mouth Cancer><Murine><Mus><Nature><Neoplasm Metastasis><Neoplasm Vaccines><Operative Procedures><Operative Surgical Procedures><Oral Cancer><PD 1><PD-1><PD-1 antibody><PD1><PD1 antibody><Particulate><Pathway interactions><Patients><Pb element><Peptides><Pharmaceutical Preparations><Phase><Phase 1b Clinical Trial><Phase Ib Clinical Trial><Play><Progression-Free Survivals><Proteins><Recommendation><Recurrence><Recurrent><Reporting><Resistance><Role><SCCHN><Safety><Schedule><Secondary Neoplasm><Secondary Tumor><Source><Surgical><Surgical Interventions><Surgical Procedure><T cell infiltration><T cell response><T-Cells><T-Lymphocyte><Testing><Translating><Tumor Antigens><Tumor Cell Derivative Vaccine><Tumor Expansion><Tumor Immunity><Tumor Tissue><Tumor Vaccines><Tumor-Associated Antigen><Vaccination><Vaccines><Vesicle><Weight><Whole Cell Vaccine><Work><aPD-1><aPD1><adulthood><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immune response><anti-tumor immunity><anti-tumor response><anti-tumor vaccine><antiPD-1><antigen-specific T cells><antitumor immunity><biologic><cancer antigens><cancer cell><cancer immunity><cancer metastasis><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical relevance><clinically relevant><cohort><cost effective><develop a vaccine><develop vaccines><development of a vaccine><dose information><drug/agent><established cell line><exhaustion><gene defect><head and neck squamous carcinoma><head and neck squamous cell cancer><head/neck cancer><heavy metal Pb><heavy metal lead><heterogeneity in tumors><host response><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune response to vaccination><immune response to vaccines><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunological biomarkers><immunological markers><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><intra-tumoral heterogeneity><intratumor heterogeneity><mAbs><malignancy><malignant head and neck tumor><malignant mouth neoplasm><malignant mouth tumor><membrane structure><model of animal><monoclonal Abs><mouse model><murine model><mutant allele><neoplasm/cancer><new vaccines><next generation vaccines><novel><novel vaccines><oral cavity cancer><pathway><patient variability><patient variation><pembrolizumab><personalized immunotherapy><precision immunotherapy><prevent><preventing><primary end point><primary endpoint><programmed cell death 1><programmed cell death protein 1><programmed death 1><resistant><response><scaffold><scaffolding><secondary end point><secondary endpoint><sle2><social role><surgery><synergism><systemic lupus erythematosus susceptibility 2><therapeutic vaccine><therapeutically effective><thymus derived lymphocyte><treatment vaccines><tumor><tumor antigen vaccine><tumor cell metastasis><tumor growth><tumor heterogeneity><tumor lysate vaccine><tumor-specific antigen><vaccination study><vaccination trial><vaccine associated immune response><vaccine development><vaccine for cancer><vaccine for immunotherapy><vaccine for the treatment><vaccine for treatment><vaccine immune response><vaccine immunogenicity><vaccine immunotherapy><vaccine induced immune response><vaccine study><vaccine trial><vaccine-based immunotherapy><variability between patients><variation between patients><weights><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Periasamy Selvaraj

EMORY UNIVERSITY, ATLANTA, GA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$619,091

FY 2026

Project Title

Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck

Grant Number:

5R01CA262123-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/18/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immune checkpoint inhibitors (ICI) such as anti-PD-1 antibodies, have improved the survival of patients with metastatic head and neck squamous cell carcinoma (HNSCC). However, only a subset (<20%) of patients responds to single agent ICI. Since ICI acts by blocking the negat...

Research Terms

<21+ years old><Address><Adjuvant><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Antigen Targeting><Antigenic Determinants><Antigens><Antineoplastic Vaccine><Antitumor Response><Applications Grants><Autologous><Binding Determinants><Biological><Blood><Blood Reticuloendothelial System><Cancer Cause><Cancer Etiology><Cancer Model><Cancer Vaccines><CancerModel><Cancers><Carbohydrates><Cell Body><Cells><Cessation of life><Checkpoint inhibitor><Clinical><Clinical Treatment Moab><Clinical Trials><Clinical Trials Design><Data><Death><Dependence><Dose><Drugs><Epitopes><Exhibits><Gene Alteration><Gene Mutation><Gene Targeting><Grant Proposals><HNSCC><Head and Neck Cancer><Head and Neck Carcinoma><Head and Neck Squamous Cell Carcinoma><Heterogeneity><Histocompatibility Complex><Histocompatibility Complices><Human><Immune><Immune Markers><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunity><Immunologic Markers><Immunologic Stimulation><Immunological Stimulation><Immunologically Directed Therapy><Immunostimulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Intratumoral heterogeneity><Keytruda><Lead><Link><Logistics><Major Histocompatibility Complex><Major Histocompatibility Complices><Malignant Cell><Malignant Head and Neck Neoplasm><Malignant Neoplasms><Malignant Oral Cavity Neoplasm><Malignant Oral Cavity Tumor><Malignant Oral Neoplasm><Malignant Tumor><Medication><Membrane><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Squamous Cell Carcinoma><Metastatic Tumor><Mice><Mice Mammals><Modern Man><Monoclonal Antibodies><Mouth Cancer><Murine><Mus><Nature><Neoplasm Metastasis><Neoplasm Vaccines><Operative Procedures><Operative Surgical Procedures><Oral Cancer><PD 1><PD-1><PD-1 antibody><PD1><PD1 antibody><Particulate><Pathway interactions><Patients><Pb element><Peptides><Pharmaceutical Preparations><Phase><Phase 1b Clinical Trial><Phase Ib Clinical Trial><Play><Progression-Free Survivals><Proteins><Recommendation><Recurrence><Recurrent><Reporting><Resistance><Role><SCCHN><Safety><Schedule><Secondary Neoplasm><Secondary Tumor><Source><Surgical><Surgical Interventions><Surgical Procedure><T cell infiltration><T cell response><T-Cells><T-Lymphocyte><Testing><Translating><Tumor Antigens><Tumor Cell Derivative Vaccine><Tumor Expansion><Tumor Immunity><Tumor Tissue><Tumor Vaccines><Tumor-Associated Antigen><Vaccination><Vaccines><Vesicle><Weight><Whole Cell Vaccine><Work><aPD-1><aPD1><adulthood><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immune response><anti-tumor immunity><anti-tumor response><anti-tumor vaccine><antiPD-1><antigen-specific T cells><antitumor immunity><biologic><cancer antigens><cancer cell><cancer immunity><cancer metastasis><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical relevance><clinically relevant><cohort><cost effective><develop a vaccine><develop vaccines><development of a vaccine><dose information><drug/agent><established cell line><exhaustion><gene defect><head and neck squamous carcinoma><head and neck squamous cell cancer><head/neck cancer><heavy metal Pb><heavy metal lead><heterogeneity in tumors><host response><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune response to vaccination><immune response to vaccines><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunological biomarkers><immunological markers><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><intra-tumoral heterogeneity><intratumor heterogeneity><mAbs><malignancy><malignant head and neck tumor><malignant mouth neoplasm><malignant mouth tumor><membrane structure><model of animal><monoclonal Abs><mouse model><murine model><mutant allele><neoplasm/cancer><new vaccines><next generation vaccines><novel><novel vaccines><oral cavity cancer><pathway><patient variability><patient variation><pembrolizumab><personalized immunotherapy><precision immunotherapy><prevent><preventing><primary end point><primary endpoint><programmed cell death 1><programmed cell death protein 1><programmed death 1><resistant><response><scaffold><scaffolding><secondary end point><secondary endpoint><sle2><social role><surgery><synergism><systemic lupus erythematosus susceptibility 2><therapeutic vaccine><therapeutically effective><thymus derived lymphocyte><treatment vaccines><tumor><tumor antigen vaccine><tumor cell metastasis><tumor growth><tumor heterogeneity><tumor lysate vaccine><tumor-specific antigen><vaccination study><vaccination trial><vaccine associated immune response><vaccine development><vaccine for cancer><vaccine for immunotherapy><vaccine for the treatment><vaccine for treatment><vaccine immune response><vaccine immunogenicity><vaccine immunotherapy><vaccine induced immune response><vaccine study><vaccine trial><vaccine-based immunotherapy><variability between patients><variation between patients><weights><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ruoning Wang

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$608,558

FY 2026

Project Title

Genetically and metabolically defining high-risk neuroblastoma to exploit effective therapeutic strategies

Grant Number:

1R01CA299046-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Summary: Neuroblastoma is the most common type of cancer in infancy and causes as much as 15% of childhood cancer mortality. The 5-year survival rates for patients with high-risk neuroblastoma remain at about 50% even with intensive multimodal therapies. Developing novel precision- and immuno-therap...

Research Terms

<4-Aminobutanoic Acid><4-Aminobutyric Acid><4-amino-butanoic acid><Address><Adopted><Affect><Allografting><Aminalon><Aminalone><Animal Model><Animal Models and Related Studies><Antitumor Response><Arginine><Automobile Driving><Body Tissues><C57BL/6 Mouse><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cancer Treatment><Cell Communication and Signaling><Cell Growth in Number><Cell Line><Cell Multiplication><Cell Proliferation><Cell Signaling><CellLine><Cellular Metabolic Process><Cellular Proliferation><Characteristics><Childhood Cancers><Childhood Neoplasm><Childhood Tumor><Clinical><Combined Modality Therapy><Data><Development><Disease><Disorder><Energy Expenditure><Energy Metabolism><Environment><Excretory function><Fostering><GABA><GABA Receptor><GEM model><GEMM model><Genes><Genetic><Genetically Engineered Mouse><Genomics><Gln><Glutamine><Histologic><Histologically><Human><Human Characteristics><Human Nature><Immune><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunocompetent><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunooncology><Immunotherapy><In Vitro><Intermediary Metabolism><Intracellular Communication and Signaling><L-Arginine><L-Glutamine><LYT3><MYC-Family Oncogene><MYCN><MYCN gene><Malignant><Malignant - descriptor><Malignant Cell><Malignant Childhood Neoplasm><Malignant Childhood Tumor><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Pediatric Neoplasm><Malignant Pediatric Tumor><Malignant childhood cancer><Mediating><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Mission><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NIH><NMYC><NMYC Gene><National Institutes of Health><Nerve Cells><Nerve Unit><Neural Cell><Neuroblastoma><Neurocyte><Neurons><Ohio><Oncogenesis><Oncogenic><Patients><Pediatric Neoplasm><Pediatric Tumor><Peripheral><Precision therapeutics><Preclinical data><Primary Neoplasm><Primary Tumor><Proliferating><Public Health><Q Levoglutamide><Q. Levoglutamide><Receptor Signaling><Recurrent disease><Relapsed Disease><Role><Sampling><Signal Transduction><Signal Transduction Systems><Signaling><Strains Cell Lines><Survival Rate><Sympathetic Nervous System><T cells for CAR><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Teff cell><Testing><Tissues><Toxic effect><Toxicities><Transplantation><Tumor Cell><Tumor Immunity><Tumor Tissue><United States National Institutes of Health><Universities><anti-cancer immunotherapy><anti-cancer research><anti-cancer therapy><anti-tumor immunity><anti-tumor response><anticancer immunotherapy><antitumor immunity><biological signal transduction><c myc><c-myc Genes><cancer cell><cancer death in children><cancer immunity><cancer immunotherapy><cancer in a child><cancer in children><cancer microenvironment><cancer mortality in children><cancer related death in children><cancer research><cancer therapy><cancer type><cancer-directed therapy><cell metabolism><cellular metabaolism><check point blockade><checkpoint blockade><child with cancer><childhood cancer death><childhood cancer mortality><childhood malignancy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical relevance><clinically relevant><cmyc><combination therapy><combined modality treatment><combined treatment><cultured cell line><developmental><driving><effector T cell><established cell line><excretion><gamma-Aminobutyric Acid><gamma-Aminobutyric Acid Receptors><gene signatures><genetic signature><genetically engineered mouse model><genetically engineered murine model><high risk><human disease><immune check point blockade><immune checkpoint blockade><immune competent><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immune-oncology><immuno oncology><immuno therapy><immunogenic><immunology oncology><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><infancy><infantile><inhibitor><innovate><innovation><innovative><metabolome><metabonome><mitochondrial metabolism><model of animal><mouse model><multi-modal therapy><multi-modal treatment><murine model><neoplastic cell><neuroblastoma cell><neuronal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncoimmunology><overexpress><overexpression><paracrine><pediatric cancer><pediatric malignancy><personalized immunotherapy><pharmacologic><precision immunotherapy><precision therapies><precision treatment><preclinical findings><preclinical information><pressure><prevent><preventing><reconstitute><reconstitution><social role><stable isotope><therapeutic target><therapeutically effective><thymus derived lymphocyte><transplant><tumor><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><tumorigenesis><tumors in children><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog><γ-Aminobutyric Acid>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kian H Lim

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$602,576

FY 2026

Project Title

Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer

Grant Number:

5R01CA262414-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Effective treatment is an unmet and urgent need for patients with pancreatic ductal adenocarcinoma (PDAC). PDAC is characterized by mutations of the KRAS gene, which occurs in >95% of cases. However, targeting KRAS and its downstream signaling pathways, particularly the RAF-MEK-ERK m...

Research Terms

<(TNF)-α><1-Phosphatidylinositol 3-Kinase><3-D><3-Dimensional><3D><AKT><Akt protein><Assay><Autoimmune Diseases><Autophagocytosis><Bioassay><Bioinformatics><Biological Assay><Biology><Biometrics><Biometry><Biostatistics><Biotin><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cachectin><Cancer Genes><Cancer-Promoting Gene><Cancers><Cell Body><Cell Communication and Signaling><Cell Compartmentation><Cell Compartmentations><Cell Death><Cell Death Induction><Cell Signaling><Cell Survival><Cell Viability><Cells><Cessation of life><Clinic><Clinical><Clinical Trials><Co(beta)-cyano-7''-(2-methyl)adeninylcobamide><Co-culture><Cocultivation><Coculture><Coculture Techniques><Collaborations><Cytolysis><DNA mutation><Data><Death><Development><Elements><Ensure><Exposure to><Fibroblasts><Foundations><GEM model><GEMM model><Genes><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Genotoxic Stress><Goals><Hydroxychlorochin><Hydroxychloroquine><Immune><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunocompetent><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><Intracellular Communication and Signaling><Investigators><Label><Lysis><MAP kinase><MAP-kinase-activated kinase 2><MAP-kinase-activated protein kinase 2><MAPK Inhibitors><MAPKAP kinase 2><MAPKAPK2><MAPKAPK2 gene><MEKs><Macrophage-Derived TNF><Malignant Cell><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mediating><Mice><Mice Mammals><Mitogen-Activated Protein Kinase Inhibitor><Mitogen-Activated Protein Kinases><Modeling><Modernization><Monocyte-Derived TNF><Murine><Mus><Mutation><Myeloid Cells><Oncogenes><Oncogenic><Oncology><Oncology Cancer><Oxychlorochin><Oxychloroquine><PDAC cancer cell><PDAC cell><PDX model><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pathology><Pathway interactions><Patient derived xenograft><Patients><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phenotype><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Phosphorylation><Principal Investigator><Process><Production><Protein Kinase B><Protein Phosphorylation><Proteins><Proteomics><Proto-Oncogene Proteins c-akt><PtdIns 3-Kinase><RAC-PK protein><Regimen><Research Personnel><Researchers><Role><Safety><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid><Structure><System><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Techniques><Testing><Therapeutic Effect><Transforming Genes><Tumor Cell><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor-associated macrophages><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><Vitamin H><Work><anti-tumor effect><antitumor effect><autoimmune condition><autoimmune disorder><autoimmunity disease><autophagy><biological signal transduction><c-akt protein><cancer cell><cancer immunology><cancer microenvironment><cell type><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemotherapy><clinical efficacy><coenzyme R><cost effective><cytokine><design><designing><developmental><effective therapy><effective treatment><factor A><genetically engineered mouse model><genetically engineered murine model><genome mutation><immune check point therapy><immune checkpoint therapy><immune competent><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunologic therapeutics><immunotherapeutics><immunotherapy agent><improved><inhibitor><malignancy><mouse model><murine model><necrocytosis><neoplasm immunology><neoplasm/cancer><neoplastic cell><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><pancreatic cancer cells><pancreatic ductal adenocarcinoma cell><pancreatic malignancy><pancreatic tumor cells><pathway><patient derived xenograft model><pharmaceutical><pre-clinical efficacy><pre-clinical trial><preclinical efficacy><preclinical trial><programs><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><related to A and C-protein><response><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spheroids><success><therapeutic response><therapy response><three dimensional><thymus derived lymphocyte><translational impact><translational opportunities><translational potential><treatment response><treatment responsiveness><tumor immunology><tumor microenvironment><tumorigenic>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Craig Alan Byersdorfer

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$573,262

FY 2026

Project Title

Development of autologous humanized leukemia models for immunotherapy testing

Grant Number:

1R01CA308970-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Immunotherapies such as bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T cells have shown significant promise in treating hematologic malignancies. However, therapeutic responses vary between patients and across the different subtypes of leukemia and lymphoma....

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PETER M GORDON

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$573,262

FY 2026

Project Title

Development of autologous humanized leukemia models for immunotherapy testing

Grant Number:

1R01CA308970-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Immunotherapies such as bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T cells have shown significant promise in treating hematologic malignancies. However, therapeutic responses vary between patients and across the different subtypes of leukemia and lymphoma....

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Shikhar Mehrotra

MEDICAL UNIVERSITY OF SOUTH CAROLINA, CHARLESTON, SC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$563,233

FY 2026

Project Title

Targeting S1P-ACC Axis to Overcome MDSC Suppression

Grant Number:

5R01CA300284-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT One of the key-confounding factors that hampers the adoptive T cell therapy is the presence of immunosuppressive cells like myeloid-derived suppressor cells (MDSCs), Tumor associated macrophages (TAMs) in the tumor microenvironment (TME). Thus, strategies to boost the anti-tumor T cell func...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia Ernst

UNIVERSITY OF COLORADO DENVER, Aurora, CO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$550,276

FY 2026

Project Title

Escape from CAR T surveillance through lineage plasticity

Grant Number:

5R01CA269269-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Cancer cell genomic plasticity can enable resistance to cancer therapy for both solid tumors and hematologic malignancy. Escape from cytotoxic or molecularly targeted therapy through an inherent capacity to reprogram differentiation state or lineage has now been described following a...

Research Terms

<0-4 weeks old><21+ years old><ALL1><ALL1 gene><Acute B-Lymphocytic Leukemia><Acute Lymphoblastic Leukemia Protein 1><Adoptive Cell Transfers><Adult><Adult Human><Affect><Antigens><B-ALL><B-ALL cell><B-Cell Acute Lymphocytic Leukemia><B-Cell Acute Lymphoblastic Leukemia><B-Cell Childhood ALL><B-Cell Childhood Acute Lymphoblastic Leukemia><B-Cell Childhood Acute Lymphogenous Leukemia><B-Cell Childhood Acute Lymphoid Leukemia><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Lymphoblastic Leukemia><B-Cell Pediatric ALL><B-Cell Pediatric Acute Lymphoblastic Leukemia><B-Cell Pediatric Acute Lymphogenous Leukemia><B-Cell Pediatric Acute Lymphoid Leukemia><B-Cell Stimulatory Factor-2><B-Cells><B-Lymphocyte Antigen CD19><B-Lymphocyte Surface Antigen B4><B-Lymphocytes><B-cell><B-cell ALL><B-cell acute lymphoblastic leukemia cell><B-cell acute lymphocytic leukemia cell><B-cell precursor acute lymphoblastic leukemia><B-cell precursor acute lymphoblastic leukemia cell><B-cell precursor acute lymphocytic leukemia cell><BCDF><BCR-ABL><BCR-ABL Oncoprotein><BCR-ABL Protein Tyrosine Kinase><BCR/ABL><BSF-2><BSF2><Biologic Models><Biological Models><Biology><Blocking Antibodies><Bone Marrow><Bone Marrow Reticuloendothelial System><CD19><CD19 Antigens><CD19 gene><CD19 molecule><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CXXC7><Cancer Model><Cancer Treatment><CancerModel><Cancers><Cas nuclease technology><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Interaction><Cell Line><Cell Reprogramming><Cell Signaling><Cell Surface Antigens><Cell Therapy><Cell-to-Cell Interaction><CellLine><Cells><Characteristics><Checkpoint inhibitor><Childhood><Childhood Precursor B Lymphoblastic Leukemia><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Coupled><Cytokine Signal Transduction><Cytokine Signaling><Data><Development><Differentiation Antigen CD19><Disease remission><Drosophila Homolog of Trithorax><E2A><E2A Immunoglobulin Enhancer Binding Factors E12/E47 Gene><Effectiveness><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Epithelium><Evolution><Exhibits><Expression Signature><Frequencies><Gene Expression Profile><Genetic><Genomics><Germinoblastic Sarcoma><Germinoblastoma><HPGF><HRX><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic Cancer><Hematopoietic Cellular Control Mechanisms><Hepatocyte-Stimulating Factor><Heterogeneity><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-1><IL-6><IL1><IL6 Protein><ITF1><Immune><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunological Surface Markers><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><Infant><Inflammatory><Interleukin I><Interleukin-1><Interleukin-6><Intervention><Intracellular Communication and Signaling><Intrinsic factor><KMT2A><KO mice><Knock-out Mice><Knockout Mice><Leu 12><Lymphocyte-Stimulating Hormone><Lymphoma><Lysine-Specific Methyltransferase 2A><MGI-2><MLL gene><MLL rearranged><MLL rearrangement><MLL-rearranged leukemia><MLL1><Macrophage Cell Factor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Lymphoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mixed Lineage Leukemia Gene><Mixed-Lineage Leukemia Protein><Model System><Modeling><Mouse Strains><Multiple Myeloma><Multiple lineage leukemia 1><Myelogenous><Myeloid><Myeloid Differentiation-Inducing Protein><Myeloid-Lymphoid Leukemia Gene><Myeloid-Lymphoid Leukemia Protein><Myeloid/Lymphoid Leukemia Gene><Myeloid/Lymphoid Or Mixed Lineage Leukemia Protein><Myeloid/Lymphoid or Mixed Lineage Leukemia Gene><Newborn Infant><Newborns><Null Mouse><Pathogenesis><Patients><Pattern><Phenotype><Plasma-Cell Myeloma><Plasmacytoma Growth Factor><Pre-B-Cell Leukemia><Precursor B Lymphoblastic Leukemia><Production><Proto Oncogene Proteins MLL><Protocol><Protocols documentation><Receptor Cell><Refractory><Relapse><Remission><Remission Induction><Resistance><Reticulolymphosarcoma><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Study models><Surface Antigens><System><T Helper Factor><T-Cells><T-Lymphocyte><TCF3><TCF3 gene><Testing><Therapeutic><Zinc Finger Protein HRX><adoptive cell therapy><adoptive cellular therapy><adulthood><anti-cancer therapy><bcr-abl Fusion Proteins><biological signal transduction><blood cell formation><cancer cell><cancer therapy><cancer-directed therapy><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular reprogramming><cellular therapeutic><cellular therapy><check point blockade><checkpoint blockade><chimeric antigen receptor><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><cytokine><cytotoxic><design><designing><developmental><epigenetically><gene expression pattern><gene expression signature><genetically engineered cells><genetically modified cells><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><improved><in vivo><inflammatory modulation><innovate><innovation><innovative><interferon beta 2><leukemia><leukemia treatment><leukemic therapy><lymphocyte activating factor><malignancy><mixed lineage leukemia 1><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><murine model><myeloma><myelomatosis><neoplasm/cancer><new approaches><newborn child><newborn children><novel><novel approaches><novel strategies><novel strategy><pediatric><phenotypic biomarker><phenotypic marker><pre-B acute lymphoblastic leukemia cell><pressure><prevent><preventing><programs><relapse patients><resistant><response><social role><therapeutic target><thymus derived lymphocyte><transcriptional profile><transcriptional signature><transplant model><tumor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Terry J. Fry

UNIVERSITY OF COLORADO DENVER, Aurora, CO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$550,276

FY 2026

Project Title

Escape from CAR T surveillance through lineage plasticity

Grant Number:

5R01CA269269-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Cancer cell genomic plasticity can enable resistance to cancer therapy for both solid tumors and hematologic malignancy. Escape from cytotoxic or molecularly targeted therapy through an inherent capacity to reprogram differentiation state or lineage has now been described following a...

Research Terms

<0-4 weeks old><21+ years old><ALL1><ALL1 gene><Acute B-Lymphocytic Leukemia><Acute Lymphoblastic Leukemia Protein 1><Adoptive Cell Transfers><Adult><Adult Human><Affect><Antigens><B-ALL><B-ALL cell><B-Cell Acute Lymphocytic Leukemia><B-Cell Acute Lymphoblastic Leukemia><B-Cell Childhood ALL><B-Cell Childhood Acute Lymphoblastic Leukemia><B-Cell Childhood Acute Lymphogenous Leukemia><B-Cell Childhood Acute Lymphoid Leukemia><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Lymphoblastic Leukemia><B-Cell Pediatric ALL><B-Cell Pediatric Acute Lymphoblastic Leukemia><B-Cell Pediatric Acute Lymphogenous Leukemia><B-Cell Pediatric Acute Lymphoid Leukemia><B-Cell Stimulatory Factor-2><B-Cells><B-Lymphocyte Antigen CD19><B-Lymphocyte Surface Antigen B4><B-Lymphocytes><B-cell><B-cell ALL><B-cell acute lymphoblastic leukemia cell><B-cell acute lymphocytic leukemia cell><B-cell precursor acute lymphoblastic leukemia><B-cell precursor acute lymphoblastic leukemia cell><B-cell precursor acute lymphocytic leukemia cell><BCDF><BCR-ABL><BCR-ABL Oncoprotein><BCR-ABL Protein Tyrosine Kinase><BCR/ABL><BSF-2><BSF2><Biologic Models><Biological Models><Biology><Blocking Antibodies><Bone Marrow><Bone Marrow Reticuloendothelial System><CD19><CD19 Antigens><CD19 gene><CD19 molecule><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CXXC7><Cancer Model><Cancer Treatment><CancerModel><Cancers><Cas nuclease technology><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Interaction><Cell Line><Cell Reprogramming><Cell Signaling><Cell Surface Antigens><Cell Therapy><Cell-to-Cell Interaction><CellLine><Cells><Characteristics><Checkpoint inhibitor><Childhood><Childhood Precursor B Lymphoblastic Leukemia><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Coupled><Cytokine Signal Transduction><Cytokine Signaling><Data><Development><Differentiation Antigen CD19><Disease remission><Drosophila Homolog of Trithorax><E2A><E2A Immunoglobulin Enhancer Binding Factors E12/E47 Gene><Effectiveness><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Epithelium><Evolution><Exhibits><Expression Signature><Frequencies><Gene Expression Profile><Genetic><Genomics><Germinoblastic Sarcoma><Germinoblastoma><HPGF><HRX><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic Cancer><Hematopoietic Cellular Control Mechanisms><Hepatocyte-Stimulating Factor><Heterogeneity><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-1><IL-6><IL1><IL6 Protein><ITF1><Immune><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunological Surface Markers><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><Infant><Inflammatory><Interleukin I><Interleukin-1><Interleukin-6><Intervention><Intracellular Communication and Signaling><Intrinsic factor><KMT2A><KO mice><Knock-out Mice><Knockout Mice><Leu 12><Lymphocyte-Stimulating Hormone><Lymphoma><Lysine-Specific Methyltransferase 2A><MGI-2><MLL gene><MLL rearranged><MLL rearrangement><MLL-rearranged leukemia><MLL1><Macrophage Cell Factor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Lymphoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mixed Lineage Leukemia Gene><Mixed-Lineage Leukemia Protein><Model System><Modeling><Mouse Strains><Multiple Myeloma><Multiple lineage leukemia 1><Myelogenous><Myeloid><Myeloid Differentiation-Inducing Protein><Myeloid-Lymphoid Leukemia Gene><Myeloid-Lymphoid Leukemia Protein><Myeloid/Lymphoid Leukemia Gene><Myeloid/Lymphoid Or Mixed Lineage Leukemia Protein><Myeloid/Lymphoid or Mixed Lineage Leukemia Gene><Newborn Infant><Newborns><Null Mouse><Pathogenesis><Patients><Pattern><Phenotype><Plasma-Cell Myeloma><Plasmacytoma Growth Factor><Pre-B-Cell Leukemia><Precursor B Lymphoblastic Leukemia><Production><Proto Oncogene Proteins MLL><Protocol><Protocols documentation><Receptor Cell><Refractory><Relapse><Remission><Remission Induction><Resistance><Reticulolymphosarcoma><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Study models><Surface Antigens><System><T Helper Factor><T-Cells><T-Lymphocyte><TCF3><TCF3 gene><Testing><Therapeutic><Zinc Finger Protein HRX><adoptive cell therapy><adoptive cellular therapy><adulthood><anti-cancer therapy><bcr-abl Fusion Proteins><biological signal transduction><blood cell formation><cancer cell><cancer therapy><cancer-directed therapy><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular reprogramming><cellular therapeutic><cellular therapy><check point blockade><checkpoint blockade><chimeric antigen receptor><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><cytokine><cytotoxic><design><designing><developmental><epigenetically><gene expression pattern><gene expression signature><genetically engineered cells><genetically modified cells><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><improved><in vivo><inflammatory modulation><innovate><innovation><innovative><interferon beta 2><leukemia><leukemia treatment><leukemic therapy><lymphocyte activating factor><malignancy><mixed lineage leukemia 1><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><murine model><myeloma><myelomatosis><neoplasm/cancer><new approaches><newborn child><newborn children><novel><novel approaches><novel strategies><novel strategy><pediatric><phenotypic biomarker><phenotypic marker><pre-B acute lymphoblastic leukemia cell><pressure><prevent><preventing><programs><relapse patients><resistant><response><social role><therapeutic target><thymus derived lymphocyte><transcriptional profile><transcriptional signature><transplant model><tumor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vincent Christopher Luca

H. LEE MOFFITT CANCER CTR & RES INST, TAMPA, FL

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$549,962

FY 2026

Project Title

Structure-function studies of LAG3 interactions with antibodies and cellular ligands

Grant Number:

5R01CA299899-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT ABSTRACT In this proposal, we will determine how antibodies and cellular ligands regulate the immunosuppressive function of Lymphocyte-Activation Gene 3 (LAG3). LAG3 is an immune checkpoint protein that suppresses T cell activation upon engagement of the ligands Major Histocompatibility Comp...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Keiran Smalley

H. LEE MOFFITT CANCER CTR & RES INST, TAMPA, FL

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$549,962

FY 2026

Project Title

Structure-function studies of LAG3 interactions with antibodies and cellular ligands

Grant Number:

5R01CA299899-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT ABSTRACT In this proposal, we will determine how antibodies and cellular ligands regulate the immunosuppressive function of Lymphocyte-Activation Gene 3 (LAG3). LAG3 is an immune checkpoint protein that suppresses T cell activation upon engagement of the ligands Major Histocompatibility Comp...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vaishali Kapoor

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$542,644

FY 2026

Project Title

Radiation-guided antibody-drug conjugates for cancer therapy

Grant Number:

1R01CA298938-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Lung cancer is the leading cause of cancer death in both men and women, with non-small cell lung cancer (NSCLC) comprising about 85% of cases. Standard-of-care for locally advanced, non-metastatic NSCLC includes cytotoxic chemotherapy, external beam radiation therapy (XRT), and immunotherap...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alice Oliffson Kamphorst

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$532,970

FY 2026

Project Title

CD4 helper programs that regulate intratumoral immunity

Grant Number:

5R01CA300217-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

SUMMARY Immunotherapies have changed the landscape of cancer treatment, but remain mostly focused on CD8 T cells. In liver cancer patients, we found that in addition to expansion of PD-1+ effector- like CD8 T cells, expansion of CD4 T cells with similarities to follicular helper cells (Tfh) was asso...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anant Madabhushi

EMORY UNIVERSITY, ATLANTA, GA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$518,789

FY 2026

Project Title

Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer

Grant Number:

5R01CA257612-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2021

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT: In 2019, an estimated 228,150 patients in the US are expected to be diagnosed with non-small cell lung cancer (NSCLC). A recent landmark development has been the approval of the immune checkpoint inhibitors (anti-PD-1 and anti-PD-L1) for the treatment of locally advanced and metastatic NSC...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vamsidhar Velcheti

EMORY UNIVERSITY, ATLANTA, GA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$518,789

FY 2026

Project Title

Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer

Grant Number:

5R01CA257612-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2021

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT: In 2019, an estimated 228,150 patients in the US are expected to be diagnosed with non-small cell lung cancer (NSCLC). A recent landmark development has been the approval of the immune checkpoint inhibitors (anti-PD-1 and anti-PD-L1) for the treatment of locally advanced and metastatic NSC...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mehmet Asim Bilen

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$927,329

FY 2026

Project Title

Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma

Grant Number:

5R01CA255322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT In 2021, approximately 76,080 individuals in the United States will be diagnosed with kidney cancer, with renal cell carcinoma (RCC) accounting for >90% of all cases. Approximately 25% of patients with RCC present with metastasis at the time of initial diagnosis and up to 20-30% of patients...

Research Terms

<16S RNA sequencing><16S RNAseq><16S gene sequencing><16S rDNA amplicon sequencing><16S rRNA DNA sequencing><16S rRNA amplicon sequencing><16S rRNA gene amplicon sequencing><16S rRNA gene sequencing><16S rRNA genomic profiling><16S rRNA sequencing><16S ribosomal RNA gene sequencing><16S ribosomal RNA sequencing><16S seq><16S sequencing><16s rRNA seq><Accounting><Adverse Experience><Adverse event><After Care><After-Treatment><Aftercare><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Sample><Blood specimen><Butyrates><Cancer Center><Cancer Patient><Cancer Treatment><Cancers><Caucasian male><Caucasian men><Checkpoint inhibitor><Clinical><Complex><Data><Development><Diagnosis><Diet><Diet Modification><Dietary Modifications><Disease Progression><Disease remission><Drugs><Ethnic Group><Ethnic Origin><Ethnic People><Ethnic Population><Ethnic individual><Ethnicity><Ethnicity People><Ethnicity Population><Freezing><Future><GI microbiome><Genes><Goals><Grawitz Tumor><High-Throughput Nucleotide Sequencing><High-Throughput Sequencing><Host Factor><Host Factor Protein><Human Microbiome><Hypernephroid Carcinoma><Hypernephroma><Immune checkpoint inhibitor><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Individual><Inflammation><Integration Host Factors><Kidney Cancer><Kidney Carcinoma><Life Style><Lifestyle><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measurement><Mediating><Medication><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Neoplasm Metastasis><Nephrectomy><Nephroid Carcinoma><Outcome><Pathogenesis><Pathway interactions><Patient Recruitments><Patient Selection><Patient risk><Patients><Pharmaceutical Preparations><Phase><Preventative strategy><Prevention strategy><Preventive strategy><Production><Progression-Free Survivals><Questionnaires><Race><Races><Racial Group><Recommendation><Recurrent disease><Relapsed Disease><Remission><Renal Adenocarcinoma><Renal Cancer><Renal Carcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Reporting><Research><Resolution><Risk><Role><Secondary Neoplasm><Secondary Tumor><Short-Chain Fatty Acids><Shotguns><Specific qualifier value><Specified><Supplementation><T-Cell Activation><Time><Toxin><Treatment outcome><Treatment-related toxicity><United States><Universities><Validation><Volatile Fatty Acids><Woman><activate T cells><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><bio-markers><biologic marker><biomarker><cancer immunotherapy><cancer metastasis><cancer therapy><cancer-directed therapy><demographics><design><designing><developmental><diet alteration><dietary alteration><diets><digestive tract microbiome><drug/agent><enteric microbiome><entire genome><ethnic subgroup><ethnicity group><experience><fecal sample><full genome><gastrointestinal microbiome><gut microbes><gut microbial species><gut microbiome><gut-associated microbiome><human-associated microbiome><immune check point inhibitor><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy for cancer><immunotherapy of cancer><improved><intestinal biome><intestinal microbes><intestinal microbiome><kidney adenocarcinoma><malignancy><men><metagenome sequencing><metagenomic sequencing><microbial><microbiome><neoplasm/cancer><participant recruitment><pathway><post treatment><prebiotics><prevent><preventing><prospective><racial><racial background><racial origin><racial population><racial subgroup><resolutions><response><response to therapy><response to treatment><risk stratification><sex><shot gun><social role><standard of care><stool sample><stool specimen><stratify risk><therapeutic response><therapeutic toxicity><therapy associated toxicity><therapy related toxicity><therapy response><therapy toxicity><treatment response><treatment responsiveness><treatment toxicity><treatment-associated toxicity><tumor cell metastasis><validations><white male><white men><whole genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Veronika Fedirko

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$927,329

FY 2026

Project Title

Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma

Grant Number:

5R01CA255322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT In 2021, approximately 76,080 individuals in the United States will be diagnosed with kidney cancer, with renal cell carcinoma (RCC) accounting for >90% of all cases. Approximately 25% of patients with RCC present with metastasis at the time of initial diagnosis and up to 20-30% of patients...

Research Terms

<16S RNA sequencing><16S RNAseq><16S gene sequencing><16S rDNA amplicon sequencing><16S rRNA DNA sequencing><16S rRNA amplicon sequencing><16S rRNA gene amplicon sequencing><16S rRNA gene sequencing><16S rRNA genomic profiling><16S rRNA sequencing><16S ribosomal RNA gene sequencing><16S ribosomal RNA sequencing><16S seq><16S sequencing><16s rRNA seq><Accounting><Adverse Experience><Adverse event><After Care><After-Treatment><Aftercare><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Sample><Blood specimen><Butyrates><Cancer Center><Cancer Patient><Cancer Treatment><Cancers><Caucasian male><Caucasian men><Checkpoint inhibitor><Clinical><Complex><Data><Development><Diagnosis><Diet><Diet Modification><Dietary Modifications><Disease Progression><Disease remission><Drugs><Ethnic Group><Ethnic Origin><Ethnic People><Ethnic Population><Ethnic individual><Ethnicity><Ethnicity People><Ethnicity Population><Freezing><Future><GI microbiome><Genes><Goals><Grawitz Tumor><High-Throughput Nucleotide Sequencing><High-Throughput Sequencing><Host Factor><Host Factor Protein><Human Microbiome><Hypernephroid Carcinoma><Hypernephroma><Immune checkpoint inhibitor><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Individual><Inflammation><Integration Host Factors><Kidney Cancer><Kidney Carcinoma><Life Style><Lifestyle><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measurement><Mediating><Medication><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Neoplasm Metastasis><Nephrectomy><Nephroid Carcinoma><Outcome><Pathogenesis><Pathway interactions><Patient Recruitments><Patient Selection><Patient risk><Patients><Pharmaceutical Preparations><Phase><Preventative strategy><Prevention strategy><Preventive strategy><Production><Progression-Free Survivals><Questionnaires><Race><Races><Racial Group><Recommendation><Recurrent disease><Relapsed Disease><Remission><Renal Adenocarcinoma><Renal Cancer><Renal Carcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Reporting><Research><Resolution><Risk><Role><Secondary Neoplasm><Secondary Tumor><Short-Chain Fatty Acids><Shotguns><Specific qualifier value><Specified><Supplementation><T-Cell Activation><Time><Toxin><Treatment outcome><Treatment-related toxicity><United States><Universities><Validation><Volatile Fatty Acids><Woman><activate T cells><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><bio-markers><biologic marker><biomarker><cancer immunotherapy><cancer metastasis><cancer therapy><cancer-directed therapy><demographics><design><designing><developmental><diet alteration><dietary alteration><diets><digestive tract microbiome><drug/agent><enteric microbiome><entire genome><ethnic subgroup><ethnicity group><experience><fecal sample><full genome><gastrointestinal microbiome><gut microbes><gut microbial species><gut microbiome><gut-associated microbiome><human-associated microbiome><immune check point inhibitor><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy for cancer><immunotherapy of cancer><improved><intestinal biome><intestinal microbes><intestinal microbiome><kidney adenocarcinoma><malignancy><men><metagenome sequencing><metagenomic sequencing><microbial><microbiome><neoplasm/cancer><participant recruitment><pathway><post treatment><prebiotics><prevent><preventing><prospective><racial><racial background><racial origin><racial population><racial subgroup><resolutions><response><response to therapy><response to treatment><risk stratification><sex><shot gun><social role><standard of care><stool sample><stool specimen><stratify risk><therapeutic response><therapeutic toxicity><therapy associated toxicity><therapy related toxicity><therapy response><therapy toxicity><treatment response><treatment responsiveness><treatment toxicity><treatment-associated toxicity><tumor cell metastasis><validations><white male><white men><whole genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ULRICH H VON ANDRIAN

HARVARD MEDICAL SCHOOL, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$835,269

FY 2026

Project Title

Deciphering Cytokine Regulation of Lymphocyte Trafficking

Grant Number:

1R01AI195726-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/6/2026

End Date:

1/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

The mammalian body is continuously monitored by migratory lymphocytes that traffic via the blood to secondary lymphoid organs (SLO) in search of cognate antigens. In lymph nodes (LN) and Peyer's patches (PP), this critical surveillance mechanism depends on high endothelial venules (HEV), specialized...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Stephanie Jost

DUKE UNIVERSITY, DURHAM, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$807,044

FY 2026

Project Title

Impact of NK Cells on Control of BK Polyomavirus

Grant Number:

1R01AI189613-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/6/2026

End Date:

1/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Most healthy individuals are persistently infected with the human polyomavirus BK (BKPyV) without significant consequences, yet in immunocompromised hosts such as kidney transplant or bone marrow transplant recipients, BKPyV is associated with significant morbidity. In particular, kidney transplant ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Chen Sabrina Tan

DUKE UNIVERSITY, DURHAM, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$807,044

FY 2026

Project Title

Impact of NK Cells on Control of BK Polyomavirus

Grant Number:

1R01AI189613-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/6/2026

End Date:

1/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Most healthy individuals are persistently infected with the human polyomavirus BK (BKPyV) without significant consequences, yet in immunocompromised hosts such as kidney transplant or bone marrow transplant recipients, BKPyV is associated with significant morbidity. In particular, kidney transplant ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert L. Ferris

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$750,429

FY 2026

Project Title

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs

Grant Number:

5R01DE031947-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/9/2025

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Cancer immunotherapy has become one of the pillar therapies in treating cancer patients, exemplified by immune checkpoint inhibitors (ICI) (e.g., anti-PD1). While ICIs have significantly improved the prognosis of cancer patients, the response rate to ICI monotherapy remains ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lazar Vujanovic

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$750,429

FY 2026

Project Title

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs

Grant Number:

5R01DE031947-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/9/2025

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Cancer immunotherapy has become one of the pillar therapies in treating cancer patients, exemplified by immune checkpoint inhibitors (ICI) (e.g., anti-PD1). While ICIs have significantly improved the prognosis of cancer patients, the response rate to ICI monotherapy remains ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jing Hong Wang

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$750,429

FY 2026

Project Title

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs

Grant Number:

5R01DE031947-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/9/2025

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Cancer immunotherapy has become one of the pillar therapies in treating cancer patients, exemplified by immune checkpoint inhibitors (ICI) (e.g., anti-PD1). While ICIs have significantly improved the prognosis of cancer patients, the response rate to ICI monotherapy remains ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yu Leo Lei

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$692,603

FY 2026

Project Title

Engineered Nano-formulations for STING Activation

Grant Number:

5R01DE031951-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/6/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Head and neck squamous cell carcinoma (HNSCC) is an extremely aggressive disease with poor overall survival. Despite the success of immune checkpoint blockade (ICB), the current forms of immunotherapy benefit only less than 15% of HNSCC patients. Therefore, there exists a critical need for ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James J. Moon

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$692,603

FY 2026

Project Title

Engineered Nano-formulations for STING Activation

Grant Number:

5R01DE031951-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/6/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Head and neck squamous cell carcinoma (HNSCC) is an extremely aggressive disease with poor overall survival. Despite the success of immune checkpoint blockade (ICB), the current forms of immunotherapy benefit only less than 15% of HNSCC patients. Therefore, there exists a critical need for ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Richard Flavell

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$678,334

FY 2026

Project Title

Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2

Grant Number:

5R01CA297845-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT The Problem: Acute myeloid leukemia is a common blood cancer diagnosed in >20,000 Americans per year, but current therapies only lead to a dismal 5-year survival of ~30%. New treatments are urgently needed. While antibody-based immunotherapies targeting tumor surface protein...

Research Terms

<7S Gamma Globulin><AML - Acute Myeloid Leukemia><Acute><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><American><Anti-Cancer Agents><Antibodies><Antibody Therapy><Antigens><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Award><Beta 2 Integrin Chain><Biologic Models><Biological Models><Bone Marrow><Bone Marrow Reticuloendothelial System><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CD11a Beta Subunit><CD11b Beta Subunit><CD11c Beta Subunit><CD123><CD123 Antigen><CD18><CD18 Antigens><CD33 antigen><Cancer Drug><Cancers><Cell Body><Cell Line><Cell Surface Antigens><Cell Surface Proteins><CellLine><Cells><Clinical><Clinical Trials><Collaborations><Data><Development><Diagnosis><Disease><Disorder><Down-Regulation><Drugs><Early-Stage Clinical Trials><Endothelial Cells><FDA approved><Failure><Funding><Future><Goals><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Cellular Control Mechanisms><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Heterograft><Heterologous Transplantation><Human><Human Cell Line><IL3R><IL3RA><IL3RA gene><IL3RAX><IL3RX><ITGB2><ITGB2 gene><IgG><Immune mediated therapy><Immune system><Immunoglobulin G><Immunological Surface Markers><Immunologically Directed Therapy><Immunoradiotherapy><Immunotherapy><In vivo analysis><Increase lifespan><Integrin Beta-2><Integrin beta2><Integrins><Integrins Extracellular Matrix><Interleukin 3 Receptor Alpha><LCAMB><Lead><Leukemic Cell><Literature><MF17><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Measures><Medical><Medication><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Mice><Mice Mammals><Modality><Model System><Modeling><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><Multiple Myeloma><Murine><Mus><Myelogenous><Myeloid><Myeloid Cells><Nature><Neoplastic Disease Chemotherapeutic Agents><Neuroendocrine Neoplasm><Neuroendocrine Tumors><Outcome><PDX model><Patient derived xenograft><Patients><Pb element><Pharmaceutical Preparations><Phase 1 Clinical Trials><Phase I Clinical Trials><Phenotype><Plasma-Cell Myeloma><Prognosis><Prostate CA><Prostate Cancer><Prostate malignancy><Protein Conformation><Proteomics><Publishing><Radiation Dosimetry><Radioimmunotherapy><Radiometry><Radionuclide therapy><Radiopharmaceutical Compound><Radiopharmaceuticals><Radiotheranostics><Research><Resistance><Safety><Sampling><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Surface Antigens><Surface Proteins><T cells for CAR><Technology><Testing><Theranostic Radiopharmaceuticals><Therapeutic><Therapeutic Index><Therapeutic Uses><Therapeutic antibodies><Toxic effect><Toxicities><Treatment Efficacy><Tumor-Specific Treatment Agents><Validation><Work><Xenograft><Xenograft procedure><Xenotransplantation><acute granulocytic leukemia><acute myeloid leukemia><anti-cancer><anti-cancer drug><anti-cancer immunotherapy><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><blood cancer><blood cell formation><boost longevity><cancer diagnosis><cancer immunotherapy><cancer microenvironment><cancer of blood><cancer of the blood><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical efficacy><clinical investigation><clinical translation><clinically translatable><conformation><conformational><conformational state><conformationally><conformations><cultured cell line><developmental><drug/agent><effective therapy><effective treatment><elongating the lifespan><enhance longevity><extend life span><extend lifespan><extend longevity><foster longevity><glycoprotein gp67><heavy metal Pb><heavy metal lead><hematopoietic tissue><hemopoietic><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><improve lifespan><improve longevity><improved><in vitro testing><in vivo><in vivo evaluation><in vivo testing><innovate><innovation><innovative><interest><intervention efficacy><leukemia treatment><leukemic therapy><lifespan extension><malignancy><multiomics><multiple omics><myeloma><myelomatosis><neoplasm/cancer><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><panomics><patient derived xenograft model><phase 1 trial><phase I protocol><phase I trial><pre-clinical><pre-clinical efficacy><pre-clinical evaluation><pre-clinical safety><pre-clinical toxicity><preclinical><preclinical efficacy><preclinical evaluation><preclinical safety><preclinical toxicity><prevent><preventing><prolong lifespan><prolong longevity><promote lifespan><promote longevity><radioactive drugs><radioassay><radionuclide theranostics><radionuclide-based theranostics><radiopharmaceutical-based theranostics><radiotherapeutic drugs><resistance mechanism><resistant><resistant mechanism><support longevity><therapeutic efficacy><therapeutic radionuclide><therapy efficacy><translation strategy><translational approach><translational strategy><trial design><tumor><tumor immune microenvironment><tumor microenvironment><tumor specificity><tumor-immune system interactions><validations><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Arun P. Wiita

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$678,334

FY 2026

Project Title

Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2

Grant Number:

5R01CA297845-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT The Problem: Acute myeloid leukemia is a common blood cancer diagnosed in >20,000 Americans per year, but current therapies only lead to a dismal 5-year survival of ~30%. New treatments are urgently needed. While antibody-based immunotherapies targeting tumor surface protein...

Research Terms

<7S Gamma Globulin><AML - Acute Myeloid Leukemia><Acute><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><American><Anti-Cancer Agents><Antibodies><Antibody Therapy><Antigens><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Award><Beta 2 Integrin Chain><Biologic Models><Biological Models><Bone Marrow><Bone Marrow Reticuloendothelial System><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CD11a Beta Subunit><CD11b Beta Subunit><CD11c Beta Subunit><CD123><CD123 Antigen><CD18><CD18 Antigens><CD33 antigen><Cancer Drug><Cancers><Cell Body><Cell Line><Cell Surface Antigens><Cell Surface Proteins><CellLine><Cells><Clinical><Clinical Trials><Collaborations><Data><Development><Diagnosis><Disease><Disorder><Down-Regulation><Drugs><Early-Stage Clinical Trials><Endothelial Cells><FDA approved><Failure><Funding><Future><Goals><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Cellular Control Mechanisms><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Heterograft><Heterologous Transplantation><Human><Human Cell Line><IL3R><IL3RA><IL3RA gene><IL3RAX><IL3RX><ITGB2><ITGB2 gene><IgG><Immune mediated therapy><Immune system><Immunoglobulin G><Immunological Surface Markers><Immunologically Directed Therapy><Immunoradiotherapy><Immunotherapy><In vivo analysis><Increase lifespan><Integrin Beta-2><Integrin beta2><Integrins><Integrins Extracellular Matrix><Interleukin 3 Receptor Alpha><LCAMB><Lead><Leukemic Cell><Literature><MF17><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Measures><Medical><Medication><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Mice><Mice Mammals><Modality><Model System><Modeling><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><Multiple Myeloma><Murine><Mus><Myelogenous><Myeloid><Myeloid Cells><Nature><Neoplastic Disease Chemotherapeutic Agents><Neuroendocrine Neoplasm><Neuroendocrine Tumors><Outcome><PDX model><Patient derived xenograft><Patients><Pb element><Pharmaceutical Preparations><Phase 1 Clinical Trials><Phase I Clinical Trials><Phenotype><Plasma-Cell Myeloma><Prognosis><Prostate CA><Prostate Cancer><Prostate malignancy><Protein Conformation><Proteomics><Publishing><Radiation Dosimetry><Radioimmunotherapy><Radiometry><Radionuclide therapy><Radiopharmaceutical Compound><Radiopharmaceuticals><Radiotheranostics><Research><Resistance><Safety><Sampling><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Surface Antigens><Surface Proteins><T cells for CAR><Technology><Testing><Theranostic Radiopharmaceuticals><Therapeutic><Therapeutic Index><Therapeutic Uses><Therapeutic antibodies><Toxic effect><Toxicities><Treatment Efficacy><Tumor-Specific Treatment Agents><Validation><Work><Xenograft><Xenograft procedure><Xenotransplantation><acute granulocytic leukemia><acute myeloid leukemia><anti-cancer><anti-cancer drug><anti-cancer immunotherapy><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><blood cancer><blood cell formation><boost longevity><cancer diagnosis><cancer immunotherapy><cancer microenvironment><cancer of blood><cancer of the blood><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical efficacy><clinical investigation><clinical translation><clinically translatable><conformation><conformational><conformational state><conformationally><conformations><cultured cell line><developmental><drug/agent><effective therapy><effective treatment><elongating the lifespan><enhance longevity><extend life span><extend lifespan><extend longevity><foster longevity><glycoprotein gp67><heavy metal Pb><heavy metal lead><hematopoietic tissue><hemopoietic><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><improve lifespan><improve longevity><improved><in vitro testing><in vivo><in vivo evaluation><in vivo testing><innovate><innovation><innovative><interest><intervention efficacy><leukemia treatment><leukemic therapy><lifespan extension><malignancy><multiomics><multiple omics><myeloma><myelomatosis><neoplasm/cancer><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><panomics><patient derived xenograft model><phase 1 trial><phase I protocol><phase I trial><pre-clinical><pre-clinical efficacy><pre-clinical evaluation><pre-clinical safety><pre-clinical toxicity><preclinical><preclinical efficacy><preclinical evaluation><preclinical safety><preclinical toxicity><prevent><preventing><prolong lifespan><prolong longevity><promote lifespan><promote longevity><radioactive drugs><radioassay><radionuclide theranostics><radionuclide-based theranostics><radiopharmaceutical-based theranostics><radiotherapeutic drugs><resistance mechanism><resistant><resistant mechanism><support longevity><therapeutic efficacy><therapeutic radionuclide><therapy efficacy><translation strategy><translational approach><translational strategy><trial design><tumor><tumor immune microenvironment><tumor microenvironment><tumor specificity><tumor-immune system interactions><validations><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ELLIS L REINHERZ

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$674,251

FY 2026

Project Title

A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies

Grant Number:

5R01CA265928-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Programming the immune system to detect neoantigens and destroy tumors is critical for effective immunotherapy. Until now, bioinformatic prediction of neoepitopes on tumors from Next Generation Sequencing (NGS) information has been used alone or in conjunction with immunological assays to i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Harriet M. Kluger

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$674,193

FY 2026

Project Title

Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy

Grant Number:

5R01CA269349-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/7/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY While significant progress has been made in the past decade with immunotherapy for metastatic melanoma and renal cell carcinoma (RCC), not all patients respond, and others develop resistance over time. Hundreds of novel regimens are being developed to overcome primary and acquired resistance...

Research Terms

<7S Gamma Globulin><Affect><Affinity><Antibodies><Antigens><Binding><Biodistribution><Biological Markers><Biopsy><Body Tissues><CD68 antigen><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cd68><Cell Body><Cell-Mediated Lympholytic Cells><Cells><Chelating Agents><Chelators><Clinical Trials><Combination immunotherapy><Combined Modality Therapy><Complement><Complement Proteins><Complexons><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Cytotoxic agent><Cytotoxic drug><Data><Early treatment><Foundations><Future><Goals><Grawitz Tumor><Hypernephroid Carcinoma><Hypernephroma><IgG><Image><Imaging Procedures><Imaging Technics><Imaging Techniques><Immune><Immune mediated therapy><Immune system><Immunes><Immunoglobulin G><Immunologic Subtyping><Immunologically Directed Therapy><Immunophenotyping><Immunotherapy><In Situ><In Vitro><Infiltration><Inflammatory><Isotopes><LYT3><Macrophage><Macrophage Activation><Malignant Cell><Measures><Melanoma Cell><Melanoma Metastasis><Melanoma patient><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Melanoma><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Modeling><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Mφ><Neoplasm Metastasis><Nephroid Carcinoma><Pathology><Patients><Prediction of Response to Therapy><Property><Radioactive Isotopes><Radioimmunoconjugate><Radioisotopes><Radiolabeled Antibodies><Radionuclides><Regimen><Renal Adenocarcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Resistance><Resistance development><Resistant development><SPECT><SPECT imaging><Secondary Neoplasm><Secondary Tumor><Single-Photon Emission-Computed Radionuclide Tomography><Spatial Distribution><Specificity><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Techniques><Testing><Time><Tissues><Toxic effect><Toxicities><Tumor-associated macrophages><Work><anatomic imaging><anatomical imaging><bio-markers><biologic marker><biomarker><biophysical chemistry><cancer cell><cancer imaging><cancer metastasis><cancer microenvironment><clinical relevance><clinical significance><clinically relevant><clinically significant><combination therapy><combinatorial immunotherapy><combined modality treatment><combined treatment><complementation><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><developing resistance><digital><dual immunotherapy><early therapy><financial toxicity><imaging><imaging probe><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunological status><in vitro Assay><in vivo><kidney adenocarcinoma><killer T cell><melanoma cancer model><melanoma model><melanoma tumor model><mouse model><multi-modal therapy><multi-modal treatment><murine model><non-invasive imaging><noninvasive imaging><novel><oncologic imaging><oncology imaging><pathology imaging><patients suffering from melanoma><patients with melanoma><predict responsiveness><predict therapeutic response><predict therapy response><predicting response><preservation><radioligand><resistant><response><response to therapy><response to treatment><single photon emission computed tomography><subcutaneous><subdermal><therapeutic response><therapy prediction><therapy response><thymus derived lymphocyte><tool><treatment prediction><treatment response><treatment response prediction><treatment responsiveness><tumor><tumor cell metastasis><tumor imaging><tumor microenvironment><uptake>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bernadette Marquez-Nostra

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$674,193

FY 2026

Project Title

Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy

Grant Number:

5R01CA269349-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/7/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY While significant progress has been made in the past decade with immunotherapy for metastatic melanoma and renal cell carcinoma (RCC), not all patients respond, and others develop resistance over time. Hundreds of novel regimens are being developed to overcome primary and acquired resistance...

Research Terms

<7S Gamma Globulin><Affect><Affinity><Antibodies><Antigens><Binding><Biodistribution><Biological Markers><Biopsy><Body Tissues><CD68 antigen><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cd68><Cell Body><Cell-Mediated Lympholytic Cells><Cells><Chelating Agents><Chelators><Clinical Trials><Combination immunotherapy><Combined Modality Therapy><Complement><Complement Proteins><Complexons><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Cytotoxic agent><Cytotoxic drug><Data><Early treatment><Foundations><Future><Goals><Grawitz Tumor><Hypernephroid Carcinoma><Hypernephroma><IgG><Image><Imaging Procedures><Imaging Technics><Imaging Techniques><Immune><Immune mediated therapy><Immune system><Immunes><Immunoglobulin G><Immunologic Subtyping><Immunologically Directed Therapy><Immunophenotyping><Immunotherapy><In Situ><In Vitro><Infiltration><Inflammatory><Isotopes><LYT3><Macrophage><Macrophage Activation><Malignant Cell><Measures><Melanoma Cell><Melanoma Metastasis><Melanoma patient><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Melanoma><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Modeling><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Mφ><Neoplasm Metastasis><Nephroid Carcinoma><Pathology><Patients><Prediction of Response to Therapy><Property><Radioactive Isotopes><Radioimmunoconjugate><Radioisotopes><Radiolabeled Antibodies><Radionuclides><Regimen><Renal Adenocarcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Resistance><Resistance development><Resistant development><SPECT><SPECT imaging><Secondary Neoplasm><Secondary Tumor><Single-Photon Emission-Computed Radionuclide Tomography><Spatial Distribution><Specificity><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Techniques><Testing><Time><Tissues><Toxic effect><Toxicities><Tumor-associated macrophages><Work><anatomic imaging><anatomical imaging><bio-markers><biologic marker><biomarker><biophysical chemistry><cancer cell><cancer imaging><cancer metastasis><cancer microenvironment><clinical relevance><clinical significance><clinically relevant><clinically significant><combination therapy><combinatorial immunotherapy><combined modality treatment><combined treatment><complementation><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><developing resistance><digital><dual immunotherapy><early therapy><financial toxicity><imaging><imaging probe><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunological status><in vitro Assay><in vivo><kidney adenocarcinoma><killer T cell><melanoma cancer model><melanoma model><melanoma tumor model><mouse model><multi-modal therapy><multi-modal treatment><murine model><non-invasive imaging><noninvasive imaging><novel><oncologic imaging><oncology imaging><pathology imaging><patients suffering from melanoma><patients with melanoma><predict responsiveness><predict therapeutic response><predict therapy response><predicting response><preservation><radioligand><resistant><response><response to therapy><response to treatment><single photon emission computed tomography><subcutaneous><subdermal><therapeutic response><therapy prediction><therapy response><thymus derived lymphocyte><tool><treatment prediction><treatment response><treatment response prediction><treatment responsiveness><tumor><tumor cell metastasis><tumor imaging><tumor microenvironment><uptake>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Oliver Jonas

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$664,040

FY 2026

Project Title

Development and optimization of highly effective treatments in patients with head and neck cancer using in situ implantable microdevices

Grant Number:

5R01CA295683-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/13/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

The ability to predict the optimal therapy for an individual patient is a major unmet need in the treatment of cancer and other diseases. The majority of therapies in clinical cancer treatment, particularly cytotoxics and immunotherapies as well as combinations of multiple drugs, have no reliable pr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Haixun Guo

UNIVERSITY OF LOUISVILLE, LOUISVILLE, KY

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$649,473

FY 2026

Project Title

Understanding Pancreatic Cancer Immune Microenvironment and Treatment Response through Integrating in vivo Imaging with Immunophenotyping

Grant Number:

5R01CA278941-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/8/2024

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Although cancer immunotherapy has been proclaimed a breakthrough in many types of cancer, pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint blockade (ICB) therapy. PDAC is classified as immunologically “cold” tumor with pronounced presence of immunosuppres...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JUN YAN

UNIVERSITY OF LOUISVILLE, LOUISVILLE, KY

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$649,473

FY 2026

Project Title

Understanding Pancreatic Cancer Immune Microenvironment and Treatment Response through Integrating in vivo Imaging with Immunophenotyping

Grant Number:

5R01CA278941-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/8/2024

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Although cancer immunotherapy has been proclaimed a breakthrough in many types of cancer, pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint blockade (ICB) therapy. PDAC is classified as immunologically “cold” tumor with pronounced presence of immunosuppres...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Heide L. Ford

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$647,118

FY 2026

Project Title

Deciphering the role of EYA3/PP2A in triple negative breast cancer metastasis

Grant Number:

5R01CA301267-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Breast cancer (BC) is one of the most diagnosed cancers in women (second only to skin cancer) and comprises ~30% of all new female cancers each year. Nearly all BC-related deaths are caused by metastatic dissemination. Triple negative breast cancer (TNBC), which is characterized by the absence of es...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RUI ZHAO

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$647,118

FY 2026

Project Title

Deciphering the role of EYA3/PP2A in triple negative breast cancer metastasis

Grant Number:

5R01CA301267-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Breast cancer (BC) is one of the most diagnosed cancers in women (second only to skin cancer) and comprises ~30% of all new female cancers each year. Nearly all BC-related deaths are caused by metastatic dissemination. Triple negative breast cancer (TNBC), which is characterized by the absence of es...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yong Teng

UNIVERSITY OF GEORGIA, ATHENS, GA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$644,452

FY 2026

Project Title

Engineered Synthetic Low-Density Lipoprotein Nanoparticles for Enhanced Cancer Immunotherapy in Head and Neck Cancer

Grant Number:

1R01DE035487-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. Despite technological advancements, the 5-year survival rate for advanced HNSCC has remained stagnant for the past three decades. The FDA has approved immune checkpoint inhibitors (ICIs), including...

Research Terms

<55-kDa High-Affinity Calcium Binding Protein><7-DHC><7-dehydrocholesterol><7-dehydrocholesterol reductase><7-dehydrocholesterol-delta-7-reductase><Active Oxygen><Address><Adjuvant><Adjuvanticity><Arachidonic Acids><Beta Proprotein Interleukin 1><Binding><Biodistribution><CAB-63><CDDP><Calcium-Binding Protein-3><Calregulin><Cancers><Cell Body><Cell Death><Cell Locomotion><Cell Maturation><Cell Migration><Cell Movement><Cell membrane><Cells><Cellular Migration><Cellular Motility><Checkpoint inhibitor><Cholesterol><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinical><Clinical Trials><Clonal Expansion><Colorectal Cancer><Combined Modality Therapy><Cross-Priming><Cysplatyna><Cytoplasmic Membrane><DHCR7 enzyme><DNA Damage><DNA Injury><Data><Dehydrocholesterols><Dehydrogenases><Dendritic Cells><Dendritic cell activation><Dichlorodiammineplatinum><Disease remission><Dose><Down-Regulation><Drug Kinetics><ERp60><Encapsulated><Engineering><Exhibits><Failure><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Free Radicals><Goals><HACBP><HNSCC><HPV [-]><HPV negative><HPV positive><HPV(+)><HPV(-)><HPV(-) HNSCC><HPV(-) head and neck squamous cell carcinoma><HPV+><HPV- HNSCC><HPV-negative HNSCC><HPV-negative head and neck cancer><HPV-negative head and neck squamous cell carcinoma><Head and Neck Cancer><Head and Neck Carcinoma><Head and Neck Squamous Cell Carcinoma><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Immune checkpoint inhibitor><Immune mediated therapy><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunoradiotherapy><Immunotherapy><Impairment><In Situ><Infiltration><Inflammatory><Interferon Type I><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Investigation><Keytruda><LDL><LDL Lipoproteins><LDL Receptors><LDLR gene><Lipid Peroxidation><Lipids><Lipoprotein LDL Receptors><Low Density Lipoprotein Receptor><Low-Density Lipoproteins><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Malignant Cell><Malignant Head and Neck Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Malignant neoplasm of prostate><Malignant prostatic tumor><Membrane><Metastatic/Recurrent><Microfluidics><Modeling><Molecular><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><NADPH-sterol delta 7-reductase><Nanotechnology><Nivolumab><Normal Tissue><Normal tissue morphology><Opdivo><Oxidative Stress><Oxidoreductase><Oxidoreductase Gene><Oxygen Radicals><PD-L1 antibody><PD-L1 blockade><PDL1 blockade><Patients><Pattern><Peyrone's Chloride><Peyrone's Salt><Pharmacokinetics><Phosphatides><Phospholipids><Plasma Membrane><Platinum Diamminodichloride><Polyunsaturated Fatty Acids><Preinterleukin 1 Beta><Pro-Oxidants><Prostate CA><Prostate Cancer><Prostate malignancy><Pulmonary Cancer><Pulmonary malignant Neoplasm><Radiation><Radiation Sensitizers><Radiation therapy><Radiation-Sensitizing Agents><Radiation-Sensitizing Drugs><Radioimmunotherapy><Radiosensitization><Radiosensitizing Agents><Radiosensitizing Drugs><Radiotherapeutics><Radiotherapy><Radiotherapy sensitizer><Reaction><Reactive Oxygen Species><Reductases><Remission><Rupture><SCCHN><Scheme><Shapes><Survival Rate><System><T-Cells><T-Lymphocyte><Technology><Testing><Therapeutic><Toxic effect><Toxicities><Treatment Efficacy><Tumor Antigens><Tumor Expansion><Tumor Immunity><Tumor-Associated Antigen><Upregulation><Veiled Cells><aPD-L1><aPD-L1 antibodies><absence of HPV><absence of human papillomavirus><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 blockade><anti-PD-L1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer immunotherapy><anti-tumor immunity><antiPD-L1><anticancer immunotherapy><antitumor immunity><beta-Lipoproteins><cC1qR Protein><calreticulin><cancer antigens><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cell killing><cell motility><check point blockade><checkpoint blockade><chemo-/radio-sensitization><chemo-/radio-therapy><chemo-radiotherapy><chemoradiation><chemoradiation therapy><chemoradiation treatment><chemoradiotherapy><chemotherapy><cholesterol analog><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><combination therapy><combinatorial><combined modality treatment><combined treatment><commercial scale manufacturing><cytokine><determine efficacy><draining lymph node><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><flow cytophotometry><head and neck squamous carcinoma><head and neck squamous cell cancer><head/neck cancer><human papillomavirus (-) head and neck squamous cell carcinoma><human papillomavirus +><human papillomavirus - head and neck squamous cell carcinoma><human papillomavirus negative><human papillomavirus negative head and neck cancer><human papillomavirus negative head and neck squamous cell carcinoma><human papillomavirus positive><human papillomavirus- head and neck squamous cell carcinoma><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy for cancer><immunotherapy of cancer><improved><innovate><innovation><innovative><interest><intervention efficacy><lung cancer><lymph gland><lymph nodes><lymphnodes><malignancy><malignant head and neck tumor><manufacturing ramp-up><manufacturing scale-up><membrane structure><multi-modal therapy><multi-modal treatment><nano particle delivery><nano tech><nano technology><nano-technological><nanolipoprotein particles><nanoparticle delivered><nanoparticle delivery><nanotech><nanotechnological><necrocytosis><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-HPV HNSCC><non-human papillomavirus head and neck squamous cell carcinoma><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pembrolizumab><plasmalemma><presence of HPV><presence of human papillomavirus><radiation effect><radiation sensitization><radiation treatment><radio-/chemo-sensitization><radio-chemo-therapy><radio-chemotherapy><radio-sensitization><radiochemotherapy><radiosensitizer><radiotherapy sensitization><receptor expression><regional lymph node><scRNA sequencing><scRNA-seq><scale up batch><scale up production><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><synergism><systemic toxicity><therapeutic efficacy><therapy efficacy><thymus derived lymphocyte><treatment with radiation><tumor><tumor microenvironment><tumor-specific antigen><upscale manufacturing><uptake><µfluidic><αPD-L1><αPD-L1 antibodies><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jin Xie

UNIVERSITY OF GEORGIA, ATHENS, GA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$644,452

FY 2026

Project Title

Engineered Synthetic Low-Density Lipoprotein Nanoparticles for Enhanced Cancer Immunotherapy in Head and Neck Cancer

Grant Number:

1R01DE035487-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. Despite technological advancements, the 5-year survival rate for advanced HNSCC has remained stagnant for the past three decades. The FDA has approved immune checkpoint inhibitors (ICIs), including...

Research Terms

<55-kDa High-Affinity Calcium Binding Protein><7-DHC><7-dehydrocholesterol><7-dehydrocholesterol reductase><7-dehydrocholesterol-delta-7-reductase><Active Oxygen><Address><Adjuvant><Adjuvanticity><Arachidonic Acids><Beta Proprotein Interleukin 1><Binding><Biodistribution><CAB-63><CDDP><Calcium-Binding Protein-3><Calregulin><Cancers><Cell Body><Cell Death><Cell Locomotion><Cell Maturation><Cell Migration><Cell Movement><Cell membrane><Cells><Cellular Migration><Cellular Motility><Checkpoint inhibitor><Cholesterol><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinical><Clinical Trials><Clonal Expansion><Colorectal Cancer><Combined Modality Therapy><Cross-Priming><Cysplatyna><Cytoplasmic Membrane><DHCR7 enzyme><DNA Damage><DNA Injury><Data><Dehydrocholesterols><Dehydrogenases><Dendritic Cells><Dendritic cell activation><Dichlorodiammineplatinum><Disease remission><Dose><Down-Regulation><Drug Kinetics><ERp60><Encapsulated><Engineering><Exhibits><Failure><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Free Radicals><Goals><HACBP><HNSCC><HPV [-]><HPV negative><HPV positive><HPV(+)><HPV(-)><HPV(-) HNSCC><HPV(-) head and neck squamous cell carcinoma><HPV+><HPV- HNSCC><HPV-negative HNSCC><HPV-negative head and neck cancer><HPV-negative head and neck squamous cell carcinoma><Head and Neck Cancer><Head and Neck Carcinoma><Head and Neck Squamous Cell Carcinoma><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Immune checkpoint inhibitor><Immune mediated therapy><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunoradiotherapy><Immunotherapy><Impairment><In Situ><Infiltration><Inflammatory><Interferon Type I><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Investigation><Keytruda><LDL><LDL Lipoproteins><LDL Receptors><LDLR gene><Lipid Peroxidation><Lipids><Lipoprotein LDL Receptors><Low Density Lipoprotein Receptor><Low-Density Lipoproteins><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Malignant Cell><Malignant Head and Neck Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Malignant neoplasm of prostate><Malignant prostatic tumor><Membrane><Metastatic/Recurrent><Microfluidics><Modeling><Molecular><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><NADPH-sterol delta 7-reductase><Nanotechnology><Nivolumab><Normal Tissue><Normal tissue morphology><Opdivo><Oxidative Stress><Oxidoreductase><Oxidoreductase Gene><Oxygen Radicals><PD-L1 antibody><PD-L1 blockade><PDL1 blockade><Patients><Pattern><Peyrone's Chloride><Peyrone's Salt><Pharmacokinetics><Phosphatides><Phospholipids><Plasma Membrane><Platinum Diamminodichloride><Polyunsaturated Fatty Acids><Preinterleukin 1 Beta><Pro-Oxidants><Prostate CA><Prostate Cancer><Prostate malignancy><Pulmonary Cancer><Pulmonary malignant Neoplasm><Radiation><Radiation Sensitizers><Radiation therapy><Radiation-Sensitizing Agents><Radiation-Sensitizing Drugs><Radioimmunotherapy><Radiosensitization><Radiosensitizing Agents><Radiosensitizing Drugs><Radiotherapeutics><Radiotherapy><Radiotherapy sensitizer><Reaction><Reactive Oxygen Species><Reductases><Remission><Rupture><SCCHN><Scheme><Shapes><Survival Rate><System><T-Cells><T-Lymphocyte><Technology><Testing><Therapeutic><Toxic effect><Toxicities><Treatment Efficacy><Tumor Antigens><Tumor Expansion><Tumor Immunity><Tumor-Associated Antigen><Upregulation><Veiled Cells><aPD-L1><aPD-L1 antibodies><absence of HPV><absence of human papillomavirus><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 blockade><anti-PD-L1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer immunotherapy><anti-tumor immunity><antiPD-L1><anticancer immunotherapy><antitumor immunity><beta-Lipoproteins><cC1qR Protein><calreticulin><cancer antigens><cancer cell><cancer immunity><cancer immunotherapy><cancer microenvironment><cell killing><cell motility><check point blockade><checkpoint blockade><chemo-/radio-sensitization><chemo-/radio-therapy><chemo-radiotherapy><chemoradiation><chemoradiation therapy><chemoradiation treatment><chemoradiotherapy><chemotherapy><cholesterol analog><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><combination therapy><combinatorial><combined modality treatment><combined treatment><commercial scale manufacturing><cytokine><determine efficacy><draining lymph node><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><flow cytophotometry><head and neck squamous carcinoma><head and neck squamous cell cancer><head/neck cancer><human papillomavirus (-) head and neck squamous cell carcinoma><human papillomavirus +><human papillomavirus - head and neck squamous cell carcinoma><human papillomavirus negative><human papillomavirus negative head and neck cancer><human papillomavirus negative head and neck squamous cell carcinoma><human papillomavirus positive><human papillomavirus- head and neck squamous cell carcinoma><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy for cancer><immunotherapy of cancer><improved><innovate><innovation><innovative><interest><intervention efficacy><lung cancer><lymph gland><lymph nodes><lymphnodes><malignancy><malignant head and neck tumor><manufacturing ramp-up><manufacturing scale-up><membrane structure><multi-modal therapy><multi-modal treatment><nano particle delivery><nano tech><nano technology><nano-technological><nanolipoprotein particles><nanoparticle delivered><nanoparticle delivery><nanotech><nanotechnological><necrocytosis><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-HPV HNSCC><non-human papillomavirus head and neck squamous cell carcinoma><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pembrolizumab><plasmalemma><presence of HPV><presence of human papillomavirus><radiation effect><radiation sensitization><radiation treatment><radio-/chemo-sensitization><radio-chemo-therapy><radio-chemotherapy><radio-sensitization><radiochemotherapy><radiosensitizer><radiotherapy sensitization><receptor expression><regional lymph node><scRNA sequencing><scRNA-seq><scale up batch><scale up production><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><synergism><systemic toxicity><therapeutic efficacy><therapy efficacy><thymus derived lymphocyte><treatment with radiation><tumor><tumor microenvironment><tumor-specific antigen><upscale manufacturing><uptake><µfluidic><αPD-L1><αPD-L1 antibodies><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Igor Astsaturov

RESEARCH INST OF FOX CHASE CAN CTR, PHILADELPHIA, PA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$642,755

FY 2026

Project Title

Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts

Grant Number:

5R01CA289629-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary The fibroblastic stroma comprises most of pancreatic adenocarcinoma mass and is remarkably devoid of functional blood vessels. It has been assumed that the pancreatic cancer cells obtain their essential metabolites, such as lipids, directly from the interstitial fluid, but we have fo...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jonathan A Soboloff

RESEARCH INST OF FOX CHASE CAN CTR, PHILADELPHIA, PA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$642,755

FY 2026

Project Title

Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts

Grant Number:

5R01CA289629-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary The fibroblastic stroma comprises most of pancreatic adenocarcinoma mass and is remarkably devoid of functional blood vessels. It has been assumed that the pancreatic cancer cells obtain their essential metabolites, such as lipids, directly from the interstitial fluid, but we have fo...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Guangfu Li

UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, FARMINGTON, CT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$627,562

FY 2026

Project Title

Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer

Grant Number:

5R01CA274959-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2023

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Anti-programmed death-1 antibody (αPD-1 Ab) as a single agent for treating human hepatocellular cancer (HCC) was withdrawn from the US market on July 26, 2021, because a multi-center phase III study did not demonstrate its efficacy in improving patient survival over controls. Thus, there is...

Research Terms

<16S RNA sequencing><16S RNAseq><16S gene sequencing><16S rDNA amplicon sequencing><16S rRNA DNA sequencing><16S rRNA amplicon sequencing><16S rRNA gene amplicon sequencing><16S rRNA gene sequencing><16S rRNA genomic profiling><16S rRNA sequencing><16S ribosomal RNA gene sequencing><16S ribosomal RNA sequencing><16S seq><16S sequencing><16s rRNA seq><Adoptive Cell Transfers><Agonist><Androgenic Agents><Androgenic Compounds><Androgens><Antibiotic Therapy><Antibiotic Treatment><Antibodies><Antibody Therapy><Antigens><Autoregulation><B. thetaiotaomicron><B7-H1><BAY 54-9085><Bacillus thetaiotaomicron><Bacteroides><Bacteroides thetaiotaomicron><Basal Transcription Factor><Basal transcription factor genes><Blood monocyte><C57BL/6 Mouse><CD152><CD152 Antigen><CD152 Gene><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Model><CancerModel><Cancers><Carbon Tetrachloride><Cell Body><Cells><Combined Modality Therapy><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Development><Disease><Disorder><GI microbiota><Gastrointestinal microbiota><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Growth><Hepatic><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocarcinogenesis><Hepatocarcinoma><Hepatocellular Carcinoma><Hepatocellular cancer><Hepatocyte><Hepatoma><Histology><Homeostasis><Human><Immune><Immune Cell Activation><Immune Tolerance><Immune mediated therapy><Immune response><Immunes><Immunity><Immunization><Immunologic Tolerance><Immunologically Directed Therapy><Immunology><Immunotherapeutic agent><Immunotherapy><Inflammatory><Knowledge><Ligands><Liver><Liver Carcinogenesis><Liver Cells><Liver Cells Carcinoma><Liver Fibrosis><MFR gene><MFR protein><MYD-1><Macrophage><Macrophage Fusion Receptor><Malignant Neoplasms><Malignant Tumor><Marketing><Marrow monocyte><Mediating><Melanoma patient><Mice><Mice Mammals><Microbe><Modeling><Modern Man><Molecular><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Myeloid-derived suppressor cells><Mφ><Nucleic Acids><Oncogenesis><Oncogenic><P84><PD 1><PD-1><PD-1 antibody><PD-L1><PD-L1 antibody><PD1><PD1 antibody><PDL-1><PTPNS1><PTPNS1 gene><Pathogenesis><Patients><Phagocytosis><Phase III study><Phenotype><Physiological Homeostasis><Play><Population><Primary carcinoma of the liver cells><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Progression-Free Survivals><Protein-Tyrosine Phosphatase, Nonreceptor Type, Substrate 1><Regulatory T-Lymphocyte><Resistance><Role><S thetaiotaomicron><S. thetaiotaomicron><SHP Substrate 1><SHPS-1 protein><SHPS1><SIRP-Alpha-1><SIRPA><SIRPalpha1><SV40 T Antigens><SV40 T Proteins><Shapes><Signal Regulatory Protein, Alpha Type, 1><Sorafenib><Sphaerocillus thetaiotaomicron><T8 Cells><T8 Lymphocytes><Testing><Tetrachloromethane><Therapeutic><Therapeutic Androgen><Therapeutic Effect><Therapeutic antibodies><Tissue Growth><Transcription Factor Proto-Oncogene><Transcription factor genes><Transgenic Mice><Treatment Efficacy><Treg><Tumor Antigens><Tumor Biology><Tumor Immunity><Tumor-Associated Antigen><Tumor-associated macrophages><Tyrosine Phosphatase SHP Substrate 1><Unresectable><Upregulation><aPD-1><aPD-L1><aPD-L1 antibodies><aPD1><adoptive cell therapy><adoptive cellular therapy><anti programmed cell death 1><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><antitumor immunity><bacterial disease treatment><bacterial infectious disease treatment><cancer antigens><cancer immunity><cancer immunotherapy><cancer initiation><cancer progression><carcinogenesis in the liver><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical relevance><clinically relevant><combination therapy><combined modality treatment><combined treatment><cytotoxic T-lymphocyte antigen 4><design><designing><developmental><enteric microbial community><enteric microbiota><exhaust><fecal microbial transplantation><fecal microbiome transplantation><fecal microbiota transplant><fecal microbiota transplantation><fecal transplant><fecal transplantation><fibrotic liver><gastrointestinal microbial flora><gut community><gut flora><gut microbe community><gut microbial community><gut microbial composition><gut microbial consortia><gut microbiota><gut microbiotic><gut microflora><hepatic body system><hepatic carcinogenesis><hepatic fibrosis><hepatic organ system><hepatocellular carcinogenesis><host response><human disease><immune activation><immune check point therapy><immune checkpoint therapy><immune drugs><immune system response><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunological paralysis><immunoresponse><immunosuppressive myeloid cells><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><intervention efficacy><intestinal flora><intestinal microbiota><intestinal microflora><intestinal tract microflora><invention><knock-down><knockdown><liver cancer pathogenesis><liver carcinoma><liver tumorigenesis><loss of function><malignancy><member><microbial><monocyte><multi-modal therapy><multi-modal treatment><myeloid suppressor cells><myeloid-derived suppressive cells><neoplasm progression><neoplasm/cancer><neoplastic progression><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><overexpress><overexpression><patients suffering from melanoma><patients with melanoma><phase 3 study><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><programs><protein death-ligand 1><regulatory T-cells><resistant><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><signal-regulatory protein><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><tetrachloro-methane><therapeutic efficacy><therapeutic response><therapy efficacy><therapy response><transcription factor><treatment response><treatment responsiveness><tumor><tumor growth><tumor initiation><tumor microbiota><tumor progression><tumor-associated microbiota><tumor-specific antigen><tumorigenesis><αPD-1><αPD-L1><αPD-L1 antibodies><αPD1><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kevin Finnbar Staveley-O'Carroll

UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, FARMINGTON, CT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$627,562

FY 2026

Project Title

Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer

Grant Number:

5R01CA274959-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2023

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Anti-programmed death-1 antibody (αPD-1 Ab) as a single agent for treating human hepatocellular cancer (HCC) was withdrawn from the US market on July 26, 2021, because a multi-center phase III study did not demonstrate its efficacy in improving patient survival over controls. Thus, there is...

Research Terms

<16S RNA sequencing><16S RNAseq><16S gene sequencing><16S rDNA amplicon sequencing><16S rRNA DNA sequencing><16S rRNA amplicon sequencing><16S rRNA gene amplicon sequencing><16S rRNA gene sequencing><16S rRNA genomic profiling><16S rRNA sequencing><16S ribosomal RNA gene sequencing><16S ribosomal RNA sequencing><16S seq><16S sequencing><16s rRNA seq><Adoptive Cell Transfers><Agonist><Androgenic Agents><Androgenic Compounds><Androgens><Antibiotic Therapy><Antibiotic Treatment><Antibodies><Antibody Therapy><Antigens><Autoregulation><B. thetaiotaomicron><B7-H1><BAY 54-9085><Bacillus thetaiotaomicron><Bacteroides><Bacteroides thetaiotaomicron><Basal Transcription Factor><Basal transcription factor genes><Blood monocyte><C57BL/6 Mouse><CD152><CD152 Antigen><CD152 Gene><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Model><CancerModel><Cancers><Carbon Tetrachloride><Cell Body><Cells><Combined Modality Therapy><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Development><Disease><Disorder><GI microbiota><Gastrointestinal microbiota><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Growth><Hepatic><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocarcinogenesis><Hepatocarcinoma><Hepatocellular Carcinoma><Hepatocellular cancer><Hepatocyte><Hepatoma><Histology><Homeostasis><Human><Immune><Immune Cell Activation><Immune Tolerance><Immune mediated therapy><Immune response><Immunes><Immunity><Immunization><Immunologic Tolerance><Immunologically Directed Therapy><Immunology><Immunotherapeutic agent><Immunotherapy><Inflammatory><Knowledge><Ligands><Liver><Liver Carcinogenesis><Liver Cells><Liver Cells Carcinoma><Liver Fibrosis><MFR gene><MFR protein><MYD-1><Macrophage><Macrophage Fusion Receptor><Malignant Neoplasms><Malignant Tumor><Marketing><Marrow monocyte><Mediating><Melanoma patient><Mice><Mice Mammals><Microbe><Modeling><Modern Man><Molecular><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Myeloid-derived suppressor cells><Mφ><Nucleic Acids><Oncogenesis><Oncogenic><P84><PD 1><PD-1><PD-1 antibody><PD-L1><PD-L1 antibody><PD1><PD1 antibody><PDL-1><PTPNS1><PTPNS1 gene><Pathogenesis><Patients><Phagocytosis><Phase III study><Phenotype><Physiological Homeostasis><Play><Population><Primary carcinoma of the liver cells><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Progression-Free Survivals><Protein-Tyrosine Phosphatase, Nonreceptor Type, Substrate 1><Regulatory T-Lymphocyte><Resistance><Role><S thetaiotaomicron><S. thetaiotaomicron><SHP Substrate 1><SHPS-1 protein><SHPS1><SIRP-Alpha-1><SIRPA><SIRPalpha1><SV40 T Antigens><SV40 T Proteins><Shapes><Signal Regulatory Protein, Alpha Type, 1><Sorafenib><Sphaerocillus thetaiotaomicron><T8 Cells><T8 Lymphocytes><Testing><Tetrachloromethane><Therapeutic><Therapeutic Androgen><Therapeutic Effect><Therapeutic antibodies><Tissue Growth><Transcription Factor Proto-Oncogene><Transcription factor genes><Transgenic Mice><Treatment Efficacy><Treg><Tumor Antigens><Tumor Biology><Tumor Immunity><Tumor-Associated Antigen><Tumor-associated macrophages><Tyrosine Phosphatase SHP Substrate 1><Unresectable><Upregulation><aPD-1><aPD-L1><aPD-L1 antibodies><aPD1><adoptive cell therapy><adoptive cellular therapy><anti programmed cell death 1><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer immunotherapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><antitumor immunity><bacterial disease treatment><bacterial infectious disease treatment><cancer antigens><cancer immunity><cancer immunotherapy><cancer initiation><cancer progression><carcinogenesis in the liver><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical relevance><clinically relevant><combination therapy><combined modality treatment><combined treatment><cytotoxic T-lymphocyte antigen 4><design><designing><developmental><enteric microbial community><enteric microbiota><exhaust><fecal microbial transplantation><fecal microbiome transplantation><fecal microbiota transplant><fecal microbiota transplantation><fecal transplant><fecal transplantation><fibrotic liver><gastrointestinal microbial flora><gut community><gut flora><gut microbe community><gut microbial community><gut microbial composition><gut microbial consortia><gut microbiota><gut microbiotic><gut microflora><hepatic body system><hepatic carcinogenesis><hepatic fibrosis><hepatic organ system><hepatocellular carcinogenesis><host response><human disease><immune activation><immune check point therapy><immune checkpoint therapy><immune drugs><immune system response><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunological paralysis><immunoresponse><immunosuppressive myeloid cells><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><intervention efficacy><intestinal flora><intestinal microbiota><intestinal microflora><intestinal tract microflora><invention><knock-down><knockdown><liver cancer pathogenesis><liver carcinoma><liver tumorigenesis><loss of function><malignancy><member><microbial><monocyte><multi-modal therapy><multi-modal treatment><myeloid suppressor cells><myeloid-derived suppressive cells><neoplasm progression><neoplasm/cancer><neoplastic progression><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><overexpress><overexpression><patients suffering from melanoma><patients with melanoma><phase 3 study><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><programs><protein death-ligand 1><regulatory T-cells><resistant><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><signal-regulatory protein><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><tetrachloro-methane><therapeutic efficacy><therapeutic response><therapy efficacy><therapy response><transcription factor><treatment response><treatment responsiveness><tumor><tumor growth><tumor initiation><tumor microbiota><tumor progression><tumor-associated microbiota><tumor-specific antigen><tumorigenesis><αPD-1><αPD-L1><αPD-L1 antibodies><αPD1><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jun Yang

ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TN

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$617,486

FY 2026

Project Title

Transcriptional suppression of innate immunity by chimeric transcription factors

Grant Number:

1R01CA300571-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Immunosurveillance silencing by oncoproteins promotes tumor progression and immunotherapy evasion. However, little is known about the immunosuppression by chimeric transcription factors, drivers of many cancers such as alveolar rhabdomyosarcoma (aRMS). aRMS is an aggressive childhood soft t...

Research Terms

<0-11 years old><Alveolar Rhabdomyosarcoma><Automobile Driving><Autophagocytosis><Basal Transcription Factor><Basal transcription factor genes><Binding><Biological Function><Biological Process><Biology><Cancers><Cell Body><Cells><Checkpoint inhibitor><Chemotherapy and Radiation><Chemotherapy and/or radiation><Child><Child Youth><Childhood Soft Tissue Sarcoma><Children (0-21)><DNA><DNA Methylation><DNA Methyltransferase><DNA Modification Methylases><DNA Modification Methyltransferases><DNA-Methyltransferases><DNMT3a><Data><Deoxyribonucleic Acid><Development><Dnmt><Double-Stranded DNA><Double-Stranded RNA><ERVs><Embryonic Muscle Cells><Endogenous Retroviruses><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><FKHR><FOXO1><FOXO1A><FOXO1A gene><Forkhead Box O1A><Forkhead in Rhabdomyosarcoma><Fusion Oncogene Proteins><Gene Expression><Gene Inactivation><Gene Silencing><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic><Genetic Transcription><HERVs><HUP1><HUP2><Human Endogenous Retroviruses><IFN><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunity><Immunocompetent><Immunologic Surveillance><Immunologically Directed Therapy><Immunology><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapy><Innate Immunity><Interferon Type I><Interferons><Isoforms><Knock-out><Knockout><Knowledge><Lysosomes><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Mediating><Metabolic Protein Degradation><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Modification Methylases><Molecular><Molecular Interaction><Myoblasts><Native Immunity><Natural Immunity><Neoplasm Metastasis><Non-Polyadenylated RNA><Non-Specific Immunity><Nonspecific Immunity><Oncogene Products><Oncogene Proteins><Oncogenic><Oncoproteins><Outcome><PAX3><PAX3 gene><PAX7><PAX7 gene><Paired Box Gene 3><Paired Box Gene 7><Paired Box Homeotic Gene 7><Paired Domain Gene 7><Paired Domain Gene HuP2><Pathway interactions><Pediatric Soft Tissue Sarcoma><Phenotype><Position><Positioning Attribute><Precursor Muscle Cells><Protein Isoforms><Protein Turnover><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Seq><RNA sequencing><RNAseq><Regulatory Protein Degradation><Relapse><Reporting><Research><Retroelements><Ribonucleic Acid><Secondary Neoplasm><Secondary Tumor><Site-Specific DNA-methyltransferase><Source><Stimulator of Interferon Genes><Survival Rate><Testing><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tumor Immunity><Tumor Promotion><Variant><Variation><WS1><anti-tumor effect><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><antitumor effect><antitumor immunity><autophagy><cGAMP STING><cGAMP-STING><cGAMP/STING><cGAS/STING><cancer cell><cancer genomics><cancer immunity><cancer metastasis><cancer progression><chemo/radiation therapy><chemotherapy and radiotherapy><cyclic GMP-AMP synthase/STING><developmental><driving><ds-DNA><dsDNA><dsRNA><effective therapy><effective treatment><epigenetic gene silencing><epigenetic silencing><epigenetically><fusion oncoprotein><hDNA methyltransferase 3a><high risk><host response><immune check point inhibitor><immune competent><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><innovate><innovation><innovative><kids><knock-down><knockdown><malignancy><mouse model><multidisciplinary><murine model><muscle progenitor><muscle progenitor cell><muscle stem cell><neoplasm immunotherapy><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><novel><oncogenomics><pathway><pharmacologic><prevent><preventing><promoter><promotor><protein degradation><radiation or chemotherapy><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><trafficking><transcription factor><transcriptional silencing><transcriptome sequencing><transcriptomic sequencing><tumor><tumor cell metastasis><tumor growth><tumor immune therapy><tumor immunotherapy><tumor progression><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Greg M. Delgoffe

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$614,462

FY 2026

Project Title

Dissecting the role of hypoxia in T cell differentiation in cancer

Grant Number:

5R01CA277473-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immunotherapeutic treatments for cancer, especially the use of monoclonal antibody mediated blockade of `checkpoint' molecules like PD-1, has changed the treatment paradigm for patients with solid tumors like melanoma. However, only a subset of patients benefit from these th...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yana Najjar

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$614,462

FY 2026

Project Title

Dissecting the role of hypoxia in T cell differentiation in cancer

Grant Number:

5R01CA277473-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immunotherapeutic treatments for cancer, especially the use of monoclonal antibody mediated blockade of `checkpoint' molecules like PD-1, has changed the treatment paradigm for patients with solid tumors like melanoma. However, only a subset of patients benefit from these th...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Amanda Catherine Poholek

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$614,462

FY 2026

Project Title

Dissecting the role of hypoxia in T cell differentiation in cancer

Grant Number:

5R01CA277473-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immunotherapeutic treatments for cancer, especially the use of monoclonal antibody mediated blockade of `checkpoint' molecules like PD-1, has changed the treatment paradigm for patients with solid tumors like melanoma. However, only a subset of patients benefit from these th...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Soman N Abraham

DUKE UNIVERSITY, DURHAM, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$610,124

FY 2026

Project Title

BCG-Mediated Immunotherapy Against Bacteria

Grant Number:

1R01AI190532-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/4/2026

End Date:

1/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Up to 3.5 billion dollars is spent each year, in the US alone, to manage bladder infections and their recurrence. The intractability of these infections is attributable, in part, to the capacity of bladder bacteria to persist in the bladder long after infection resolution only to remerge a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

STEVEN L REINER

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$547,492

FY 2026

Project Title

Strategies to predict and overcome resistance to cancer immunotherapy

Grant Number:

5R01CA279268-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Immunotherapies such as PD-1 blockade have revolutionized cancer care. Yet most patients do not experience sustained (durable) benefit from blockade of T cell inhibitory receptors. Unfortunately, current biomarkers do not adequately predict patient response or resistance to immunotherapy; and succes...

Research Terms

<1-Phosphatidylinositol 3-Kinase><Address><Antigens><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Sample><Blood Tests><Blood specimen><Body Tissues><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancer Patient><Cancers><Cell Body><Cell Communication and Signaling><Cell Differentiation><Cell Differentiation process><Cell Signaling><Cell division><Cells><Cellular biology><Clinical><Clinical Trials><Clone Cells><Confocal Microscopy><Consensus><Defense Mechanisms><Dose><Drugs><Dysfunction><Epidermoid Cell Cancer><Equilibrium><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Frequencies><Functional disorder><HNSCC><Head and Neck Squamous Cell Carcinoma><Hematologic Tests><Hematological Tests><Hematology Testing><Image Cytometry><Immune mediated therapy><Immunity><Immunofluorescence><Immunofluorescence Immunologic><Immunologically Directed Therapy><Immunotherapy><Intracellular Communication and Signaling><Lesion><Link><Malignant Epidermoid Cell Neoplasm><Malignant Epidermoid Cell Tumor><Malignant Neoplasms><Malignant Squamous Cell Neoplasm><Malignant Squamous Cell Tumor><Malignant Tumor><Medication><Mice><Mice Mammals><Minority><Mitotic><Morphology><Murine><Mus><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Nature><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Operative Procedures><Operative Surgical Procedures><Output><PBMC><PD-1 antibody><PD-1 antibody therapy><PD-1 blockade><PD-1 therapy><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 blockade><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Patients><Peripheral Blood Mononuclear Cell><Persons><Pharmaceutical Preparations><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Physiologic pulse><Physiopathology><Production><Proliferating><PtdIns 3-Kinase><Pulse><Radiation therapy><Radiotherapeutics><Radiotherapy><Receptor Protein><Resistance><SCCHN><Siblings><Signal Transduction><Signal Transduction Systems><Signaling><Sister><Squamous Cell Cancers><Stem Cell like><Surgical><Surgical Interventions><Surgical Procedure><T cell differentiation><T-Cell Activation><T-Cell Proliferation><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Tissues><Transmission><Tumor Immunity><Tumor Tissue><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><Work><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><activate T cells><advanced disease><advanced illness><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-cancer><anti-cancer immunotherapy><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><anticancer immunotherapy><antitumor immunity><balance><balance function><bio-markers><biologic marker><biological signal transduction><biomarker><blood treatment><cancer care><cancer immunity><cancer immunotherapy><cancer type><candidate biomarker><candidate marker><cell biology><cell regeneration><cellular differentiation><cellular regeneration><check point blockade><checkpoint blockade><chemotherapy><clinical practice><confocal imaging><daughter cell><disease control><disorder control><drug/agent><experiment><experimental research><experimental study><experiments><flow cytophotometry><head and neck squamous carcinoma><head and neck squamous cell cancer><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><insight><kindred><malignancy><neoplasm/cancer><new approaches><novel approaches><novel strategies><novel strategy><pathophysiology><patient response><patient specific response><peripheral blood><pre-clinical><preclinical><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><progenitor><progenitor capacity><progenitor cell differentiation><progenitor cell division><progenitor cell like><progenitor cell renewal><progenitor differentiation><progenitor division><progenitor renewal><progenitor-like><programmed cell death protein 1 therapy><psychological defense mechanism><radiation treatment><receptor><regenerative><resistant><response><response biomarker><response markers><responsive patient><self-renew><self-renewal><stem and progenitor cell division><stem and progenitor cell renewal><stem and progenitor differentiation><stem cell characteristics><stem cell differentiation><stem cell division><stem cell renewal><stem-like><stemness><surgery><thymus derived lymphocyte><translational applications><transmission process><treatment with radiation><tumor><tumor growth><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mateusz Opyrchal

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$501,827

FY 2026

Project Title

Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy

Grant Number:

5R01CA260274-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The immune system can distinguish healthy cells from tumor cells, as the latter expresses tumor associated antigens (TAAs). In the context of CD8+ T cell-mediated immune responses, recognition of TAAs occurs through the presentation of TAAs via major histocompatibility class I (MHC-I) on tu...

Research Terms

<26 S proteasome complex><26S ATP-Dependent Protease><26S ATP-Dependent Proteasome><26S Proteasome Complex><26S Proteosome><26S protease><26S proteasome><Adoptive Cell Transfers><Antigen Presentation><Antigen Presentation Pathway><Antigen Processing and Presentation><Antigens><Architecture><Assay><Autologous><B7-H1><Bioassay><Bioinformatics><Biological Assay><CD152><CD152 Antigen><CD152 Gene><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Biology><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cell-Mediated Lympholytic Cells><Cells><Cellular Cytotoxicity><Checkpoint inhibitor><Chemicals><Class I Genes><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><Colon><Colon Cancer><Colon Carcinoma><Colon Neoplasms><Colon Tumor><Colonic Mass><Colonic Neoplasms><Colonic Tumor><Colorectal Cancer><Colorectal Neoplasms><Colorectal Tumors><Complex><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic T-Lymphocytes><DNA Molecular Biology><Deletion of DNA Sequences><Distal><Engineering / Architecture><Event><GEM model><GEMM model><Gene Transcription><Genes><Genetic Transcription><Genetically Engineered Mouse><Herbal Medicine><Histocompatibility><Human><Immune><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immune response><Immune system><Immunes><Immunologically Directed Therapy><Immunology><Immunotherapy><Impairment><Investigators><KRAS(G12D)><KRASG12D><Large Bowel Tumor><Large Intestine Neoplasm><Large Intestine Tumor><Legal patent><Lymphocyte Cytotoxicity><Lymphocytotoxicity><Lytotoxicity><MHC Class I><MHC Class I Genes><MHC Receptor><Macrophage><Major Histocompatibility Complex Receptor><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Methods><Mice><Mice Mammals><Microsatellite Instability><Microsatellite Markers><Microsatellite Repeats><Microsatellites><Modeling><Modeling of Functional Interactions><Modern Man><Molecular><Molecular Biology><Murine><Mus><Mφ><Natural Compound><Organoids><Outcome><PD 1><PD-1><PD-1 antibody><PD-L1><PD1><PD1 antibody><PDL-1><Patents><Patients><Peptides><Population><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proteins><Protocol><Protocols documentation><Public Health><RNA Expression><Regulatory T-Lymphocyte><Research Personnel><Researchers><Resistance><Sequence Deletion><Solid Neoplasm><Solid Tumor><Staining method><Stains><Standardization><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Therapeutic Intervention><Therapeutic antibodies><Tissue Compatibility><Transcription><Treg><Tumor Antigens><Tumor Cell><Tumor Escape><Tumor Immune Escape><Tumor Promotion><Tumor Tissue><Tumor-Associated Antigen><Tumor-Infiltrating Lymphocytes><Tumor-infiltrating immune cells><Ubiquitilation><Ubiquitination><Ubiquitinoylation><aPD-1><aPD1><adoptive cell therapy><adoptive cellular therapy><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-cancer therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor effect><antiPD-1><anticancer immunotherapy><antigen processing><antitumor effect><cancer antigens><cancer cell><cancer evasion><cancer immune escape><cancer immune evasion><cancer immunology><cancer immunotherapy><cancer in the colon><cancer infiltrating T cells><cancer microenvironment><cancer therapy><cancer-directed therapy><cell mediated cytotoxicity><cell mediated immune response><check point blockade><checkpoint blockade><colon cancer patients><colon neoplasia><colorectal cancer patients><colorectal neoplasia><cytotoxic><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><cytotoxic T-lymphocyte antigen 4><cytotoxicity><empowerment><genetically engineered mouse model><genetically engineered murine model><genomic deletion><host response><immune cell infiltrate><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><infiltration of tumors by immune cells><intervention therapy><intratumoral immune cell><intratumoral immune infiltrate><killer T cell><large bowel neoplasm><malignancy><naturally occurring compound><neoplasm immunology><neoplasm/cancer><neoplastic cell><preservation><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><regulatory T-cells><resistant><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><structural biology><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tumor><tumor evasion><tumor immune cell><tumor immune evasion><tumor immune infiltrate><tumor immunology><tumor infiltrating T cells><tumor infiltration of immune cells><tumor microenvironment><tumor-specific antigen><ubiquination><ubiquitin conjugation><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xinna Zhang

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$501,827

FY 2026

Project Title

Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy

Grant Number:

5R01CA260274-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The immune system can distinguish healthy cells from tumor cells, as the latter expresses tumor associated antigens (TAAs). In the context of CD8+ T cell-mediated immune responses, recognition of TAAs occurs through the presentation of TAAs via major histocompatibility class I (MHC-I) on tu...

Research Terms

<26 S proteasome complex><26S ATP-Dependent Protease><26S ATP-Dependent Proteasome><26S Proteasome Complex><26S Proteosome><26S protease><26S proteasome><Adoptive Cell Transfers><Antigen Presentation><Antigen Presentation Pathway><Antigen Processing and Presentation><Antigens><Architecture><Assay><Autologous><B7-H1><Bioassay><Bioinformatics><Biological Assay><CD152><CD152 Antigen><CD152 Gene><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Biology><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cell-Mediated Lympholytic Cells><Cells><Cellular Cytotoxicity><Checkpoint inhibitor><Chemicals><Class I Genes><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><Colon><Colon Cancer><Colon Carcinoma><Colon Neoplasms><Colon Tumor><Colonic Mass><Colonic Neoplasms><Colonic Tumor><Colorectal Cancer><Colorectal Neoplasms><Colorectal Tumors><Complex><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic T-Lymphocytes><DNA Molecular Biology><Deletion of DNA Sequences><Distal><Engineering / Architecture><Event><GEM model><GEMM model><Gene Transcription><Genes><Genetic Transcription><Genetically Engineered Mouse><Herbal Medicine><Histocompatibility><Human><Immune><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immune response><Immune system><Immunes><Immunologically Directed Therapy><Immunology><Immunotherapy><Impairment><Investigators><KRAS(G12D)><KRASG12D><Large Bowel Tumor><Large Intestine Neoplasm><Large Intestine Tumor><Legal patent><Lymphocyte Cytotoxicity><Lymphocytotoxicity><Lytotoxicity><MHC Class I><MHC Class I Genes><MHC Receptor><Macrophage><Major Histocompatibility Complex Receptor><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Methods><Mice><Mice Mammals><Microsatellite Instability><Microsatellite Markers><Microsatellite Repeats><Microsatellites><Modeling><Modeling of Functional Interactions><Modern Man><Molecular><Molecular Biology><Murine><Mus><Mφ><Natural Compound><Organoids><Outcome><PD 1><PD-1><PD-1 antibody><PD-L1><PD1><PD1 antibody><PDL-1><Patents><Patients><Peptides><Population><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proteins><Protocol><Protocols documentation><Public Health><RNA Expression><Regulatory T-Lymphocyte><Research Personnel><Researchers><Resistance><Sequence Deletion><Solid Neoplasm><Solid Tumor><Staining method><Stains><Standardization><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Therapeutic Intervention><Therapeutic antibodies><Tissue Compatibility><Transcription><Treg><Tumor Antigens><Tumor Cell><Tumor Escape><Tumor Immune Escape><Tumor Promotion><Tumor Tissue><Tumor-Associated Antigen><Tumor-Infiltrating Lymphocytes><Tumor-infiltrating immune cells><Ubiquitilation><Ubiquitination><Ubiquitinoylation><aPD-1><aPD1><adoptive cell therapy><adoptive cellular therapy><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer immunotherapy><anti-cancer therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor effect><antiPD-1><anticancer immunotherapy><antigen processing><antitumor effect><cancer antigens><cancer cell><cancer evasion><cancer immune escape><cancer immune evasion><cancer immunology><cancer immunotherapy><cancer in the colon><cancer infiltrating T cells><cancer microenvironment><cancer therapy><cancer-directed therapy><cell mediated cytotoxicity><cell mediated immune response><check point blockade><checkpoint blockade><colon cancer patients><colon neoplasia><colorectal cancer patients><colorectal neoplasia><cytotoxic><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><cytotoxic T-lymphocyte antigen 4><cytotoxicity><empowerment><genetically engineered mouse model><genetically engineered murine model><genomic deletion><host response><immune cell infiltrate><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><infiltration of tumors by immune cells><intervention therapy><intratumoral immune cell><intratumoral immune infiltrate><killer T cell><large bowel neoplasm><malignancy><naturally occurring compound><neoplasm immunology><neoplasm/cancer><neoplastic cell><preservation><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><regulatory T-cells><resistant><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><structural biology><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tumor><tumor evasion><tumor immune cell><tumor immune evasion><tumor immune infiltrate><tumor immunology><tumor infiltrating T cells><tumor infiltration of immune cells><tumor microenvironment><tumor-specific antigen><ubiquination><ubiquitin conjugation><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wei R. Chen

UNIVERSITY OF OKLAHOMA, NORMAN, OK

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$489,473

FY 2026

Project Title

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors

Grant Number:

5R01CA269897-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Pancreatic cancer (PC) is one of the deadliest diseases. Based on the 2021 U.S. cancer statistics, the majority of PC patients are diagnosed with advanced-stage disease, either with distant metastasis (50%) or local invasion (30%), resulting in a five-year survival rate of 3% and 13%...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MIN LI

UNIVERSITY OF OKLAHOMA, NORMAN, OK

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$489,473

FY 2026

Project Title

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors

Grant Number:

5R01CA269897-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Pancreatic cancer (PC) is one of the deadliest diseases. Based on the 2021 U.S. cancer statistics, the majority of PC patients are diagnosed with advanced-stage disease, either with distant metastasis (50%) or local invasion (30%), resulting in a five-year survival rate of 3% and 13%...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wei Hu

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$482,312

FY 2026

Project Title

Novel Treg inactivating approach for cancer immunotherapy via targeted protein degradation

Grant Number:

1R01CA295942-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Despite the growing success of immunotherapies, such as chimeric antigen receptor-based cell therapy, cytokine therapy, and immune checkpoint blockade (ICB), a substantial number of cancers remain unresponsive. Furthermore, these therapies can lead to off-target toxicities, known as ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michel DuPage

UNIVERSITY OF CALIFORNIA BERKELEY, BERKELEY, CA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$473,641

FY 2026

Project Title

Reversing cancer immunosuppression using attenuated Listeria monocytogenes

Grant Number:

5R01CA283604-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The past decade has witnessed a breakthrough in cancer immunotherapy, from checkpoint inhibitors to adoptive T cell therapies, a new pillar in our armament of anti-cancer drugs now exists. However, our current therapies are based on the premise that adaptive immunity alone, mediated ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DANIEL A PORTNOY

UNIVERSITY OF CALIFORNIA BERKELEY, BERKELEY, CA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$473,641

FY 2026

Project Title

Reversing cancer immunosuppression using attenuated Listeria monocytogenes

Grant Number:

5R01CA283604-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The past decade has witnessed a breakthrough in cancer immunotherapy, from checkpoint inhibitors to adoptive T cell therapies, a new pillar in our armament of anti-cancer drugs now exists. However, our current therapies are based on the premise that adaptive immunity alone, mediated ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RALPH R WEICHSELBAUM

UNIVERSITY OF CHICAGO, CHICAGO, IL

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$466,819

FY 2026

Project Title

Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer

Grant Number:

5R01CA279802-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S. The majority of CRC patients have distant or regional metastasis and a poor prognosis. Although immune checkpoint blockade (ICB) has demonstrated favorable responses and survival benefits for mC...

Research Terms

<1-OHP><Address><Agonist><Antigen Presentation><Antigens><Anzatax><Asotax><Binding><Biodistribution><Bristaxol><Cancer Cause><Cancer Etiology><Cancer Model><Cancer Treatment><CancerModel><Cell Communication and Signaling><Cell Signaling><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cellular Cytotoxicity><Cessation of life><Cholesterol><Circulation><Clinical Trials><Collaborations><Colorectal Cancer><Colorectal Neoplasms><Colorectal Tumors><Combination Drug Therapy><Cyclic GMP><Cyclicity><Death><Deposit><Deposition><Development><Dinucleoside Phosphates><Disseminated Malignant Neoplasm><Distant><Distant Cancer><Distant Metastasis><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drug Precursors><Drugs><Epithelial Cells><Exhibits><Gene Activation><Goals><Guanosine Cyclic Monophosphate><Half-Life><Hybrids><Hydrophobicity><Immune><Immune mediated therapy><Immune memory><Immunes><Immuno-Chemotherapy><Immunochemical Immunologic><Immunochemotherapy><Immunologic><Immunologic Memory><Immunological><Immunological Memory><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapy><In Vitro><Interferon Type I><Intracellular Communication and Signaling><Ions><LDL><LDL Lipoproteins><LDL Receptors><LDLR gene><Large Bowel Tumor><Large Intestine Neoplasm><Large Intestine Tumor><Lesion><Ligands><Lipoprotein LDL Receptors><Low Density Lipoprotein Receptor><Low-Density Lipoproteins><Lymphocyte Cytotoxicity><Lymphocytotoxicity><MMR deficiency><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mediating><Medication><Metals><Metastasis><Metastasize><Metastatic Cancer><Metastatic Lesion><Metastatic Malignant Neoplasm><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Microsatellite Instability><Mismatch Repair><Mismatch Repair Deficiency><Modality><Modeling><Molecular><Molecular Interaction><Morbidity - disease rate><Murine><Mus><Neoplasm Metastasis><PD-L1 antibody><Paclitaxel><Paclitaxel (Taxol)><Pathway interactions><Patients><Pattern><Periodicity><Permeability><Pharmaceutical Preparations><Pharmacokinetics><Polychemotherapy><Polymers><Post-Replication Mismatch Repair><Praxel><Pre-Clinical Model><Preclinical Models><Pro-Drugs><Prodrugs><Prognosis><RNA Seq><RNA sequencing><RNAseq><Regimen><Research><Resistance><Rhythmicity><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Solid><Stimulator of Interferon Genes><Survival Rate><T-Cell Activation><T-Cell Proliferation><T-Cells><T-Lymphocyte><Taxol><Taxol A><Taxol Konzentrat><Taxotere><Therapeutic Index><Toxic effect><Toxicities><Tumor Antigens><Tumor Immunity><Tumor Tissue><Tumor-Associated Antigen><aPD-L1><aPD-L1 antibodies><activate T cells><anamnestic reaction><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer><anti-cancer therapy><anti-tumor effect><anti-tumor immunity><antiPD-L1><antitumor effect><antitumor immunity><beta-Lipoproteins><biological signal transduction><cGAMP STING><cGAMP-STING><cGAMP/STING><cGAS/STING><cGMP><cancer antigens><cancer cell><cancer immunity><cancer metastasis><cancer microenvironment><cancer therapy><cancer-directed therapy><cell mediated cytotoxicity><check point blockade><checkpoint blockade><chemo-immuno therapy><chemoimmunotherapy><chemotherapy><clinical candidate><clinical care><clinical translation><clinically translatable><colon cancer patients><colorectal cancer patients><colorectal neoplasia><combination chemotherapy><combination pharmacotherapy><cyclic GMP-AMP synthase/STING><cytokine><developmental><dinucleotide><docetaxel><docetaxol><drug/agent><effective therapy><effective treatment><hydrophilicity><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunogenic><immunogenic apoptosis><immunogenic cell death><improved><in vivo><large bowel neoplasm><metastatic colo-rectal><metastatic colo-rectal cancer><metastatic colo-rectal carcinoma><metastatic colon cancer><metastatic colorectal><metastatic colorectal cancer><metastatic colorectal carcinoma><morbidity rate><mortality><mouse model><multi-modality><multidisciplinary><multimodality><murine model><nano medicinal><nano medicine><nano meter scale><nano meter sized><nano particle><nano-sized particle><nanomedicinal><nanomedicine><nanometer scale><nanometer sized><nanoparticle><nanoscale><nanosized particle><nanotherapeutic><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><overexpress><overexpression><oxaliplatin><oxaliplatine><particle><pathway><polymer><polymeric><polymerization><receptor mediated endocytosis><resistant><response><secondary immune response><side effect><standard of care><subcutaneous><subdermal><synergism><thymus derived lymphocyte><tool><transcriptome sequencing><transcriptomic sequencing><tumor><tumor cell metastasis><tumor microenvironment><tumor-specific antigen><uptake><αPD-L1><αPD-L1 antibodies><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DONALD W. KUFE

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$454,678

FY 2026

Project Title

Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer

Grant Number:

5R01CA097098-22

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2002

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited therapeutic options. Combining chemotherapy with immune checkpoint inhibitors (ICIs) has improved TNBC treatment, supporting the premise that DNA damage resistance and immune evasion are of importance for TNBC progression....

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew J Paszek

CORNELL UNIVERSITY, ITHACA, NY

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$441,603

FY 2026

Project Title

Physical Resistance to Immune Cell Attack by the Cellular Glycocalyx

Grant Number:

5R01CA276398-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Cancer cells construct a cellular glycocalyx with biochemical and biophysical attributes that protect against attack by effector immune cells. Currently, our mechanistic understanding of how the cancer-cell glycocalyx may physically interfere with any of the multiple pathway...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Haydn Kissick

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$409,045

FY 2026

Project Title

Genetic Mechanisms Controlling Kidney Cancer Immune Escape

Grant Number:

5R01CA280069-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract: The CD8 T-cell response to cancer is critical for disease control and response to checkpoint inhibitors. A prevailing feature of all human cancer is the extreme variability of the magnitude of this response between patients, and the factors that cause this variability are unknown. We previ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kelsey Dillehay McKillip

UNIVERSITY OF CINCINNATI, CINCINNATI, OH

Good lead · 66/100

Likely hiring

Solid budget

Recent

Active award

$369,511

FY 2026

Project Title

Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacy

Grant Number:

5U01CA267985-05

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

There is an increasing dependence on sophisticated biomarker development to allow prediction of therapeutic response as well as detection of potential underlying drug targets for novel therapeutics. A frequent limitation for solid tumors is that standard tissue biopsies are not always feasible, safe...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Trisha M Wise-Draper

UNIVERSITY OF CINCINNATI, CINCINNATI, OH

Good lead · 66/100

Likely hiring

Solid budget

Recent

Active award

$369,511

FY 2026

Project Title

Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacy

Grant Number:

5U01CA267985-05

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

There is an increasing dependence on sophisticated biomarker development to allow prediction of therapeutic response as well as detection of potential underlying drug targets for novel therapeutics. A frequent limitation for solid tumors is that standard tissue biopsies are not always feasible, safe...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gang Xin

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$360,696

FY 2026

Project Title

Targeting GPR84 to Overcome Macrophage Mediated Resistance to Immunotherapy

Grant Number:

5R01CA269984-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/18/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Immune checkpoint blockade (ICB) has produced extraordinary clinical responses in more than 25 tumor types. However, only a small number of patients benefit from this therapy owing to the immunosuppressive tu- mor microenvironment (TME). As one of the major components of the TME, tum...

Research Terms

<(TNF)-α><3'5'-cyclic ester of AMP><40-C-EBP Protein><AGP-EBP Transcription Factor><Ablation><Address><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Affect><Agonist><Basal Transcription Factor><Basal transcription factor genes><Biochemical><Bladder Cancer><Bladder Neoplasm><Bladder Tumors><C-EBP-Related Protein 2><C-EBP-beta><C-EBP-β><C-EBPbeta><C-EBPβ><CCAAT-Enhancer-Binding Protein-beta><CCAAT-Enhancer-Binding Protein-β><CRP2 Protein><Cachectin><Cancer Model><Cancer Patient><CancerModel><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular Immune Function><Chromatin><Clinical><Coupled><Cyclic AMP><Data><Data Set><Development><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Family><Fatty Acids><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fostering><Foundations><Free Fatty Acids><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><G-Proteins><GPCR><GPR84><GPR84 gene><GTP-Binding Proteins><GTP-Regulatory Proteins><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Transcription><Goals><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Hepatic Proliferation Inhibitor><Human><IL-6 DBP><IL-6-Dependent DNA Binding Protein><Immune mediated therapy><Immune response><Immunity><Immunoglobulin Enhancer-Binding Protein><Immunologic Stimulation><Immunological Stimulation><Immunologically Directed Therapy><Immunomodulation><Immunostimulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Interleukin-6 Nuclear Factor><Intermediary Metabolism><Intracellular Communication and Signaling><Knowledge><L arginine amidinohydrolase><LAP Transcription Factor><Liver Immunoregulatory Protein><Liver-Derived Inhibitory Protein><Macrophage><Macrophage-Derived TNF><Malignant Bladder Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant neoplasm of urinary bladder><Maps><Mediating><Metabolic><Metabolic Processes><Metabolism><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Monoclonal Antibody Therapy><Monocyte-Derived TNF><Murine><Mus><Myelogenous><Myeloid><Myeloid Cells><Mφ><NF-IL6><NF-kB><NF-kappa B><NF-kappaB><NFKB><Nonesterified Fatty Acids><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><PD-1 antibody><PD-1 blockade><PD1 antibody><PD1 blockade><Pathway interactions><Patients><Phenotype><Process><Production><Publishing><RNA Expression><Receptor Protein><Resistance><Role><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><T cell response><T-Cells><T-Lymphocyte><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Therapeutic><Transcription><Transcription Factor NF-kB><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Escape><Tumor Immune Escape><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor-associated macrophages><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Urinary Bladder Neoplasm><Urinary Bladder Tumor><Work><aPD-1><aPD1><adenosine 3'5' monophosphate><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><arginase><arginine amidinase><biological signal transduction><cAMP><canavanase><cancer evasion><cancer immune escape><cancer immune evasion><cancer microenvironment><check point blockade><checkpoint blockade><design><designing><determine efficacy><developmental><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epigenetically><evaluate efficacy><examine efficacy><fatty acid oxidation><flow cytophotometry><genome scale><genome-wide><genomewide><global gene expression><global transcription profile><high dimensionality><host response><immune check point blockade><immune checkpoint blockade><immune function><immune microenvironment><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune suppressive macrophages><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive macrophages><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><insight><kappa B Enhancer Binding Protein><loss of function><mAB-based therapy><mAb therapy><mAb-based therapeutics><malignancy><member><mouse model><murine model><neoplasm/cancer><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><nuclear factor kappa beta><pathway><pharmacologic><precision medicine><precision-based medicine><prevent><preventing><programs><receptor><resistant><response><sensor><signature molecule><social role><therapeutic target><thymus derived lymphocyte><transcription factor><transcriptome><tumor><tumor evasion><tumor growth><tumor immune evasion><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><tumorigenic><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dong-Hyun Kim

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$356,311

FY 2026

Project Title

Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma

Grant Number:

5R01CA278956-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Hepatocellular carcinoma (HCC) is the 5th most common malignancy in the world and the 4th leading cause of cancer death in the US. Resection and transplantation are the sole potentially curative treatments for HCC, but only 10-15% of patients are candidates. Nivolumab (human anti-PD...

Research Terms

<7S Gamma Globulin><Ablation><Abscission><After Care><After-Treatment><Aftercare><Animal Model><Animal Models and Related Studies><Antibodies><Arteries><B7-H1><BAY 54-9085><Binding><Binding Proteins><CD274><Cancer Cause><Cancer Etiology><Cancers><Catheters><Cessation of life><Checkpoint inhibitor><Clinical><Clinical Treatment Moab><Clinical Trials><Combination immunotherapy><Combined Modality Therapy><Death><Dose><Electroporation><Electroporation Therapy><Engineering><Excision><Extirpation><FDA approved><Fc domain><Feraheme><General Radiology><Hepatic Cancer><Hepatocarcinoma><Hepatocarcinoma model><Hepatocellular Carcinoma><Hepatocellular cancer><Hepatoma><Human><Hypoxic tumor><IgG><Immobilization><Immune><Immune Cell Activation><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immune system><Immunes><Immunochemical Immunologic><Immunoglobulin G><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapy><Intervention><Intra-Arterial Infusions><Intraarterial Infusions><Ligand Binding Protein><Ligand Binding Protein Gene><Ligands><Liver Cells Carcinoma><Local Therapy><Localized Therapy><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of liver><Measurement><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Modern Man><Molecular Interaction><Monitor><Monoclonal Antibodies><Multimodal Therapy><Multimodal Treatment><NMR Imaging><NMR Tomography><Nano immunotherapy><Nanoimmunotherapy><Nivolumab><Normal Tissue><Normal tissue morphology><Nuclear Magnetic Resonance Imaging><Oncology><Oncology Cancer><Opdivo><PD 1><PD-1><PD-1 antibody><PD-L1><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PD1><PD1 antibody><PDL-1><PDL1 therapy><PDL1 treatment><Patients><Primary carcinoma of the liver cells><Procedures><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein Binding><Protocol><Protocols documentation><Radiology><Radiology Specialty><Removal><Resistance><Rodent Model><Safety><Site><Sorafenib><Surgical Removal><Testing><Therapeutic Effect><Transplantation><Treatment Efficacy><Treatment outcome><Tumor Immunity><Tumor Tissue><Tumor-infiltrating immune cells><Upregulation><Zeugmatography><aPD-1><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><aPD1><anti programmed cell death 1><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer><anti-cancer therapeutic><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><antiPD-L1><antitumor immunity><bound protein><cancer immunity><cancer microenvironment><check point blockade><checkpoint blockade><combination therapy><combinatorial immunotherapy><combined modality treatment><combined treatment><curative intervention><curative therapeutic><curative therapy><curative treatments><cytokine><dosage><dual immunotherapy><electroporative delivery><ferumoxytol><gene electrotransfer><hepatocellular carcinoma cancer model><hepatocellular carcinoma model><host response><image guidance><image guided><imaging properties><immune activation><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point><immune check point blockade><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune microenvironment><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immunecheckpoint><immuno therapy><immunogenic><immunogenic apoptosis><immunogenic cell death><immunoresponse><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><improved><in vivo><infiltration of tumors by immune cells><intervention efficacy><intraarterial administration><intratumoral immune cell><intratumoral immune infiltrate><iron oxide nano particle><iron oxide nanoparticle><liver cancer><liver cancer model><liver carcinoma><liver malignancy><mAbs><malignancy><malignant liver tumor><model of animal><monoclonal Abs><multi-modal therapy><multi-modal treatment><nanocarrier><nanovessel><neoplasm/cancer><new approaches><novel approaches><novel strategies><novel strategy><orthopedic freezing><post treatment><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><resection><resistant><response><site targeted delivery><sle2><systemic lupus erythematosus susceptibility 2><targeted delivery><therapeutic efficacy><therapeutic outcome><therapy efficacy><therapy outcome><transplant><tumor><tumor hypoxia><tumor immune cell><tumor immune infiltrate><tumor immune microenvironment><tumor infiltration of immune cells><tumor microenvironment><tumor-immune system interactions><αPD-1><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPD1><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuwen Zhu

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$355,706

FY 2026

Project Title

The GPR171 pathway in cancer immunotherapy

Grant Number:

5R01CA279398-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/25/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Scientific Abstract of proposed research project Immune checkpoint blocker therapy has revolutionized our clinical approach in cancer therapy. However, the overall response rate still has room for improvement and varies greatly in different cancer types. The redundant but unique role...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kavitha Yaddanapudi

UNIVERSITY OF LOUISVILLE, LOUISVILLE, KY

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$352,896

FY 2026

Project Title

Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer

Grant Number:

5R01CA272772-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Lung cancer kills more people than any other type of cancer, including more than 130,000 people each year in the United States. Non-small cell lung cancer (NSCLC) is the most common subtype (82% of all lung cancers) and can arise from squamous or non-squamous lung epithelial cells. Combination treat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hideho Okada

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$943,253

FY 2026

Project Title

Preclinical development of breakthrough immunotherapy for brain tumors

Grant Number:

1R35NS142982-01

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/15/2026

End Date:

11/30/2033

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The ultimate success of immunotherapy for brain malignancies, such as malignant glioma, will require integration of in-depth understanding of immunology with solutions for the following long-standing challenges: 1) paucity and heterogeneous expression of glioma-specific antigens; 2) on-targ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SIDDHARTH BALACHANDRAN

RESEARCH INST OF FOX CHASE CAN CTR, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$758,985

FY 2026

Project Title

Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy

Grant Number:

5R01CA269975-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT. Immune checkpoint blockade (ICB) and other immunotherapies have revolutionized cancer treatment, but the non-responsiveness of most cancers to ICB-based monotherapy remains a significant problem. A major reason for the non-responsiveness of these so-called ‘cold’ tumors is ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VASILY M STUDITSKY

RESEARCH INST OF FOX CHASE CAN CTR, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$758,985

FY 2026

Project Title

Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy

Grant Number:

5R01CA269975-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT. Immune checkpoint blockade (ICB) and other immunotherapies have revolutionized cancer treatment, but the non-responsiveness of most cancers to ICB-based monotherapy remains a significant problem. A major reason for the non-responsiveness of these so-called ‘cold’ tumors is ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexander Marson

J. DAVID GLADSTONE INSTITUTES, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$749,187

FY 2026

Project Title

Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy

Grant Number:

5R01CA276368-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Engineered T cell-based cancer therapies are a major advancement in cancer treatment; however the majority of cancers still do not respond to adoptive cellular therapy. We need to “design” new T cell therapies with increased potency, and we need to overcome cell dysfunction that occurs as T...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kole T Roybal

J. DAVID GLADSTONE INSTITUTES, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$749,187

FY 2026

Project Title

Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy

Grant Number:

5R01CA276368-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Engineered T cell-based cancer therapies are a major advancement in cancer treatment; however the majority of cancers still do not respond to adoptive cellular therapy. We need to “design” new T cell therapies with increased potency, and we need to overcome cell dysfunction that occurs as T...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Derin B Keskin

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$726,998

FY 2026

Project Title

Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy

Grant Number:

5R01CA279391-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/9/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with an incidence of 3,000 USA cases/year. MCC carries a 2-year mortality of 40% with clear unmet medical need. Majority (65%) of MCC are virus-positive. The Merkel cell polyomavirus (MCPyV) is the main driver of virus-positive M...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VASSILIKI A BOUSSIOTIS

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$711,511

FY 2026

Project Title

Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy

Grant Number:

5R01CA257672-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PD-1 blocking agents have achieved significant success as anti-cancer therapeutics. The mechanism(s) of how PD-1 compromises anti-tumor function remain poorly understood. Although in trans engagement of PD-1 expressed in T cells by its ligands expressed on APC or cancer cells inhibits T cell activat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ioannis Vlachos

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$711,511

FY 2026

Project Title

Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy

Grant Number:

5R01CA257672-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PD-1 blocking agents have achieved significant success as anti-cancer therapeutics. The mechanism(s) of how PD-1 compromises anti-tumor function remain poorly understood. Although in trans engagement of PD-1 expressed in T cells by its ligands expressed on APC or cancer cells inhibits T cell activat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ANTHONY RONGVAUX

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$708,476

FY 2026

Project Title

Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy

Grant Number:

5R01CA258606-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/20/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Checkpoint blockade has revolutionized the field of cancer immunotherapy treatment, but many tumors remain unresponsive due to lack of effector T cell infiltration and activation in the tumor microenvironment. Innate immune priming of these “cold” tumors has emerged as a the...

Research Terms

<Anti-viral Response><Biology><Cancers><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Clinical Trials><Complex><DNA><DNA Damage><DNA Injury><DNA Repair Enzymes><DNA- PKcs protein><DNA-Activated Protein Kinase Catalytic Subunit><DNA-PK><DNA-activated protein kinase><DNA-dependent protein kinase><DNA-dependent protein serine-threonine kinase><Deoxyribonucleic Acid><Development><Engraftment><Goals><Human><Hyper-Radiosensitivity Of Murine SCID Mutation, Complementing 1><IFN><IFN-regulatory factor 3><IRF-3 protein><IRF3><IRF3 gene><Immune><Immune response><Immunes><In Vitro><Infiltration><Inflammation><Interferon Regulatory Factor 3><Interferon Type I><Interferons><Intracellular Communication and Signaling><Laboratory mice><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mediating><Melanoma><Melanoma Cell><Mice><Mice Mammals><Modality><Modeling><Modern Man><Murine><Mus><Myelogenous><Myeloid><Myeloid Cells><Myeloid Disease><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><NHEJ><Non-Homologous End Joining><Non-homologous DNA End Joining><Nonhomologous DNA End Joining><Nonhomologous End Joining><Outcome><Pathway interactions><Patients><Phosphorylation><Production><Protein Phosphorylation><SCID protein><STING agonists><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Stimulus><Strains Cell Lines><T cell infiltration><Teff cell><Testing><Therapeutic><Therapeutic Effect><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Viral><XRCC7 protein><anti-cancer immunotherapy><anti-viral immunity><anticancer immunotherapy><antigen-specific T cells><antiviral immunity><biological signal transduction><cancer antigens><cancer immunotherapy><cancer microenvironment><check point blockade><checkpoint blockade><cultured cell line><developmental><effector T cell><host response><humanized mice><humanized mouse><immune check point blockade><immune checkpoint blockade><immune system response><immune-based cancer therapies><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><in vivo><malignancy><metastatic process><mouse model><murine model><myeloproliferative neoplasm><neoplasm/cancer><neoplastic cell><novel><p460 protein><pathway><phospho-proteomics><phosphoproteomics><pre-clinical evaluation><preclinical evaluation><recruit><repair><repaired><response><sensor><tumor><tumor microenvironment><tumor-specific antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel B Stetson

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$708,476

FY 2026

Project Title

Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy

Grant Number:

5R01CA258606-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/20/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Checkpoint blockade has revolutionized the field of cancer immunotherapy treatment, but many tumors remain unresponsive due to lack of effector T cell infiltration and activation in the tumor microenvironment. Innate immune priming of these “cold” tumors has emerged as a the...

Research Terms

<Anti-viral Response><Biology><Cancers><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Clinical Trials><Complex><DNA><DNA Damage><DNA Injury><DNA Repair Enzymes><DNA- PKcs protein><DNA-Activated Protein Kinase Catalytic Subunit><DNA-PK><DNA-activated protein kinase><DNA-dependent protein kinase><DNA-dependent protein serine-threonine kinase><Deoxyribonucleic Acid><Development><Engraftment><Goals><Human><Hyper-Radiosensitivity Of Murine SCID Mutation, Complementing 1><IFN><IFN-regulatory factor 3><IRF-3 protein><IRF3><IRF3 gene><Immune><Immune response><Immunes><In Vitro><Infiltration><Inflammation><Interferon Regulatory Factor 3><Interferon Type I><Interferons><Intracellular Communication and Signaling><Laboratory mice><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mediating><Melanoma><Melanoma Cell><Mice><Mice Mammals><Modality><Modeling><Modern Man><Murine><Mus><Myelogenous><Myeloid><Myeloid Cells><Myeloid Disease><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><NHEJ><Non-Homologous End Joining><Non-homologous DNA End Joining><Nonhomologous DNA End Joining><Nonhomologous End Joining><Outcome><Pathway interactions><Patients><Phosphorylation><Production><Protein Phosphorylation><SCID protein><STING agonists><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Stimulus><Strains Cell Lines><T cell infiltration><Teff cell><Testing><Therapeutic><Therapeutic Effect><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Viral><XRCC7 protein><anti-cancer immunotherapy><anti-viral immunity><anticancer immunotherapy><antigen-specific T cells><antiviral immunity><biological signal transduction><cancer antigens><cancer immunotherapy><cancer microenvironment><check point blockade><checkpoint blockade><cultured cell line><developmental><effector T cell><host response><humanized mice><humanized mouse><immune check point blockade><immune checkpoint blockade><immune system response><immune-based cancer therapies><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><in vivo><malignancy><metastatic process><mouse model><murine model><myeloproliferative neoplasm><neoplasm/cancer><neoplastic cell><novel><p460 protein><pathway><phospho-proteomics><phosphoproteomics><pre-clinical evaluation><preclinical evaluation><recruit><repair><repaired><response><sensor><tumor><tumor microenvironment><tumor-specific antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mikala Egeblad

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$685,737

FY 2026

Project Title

Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies

Grant Number:

5R01CA297338-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Despite recent progress, most patients with solid tumors still do not respond to immunotherapies. Responders often experience immune-related adverse events (irAEs), which can be life-threatening and require treatment discontinuation. Current immunotherapies focus on enhancin...

Research Terms

<4T1><Acute><Adaptive Immune System><Address><Animal Model><Animal Models and Related Studies><Antigens><Antitumor Response><Assay><Atlases><Automobile Driving><Behavior><Bioassay><Biological Assay><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Body Tissues><Breast Cancer><Breast Cancer Model><Breast tumor model><Cancer Patient><Cancer Prognosis><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chronic><Combined Modality Therapy><Cues><Cutaneous><Data><Development><Equilibrium><Exhibits><Gene Expression Inhibitor><Genes><Genetic Models><Goals><Immune><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><In Vitro><Infiltration><Inflammation><Inflammatory><Innate Immune Response><Innate Immune System><Intervention><Intracellular Communication and Signaling><KI mice><KO mice><Knock-in Mouse><Knock-out Mice><Knockout Mice><Knowledge><Life><Lytotoxicity><Malignant Breast Neoplasm><Malignant Melanoma><Malignant Neoplasms><Malignant Skin Neoplasm><Malignant Tumor><Marrow Neutrophil><Mediating><Mediator><Melanoma><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mice><Mice Mammals><Modeling><Molecular><Molecular Target><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Nature><Neoplasm Metastasis><Neutrophil Infiltration><Neutrophil Recruitment><Neutrophilic Granulocyte><Neutrophilic Infiltrate><Neutrophilic Leukocyte><Normal Tissue><Normal tissue morphology><Null Mouse><Oncogenesis><Outcome><Pathogenicity><Pathway interactions><Patients><Phenotype><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Population><Pre-Clinical Model><Preclinical Models><Property><Proteins><Proteomics><Research><Role><Safety><Sampling><Secondary Neoplasm><Secondary Tumor><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Skin Cancer><Solid Neoplasm><Solid Tumor><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-cell therapeutics><T-cell transfer therapy><Teff cell><Testing><Therapeutic Intervention><Tissues><Toxic effect><Toxicities><Tumor Cell><Tumor Immunity><Tumor Promotion><Tumor-Derived><Variant><Variation><Work><acquired immune system><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti-cancer immunotherapy><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><anti-tumor response><anticancer immunotherapy><antitumor immunity><balance><balance function><biological signal transduction><cancer biomarkers><cancer immunity><cancer immunotherapy><cancer markers><cancer metastasis><cancer microenvironment><cancer progression><clinical relevance><clinically relevant><combination therapy><combined modality treatment><combined treatment><cytotoxicity><design><designing><developmental><driving><effector T cell><experience><extracellular vesicles><fitness><gene signatures><genetic inhibitor><genetic signature><immune check point><immune checkpoint><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immunecheckpoint><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><insight><intervention therapy><knockin mice><malignancy><malignant breast tumor><malignant skin tumor><mammary cancer model><mammary tumor model><melanoma cancer model><melanoma model><melanoma tumor model><model of animal><multi-modal therapy><multi-modal treatment><neoplasm immunotherapy><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><neutrophil><pathway><pre-clinical><preclinical><prevent><preventing><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><synergism><therapeutic T-cell platform><therapeutic outcome><therapy outcome><tumor><tumor cell metastasis><tumor eradication><tumor growth><tumor immune therapy><tumor immunotherapy><tumor microenvironment><tumor progression><tumorigenesis><tumorigenic>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Taha Merghoub

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$685,737

FY 2026

Project Title

Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies

Grant Number:

5R01CA297338-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Despite recent progress, most patients with solid tumors still do not respond to immunotherapies. Responders often experience immune-related adverse events (irAEs), which can be life-threatening and require treatment discontinuation. Current immunotherapies focus on enhancin...

Research Terms

<4T1><Acute><Adaptive Immune System><Address><Animal Model><Animal Models and Related Studies><Antigens><Antitumor Response><Assay><Atlases><Automobile Driving><Behavior><Bioassay><Biological Assay><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Body Tissues><Breast Cancer><Breast Cancer Model><Breast tumor model><Cancer Patient><Cancer Prognosis><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chronic><Combined Modality Therapy><Cues><Cutaneous><Data><Development><Equilibrium><Exhibits><Gene Expression Inhibitor><Genes><Genetic Models><Goals><Immune><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><In Vitro><Infiltration><Inflammation><Inflammatory><Innate Immune Response><Innate Immune System><Intervention><Intracellular Communication and Signaling><KI mice><KO mice><Knock-in Mouse><Knock-out Mice><Knockout Mice><Knowledge><Life><Lytotoxicity><Malignant Breast Neoplasm><Malignant Melanoma><Malignant Neoplasms><Malignant Skin Neoplasm><Malignant Tumor><Marrow Neutrophil><Mediating><Mediator><Melanoma><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mice><Mice Mammals><Modeling><Molecular><Molecular Target><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Nature><Neoplasm Metastasis><Neutrophil Infiltration><Neutrophil Recruitment><Neutrophilic Granulocyte><Neutrophilic Infiltrate><Neutrophilic Leukocyte><Normal Tissue><Normal tissue morphology><Null Mouse><Oncogenesis><Outcome><Pathogenicity><Pathway interactions><Patients><Phenotype><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Population><Pre-Clinical Model><Preclinical Models><Property><Proteins><Proteomics><Research><Role><Safety><Sampling><Secondary Neoplasm><Secondary Tumor><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Skin Cancer><Solid Neoplasm><Solid Tumor><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-cell therapeutics><T-cell transfer therapy><Teff cell><Testing><Therapeutic Intervention><Tissues><Toxic effect><Toxicities><Tumor Cell><Tumor Immunity><Tumor Promotion><Tumor-Derived><Variant><Variation><Work><acquired immune system><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti-cancer immunotherapy><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><anti-tumor response><anticancer immunotherapy><antitumor immunity><balance><balance function><biological signal transduction><cancer biomarkers><cancer immunity><cancer immunotherapy><cancer markers><cancer metastasis><cancer microenvironment><cancer progression><clinical relevance><clinically relevant><combination therapy><combined modality treatment><combined treatment><cytotoxicity><design><designing><developmental><driving><effector T cell><experience><extracellular vesicles><fitness><gene signatures><genetic inhibitor><genetic signature><immune check point><immune checkpoint><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immunecheckpoint><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><insight><intervention therapy><knockin mice><malignancy><malignant breast tumor><malignant skin tumor><mammary cancer model><mammary tumor model><melanoma cancer model><melanoma model><melanoma tumor model><model of animal><multi-modal therapy><multi-modal treatment><neoplasm immunotherapy><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><neutrophil><pathway><pre-clinical><preclinical><prevent><preventing><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><synergism><therapeutic T-cell platform><therapeutic outcome><therapy outcome><tumor><tumor cell metastasis><tumor eradication><tumor growth><tumor immune therapy><tumor immunotherapy><tumor microenvironment><tumor progression><tumorigenesis><tumorigenic>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jedd D. Wolchok

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$685,737

FY 2026

Project Title

Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies

Grant Number:

5R01CA297338-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Despite recent progress, most patients with solid tumors still do not respond to immunotherapies. Responders often experience immune-related adverse events (irAEs), which can be life-threatening and require treatment discontinuation. Current immunotherapies focus on enhancin...

Research Terms

<4T1><Acute><Adaptive Immune System><Address><Animal Model><Animal Models and Related Studies><Antigens><Antitumor Response><Assay><Atlases><Automobile Driving><Behavior><Bioassay><Biological Assay><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Body Tissues><Breast Cancer><Breast Cancer Model><Breast tumor model><Cancer Patient><Cancer Prognosis><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chronic><Combined Modality Therapy><Cues><Cutaneous><Data><Development><Equilibrium><Exhibits><Gene Expression Inhibitor><Genes><Genetic Models><Goals><Immune><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><In Vitro><Infiltration><Inflammation><Inflammatory><Innate Immune Response><Innate Immune System><Intervention><Intracellular Communication and Signaling><KI mice><KO mice><Knock-in Mouse><Knock-out Mice><Knockout Mice><Knowledge><Life><Lytotoxicity><Malignant Breast Neoplasm><Malignant Melanoma><Malignant Neoplasms><Malignant Skin Neoplasm><Malignant Tumor><Marrow Neutrophil><Mediating><Mediator><Melanoma><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mice><Mice Mammals><Modeling><Molecular><Molecular Target><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Nature><Neoplasm Metastasis><Neutrophil Infiltration><Neutrophil Recruitment><Neutrophilic Granulocyte><Neutrophilic Infiltrate><Neutrophilic Leukocyte><Normal Tissue><Normal tissue morphology><Null Mouse><Oncogenesis><Outcome><Pathogenicity><Pathway interactions><Patients><Phenotype><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Population><Pre-Clinical Model><Preclinical Models><Property><Proteins><Proteomics><Research><Role><Safety><Sampling><Secondary Neoplasm><Secondary Tumor><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Skin Cancer><Solid Neoplasm><Solid Tumor><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-cell therapeutics><T-cell transfer therapy><Teff cell><Testing><Therapeutic Intervention><Tissues><Toxic effect><Toxicities><Tumor Cell><Tumor Immunity><Tumor Promotion><Tumor-Derived><Variant><Variation><Work><acquired immune system><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti-cancer immunotherapy><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><anti-tumor response><anticancer immunotherapy><antitumor immunity><balance><balance function><biological signal transduction><cancer biomarkers><cancer immunity><cancer immunotherapy><cancer markers><cancer metastasis><cancer microenvironment><cancer progression><clinical relevance><clinically relevant><combination therapy><combined modality treatment><combined treatment><cytotoxicity><design><designing><developmental><driving><effector T cell><experience><extracellular vesicles><fitness><gene signatures><genetic inhibitor><genetic signature><immune check point><immune checkpoint><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immunecheckpoint><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><insight><intervention therapy><knockin mice><malignancy><malignant breast tumor><malignant skin tumor><mammary cancer model><mammary tumor model><melanoma cancer model><melanoma model><melanoma tumor model><model of animal><multi-modal therapy><multi-modal treatment><neoplasm immunotherapy><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><neutrophil><pathway><pre-clinical><preclinical><prevent><preventing><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><synergism><therapeutic T-cell platform><therapeutic outcome><therapy outcome><tumor><tumor cell metastasis><tumor eradication><tumor growth><tumor immune therapy><tumor immunotherapy><tumor microenvironment><tumor progression><tumorigenesis><tumorigenic>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Minsoo Kim

UNIVERSITY OF ROCHESTER, ROCHESTER, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$683,310

FY 2026

Project Title

T cell migration and cardiovascular toxicity in immunotherapy

Grant Number:

5R01AI147362-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/22/2019

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

T cell migration and cardiovascular toxicity in immunotherapy. Adoptive T-cell transfer therapy has emerged as a promising therapeutic option with complete and durable responses in several disease conditions such as viral infection, autoimmune disease, atherosclerosis, and cancer. However, severe im...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard E Waugh

UNIVERSITY OF ROCHESTER, ROCHESTER, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$683,310

FY 2026

Project Title

T cell migration and cardiovascular toxicity in immunotherapy

Grant Number:

5R01AI147362-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/22/2019

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

T cell migration and cardiovascular toxicity in immunotherapy. Adoptive T-cell transfer therapy has emerged as a promising therapeutic option with complete and durable responses in several disease conditions such as viral infection, autoimmune disease, atherosclerosis, and cancer. However, severe im...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mekhail Anwar

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$676,339

FY 2026

Project Title

Early identification of immunotherapy resistance through integrated multiparameter imaging

Grant Number:

5R01CA290027-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Immunotherapies for cancer have revolutionized oncology, but most patients do not experience durable responses. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are now FDA-approved for a wide variety of tumors, but non-invasive strategies to monitor response and identify mechan...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew Spitzer

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$676,339

FY 2026

Project Title

Early identification of immunotherapy resistance through integrated multiparameter imaging

Grant Number:

5R01CA290027-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Immunotherapies for cancer have revolutionized oncology, but most patients do not experience durable responses. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are now FDA-approved for a wide variety of tumors, but non-invasive strategies to monitor response and identify mechan...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Pavithra Viswanath

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$671,958

FY 2026

Project Title

Probing citrate metabolism in tumor and immune cells in diffuse midline gliomas

Grant Number:

5R01CA296817-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/3/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Diffuse midline gliomas (DMGs) are malignant primary brain tumors in children. Patient prognosis is bleak with median survival of ~9 months after initial diagnosis. Tumorigenesis in DMGs is driven by lysine to methionine mutations in histone H3 (H3K27M) that cause epigenetic dysregul...

Research Terms

<0-11 years old><ATP-3-phospho-D-glycerate 1-phosphotransferase><Ablation><Acetyl CoA><Acetyl Coenzyme A><Acetylation><Anabolism><Astrocytes><Astrocytus><Astroglia><Attenuated><BBB crossing><BBB penetration><Biological Markers><Biopsy><Body Tissues><Bone-Derived Transforming Growth Factor><Brain><Brain Cancer><Brain Nervous System><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancers><Cell Body><Cells><Cerebrospinal Fluid><Child><Child Youth><Childhood><Childhood Cancers><Childhood Neoplasm><Childhood Tumor><Children (0-21)><Citrates><Citric Acid Cycle><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><D-Glucose><DNA mutation><Data><Deuterium><Development><Dextrose><Diagnosis><Doxycycline><Drug Targeting><Drugs><Encephalon><Enzyme Gene><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Gene Expression><Genetic Change><Genetic defect><Genetic mutation><Glucose><Glycolysis><Goals><H2 isotope><H3 K27M mutant><H3 K27M mutation><H3K27M mutant><H3K27M mutation><Histone Acetylation><Histone H3><Histones><Hortega cell><Image><Immune><Immune mediated therapy><Immune memory><Immunes><Immunochemical Immunologic><Immunologic><Immunologic Memory><Immunological><Immunological Memory><Immunologically><Immunologically Directed Therapy><Immunologics><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Intermediary Metabolism><Knowledge><Krebs Cycle><L-Lysine><Link><Lipids><Lysine><Lytotoxicity><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Malignant Childhood Neoplasm><Malignant Childhood Tumor><Malignant Glial Neoplasm><Malignant Glial Tumor><Malignant Glioma><Malignant Neoplasms><Malignant Neuroglial Neoplasm><Malignant Neuroglial Tumor><Malignant Pediatric Neoplasm><Malignant Pediatric Tumor><Malignant Tumor><Malignant Tumor of the Brain><Malignant childhood cancer><Malignant neoplasm of brain><Measures><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medication><Metabolic><Metabolic Processes><Metabolism><Methionine><Methods><Mice><Mice Mammals><Microglia><Milk Growth Factor><Modeling><Murine><Mus><Mutation><NMR Imaging><NMR Tomography><Nature><Nuclear Magnetic Resonance Imaging><Oncogenesis><Outcome><Patients><Pediatric Neoplasm><Pediatric Tumor><Penetrance><Pharmaceutical Preparations><Phosphoglycerate Kinase><Platelet Transforming Growth Factor><Primary Brain Neoplasms><Primary Brain Tumors><Production><Proliferating><QOL><Quality of life><Radiation><Reporting><S-acetate Coenzyme A><Safety><Shapes><T cell infiltration><T cells for CAR><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><TCA cycle><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Testing><Therapeutic Agents><Time><Tissues><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Treatment Efficacy><Tricarboxylic Acid Cycle><Tumor Cell><Tumor Immunity><Tumor-associated macrophages><Upregulation><Vibramycin><Visualization><Zeugmatography><alpha-6-Deoxyoxytetracycline><anamnestic reaction><anatomic imaging><anatomical imaging><anti-tumor immunity><antitumor immunity><astrocytic glia><attenuate><attenuates><bio-markers><biologic marker><biomarker><biosynthesis><blood-brain barrier crossing><blood-brain barrier penetration><bloodbrain barrier crossing><bloodbrain barrier penetration><cancer cell metabolism><cancer immunity><cancer in a child><cancer in children><cancer metabolism><cancer microenvironment><cerebral spinal fluid><child with cancer><childhood malignancy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical translation><clinically translatable><cytokine><cytotoxicity><developmental><diffuse midline glioma><disease control><disorder control><drug/agent><effective therapy><effective treatment><epigenetically><genome mutation><gitter cell><glucometer><glucose metabolism><glucose meter><glucose monitor><image-based method><imaging><imaging agent><imaging method><imaging modality><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved><improved outcome><in vivo><inhibitor><innovate><innovation><innovative><insight><intervention efficacy><irradiation response><kids><malignancy><mesoglia><metabolic imaging><microglial cell><microgliocyte><neoplasm/cancer><neoplastic cell><neuro-oncology><neurooncology><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-invasive monitor><noninvasive monitor><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><patient prognosis><pediatric><pediatric cancer><pediatric malignancy><perivascular glial cell><promoter><promotor><radiation response><response><response biomarker><response markers><response to radiation><response to therapy><response to treatment><secondary immune response><shRNA><short hairpin RNA><spinal fluid><standard of care><therapeutic efficacy><therapeutic response><therapeutic target><therapy efficacy><therapy response><thymus derived lymphocyte><tissue biomarkers><treatment response><treatment responsiveness><tumor><tumor cell metabolism><tumor growth><tumor immune microenvironment><tumor metabolism><tumor microenvironment><tumor xenograft><tumor-immune system interactions><tumorigenesis><tumors in children><uptake><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yong Li

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$663,723

FY 2026

Project Title

PD-L1 MODIFICATIONS IN CANCER DIAGNOSIS AND TREATMENT

Grant Number:

5R01CA289250-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/21/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PD-L1 Modifications in Cancer Diagnosis and Treatment PROJECT SUMMARY Programmed death ligand 1 (PD-L1, also known as CD274 or B7-H1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor on activated T cells. In the tumor microenvironment, PD-L1 overexpression is an immune e...

Research Terms

<20S Catalytic Proteasome><20S Core Proteasome><20S Proteasome><20S Proteosome><Acetylation><Affect><Antibodies><Antibody Therapy><Attenuated><B7-H1><Binding><Body Tissues><CD274><Cancer Burden><Cancer Patient><Cancer Prognosis><Cancer Treatment><Cell Body><Cell Communication><Cell Interaction><Cell Nucleus><Cell membrane><Cell surface><Cell-to-Cell Interaction><Cells><Cessation of life><Circulation><Clinical><Clinical Treatment Moab><Combined Modality Therapy><Companions><Complex><Cytoplasmic Membrane><Cytosol><Data><Death><Detection><Development><Diagnostic><Diagnostic Device><Diagnostic Equipment><E3 Ligase><E3 Ubiquitin Ligase><Endoplasmic Reticulum><Enzyme Gene><Enzymes><Ergastoplasm><External Domain><Extracellular Domain><Food and Drug Administration><Foundations><GeneHomolog><Genes><Golgi><Golgi Apparatus><Golgi Complex><Homolog><Homologous Gene><Homologue><Human><Ig Variable Region><Immune><Immune Evasion><Immune Markers><Immune Surveillance><Immune mediated therapy><Immunes><Immunocompetent><Immunodeficient Mouse><Immunoglobulin V><Immunoglobulin Variable Region><Immunologic Markers><Immunologic Surveillance><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapy><Integral Membrane Protein><Intrinsic Membrane Protein><Kinases><Ligands><Link><Lung Neoplasms><Lung Tumor><Lysosomes><MAb Therapeutics><Macropain><Macroxyproteinase><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Membrane><Metabolic Glycosylation><Metastasis to the Lung><Metastatic Neoplasm to the Lung><Metastatic Tumor to the Lung><Mice><Mice Mammals><Mind><Modeling><Modern Man><Modification><Molecular><Molecular Fingerprinting><Molecular Interaction><Molecular Profiling><Monoclonal Antibodies><Monoclonal Antibody Therapy><Multicatalytic Proteinase><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Mutate><National Cancer Burden><Nature><Nucleus><Oncogenesis><Oncogenic><PD 1><PD-1><PD-L1><PD1><PDL-1><Patients><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Plasma Membrane><Play><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Pre-Clinical Model><Preclinical Models><Process><Prognosis><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Prosome><Proteasome><Proteasome Endopeptidase Complex><Protein Modification><Protein Phosphorylation><Proteins><Proteosome><Publishing><Pulmonary Cancer><Pulmonary Neoplasms><Pulmonary malignant Neoplasm><Receptor Protein><Recommendation><Regulation><Reporting><Research Specimen><Role><Solid><Sorting><Specimen><Staining method><Stains><Structure><System><T-Cell Activation><T-Cells><T-Lymphocyte><Therapeutic><Therapeutic Monoclonal Antibodies><Tissues><Transmembrane Protein><Transmembrane Protein Gene><Transphosphorylases><Tumor Cell><Tumor Immunity><Tumor Promotion><USFDA><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><United States><United States Food and Drug Administration><Work><activate T cells><anti-cancer therapy><anti-tumor immunity><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antitumor immunity><attenuate><attenuates><cancer care><cancer diagnosis><cancer immunity><cancer microenvironment><cancer therapy><cancer type><cancer-directed therapy><cell killing><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><clinical significance><clinically significant><combination therapy><combined modality treatment><combined treatment><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><developmental><diagnostic biomarker><diagnostic marker><glycosylation><human tissue><humanized mice><humanized mouse><immune check point blockade><immune check point inhibition><immune checkpoint blockade><immune checkpoint inhibition><immune competent><immune evasive><immune resistance><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based therapies><immune-based treatments><immune-resistant><immuno therapy><immunological biomarkers><immunological markers><immunoresistance><immunosuppressive activity><immunosuppressive function><immunosuppressive response><inhibiting antibody><insight><lung cancer><lung cancer cell><lung metastasis><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><membrane structure><metastasize to the lung><molecular diagnostics><molecular profile><molecular signature><monoclonal Abs><monoclonal antibody drugs><multi-modal therapy><multi-modal treatment><multicatalytic endopeptidase complex><neoplastic cell><overexpress><overexpression><palmitoylation><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><plasmalemma><prevent><preventing><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><pulmonary metastasis><receptor><response to therapy><response to treatment><sle2><social role><systemic lupus erythematosus susceptibility 2><therapeutic mAbs><therapeutic response><therapy response><thymus derived lymphocyte><trafficking><treatment response><treatment responsiveness><tumor><tumor microenvironment><tumorigenesis><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ZHENG-RONG LU

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$654,681

FY 2026

Project Title

Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer

Grant Number:

5R01CA297621-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

The ultimate goal of this project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). PDAC is recognized for its aggressive nature and notably poor long- term survival rates, p...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Li Lily Wang

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$654,681

FY 2026

Project Title

Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer

Grant Number:

5R01CA297621-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

The ultimate goal of this project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). PDAC is recognized for its aggressive nature and notably poor long- term survival rates, p...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Deyu Fang

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$646,072

FY 2026

Project Title

Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer

Grant Number:

5R01CA288387-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

While with the recent breakthrough in immunotherapy, which has transformed into a standard care for therapy in treatment of many advanced cancers, cancer remains as the second leading cause of death. This is in part due to the efficacy of cancer immunotherapy is still limited in treatment of most so...

Research Terms

<4T1><APF-1><ATP-Dependent Proteolysis Factor 1><Advanced Cancer><Advanced Malignant Neoplasm><Adverse Experience><Adverse event><Antioncogene Protein p53><Blood><Blood Reticuloendothelial System><Body Tissues><Breast><Breast Cancer Patient><Breast Cancer Treatment><Breast Metastasis><Breast Tumor Patient><Cancer Genes><Cancer Treatment><Cancer-Promoting Gene><Cancers><Cause of Death><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Tumor Antigen P53><Checkpoint inhibitor><Chemicals><Chemistry><Clinical Trials><Collaborations><Colon><Common Rat Strains><Core Facility><Data><Diagnosis><Drug Kinetics><Early-Stage Clinical Trials><Esteroproteases><Evaluation><Frequencies><Future><Genetic><HMG-20><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><High Mobility Protein 20><Human><Immune><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immuno-Chemotherapy><Immunochemotherapy><Immunologic Surveillance><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapeutic agent><Immunotherapy><Impairment><Inhibition of Cancer Cell Growth><Innovative Therapy><Investigational Drugs><Investigational New Drugs><LLC1><Laboratories><Lead><Legal patent><Lewis lung carcinoma cell><Lung><Lung Respiratory System><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medicine><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Metastatic breast cancer><Mice><Mice Mammals><Modern Man><Molecular><Murine><Mus><Nature><Neoplasm Metastasis><New Drug Approvals><Oncogenes><Oncology><Oncology Cancer><Oncoprotein p53><Organ><P53><PK/PD><Patents><Pb element><Peptidases><Peptide Hydrolases><Pharmaceutical Agent><Pharmaceuticals><Pharmacokinetics><Pharmacologic Substance><Pharmacological Substance><Phase 1 Clinical Trials><Phase I Clinical Trials><Phosphoprotein P53><Phosphoprotein pp53><Precision therapeutics><Process><Prognosis><Protease Gene><Proteases><Protein TP53><Proteinases><Proteolytic Enzymes><Publications><Pulmonary Cancer><Pulmonary malignant Neoplasm><Rat><Rats Mammals><Rattus><Recurrence><Recurrent><Regimen><Regulatory T-Lymphocyte><Research Specimen><Resistance><Rodent><Rodentia><Rodents Mammals><Role><Science><Scientific Publication><Secondary Neoplasm><Secondary Tumor><Services><Solid><Solid Neoplasm><Solid Tumor><Specimen><Subcellular Process><TNBC><TP53><TP53 gene><TRP53><Technology><Therapeutic><Tissues><Toxic effect><Toxicities><Toxicology><Transforming Genes><Translating><Translations><Treatment Efficacy><Treg><Tumor Cell><Tumor Immunity><Tumor Protein p53><Tumor Protein p53 Gene><Ubiquitin><Universities><Work><acute toxicity><antagonism><antagonist><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><anticancer immunotherapy><antitumor immunity><autoimmune inflammation><breast cancer metastasis><c myc><c-myc Genes><cancer cell><cancer cell stemness><cancer immunity><cancer immunotherapy><cancer metastasis><cancer microenvironment><cancer progenitor><cancer progenitor cells><cancer stem cell><cancer stem cell like><cancer stem like cell><cancer stemness><cancer therapy><cancer type><cancer-directed therapy><check point blockade><checkpoint blockade><chemical synthesis><chemo-immuno therapy><chemoimmunotherapy><chemotherapeutic agent><chemotherapeutic compounds><chemotherapeutic drugs><chemotherapeutic medications><chemotherapy><clinical applicability><clinical application><cmyc><drug development><heavy metal Pb><heavy metal lead><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune drugs><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunologic therapeutics><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><individuals with breast cancer><industrial partnership><industry partner><industry partnership><inhibitor><intervention efficacy><irradiation><lung cancer><malignancy><malignant progenitor><malignant stem cell><manufacture><metastatic breast tumor><metastatic mammary cancer><metastatic mammary tumor><neoplasm immunotherapy><neoplasm/cancer><neoplastic cell><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncogenic progenitor><oncogenic stem cells><p53 Antigen><p53 Genes><p53 Tumor Suppressor><patients with breast cancer><person with breast cancer><pharmaceutical><pharmacokinetics and pharmacodynamics><phase I protocol><pre-clinical><pre-clinical efficacy><precision therapies><precision treatment><preclinical><preclinical efficacy><progenitor biology><progenitor cell biology><progenitor like cancer cell><protein p53><regulatory T-cells><resistant><response><social role><standard care><standard of care><standard treatment><stem and progenitor biology><stem cell biology><stem like cancer cell><stemness in cancer><therapeutic candidate><therapeutic efficacy><therapeutic evaluation><therapeutic testing><therapy efficacy><translation><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor cell metastasis><tumor immune therapy><tumor immunotherapy><tumor microenvironment><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Huiping Liu

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$646,072

FY 2026

Project Title

Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer

Grant Number:

5R01CA288387-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

While with the recent breakthrough in immunotherapy, which has transformed into a standard care for therapy in treatment of many advanced cancers, cancer remains as the second leading cause of death. This is in part due to the efficacy of cancer immunotherapy is still limited in treatment of most so...

Research Terms

<4T1><APF-1><ATP-Dependent Proteolysis Factor 1><Advanced Cancer><Advanced Malignant Neoplasm><Adverse Experience><Adverse event><Antioncogene Protein p53><Blood><Blood Reticuloendothelial System><Body Tissues><Breast><Breast Cancer Patient><Breast Cancer Treatment><Breast Metastasis><Breast Tumor Patient><Cancer Genes><Cancer Treatment><Cancer-Promoting Gene><Cancers><Cause of Death><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Tumor Antigen P53><Checkpoint inhibitor><Chemicals><Chemistry><Clinical Trials><Collaborations><Colon><Common Rat Strains><Core Facility><Data><Diagnosis><Drug Kinetics><Early-Stage Clinical Trials><Esteroproteases><Evaluation><Frequencies><Future><Genetic><HMG-20><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><High Mobility Protein 20><Human><Immune><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immuno-Chemotherapy><Immunochemotherapy><Immunologic Surveillance><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapeutic agent><Immunotherapy><Impairment><Inhibition of Cancer Cell Growth><Innovative Therapy><Investigational Drugs><Investigational New Drugs><LLC1><Laboratories><Lead><Legal patent><Lewis lung carcinoma cell><Lung><Lung Respiratory System><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medicine><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Metastatic breast cancer><Mice><Mice Mammals><Modern Man><Molecular><Murine><Mus><Nature><Neoplasm Metastasis><New Drug Approvals><Oncogenes><Oncology><Oncology Cancer><Oncoprotein p53><Organ><P53><PK/PD><Patents><Pb element><Peptidases><Peptide Hydrolases><Pharmaceutical Agent><Pharmaceuticals><Pharmacokinetics><Pharmacologic Substance><Pharmacological Substance><Phase 1 Clinical Trials><Phase I Clinical Trials><Phosphoprotein P53><Phosphoprotein pp53><Precision therapeutics><Process><Prognosis><Protease Gene><Proteases><Protein TP53><Proteinases><Proteolytic Enzymes><Publications><Pulmonary Cancer><Pulmonary malignant Neoplasm><Rat><Rats Mammals><Rattus><Recurrence><Recurrent><Regimen><Regulatory T-Lymphocyte><Research Specimen><Resistance><Rodent><Rodentia><Rodents Mammals><Role><Science><Scientific Publication><Secondary Neoplasm><Secondary Tumor><Services><Solid><Solid Neoplasm><Solid Tumor><Specimen><Subcellular Process><TNBC><TP53><TP53 gene><TRP53><Technology><Therapeutic><Tissues><Toxic effect><Toxicities><Toxicology><Transforming Genes><Translating><Translations><Treatment Efficacy><Treg><Tumor Cell><Tumor Immunity><Tumor Protein p53><Tumor Protein p53 Gene><Ubiquitin><Universities><Work><acute toxicity><antagonism><antagonist><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><anticancer immunotherapy><antitumor immunity><autoimmune inflammation><breast cancer metastasis><c myc><c-myc Genes><cancer cell><cancer cell stemness><cancer immunity><cancer immunotherapy><cancer metastasis><cancer microenvironment><cancer progenitor><cancer progenitor cells><cancer stem cell><cancer stem cell like><cancer stem like cell><cancer stemness><cancer therapy><cancer type><cancer-directed therapy><check point blockade><checkpoint blockade><chemical synthesis><chemo-immuno therapy><chemoimmunotherapy><chemotherapeutic agent><chemotherapeutic compounds><chemotherapeutic drugs><chemotherapeutic medications><chemotherapy><clinical applicability><clinical application><cmyc><drug development><heavy metal Pb><heavy metal lead><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune drugs><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunologic therapeutics><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><individuals with breast cancer><industrial partnership><industry partner><industry partnership><inhibitor><intervention efficacy><irradiation><lung cancer><malignancy><malignant progenitor><malignant stem cell><manufacture><metastatic breast tumor><metastatic mammary cancer><metastatic mammary tumor><neoplasm immunotherapy><neoplasm/cancer><neoplastic cell><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncogenic progenitor><oncogenic stem cells><p53 Antigen><p53 Genes><p53 Tumor Suppressor><patients with breast cancer><person with breast cancer><pharmaceutical><pharmacokinetics and pharmacodynamics><phase I protocol><pre-clinical><pre-clinical efficacy><precision therapies><precision treatment><preclinical><preclinical efficacy><progenitor biology><progenitor cell biology><progenitor like cancer cell><protein p53><regulatory T-cells><resistant><response><social role><standard care><standard of care><standard treatment><stem and progenitor biology><stem cell biology><stem like cancer cell><stemness in cancer><therapeutic candidate><therapeutic efficacy><therapeutic evaluation><therapeutic testing><therapy efficacy><translation><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor cell metastasis><tumor immune therapy><tumor immunotherapy><tumor microenvironment><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dongfang Liu

RUTGERS BIOMEDICAL AND HEALTH SCIENCES, Newark, NJ

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$645,922

FY 2026

Project Title

The adaptor protein Crk in immune responses

Grant Number:

5R01AI130197-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/13/2018

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary: This proposal is a renewal application of R01 (AI130197). In the previous funding cycle, we sought to identify the mechanism(s) by which the small adaptor protein Crk controls NK cell activation and inhibition, using human NK cells and NK cell-specific conditional knockout mice. We ...

Research Terms

<22q11><22q11 Chromosomal Microdeletion Syndrome><22q11 Deletion Syndrome><22q11.2 deletion syndrome><22q11.2DS><22q11DS><Actins><Activated Lymphocyte><Adapter Molecule CRK><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Adhesions><Affect><Agonist><Antibodies><Assay><Autosomal dominant Opitz G/BBB syndrome><Bioassay><Biological Assay><Breast Cancer Model><Breast tumor model><CRK Protein><CRKL><CRKL gene><CT10 regulator of kinase protein><Cancer Treatment><Cancers><Cayler cardiofacial syndrome><Cell Body><Cell Communication and Signaling><Cell Death><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Immune Function><Cellular Matrix><Cellular Physiology><Cellular Process><Chromosome 22q11.2 deletion syndrome><Clinical Treatment Moab><Cytoplasmic Granules><Cytoskeletal Modeling><Cytoskeletal Organization><Cytoskeletal Organization Process><Cytoskeletal Reorganization><Cytoskeletal System><Cytoskeleton><Cytotoxic cell><Data><Dephosphorylation><Di George syndrome><DiGeorge Syndrome><DiGeorge anomaly><DiGeorge sequence><Disease><Disorder><Exhibits><F-Actin><Filamentous Actin><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Funding><Genetic><Goals><Grant><Human><Image><Immune><Immune response><Immunes><Immunoblotting><Immunodeficiency and Cancer><Impairment><Inhibitory Synapse><Integrin alphaLbeta2><Integrins><Integrins Extracellular Matrix><Intracellular Communication and Signaling><K lymphocyte><KO mice><Knock-out Mice><Knockout Mice><Legal patent><Leukocyte Function Associated Antigen-1><Lipid Bilayers><Lymphocyte Function-Associated Antigen-1><Lytic><Lytotoxicity><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Microscopy><Modern Man><Molecular><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><Molecular Tumor Suppression><Monoclonal Antibodies><NK Cell Activation><NK Cells><Natural Killer Cell Activation><Natural Killer Cells><Neoplasm Metastasis><Null Mouse><Outcome><Patents><Patients><Phosphorylation><Play><Primary Immunodeficiency><Protein Dephosphorylation><Protein Family><Protein Phosphorylation><Proto-Oncogene c-CRK><RNA Seq><RNA sequencing><RNAseq><Receptor Protein><Regulation><Resolution><Role><Secondary Neoplasm><Secondary Tumor><Sedlackova syndrome><Shapes><Short interfering RNA><Shprintzen syndrome><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Subcellular Process><Syndrome><System><T-Cells><T-Lymphocyte><TNBC><Techniques><Testing><Transfection><Tumor Cell><Tumor Suppression><Western Blotting><Western Immunoblotting><Work><adapter protein><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><arm><biological signal transduction><c-crk protein><cancer immunotherapy><cancer metastasis><cancer microenvironment><cancer therapy><cancer-directed therapy><cell imaging><cell killing><cellular imaging><clinical applicability><clinical application><clinical relevance><clinically relevant><conditional knock-out><conditional knockout><conformation><conformational><conformational state><conformationally><conformations><congenital immune deficiency><congenital immunodeficiency><conotruncal anomaly face syndrome><cytotoxic><cytotoxicity><exhaust><exhaustion><experiment><experimental research><experimental study><experiments><familial third and fourth pharyngeal pouch syndrome><flow cytophotometry><genetic immune defect><genetic immune deficiency><genetic immunodeficiency><granule><host response><hypoimmunity><imaging><imaging system><immune deficiency><immune function><immune system response><immune-based cancer therapies><immunodeficiency><immunological synapse><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><inborn errors in immunity><inborn errors of immunity><inborn immunodeficiency><inherited immune defect><inherited immune deficiency><inherited immunodeficiency><inhibitor><intracellular skeleton><lipid bilayer membrane><mAbs><malignancy><mammary cancer model><mammary tumor model><monoclonal Abs><mouse model><murine model><necrocytosis><neoplasm/cancer><neoplastic cell><novel><pharyngeal pouch syndrome><primary immune defect><primary immune deficiency><programs><protein blotting><proto-oncogene protein c-crk><receptor><resolutions><restoration><siRNA><single-molecule FRET><single-molecule fluorescence resonance energy transfer><smFRET><social role><superresolution microscopy><synergism><third and fourth pharyngeal pouch syndrome><thymic and parathyroid agenesis syndrome><thymus derived lymphocyte><tool><transcriptome sequencing><transcriptomic sequencing><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor cell metastasis><tumor growth><tumor microenvironment><velo-cardio-facial syndrome><velocardiofacial syndrome><velofacial hypoplasia>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Quanyin Hu

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$639,124

FY 2026

Project Title

Improving the platelet-mediated immune checkpoint inhibitor delivery for treating triple-negative breast cancer

Grant Number:

5R01CA288851-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/10/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Despite the great success of immune checkpoint inhibitors in treating a subset of cancer patients by blocking PD1/PDL1 pathway, the treatment outcomes in triple-negative breast cancer (TNBC) remain dismal partially due to the immunosuppressive microenvironment and impaired T cell inf...

Research Terms

<4T1><Address><Antibodies><B16F10><B7-H1><Binding><Bleeding><Blood Coagulation Factor III><Blood Platelets><Blood Vessels><Breast Cancer Model><Breast Cancer Patient><Breast Tumor Patient><Breast tumor model><CD115 Antigens><CD142 Antigens><CD274><CSF-1 Receptor><CSF-1-R><CSF1R Gene Product><Cancer Patient><Cell Body><Cells><Checkpoint inhibitor><Circulation><Clinic><Clinical><Coagulation Factor III><Coagulin><Colony Stimulating Factor 1 Receptor><Combination immunotherapy><Combined Modality Therapy><Dose><Dysfunction><ERBB2><ERBB2 gene><ERalpha><ERα><ESR1><ESR1 gene><Encapsulated><Estradiol Receptor alpha><Estradiol Receptor α><Estrogen Receptor 1><Estrogen Receptor alpha><Estrogen Receptor α><Evaluation><Factor III><Functional disorder><Glomerular Procoagulant Activity><HER -2><HER-2><HER2><HER2 Genes><HER2/neu><Hemorrhage><Homing><Human><Immune><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapeutic agent><Immunotherapy><Impairment><Infiltration><Injections><Intravenous><M-CSF Receptors><Macrophage Colony Stimulating Factor I Receptor><Macrophage Colony-Stimulating Factor Receptor><Malignant Melanoma><Marrow platelet><Mediating><Melanoma><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NEU Oncogene><NEU protein><NR3A1><Neoplasm Metastasis><Oncogene ErbB2><Operative Procedures><Operative Surgical Procedures><PD 1><PD-1><PD-L1><PD-L1 antibody><PD1><PDL-1><PDX model><Pathway interactions><Patient derived xenograft><Penetration><Physiopathology><Platelet Activation><Platelets><Primary Neoplasm><Primary Tumor><Progesterone Receptors><Progestin Receptors><Prognosis><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Prothrombinase><Proto-Oncogene Protein fms><Recurrent Neoplasm><Recurrent tumor><Relapse><Resistance><Secondary Neoplasm><Secondary Tumor><Secondary to><Site><Somatic Mutation><Surface><Surgical><Surgical Interventions><Surgical Procedure><Survival Rate><System><T cell infiltration><T cell response><T-Cell Activation><T-Cells><T-Lymphocyte><TKR1><TNBC><Techniques><Teff cell><Testing><Thrombocytes><Thromboplastin><Thrombosis><Thrombus><Time><Tissue Factor><Tissue Factor Procoagulant><Tissue Thromboplastin><Treatment Efficacy><Treatment outcome><Tumor Tissue><Tumor-associated macrophages><Urothromboplastin><aPD-L1><aPD-L1 antibodies><activate T cells><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer immunotherapy><antiPD-L1><anticancer immunotherapy><blood damage><blood loss><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><c-fms Protein><cancer immunotherapy><cancer location><cancer metastasis><cancer site><cancer type><check point blockade><checkpoint blockade><chemotherapy><combination therapy><combinatorial immunotherapy><combined modality treatment><combined treatment><dosage><dual immunotherapy><effector T cell><erbB-2 Genes><herstatin><humanized mice><humanized mouse><immune check point><immune check point blockade><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune drugs><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunologic therapeutics><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><individuals with breast cancer><inflammatory environment><inflammatory milieu><insight><intervention efficacy><intravenous injection><mammary cancer model><mammary tumor model><mouse model><multi-modal therapy><multi-modal treatment><murine model><nano particle><nano-sized particle><nanoparticle><nanosized particle><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm recurrence><neu Genes><objective response rate><overexpress><overexpression><particle><pathophysiology><pathway><patient derived xenograft model><patients with breast cancer><person with breast cancer><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><public health relevance><resistant><scRNA sequencing><scRNA-seq><side effect><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><somatic variant><success><surgery><synergism><systemic lupus erythematosus susceptibility 2><therapeutic efficacy><therapy efficacy><thrombotic disease><thrombotic disorder><thymus derived lymphocyte><time interval><treatment strategy><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor cell metastasis><tumor immune microenvironment><tumor-immune system interactions><vascular><αPD-L1><αPD-L1 antibodies><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robbie B Mailliard

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$637,792

FY 2026

Project Title

Antigen-specific ‘kick and kill’ of the latent HIV reservoir using dendritic cells

Grant Number:

5R01AI152655-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/5/2021

End Date:

10/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT The persistence of the latent viral reservoir remains a hurdle for the cure of chronic HIV infection. Finding an effective and non-toxic means to purge and expose the viral reservoir has been elusive and is considered a major barrier to the cure. Because of their pivotal role in the initiat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aung Naing

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$635,751

FY 2026

Project Title

Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events

Grant Number:

5R01CA279749-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/19/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract. This proposal is disease agnostic and patient centered, focusing on symptoms associated with side effects of immune checkpoint inhibitors (ICPis). Although ICPis are effective in the treatment of several can- cers, the risk of immune-related adverse events (irAEs) due to unrestrained activ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lishan Su

UNIVERSITY OF MARYLAND BALTIMORE, BALTIMORE, MD

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$634,061

FY 2026

Project Title

Tumor-associated pDC (TApDC) in liver cancer with HIV infection

Grant Number:

5R01CA298839-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/5/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

The long-term goals are to study functions of tumor-associated plasmacytoid dendritic cells (TApDC) in tumor immune microenvironment (TIME) of liver cancer or hepatocellular carcinoma (HCC) during HIV infection and immunotherapy, and to develop novel therapeutics to treat HCC in HIV-infected patient...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexey V. Danilov

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$632,001

FY 2026

Project Title

Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation

Grant Number:

5R01CA283171-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/16/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The ability of cancer cells to progress and transform to more aggressive disease is the leading cause for failure of cancer-directed treatment. This is the case in Richter’s transformation (RT), a devastating complication of chronic lymphocytic leukemia (CLL). RT is associated with an overa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lili Wang

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$632,001

FY 2026

Project Title

Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation

Grant Number:

5R01CA283171-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/16/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The ability of cancer cells to progress and transform to more aggressive disease is the leading cause for failure of cancer-directed treatment. This is the case in Richter’s transformation (RT), a devastating complication of chronic lymphocytic leukemia (CLL). RT is associated with an overa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zheng Xia

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$632,001

FY 2026

Project Title

Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation

Grant Number:

5R01CA283171-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/16/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The ability of cancer cells to progress and transform to more aggressive disease is the leading cause for failure of cancer-directed treatment. This is the case in Richter’s transformation (RT), a devastating complication of chronic lymphocytic leukemia (CLL). RT is associated with an overa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Meenhard F Herlyn

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$628,298

FY 2026

Project Title

Gamma delta T cell based melanoma therapies

Grant Number:

5R01CA258113-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/13/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY Our long-term objective is to develop highly translatable animal models for testing cancer immunotherapies. Animal models have been essential in cancer research. However, mouse tumor transplantation or tumor genetic models lack critical components for studying human anti-tumor responses such...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xiaowei Xu

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$628,298

FY 2026

Project Title

Gamma delta T cell based melanoma therapies

Grant Number:

5R01CA258113-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/13/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY Our long-term objective is to develop highly translatable animal models for testing cancer immunotherapies. Animal models have been essential in cancer research. However, mouse tumor transplantation or tumor genetic models lack critical components for studying human anti-tumor responses such...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

William C. Hahn

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$610,472

FY 2026

Project Title

Investigating CREB5-driven mechanisms of immune therapy resistance

Grant Number:

5R01CA285582-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2024

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary: Treatment with immune checkpoint inhibitors induce remarkable clinical responses in several cancer types. However, most cancer patients do not respond to immunotherapy, and patients who initially respond often exhibit acquired resistance. Understanding the universe of immune evasion...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert Thomas Manguso

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$610,472

FY 2026

Project Title

Investigating CREB5-driven mechanisms of immune therapy resistance

Grant Number:

5R01CA285582-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2024

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary: Treatment with immune checkpoint inhibitors induce remarkable clinical responses in several cancer types. However, most cancer patients do not respond to immunotherapy, and patients who initially respond often exhibit acquired resistance. Understanding the universe of immune evasion...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jae-Il Park

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$608,948

FY 2026

Project Title

CRACD-controlled cell plasticity and small cell lung cancer

Grant Number:

5R01CA278967-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Small cell lung cancer (SCLC) is an extremely deadly cancer, and current chemo/radiation therapies lack durable effects. Immunotherapy with immune checkpoint blockades is effective for only ~13% of SCLC patients and rarely results in sustained responses in extensive-stage SC...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kwon-Sik Park

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$608,948

FY 2026

Project Title

CRACD-controlled cell plasticity and small cell lung cancer

Grant Number:

5R01CA278967-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Small cell lung cancer (SCLC) is an extremely deadly cancer, and current chemo/radiation therapies lack durable effects. Immunotherapy with immune checkpoint blockades is effective for only ~13% of SCLC patients and rarely results in sustained responses in extensive-stage SC...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Andrea Schietinger

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$602,850

FY 2026

Project Title

TOX-driven CD8 T cell differentiation and dysfunction in tumors

Grant Number:

5R01CA269733-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY CD8 T cells specific for cancer cells are found within human tumors, but despite their presence, tumors progress, suggesting that T cells become unresponsive. To design predictably effective immunotherapies, we must elucidate the mechanisms controlling tumor-specific T cell dysfuncti...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Fukun Guo

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$594,402

FY 2026

Project Title

Rational targeting of Cdc42 to benefit immunotherapy

Grant Number:

5R01CA278756-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT T cells play important role in cancer cell immunosuppression. Cancer cells can interact with immune checkpoint proteins expressed on effector T cells to cause T cell exhaustion and facilitate regulatory T (Treg) cell suppression of effector T cells. Understanding T cell immunity is an impor...

Research Terms

<3-D structure><3-dimensional structure><3D structure><Assay><Autoantibodies><Autoimmune Responses><Autoimmune Status><Autoimmunity><Autoregulation><Binding><Bioassay><Biochemical><Biological Assay><Blood Cell Count><Blood Cell Number><Blood Serum><Body Tissues><Body Weight><CAR T cell therapy><CAR T therapy><Cancer Patient><Cancer Treatment><Cancers><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Communication and Signaling><Cell Function><Cell Membrane Permeability><Cell Physiology><Cell Process><Cell Signaling><Cellular Function><Cellular Physiology><Cellular Process><Checkpoint inhibitor><Complex><Dose><Drug Kinetics><Enhancer-Binding Protein GATA3><GATA-3 factors><GATA-3 protein><GATA-Binding Protein 3><GATA3><GATA3 gene><GATA3 protein><GATA3 transcription factor><GDP Dissociation Factor><GDP Dissociation Stimulators><GDP Exchange Factors><GDP-GTP Exchange Protein><GDP-GTP Reversing Factors><GTP GDP exchange factor><GTP Phosphohydrolases><GTPases><Genetic study><Goals><Guanine Nucleotide Exchange Factors><Guanine Nucleotide Exchange Protein><Guanine Nucleotide Releasing Factors><Guanosine Triphosphate Phosphohydrolases><Guanosinetriphosphatases><Guanyl-Nucleotide Exchange Factor><Guanyl-Nucleotide Releasing Factor><Heterozygote><Homeostasis><Human><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immunity><Immunologic Surveillance><Immunologically Directed Therapy><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapy><In Vitro><Inflammatory><Intracellular Communication and Signaling><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Medicinal Chemistry><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Molecular Tumor Suppression><Morbidity><Murine><Mus><PK/PD><Pathology><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacokinetics><Pharmacology><Physiological Homeostasis><Play><Property><Proteins><Regimen><Regulatory T-Lymphocyte><Reporter><Resolution><Role><Serum><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solubility><Structure><Structure-Activity Relationship><Subcellular Process><T cell response><T-Cell Activation><T-Cell Depletion><T-Cells><T-Lymphocyte><T-cell depletion therapy><T-lymphocyte depletion therapy><Teff cell><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Treg><Tumor Cell><Tumor Immunity><Tumor Suppression><Variant><Variation><Work><activate T cells><anti-cancer><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immunity><anticancer immunotherapy><antitumor immunity><autoimmune antibody><autoreactive antibody><biological signal transduction><cancer cell><cancer immunity><cancer immunotherapy><cancer therapy><cancer-directed therapy><cell mediated immune response><cell type><chemical structure function><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor T cell therapy><chimeric antigen receptor T therapy><combat><cytokine><derepression><effector T cell><enantiomer><exchange factor><exhaustion><guanosinetriphosphatase><heterozygosity><immune check point><immune check point inhibitor><immune checkpoint><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><improved><inhibitor><lead optimization><malignancy><membrane permeability><mortality><mouse genetics><mouse model><murine model><neoplasm/cancer><neoplastic cell><new approaches><novel><novel approaches><novel strategies><novel strategy><patient response><patient specific response><pharmacokinetics and pharmacodynamics><pharmacologic><pre-clinical efficacy><preclinical efficacy><rational design><regulatory T-cells><resolutions><responsive patient><rho G-Proteins><rho GTP-Binding Proteins><rho GTPases><rho Protein P21><rho Small GTP-Binding Proteins><self reactive antibody><side effect><social role><structure function relationship><success><three dimensional structure><thymus derived lymphocyte><translational applications><tumor><tumor growth>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

YI ZHENG

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$594,402

FY 2026

Project Title

Rational targeting of Cdc42 to benefit immunotherapy

Grant Number:

5R01CA278756-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT T cells play important role in cancer cell immunosuppression. Cancer cells can interact with immune checkpoint proteins expressed on effector T cells to cause T cell exhaustion and facilitate regulatory T (Treg) cell suppression of effector T cells. Understanding T cell immunity is an impor...

Research Terms

<3-D structure><3-dimensional structure><3D structure><Assay><Autoantibodies><Autoimmune Responses><Autoimmune Status><Autoimmunity><Autoregulation><Binding><Bioassay><Biochemical><Biological Assay><Blood Cell Count><Blood Cell Number><Blood Serum><Body Tissues><Body Weight><CAR T cell therapy><CAR T therapy><Cancer Patient><Cancer Treatment><Cancers><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Communication and Signaling><Cell Function><Cell Membrane Permeability><Cell Physiology><Cell Process><Cell Signaling><Cellular Function><Cellular Physiology><Cellular Process><Checkpoint inhibitor><Complex><Dose><Drug Kinetics><Enhancer-Binding Protein GATA3><GATA-3 factors><GATA-3 protein><GATA-Binding Protein 3><GATA3><GATA3 gene><GATA3 protein><GATA3 transcription factor><GDP Dissociation Factor><GDP Dissociation Stimulators><GDP Exchange Factors><GDP-GTP Exchange Protein><GDP-GTP Reversing Factors><GTP GDP exchange factor><GTP Phosphohydrolases><GTPases><Genetic study><Goals><Guanine Nucleotide Exchange Factors><Guanine Nucleotide Exchange Protein><Guanine Nucleotide Releasing Factors><Guanosine Triphosphate Phosphohydrolases><Guanosinetriphosphatases><Guanyl-Nucleotide Exchange Factor><Guanyl-Nucleotide Releasing Factor><Heterozygote><Homeostasis><Human><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immunity><Immunologic Surveillance><Immunologically Directed Therapy><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapy><In Vitro><Inflammatory><Intracellular Communication and Signaling><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Medicinal Chemistry><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Molecular Tumor Suppression><Morbidity><Murine><Mus><PK/PD><Pathology><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacokinetics><Pharmacology><Physiological Homeostasis><Play><Property><Proteins><Regimen><Regulatory T-Lymphocyte><Reporter><Resolution><Role><Serum><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solubility><Structure><Structure-Activity Relationship><Subcellular Process><T cell response><T-Cell Activation><T-Cell Depletion><T-Cells><T-Lymphocyte><T-cell depletion therapy><T-lymphocyte depletion therapy><Teff cell><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Treg><Tumor Cell><Tumor Immunity><Tumor Suppression><Variant><Variation><Work><activate T cells><anti-cancer><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immunity><anticancer immunotherapy><antitumor immunity><autoimmune antibody><autoreactive antibody><biological signal transduction><cancer cell><cancer immunity><cancer immunotherapy><cancer therapy><cancer-directed therapy><cell mediated immune response><cell type><chemical structure function><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor T cell therapy><chimeric antigen receptor T therapy><combat><cytokine><derepression><effector T cell><enantiomer><exchange factor><exhaustion><guanosinetriphosphatase><heterozygosity><immune check point><immune check point inhibitor><immune checkpoint><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><improved><inhibitor><lead optimization><malignancy><membrane permeability><mortality><mouse genetics><mouse model><murine model><neoplasm/cancer><neoplastic cell><new approaches><novel><novel approaches><novel strategies><novel strategy><patient response><patient specific response><pharmacokinetics and pharmacodynamics><pharmacologic><pre-clinical efficacy><preclinical efficacy><rational design><regulatory T-cells><resolutions><responsive patient><rho G-Proteins><rho GTP-Binding Proteins><rho GTPases><rho Protein P21><rho Small GTP-Binding Proteins><self reactive antibody><side effect><social role><structure function relationship><success><three dimensional structure><thymus derived lymphocyte><translational applications><tumor><tumor growth>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michelle Louise James

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$594,388

FY 2026

Project Title

Developing clinically relevant PET tracers to image T cell activation for improved cancer immunotherapy monitoring

Grant Number:

5R01CA286998-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY Chimeric antigen receptor (CAR) T cell therapies represent a major advancement in the cancer immunotherapy (IOT) field and have shown remarkable success particularly for treating hematologic malignancies. Despite their meteoric rise, these “living drugs” face a number of challenges that have...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Di Zhao

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$588,065

FY 2026

Project Title

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

Grant Number:

5R01CA275990-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT More than 60% of metastatic castration-resistant prostate cancers (CRPC) contain PTEN and TP53 gene deletions and mutations. To date, there are limited treatment options for this molecular subtype. The overall objective of this application is to elucidate the complex role of B7-H3 signaling...

Research Terms

<Anti-androgen Therapy><Anti-androgen Treatment><Antibody-drug conjugates><Antioncogene Protein p53><B7-H3><B7H3><Biological><Biological Function><Biological Process><Biology><CD276><CD276 gene><CTLA-4 blockade><CTLA4 blockade><Cancer Patient><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular Tumor Antigen P53><Clinical><Clinical Treatment Moab><Combination immunotherapy><Complex><Cytometry><DNA mutation><Data><Defect><Development><Disease><Disease Progression><Disorder><GEM model><GEMM model><Gene Deletion><Genetic Change><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Goals><Human><Immune><Immunes><Impairment><In Vitro><Infiltration><Intracellular Communication and Signaling><MMAC1><MMAC1 protein><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Mediating><Modeling><Modern Man><Molecular><Monoclonal Antibodies><Mutated in Multiple Advanced Cancers 1><Mutation><Myeloid Cells><Myeloid-derived suppressor cells><Nature><Oncoprotein p53><Outcome><P53><PD 1><PD-1><PD1><PDX model><PHTS gene><PHTS protein><PTEN><PTEN gene><PTEN protein><PTEN1><Pathway interactions><Patient derived xenograft><Patients><Phenotype><Phosphatase and Tensin Homolog><Phosphatase and Tensin Homolog Deleted on Chromosome 10><Phosphoprotein P53><Phosphoprotein pp53><Pilot Projects><Play><Pre-Clinical Model><Preclinical Models><Prostate><Prostate CA><Prostate Cancer><Prostate Gland><Prostate malignancy><Prostatic Gland><Protein TP53><RB1><RB1 gene><Receptor Protein><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Research><Resistance><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><T cell infiltration><T-Cells><T-Lymphocyte><TP53><TP53 gene><TRP53><Testing><Therapeutic><Time><Tumor Protein p53><Tumor Protein p53 Gene><Tumor-associated macrophages><Variant><Variation><advanced prostate cancer><androgen ablation therapy><androgen blockade therapy><androgen deprivation therapy><androgen deprivation treatment><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen resistance in prostate cancer><androgen resistant prostate cancer><anti-tumor effect><antitumor effect><biologic><biological signal transduction><biomarker driven><cancer cell><cancer microenvironment><cancer recurrence><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical relevance><clinically relevant><combinatorial immunotherapy><developmental><dual immunotherapy><expression subtypes><gene deletion mutation><genetically engineered mouse model><genetically engineered murine model><genome mutation><hormone refractory prostate cancer><immune check point><immune check point therapy><immune checkpoint><immune checkpoint therapy><immunecheckpoint><immunosuppressive myeloid cells><in vivo><inhibitor><mAbs><malignancy><molecular biomarker><molecular marker><molecular sub-types><molecular subsets><molecular subtypes><monoclonal Abs><mouse model><murine model><mutated in multiple advanced cancers 1 protein><myeloid suppressor cells><myeloid-derived suppressive cells><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><overexpress><overexpression><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient derived xenograft model><phosphatase and tensin homologue on chromosome ten><pilot study><predict responsiveness><predicting response><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><programmed cell death 1><programmed cell death protein 1><programmed death 1><prostate cancer model><prostate cancer progression><prostate cancer resistant to androgen><prostate tumor model><protein p53><receptor><resistance to therapy><resistant><resistant to therapy><response><retinoblastoma-1><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><thymus derived lymphocyte><tool><transcriptome profiling><transcriptomic profiling><transcriptomics><treatment resistance><tumor><tumor microenvironment>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JUN WANG

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$578,201

FY 2026

Project Title

Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment

Grant Number:

5R01CA269898-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Immunomodulatory agents blocking the immune checkpoint PD-1/PD-L1 (PD) pathway have shown remarkable clinical benefits and constitute a new standard of care for cancer treatment. The success of these agents is due to the prominent immunosuppressive function of the PD-1 receptor alongside the selecti...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHUN LI

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$576,605

FY 2026

Project Title

Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma

Grant Number:

5R01CA258540-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers, with a 5-year overall survival (OS) rate of 7% for metastatic disease and less than 20% for locally advanced disease. Benefit from current therapies including chemoradiation and surgery is often modest a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Y. Alan Wang

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$576,605

FY 2026

Project Title

Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma

Grant Number:

5R01CA258540-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers, with a 5-year overall survival (OS) rate of 7% for metastatic disease and less than 20% for locally advanced disease. Benefit from current therapies including chemoradiation and surgery is often modest a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Diana Clare Hargreaves

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$573,836

FY 2026

Project Title

The Role of the Tumor Suppressor ARID1A in R loop Homeostasis and Tumor Immunity

Grant Number:

5R01CA285867-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Cancer immunotherapy is the practice of harnessing the activity of the immune system to combat cancer. Immune checkpoint blockade (ICB) is a type of cancer immunotherapy that unleashes the activity of cytotoxic T cells by blocking the interaction of inhibitory receptors on T cells wi...

Research Terms

<3 Prime Repair Exonuclease 1 Gene><ARID1A><ARID1A gene><AT- rich interactive domain-containing protein 1A><AT-rich interactive domain 1A gene><ATP Hydrolysis><ATR-Interacting Protein Gene><ATRIP><ATRIP Gene><Abscission><Affect><Antigen Presentation><Antigen Presentation Pathway><Antigen Processing and Presentation><Antioncogene Protein p53><Automobile Driving><Autoregulation><Back><Biological Function><Biological Process><Biology><CDK4I><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CMM2><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cancer Patient><Cancer Treatment><Cancer cell line><Cancers><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Mediated Lympholytic Cells><Cells><Cellular Tumor Antigen P53><Chemotactic Cytokines><Chromatin><Chromatin Remodeling Complex><Chromatin Remodeling Factor><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cyclin-Dependent Kinase Inhibitor 2A Gene><Cytolytic T-Cell><Cytoplasm><Cytosol><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><DKFZp434J0310 Gene><DNA><DNA Replication><DNA Synthesis><DNA biosynthesis><DNA mutation><DNase III Gene><DRN3 Gene><Defect><Deoxyribonuclease III, DnaQ/MutD (E. coli)-Like Gene><Deoxyribonucleic Acid><Dorsum><Endosomes><Enzyme Gene><Enzymes><Excision><Exhibits><Expression Signature><Extirpation><FLJ12343 Gene><Failure><Gene Expression><Gene Expression Profile><Genes><Genetic><Genetic Change><Genetic Markers><Genetic defect><Genetic mutation><Goals><Homeostasis><Homologous Chemotactic Cytokines><Human><Hybrids><IFN><IFNAR><IFNAR1><IFNAR1 gene><INK4><INK4A><Immune Markers><Immune Precipitation><Immune infiltrates><Immune mediated therapy><Immune system><Immunologic Markers><Immunologically Directed Therapy><Immunoprecipitation><Immunotherapy><Individual><Inflammatory><Inflammatory Response><Intercrines><Interferon Type I><Interferons><Intracellular Communication and Signaling><Ligands><Lymphocytic Infiltrate><MTS1><MTS1 Genes><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mating Type Switching/Sucrose Nonfermenting Protein><Measures><Mediating><Mice><Mice Mammals><Microsatellite Markers><Microsatellite Repeats><Microsatellites><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Profiling><Murine><Mus><Mutate><Mutation><Non-Polyadenylated RNA><Nuclear><Nucleic Acids><Nucleosomes><Oncoprotein p53><Outcome><P53><PARP Inhibitor><PARP-1 inhibitor><PARPi><Pathway interactions><Patient Selection><Patients><Pattern recognition receptor><Phosphoprotein P53><Phosphoprotein pp53><Physiological Homeostasis><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) polymerase 1 inhibitor><Protein TP53><RNA><RNA Gene Products><Receptor Protein><Receptosomes><Removal><Retrospective Studies><Ribonucleic Acid><Role><SIS cytokines><SWI/SNF Complex><SWI/SNF Family Complex><Signal Transduction><Signal Transduction Systems><Signaling><Single-Stranded DNA><Solid Neoplasm><Solid Tumor><Surgical Removal><T-Cell Activation><T-Cells><T-Lymphocyte><TLR3><TLR3 gene><TP16><TP53><TP53 gene><TREX1><TREX1 gene><TRP53><TSG9A><Testing><Three Prime Repair Exonuclease 1 Gene><Toll-Like Receptor 3><Tumor Cell><Tumor Immunity><Tumor Protein p53><Tumor Protein p53 Gene><Tumor Suppressor Proteins><Work><activate T cells><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immune response><anti-tumor immunity><anticancer immunotherapy><antitumor immunity><biological signal transduction><cancer biomarkers><cancer cell><cancer immunity><cancer immunotherapy><cancer markers><cancer therapy><cancer type><cancer-directed therapy><cell killing><check point blockade><checkpoint blockade><chemoattractant cytokine><chemokine><chromatin modifier><combat><driving><effective therapy><effective treatment><endonuclease><gene biomarker><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><gene signatures><genetic biomarker><genetic signature><genome mutation><immune cell infiltrate><immune check point blockade><immune checkpoint blockade><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunological biomarkers><immunological markers><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><inhibitor><killer T cell><knock-down><knockdown><malignancy><molecular biomarker><molecular marker><molecular profile><molecular signature><mouse model><murine model><mutant><neoplasm/cancer><neoplastic cell><overexpress><overexpression><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient response><patient specific response><pharmacologic><pre-clinical><preclinical><prevent><preventing><programs><protein p53><receptor><replication stress><resection><response><response to therapy><response to treatment><responsive patient><retrospective research study><retrospective survey><social role><ssDNA><synthetic lethal interaction><synthetic lethality><therapeutic response><therapy response><thymus derived lymphocyte><transcriptional profile><transcriptional signature><transcriptomics><translational impact><treatment response><treatment responsiveness><tumor><tumor growth><tumor immune microenvironment><tumor suppressor><tumor-immune system interactions>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ALBERT KOONG

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$572,667

FY 2026

Project Title

The Role of HIF2 in Pancreatic Ductal Adenocarcinoma

Grant Number:

5R01CA269565-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) contains a desmoplastic stroma that limits blood perfusion and thus the delivery of nutrients, oxygen, and therapeutics, creating a hypoxic microenvironment that is able to resist nearly all forms of treatment, including immunomodulati...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ioannis Vlachos

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$564,025

FY 2026

Project Title

Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion

Grant Number:

5R01CA258776-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY All stages of neoplastic disease, from its development to metastasis, are intertwined with cancer immune evasion. The epigenetic mechanisms involved in the regulation of the tumor immune landscape are intensely investigated as biomarkers or therapeutic targets. 3' untranslated regions (3'UTR...

Research Terms

<3' Untranslated Regions><3'UTR><3-D><3-Dimensional><3D><Affect><Alleles><Allelomorphs><Assay><BRCA 1/2><BRCA1/2><Bioassay><Bioinformatics><Biological Assay><Biological Markers><Biological Mimetics><Biomimetics><Breast Cancer><Bypass><Cancer Genes><Cancer Patient><Cancer-Promoting Gene><Cancers><Cell Body><Cell Fraction><Cells><Checkpoint inhibitor><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><Code><Coding System><DNA mutation><Data><Data Set><Detection><Development><Devices><Disease><Disorder><ERBB2><ERBB2 gene><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Evaluation><Event><Exhibits><Functional RNA><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Genes><Genetic Change><Genetic defect><Genetic mutation><H and E><HER -2><HER-2><HER2><HER2 Genes><HER2/neu><Hematoxylin and Eosin><Hematoxylin and Eosin Staining Method><Image><Immune><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immune system><Immunes><Immunologic Subtyping><Immunologic Surveillance><Immunologically Directed Therapy><Immunomodulation><Immunooncology><Immunophenotyping><Immunosurveillance><Immunotherapeutic agent><Immunotherapy><In Situ><In Vitro><Innate Immunity><Investigation><Investigators><Light><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Massive Parallel Sequencing><Massively Parallel DNA Sequencing><Massively Parallel Sequencing><Mediating><Messenger RNA><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><MicroRNAs><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Minority><Molecular><Multiomic Data><Mutate><Mutation><NEU Oncogene><NEU protein><Native Immunity><Natural Immunity><Neoplasm Metastasis><Non-Specific Immunity><Noncoding RNA><Nonspecific Immunity><Nontranslated RNA><Nucleic Acid Regulator Regions><Nucleic Acid Regulatory Sequences><Oncogene ErbB2><Oncogenes><Oncogenic><Outcome><Pathology><Pathway interactions><Patients><Phenotype><Photoradiation><Polyadenylation><Post-Transcriptional Control><Post-Transcriptional Regulation><Process><QTL><Quantitative Trait Loci><RNA Editing><RNA Polyadenylation><RNA Seq><RNA sequencing><RNA, Messenger, Editing><RNA-Binding Proteins><RNAseq><Regulation><Regulatory Regions><Research><Research Personnel><Research Resources><Researchers><Resistance><Resources><Role><Sampling><Secondary Neoplasm><Secondary Tumor><Somatic Mutation><T-Cells><T-Lymphocyte><TCGA><TKR1><Technology><The Cancer Genome Atlas><Time><Transforming Genes><Translations><Tumor Cell><Tumor Escape><Tumor Immune Escape><Tumor-Infiltrating Lymphocytes><Untranslated RNA><Validation><Variant><Variation><adaptive immunity><anti-cancer immunotherapy><anticancer immunotherapy><bio-markers><biologic marker><biomarker><brca gene><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer evasion><cancer immune escape><cancer immune evasion><cancer immunology><cancer immunotherapy><cancer metastasis><cancer microenvironment><cancer type><cell killing><check point inhibition><checkpoint inhibition><cohort><deep learning based model><deep learning model><developmental><epigenetically><erbB-2 Genes><exome><genetic regulatory element><genome mutation><genome sequencing><genomic data><genomic dataset><global gene expression><global transcription profile><herstatin><imaging><immune check point><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint inhibition><immune drugs><immune modulation><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-oncology><immunecheckpoint><immuno oncology><immuno therapy><immunologic reactivity control><immunologic therapeutics><immunology oncology><immunomodulatory><immunoregulation><immunoregulatory><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><in silico><innovate><innovation><innovative><mRNA><malignancy><malignant breast tumor><miRNA><microfluidic chip><multi-modal data><multi-modal datasets><multimodal data><multimodal datasets><multiple omic data><neoplasm immunology><neoplasm/cancer><neoplastic><neoplastic cell><neu Genes><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><noncoding><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><oncoimmunology><pathway><patient stratification><post-transcriptional gene regulation><posttranscriptional><predict responsiveness><predicting response><resistant><response><response to therapy><response to treatment><social role><somatic variant><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><statistical learning><stratified patient><therapeutic response><therapeutic target><therapy response><three dimensional><thymus derived lymphocyte><transcriptome><transcriptome sequencing><transcriptomic sequencing><translation><translational opportunities><translational potential><treatment response><treatment responsiveness><tumor><tumor cell metastasis><tumor evasion><tumor immune evasion><tumor immunology><tumor microenvironment><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MARCIA HAIGIS

HARVARD MEDICAL SCHOOL, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$562,761

FY 2026

Project Title

Defining mechanisms to promote antitumor immunity by modulating one-carbon metabolism

Grant Number:

5R01CA276866-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Immune checkpoint blockade (ICB) targeting PD-1 and its ligand PD-L1 has revolutionized cancer therapy, but only a subset of patients respond, highlighting the critical need to investigate mechanisms of anti-tumor immunity to identify novel targets to enhance the effects of ICB. The goal of this pro...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Arlene H. Sharpe

HARVARD MEDICAL SCHOOL, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$562,761

FY 2026

Project Title

Defining mechanisms to promote antitumor immunity by modulating one-carbon metabolism

Grant Number:

5R01CA276866-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Immune checkpoint blockade (ICB) targeting PD-1 and its ligand PD-L1 has revolutionized cancer therapy, but only a subset of patients respond, highlighting the critical need to investigate mechanisms of anti-tumor immunity to identify novel targets to enhance the effects of ICB. The goal of this pro...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Timothy Wesley Hand

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$559,509

FY 2026

Project Title

Identifying the mechanism of anti-colorectal immunity induced by mucoinvasive colonic bacteria

Grant Number:

5R01CA269902-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Colorectal cancer (CRC) is a leading cause of cancer-related death and its incidence is on the rise in young people. Colorectal tumors are often detected at late stages where therapy often fails. Immunotherapy is revolutionizing the treatment of many types of cancer but is only effective fo...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Song Li

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$546,625

FY 2026

Project Title

Targeting iRhom to Improve Colon Cancer Immunochemotherapy

Grant Number:

5R01CA295774-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/9/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Approximately 80%- 90% metastatic CRC (mCRC) are treated with chemotherapy or molecular-targeted agents with unsatisfactory overall survivals. Immunotherapy, especially immune checkpoint blockade, has de...

Research Terms

<(TNF)-α><20-(S)-camptothecine><22-secocamptothecin-21-oic acid lactone 21><4T1><Affect><Anti-Cancer Agents><Antigen Presentation Pathway><Antigen Processing and Presentation><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Apoptosis><Apoptosis Pathway><Autophagocytosis><Biodistribution><Biological><Body Tissues><Breast Cancer><Breast Cancer cell line><Breast tumor cell line><CD44><CD44 gene><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CT-26><CT26><Cachectin><Camptothecin><Cancer Cause><Cancer Drug><Cancer Etiology><Cancer Model><Cancer Patient><CancerModel><Carcinoma><Cell Body><Cells><Cessation of life><Clinical Trials><Colon Cancer><Colon Carcinoma><Colorectal Cancer><Combination immunotherapy><DNA mutation><Data><Data Analyses><Data Analysis><Death><Development><Drug Precursors><EGF Receptor><EGFR><ERBB Protein><Endoplasmic Reticulum><Endothelial Cells><Endothelium><Enzyme Gene><Enzymes><Epidermal Growth Factor Receptor><Epidermal Growth Factor Receptor Kinase><Epidermal Growth Factor Receptor Protein-Tyrosine Kinase><Epidermal Growth Factor-Urogastrone Receptors><Epithelial cancer><Ergastoplasm><Esteroproteases><Genetic Change><Genetic defect><Genetic mutation><HER1><Head and Neck Cancer><Head and Neck Carcinoma><Human><Hydrophobicity><Immune infiltrates><Immune mediated therapy><Immuno-Chemotherapy><Immunochemotherapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Inflammatory><Isoforms><Knock-out><Knockout><Ligands><MDU3><MMR deficiency><Macrophage-Derived TNF><Malignant Breast Neoplasm><Malignant Cell><Malignant Epithelial Neoplasms><Malignant Epithelial Tumors><Malignant Head and Neck Neoplasm><Malignant Pancreatic Neoplasm><Malignant neoplasm of pancreas><Mammalia><Mammals><Mediating><Membrane><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Metallopeptidases><Metalloproteases><Metalloproteinases><Metastasis to the Lung><Metastatic Neoplasm to the Lung><Metastatic Tumor to the Lung><Mice><Mice Mammals><Microsatellite Instability><Microsatellite Markers><Microsatellite Repeats><Microsatellites><Mismatch Repair><Mismatch Repair Deficiency><Modeling><Modern Man><Molecular Target><Monocyte-Derived TNF><Murine><Mus><Mutation><Neoplastic Disease Chemotherapeutic Agents><Network Analysis><Oncogenic><Pancreas Cancer><Pancreatic Cancer><Pathway Analysis><Pathway interactions><Patients><Penetration><Peptidases><Peptide Hydrolases><Pgp1><Phenotype><Play><Post-Replication Mismatch Repair><Post-Transcriptional Gene Silencing><Pro-Drugs><Prodrugs><Programmed Cell Death><Property><Protease Gene><Proteases><Protein Isoforms><Proteinases><Proteins><Proteolytic Enzymes><RNA Interference><RNA Seq><RNA Silencing><RNA sequencing><RNAi><RNAseq><Radiation therapy><Radiotherapeutics><Radiotherapy><Reporting><Resistance><Role><SAHA><Sequence-Specific Posttranscriptional Gene Silencing><Short interfering RNA><Suberoylanilide Hydroxamic Acid><Surface Proteins><T cell infiltration><T8 Cells><T8 Lymphocytes><TCGA><TGF-alpha Receptor><TM Domain><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><The Cancer Genome Atlas><Therapeutic><Tissues><Toxic effect><Toxicities><Transforming Growth Factor alpha Receptor><Transmembrane Domain><Transmembrane Region><Treatment Efficacy><Tumor Cell><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Specific Treatment Agents><Urogastrone Receptor><Vorinostat><anti-cancer drug><anti-tumor immunity><antitumor immunity><autophagy><biologic><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><c-erbB-1><c-erbB-1 Protein><cancer cell><cancer immunity><cancer in the colon><cancer type><check point blockade><checkpoint blockade><chemo-immuno therapy><chemoimmunotherapy><chemotherapy><clinical prognosis><colon cancer patients><colorectal cancer patients><colorectal cancer therapy><colorectal cancer treatment><combinatorial immunotherapy><cytokine><data interpretation><determine efficacy><developmental><dual immunotherapy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epithelial carcinoma><erbB-1><erbB-1 Proto-Oncogene Protein><erbBl><evaluate efficacy><examine efficacy><genome mutation><head/neck cancer><immune cell infiltrate><immune check point blockade><immune checkpoint blockade><immune microenvironment><immune resistance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-resistant><immuno therapy><immunoresistance><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><improved><in vivo><intervention efficacy><knock-down><knockdown><lipophilicity><lung metastasis><malignant breast tumor><malignant head and neck tumor><membrane structure><metastasize to the lung><metastatic colo-rectal><metastatic colo-rectal cancer><metastatic colo-rectal carcinoma><metastatic colon cancer><metastatic colorectal><metastatic colorectal cancer><metastatic colorectal carcinoma><nano particle><nano-sized particle><nanocarrier><nanoparticle><nanosized particle><nanovessel><neoplastic cell><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><overexpress><overexpression><pancreatic malignancy><pathway><proto-oncogene protein c-erbB-1><pulmonary metastasis><radiation treatment><resistant><response><rhomboid><siRNA><social role><suberanilohydroxamic acid><targeted agent><therapeutic efficacy><therapy efficacy><trafficking><transcriptome sequencing><transcriptomic sequencing><transcytosis><treatment with radiation><tumor><tumor growth><tumor immune microenvironment><tumor xenograft><tumor-immune system interactions>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xue-Zhong Yu

MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$538,587

FY 2026

Project Title

Targeting PIM-2 Kinase for Improving Cancer Immunotherapy

Grant Number:

5R01CA258440-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract The adaptive immune system has the capacity to recognize and kill malignant cells. However, immune tolerant mechanisms that normally protect healthy tissues from autoimmune attack prevent the development of effective anti-tumor immunity. Tumor uses numerous immunosuppressive mechanisms to e...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

H. Shelton Earp

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$537,271

FY 2026

Project Title

Divergent Roles of MerTK,Tyro3, and Axl in Pancreatic Cancer and Metastasis

Grant Number:

5R01CA270792-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Pancreatic Ductal Adenocarcinoma (PDAC) is perhaps the most recalcitrant human neoplasm. With 10% overall 5-year survival and an increasing incidence, PDAC will be the second leading cause of cancer deaths within a decade. The constellation of chemo- and targeted therapy resistant tumor cel...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuliya Pylayeva-Gupta

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$537,271

FY 2026

Project Title

Divergent Roles of MerTK,Tyro3, and Axl in Pancreatic Cancer and Metastasis

Grant Number:

5R01CA270792-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Pancreatic Ductal Adenocarcinoma (PDAC) is perhaps the most recalcitrant human neoplasm. With 10% overall 5-year survival and an increasing incidence, PDAC will be the second leading cause of cancer deaths within a decade. The constellation of chemo- and targeted therapy resistant tumor cel...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wei Gao

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$529,077

FY 2026

Project Title

Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer Efficacy

Grant Number:

5R01CA285790-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/5/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Current cancer therapeutic vaccines that utilize both CD4 and CD8 T cell neoantigens to stimulate T cell immunity through dendritic cell/macrophage-mediated antigen presentation for their anticancer efficacy. However, despite some promising results in certain cancer types (e.g. melanoma) in...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DUXIN SUN

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$529,077

FY 2026

Project Title

Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer Efficacy

Grant Number:

5R01CA285790-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/5/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Current cancer therapeutic vaccines that utilize both CD4 and CD8 T cell neoantigens to stimulate T cell immunity through dendritic cell/macrophage-mediated antigen presentation for their anticancer efficacy. However, despite some promising results in certain cancer types (e.g. melanoma) in...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JACQUELINE SARA JERUSS

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$520,169

FY 2026

Project Title

Tissue engineering tools for monitoring the cellular and molecular response to therapy

Grant Number:

5R01CA272940-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/2/2023

End Date:

3/1/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary: Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that is treated with neoadjuvant therapy that targets both the primary tumor and systemic disease, with subsequent adjuvant immunotherapy. Even with the most cutting-edge therapeutic approach, approximately 20% of t...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lonnie D Shea

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$520,169

FY 2026

Project Title

Tissue engineering tools for monitoring the cellular and molecular response to therapy

Grant Number:

5R01CA272940-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/2/2023

End Date:

3/1/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary: Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that is treated with neoadjuvant therapy that targets both the primary tumor and systemic disease, with subsequent adjuvant immunotherapy. Even with the most cutting-edge therapeutic approach, approximately 20% of t...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mingye Feng

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$519,592

FY 2026

Project Title

Targeting tumor-associated macrophages for triple-negative breast cancer treatment

Grant Number:

5R01CA258778-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, all of which are important therapeutic targets. TNBC is the most difficult-to-treat subgroup of breast cancers and is r...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hui-Kuan Lin

DUKE UNIVERSITY, DURHAM, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$506,902

FY 2026

Project Title

Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer

Grant Number:

5R01CA270617-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/9/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Non-small cell lung cancer (NSCLC) accounts for around 85% of all lung cancer. The 5- year survival rate is about 14% for stage IIIA NSCLC, while it is about 5% for stage IIIB. However, once NSCLC has reached to the stage IV and metastasized to different places, it is very difficult to treat. The 5-...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Corinne Beinat

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$499,516

FY 2026

Project Title

A Novel Imaging Strategy to Optimize Brain Tumor Immunotherapy

Grant Number:

1R01NS143999-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2026

End Date:

1/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT. Immunotherapy has emerged as a successful therapeutic strategy for a variety of cancers. The recent success of immunotherapies in other solid tumors has sparked increased attention to treatments targeting the immune system in glioblastoma (GBM) and other brain cancers. One of the key chall...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Chih-Chi Andrew Hu

METHODIST HOSPITAL RESEARCH INSTITUTE, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$492,142

FY 2026

Project Title

Mechanisms of STING in malignant progression and therapy of CLL.

Grant Number:

5R01CA269835-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Chronic lymphocytic leukemia (CLL) represents 30% of adult leukemia and is still incurable. According to the National Cancer Institute, approximately 21,250 new cases of CLL and 4,320 deaths from CLL are projected in the United States alone in 2021. Although the Bruton's tyr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sai Ravi Kiran Pingali

METHODIST HOSPITAL RESEARCH INSTITUTE, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$492,142

FY 2026

Project Title

Mechanisms of STING in malignant progression and therapy of CLL.

Grant Number:

5R01CA269835-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Chronic lymphocytic leukemia (CLL) represents 30% of adult leukemia and is still incurable. According to the National Cancer Institute, approximately 21,250 new cases of CLL and 4,320 deaths from CLL are projected in the United States alone in 2021. Although the Bruton's tyr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KEBIN LIU

AUGUSTA UNIVERSITY, AUGUSTA, GA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$486,615

FY 2026

Project Title

Development of SUV39H1-selective inhibitor for human colon cancer therapy

Grant Number:

5R01CA278852-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Only the microsatellite instability high (MSI-H) human colorectal cancer, which accounts for 10-15% of all human colorectal cancer cases, responds to PD-(L)1 blockade immunotherapy. The vast majority (85-90%) of human colorectal cancer is the microsatellite stable (MSS) subtype that...

Research Terms

<APO-1 Antigen><APO-1 Cell Surface Antigen><Apoptosis Antigen 1><B7-H1><Biodistribution><Body Tissues><CD274><CD95 Antigens><CD95 molecule><Cell Body><Cell Death><Cell Death Induction><Cell-Mediated Lympholytic Cells><Cells><Cessation of life><Charge><Collaborations><Colon><Colon Cancer><Colon Carcinoma><Colon Neoplasms><Colon Tumor><Colonic Mass><Colonic Neoplasms><Colonic Tumor><Colorectal Cancer><Colorectal Carcinomas><Colorectal Neoplasms><Colorectal Tumors><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Data><Death><Deposit><Deposition><Development><Dose><Drug Kinetics><Drugs><Encapsulated><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Functional impairment><Gene Expression><Genes><Granzyme><Hepatic Neoplasm Secondary><Hepatic metastasis><Heterograft><Heterologous Transplantation><Histones><Human><Immune mediated therapy><Immunocompetent><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Infiltration><KO mice><Knock-out Mice><Knockout Mice><L-Lysine><Large Bowel Carcinoma><Large Bowel Tumor><Large Intestine Carcinoma><Large Intestine Neoplasm><Large Intestine Tumor><Literature><Liver secondaries><Liver secondary cancer><Lysine><Malignant Cell><Maximal Tolerated Dose><Maximally Tolerated Dose><Maximum Tolerated Dose><Mediating><Medication><Metastatic Neoplasm to the Liver><Metastatic Tumor to the Liver><Metastatic malignant neoplasm to liver><Mice><Mice Mammals><Microsatellite Instability><Microsatellite Markers><Microsatellite Repeats><Microsatellites><Modeling><Modern Man><Murine><Mus><Null Mouse><PD 1><PD-1><PD-1 antibody><PD-1 blockade><PD-L1><PD1><PD1 antibody><PD1 blockade><PDL-1><Particle Size><Pathway interactions><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacokinetics><Pharmacologic Substance><Pharmacological Substance><Phenotype><Play><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proteins><Publishing><Regulator Genes><Repression><Resistance><Role><Safety><Site><Surface><T memory cell><TNFRSF6 Receptor><Testing><Tissues><Toxic effect><Toxicities><Toxicology><Transcriptional Regulatory Elements><Tumor Cell><Tumor Necrosis Factor Receptor Superfamily, Member 6><Viral Diseases><Virus Diseases><Work><Xenograft><Xenograft procedure><Xenotransplantation><aPD-1><aPD1><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><cancer cell><cancer in the colon><colon cancer therapy><colon cancer treatment><colon neoplasia><colorectal neoplasia><cytotoxic><determine efficacy><developmental><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epigenetically><evaluate efficacy><examine efficacy><fas Antigens><fas Receptors><genetic trans acting element><hepatic heterograft><hepatic xenograft><histone H3 methyltransferase><histone methylase><histone methyltransferase><immune competent><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vivo><inhibitor><killer T cell><large bowel neoplasm><literate><liver heterograft><liver metastases><liver xenograft><malignant liver neoplasm, specified as secondary><memory T lymphocyte><metastasis in the liver><metastasis to the liver><metastasize to the liver><metastatic cancer to liver><metastatic colo-rectal><metastatic colo-rectal cancer><metastatic colo-rectal carcinoma><metastatic colon cancer><metastatic colorectal><metastatic colorectal cancer><metastatic colorectal carcinoma><metastatic liver><metastatic liver neoplasm><mouse model><murine model><nano particle><nano-sized particle><nanoparticle><nanosized particle><necrocytosis><neoplastic cell><pathway><pharmaceutical><pre-clinical><preclinical><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><promoter><promotor><protein death-ligand 1><regulatory gene><resistant><scATAC sequencing><scATAC-seq><scRNA sequencing><scRNA-seq><secondary liver malignancy><secondary malignant liver neoplasm><single cell ATAC-seq><single cell ATAC-sequencing><single cell Assay for Transposase Accessible Chromatin sequencing><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell sequencing assay for transposase accessible chromatin><single cell transcriptomic profiling><single-cell Assay for Transposase-Accessible Chromatin with sequencing><single-cell RNA sequencing><single-cell assay for transposase-accessible chromatin using sequencing><single-cell assay for transposase-accessible chromatin-seq><sle2><social role><systemic lupus erythematosus susceptibility 2><trafficking><trans acting element><tumor><tumor growth><viral infection><virus infection><virus-induced disease><xeno-transplant><xeno-transplantation><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jianjun Gao

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$480,324

FY 2026

Project Title

Molecular Mechanisms of Bladder Cancer Immunometabolism

Grant Number:

5R01CA269489-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Historically, the majority of relevant research has only interrogated classical pathways in bladder cancer cells and has had little success in developing clinical drugs against bladder cancer (BC). Immunotherapy, including PD-1/PD-L1 blockade, has recently been proven effective in tr...

Research Terms

<2-fluoro-L-erythro-citrate><3-hydroxykynurenine transaminase><Antibodies><Antisense Agent><Antisense Oligonucleotides><Astrocytes><Astrocytus><Astroglia><Attenuated><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Biology><Bladder><Bladder Cancer><Bladder Urinary System><Body Tissues><Cancer Model><Cancer Patient><Cancer Treatment><CancerModel><Cancers><Catalysis><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Checkpoint inhibitor><Clinical><Collaborations><Communities><Data><Disease><Disorder><Dissociation><Drugs><Effectiveness><Equilibrium><Functional RNA><Future><Goals><HPGF><Hepatocyte-Stimulating Factor><Human><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunologic Cytotoxicity><Immunologically Directed Therapy><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapeutic agent><Immunotherapy><Infiltration><Interdisciplinary Research><Interdisciplinary Study><Interleukin-6><Intracellular Communication and Signaling><KO mice><Kinetics><Knock-out Mice><Knockout Mice><Kynurenine><Kynurenine-oxoglutarate aminotransferase><L-Tryptophan><L-tryptophanase><Levotryptophan><MGI-2><Malignant Bladder Neoplasm><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant neoplasm of urinary bladder><Mediating><Medication><Metabolic><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mice><Mice Mammals><Mill Hill-2 Viral Oncogene Homolog><Modeling><Modern Man><Molecular><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><Myeloid Differentiation-Inducing Protein><Myeloid-derived suppressor cells><Neoplasm Metastasis><Neurilemma Cell><Neurilemmal Cell><Noncoding RNA><Nontranslated RNA><Null Mouse><Oncogenesis><Oncogenic><PD-1 antibody><PD-1/PD-L1><PD-1/PDL1><PD-L1 antibody><PD-L1 blockade><PD1 antibody><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL1 blockade><Pathway interactions><Patients><Pharmaceutical Preparations><Phosphorylation><Plasmacytoma Growth Factor><Plasmacytoma Variant Translocation 1><Platinum><Platinum Black><Play><Production><Protein Phosphorylation><Pt element><RAF-1><RAF1><RAF1 gene><RNA based therapeutics><RNA based therapy><RNA therapy><Reagent><Research><Resistance><Role><Schwann Cells><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><TDO2><TRPO><Teff cell><Therapeutic><Tissues><Toxic effect><Toxicities><Tryptamin 2,3-Dioxygenase><Tryptophan><Tryptophan 2,3-Dioxygenase><Tryptophan Indole-Lyase><Tryptophanase><Tumor Cell><Tumor Immunity><Tumor Promotion><Tumor Tissue><Tumor-infiltrating immune cells><Untranslated RNA><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Work><aPD-1><aPD-L1><aPD-L1 antibodies><aPD1><antagonism><antagonist><anti programmed cell death 1><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 blockade><anti-PD-L1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><antiPD-L1><antisense oligo><antitumor immunity><astrocytic glia><attenuate><attenuates><balance><balance function><bio-informatics tool><bioinformatics tool><biological signal transduction><cancer cell><cancer immunity><cancer metastasis><cancer microenvironment><cancer progression><cancer therapy><cancer-directed therapy><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical effect><combinatorial><design><designing><drug/agent><effector T cell><fluorocitrate><hypoimmunity><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point><immune check point inhibitor><immune check point therapy><immune checkpoint><immune checkpoint therapy><immune deficiency><immune drugs><immune microenvironment><immune modulation><immune regulation><immune resistance><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-resistant><immunecheckpoint><immuno therapy><immunodeficiency><immunologic reactivity control><immunologic therapeutics><immunomodulatory><immunoregulation><immunoregulatory><immunoresistance><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive myeloid cells><immunosuppressive response><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><improved><in vivo><infiltration of tumors by immune cells><inhibitor><innovate><innovation><innovative><interferon beta 2><intratumoral immune cell><intratumoral immune infiltrate><kynurenine aminotransferase><kynurenine aminotransferase II><kynurenine-oxoglutarate transaminase><locked nucleic acid><malignancy><myeloid suppressor cells><myeloid-derived suppressive cells><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><neutralizing antibody><new approaches><noncoding><novel><novel approaches><novel strategies><novel strategy><pathway><plasmacytoma variant translocation gene 1><prognostic ability><prognostic power><prognostic utility><prognostic value><resistant><response><social role><success><suppressive myeloid cells><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic RNA><therapeutic target><tumor><tumor cell metastasis><tumor growth><tumor immune cell><tumor immune infiltrate><tumor immune microenvironment><tumor infiltration of immune cells><tumor microenvironment><tumor progression><tumor-immune system interactions><tumorigenesis><urinary bladder><v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1><αPD-1><αPD-L1><αPD-L1 antibodies><αPD1><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Liuqing Yang

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$480,324

FY 2026

Project Title

Molecular Mechanisms of Bladder Cancer Immunometabolism

Grant Number:

5R01CA269489-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Historically, the majority of relevant research has only interrogated classical pathways in bladder cancer cells and has had little success in developing clinical drugs against bladder cancer (BC). Immunotherapy, including PD-1/PD-L1 blockade, has recently been proven effective in tr...

Research Terms

<2-fluoro-L-erythro-citrate><3-hydroxykynurenine transaminase><Antibodies><Antisense Agent><Antisense Oligonucleotides><Astrocytes><Astrocytus><Astroglia><Attenuated><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Biology><Bladder><Bladder Cancer><Bladder Urinary System><Body Tissues><Cancer Model><Cancer Patient><Cancer Treatment><CancerModel><Cancers><Catalysis><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Checkpoint inhibitor><Clinical><Collaborations><Communities><Data><Disease><Disorder><Dissociation><Drugs><Effectiveness><Equilibrium><Functional RNA><Future><Goals><HPGF><Hepatocyte-Stimulating Factor><Human><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunologic Cytotoxicity><Immunologically Directed Therapy><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapeutic agent><Immunotherapy><Infiltration><Interdisciplinary Research><Interdisciplinary Study><Interleukin-6><Intracellular Communication and Signaling><KO mice><Kinetics><Knock-out Mice><Knockout Mice><Kynurenine><Kynurenine-oxoglutarate aminotransferase><L-Tryptophan><L-tryptophanase><Levotryptophan><MGI-2><Malignant Bladder Neoplasm><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant neoplasm of urinary bladder><Mediating><Medication><Metabolic><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mice><Mice Mammals><Mill Hill-2 Viral Oncogene Homolog><Modeling><Modern Man><Molecular><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><Myeloid Differentiation-Inducing Protein><Myeloid-derived suppressor cells><Neoplasm Metastasis><Neurilemma Cell><Neurilemmal Cell><Noncoding RNA><Nontranslated RNA><Null Mouse><Oncogenesis><Oncogenic><PD-1 antibody><PD-1/PD-L1><PD-1/PDL1><PD-L1 antibody><PD-L1 blockade><PD1 antibody><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL1 blockade><Pathway interactions><Patients><Pharmaceutical Preparations><Phosphorylation><Plasmacytoma Growth Factor><Plasmacytoma Variant Translocation 1><Platinum><Platinum Black><Play><Production><Protein Phosphorylation><Pt element><RAF-1><RAF1><RAF1 gene><RNA based therapeutics><RNA based therapy><RNA therapy><Reagent><Research><Resistance><Role><Schwann Cells><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><TDO2><TRPO><Teff cell><Therapeutic><Tissues><Toxic effect><Toxicities><Tryptamin 2,3-Dioxygenase><Tryptophan><Tryptophan 2,3-Dioxygenase><Tryptophan Indole-Lyase><Tryptophanase><Tumor Cell><Tumor Immunity><Tumor Promotion><Tumor Tissue><Tumor-infiltrating immune cells><Untranslated RNA><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Work><aPD-1><aPD-L1><aPD-L1 antibodies><aPD1><antagonism><antagonist><anti programmed cell death 1><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 blockade><anti-PD-L1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor immunity><antiPD-1><antiPD-L1><antisense oligo><antitumor immunity><astrocytic glia><attenuate><attenuates><balance><balance function><bio-informatics tool><bioinformatics tool><biological signal transduction><cancer cell><cancer immunity><cancer metastasis><cancer microenvironment><cancer progression><cancer therapy><cancer-directed therapy><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical effect><combinatorial><design><designing><drug/agent><effector T cell><fluorocitrate><hypoimmunity><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point><immune check point inhibitor><immune check point therapy><immune checkpoint><immune checkpoint therapy><immune deficiency><immune drugs><immune microenvironment><immune modulation><immune regulation><immune resistance><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-resistant><immunecheckpoint><immuno therapy><immunodeficiency><immunologic reactivity control><immunologic therapeutics><immunomodulatory><immunoregulation><immunoregulatory><immunoresistance><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive myeloid cells><immunosuppressive response><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><improved><in vivo><infiltration of tumors by immune cells><inhibitor><innovate><innovation><innovative><interferon beta 2><intratumoral immune cell><intratumoral immune infiltrate><kynurenine aminotransferase><kynurenine aminotransferase II><kynurenine-oxoglutarate transaminase><locked nucleic acid><malignancy><myeloid suppressor cells><myeloid-derived suppressive cells><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><neutralizing antibody><new approaches><noncoding><novel><novel approaches><novel strategies><novel strategy><pathway><plasmacytoma variant translocation gene 1><prognostic ability><prognostic power><prognostic utility><prognostic value><resistant><response><social role><success><suppressive myeloid cells><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic RNA><therapeutic target><tumor><tumor cell metastasis><tumor growth><tumor immune cell><tumor immune infiltrate><tumor immune microenvironment><tumor infiltration of immune cells><tumor microenvironment><tumor progression><tumor-immune system interactions><tumorigenesis><urinary bladder><v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1><αPD-1><αPD-L1><αPD-L1 antibodies><αPD1><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sheila A Stewart

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$469,120

FY 2026

Project Title

Leveraging the metastatic tumor stroma to limit breast cancer progression

Grant Number:

5R01CA282810-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2024

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Abstract Over 297,790 new cases of invasive breast cancer diagnoses and 43,170 deaths from metastatic breast cancer (mBC) are expected in the USA this year (SEER database). Despite advances in the treatment of localized disease, the 5-year overall survival of patients with mBC remains at a d...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hanlee P Ji

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$444,976

FY 2026

Project Title

Integrating cancer genomics and spatial architecture of tumor infiltrating lymphocytes

Grant Number:

5R01CA280089-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/11/2023

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Tumor infiltrating lymphocytes (TILs) are an important component of the immune cells that reside in the tumor microenvironment (TME). The type and number of TILs in the TME have an impact on overall survival and are an indicator of response to immunotherapy. Despite their importance as an i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jing Yang

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$434,399

FY 2026

Project Title

Functional interplay between Hippo and estrogen receptor ESR1

Grant Number:

5R01CA268179-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Functional interplay between Hippo and estrogen receptor ESR1 Project Summary/Abstract The majority of breast cancers are estrogen receptor (ER positive and growth of ER+ cancer is dependent on ER function. Hormone therapy by inhibiting ER is most commonly used for ER+ breast cancer treatment, how...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wenquan Ou

UNIV OF MARYLAND, COLLEGE PARK, COLLEGE PARK, MD

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$404,416

FY 2026

Project Title

Cold-responsive gene and drug delivery-potentiated cryoimmunotherapy

Grant Number:

5R01CA279810-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/19/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Breast cancer (BC) is the 2nd leading cause of cancer-related death in American women and metastasis is the major reason of BC-related mortality. Harnessing the immune system to battle cancer via immunotherapy has emerged as a powerful and potentially revolutionizing strateg...

Research Terms

<4T1><Abscission><American><Anzatax><Asotax><B7-H1><Binding><Blood><Blood Reticuloendothelial System><Blood Vessels><Breast><Breast Cancer><Breast Cancer Cell><Breast Metastasis><Bristaxol><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancer Cause><Cancer Etiology><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cell Death><Cell division><Cell-Mediated Lympholytic Cells><Cells><Cessation of life><Clinic><Clinical><Conventional Surgery><Cosmetics><Cryoablation><Cryosurgery><Cytolytic T-Cell><Cytosol><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Death><Dendritic Cells><Disseminated Malignant Neoplasm><Distant><Drug Delivery><Drug Delivery Systems><Drug usage><Drugs><Echography><Echotomography><Encapsulated><Excision><Extirpation><Freezing><Frostbite><Gene Delivery><Heating><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><High temperature of physical object><Hour><Ice><Immune><Immune infiltrates><Immune mediated therapy><Immune response><Immune system><Immunes><Immunization><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapeutic agent><Immunotherapy><In Vitro><Literature><Macrophage><Malignant Breast Neoplasm><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Medical><Medical Ultrasound><Medication><Memory><Metastasis><Metastasize><Metastatic Cancer><Metastatic Lesion><Metastatic Malignant Neoplasm><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Microtubule Stabilization><Modeling><Molecular><Molecular Interaction><Monitor><Morbidity><Myeloid-derived suppressor cells><Mφ><Nanotechnology><Nature><Neoplasm Metastasis><Operative Procedures><Operative Surgical Procedures><Outcome><PD 1><PD-1><PD-L1><PD1><PDL-1><Paclitaxel><Paclitaxel (Taxol)><Pattern><Peripheral><Pharmaceutical Preparations><Praxel><Primary Neoplasm><Primary Tumor><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proliferating><Public Health><Receptor Protein><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Regulatory T-Lymphocyte><Removal><Reperfusion Therapy><Reporting><Safety><Secondary Neoplasm><Secondary Tumor><Shapes><Short interfering RNA><Solid Neoplasm><Solid Tumor><Surgical><Surgical Interventions><Surgical Procedure><Surgical Removal><T-Cell Activation><T8 Cells><T8 Lymphocytes><Taxol><Taxol A><Taxol Konzentrat><Temperature><Testing><Therapeutic><Time><Treg><Tumor Cell><Tumor Immunity><Ultrasonic Imaging><Ultrasonogram><Ultrasonography><Ultrasound Diagnosis><Ultrasound Medical Imaging><Ultrasound Test><Veiled Cells><Woman><Work><activate T cells><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immunity><anticancer immunotherapy><antitumor immunity><breast cancer metastasis><breast tumor cell><cancer cell><cancer immunity><cancer immunotherapy><cancer metastasis><cancer microenvironment><cancer recurrence><cancer therapy><cancer type><cancer-directed therapy><chemotherapy><clinical hyperthermia><cold temperature><cosmetic product><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><diagnostic ultrasound><drug use><drug/agent><high temperature><host response><hyperthermia therapy><hyperthermia treatment><immune cell infiltrate><immune drugs><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogenic apoptosis><immunogenic cell death><immunologic therapeutics><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive myeloid cells><immunosuppressive response><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><killer T cell><low temperature><lymph organ><lymphatic organ><lymphoid organ><malignancy><malignant breast tumor><minimally invasive><mortality><myeloid suppressor cells><myeloid-derived suppressive cells><nano particle><nano tech><nano technology><nano-sized particle><nano-technological><nanomaterials><nanoparticle><nanosized particle><nanotech><nanotechnological><necrocytosis><neoplasm/cancer><neoplastic cell><novel><prevent><preventing><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><receptor><regulatory T-cells><reperfusion><resection><response><siRNA><sle2><sonogram><sonography><sound measurement><success><suppressive myeloid cells><surgery><systemic lupus erythematosus susceptibility 2><time use><tumor><tumor cell metastasis><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><ultrasound imaging><ultrasound scanning><vascular>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Weiping Tang

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$398,625

FY 2026

Project Title

Development of Novel Antibody Conjugates for Cancer Immunotherapy

Grant Number:

5R01CA284689-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Targeted protein degradation by chimeric molecules has emerged as a novel therapeutic modality. The bifunctional chimeric molecules usually have one end binding to the protein of interest (POI) and the other end directing the ternary complex towards the degradation in proteasome or lysosome...

Research Terms

<20S Catalytic Proteasome><20S Core Proteasome><20S Proteasome><20S Proteosome><APF-1><ASGP-R><ATP-Dependent Proteolysis Factor 1><Adaptive Immune System><Address><Antibodies><Asialoglycoprotein Receptor><Asialoorosomucoid Receptor><Asialoorosomucoid-Binding Protein><Attention><Autophagocytosis><B7-H1><Binding><Body Tissues><CD274><CIMPR><Cancer Treatment><Cancers><Carbohydrate Chemistry><Cell Body><Cell Surface Receptors><Cell membrane><Cell secretion><Cell surface><Cells><Cellular Membrane><Cellular Secretion><Checkpoint inhibitor><Chimera><Chimera organism><Complex><Cysteine><Cytoplasmic Membrane><DNA Molecular Biology><Data><Degradation Pathway><Degradative Pathway><Development><E3 Ligase><E3 Ubiquitin Ligase><Endocytosis><Engineering><Environment><Evaluation><Experimental Designs><Extracellular Protein><Folate><Folic Acid><Foundations><Glycans><HMG-20><Half-Cystine><Head and Neck><Head and Neck Cancer><Head and Neck Carcinoma><Head and neck structure><High Mobility Protein 20><Human><IGF2R><IGF2R gene><Immune checkpoint inhibitor><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Insulin-Like Growth Factor 2 Receptor><Investigation><L-Cysteine><L-Lysine><Lectin><Ligand Binding><Ligands><Link><Liver><Lysine><Lysosomes><MPRI><Macropain><Macroxyproteinase><Malignant Cell><Malignant Head and Neck Neoplasm><Malignant Neck Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mannose 6-Phosphate Receptor, Cation-Independent><Mediating><Membrane><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Metabolic Protein Degradation><Mice><Mice Mammals><Modality><Modern Man><Molecular Biology><Molecular Interaction><Multicatalytic Proteinase><Murine><Mus><Neck Cancer><Normal Tissue><Normal tissue morphology><Organelles><PD-L1><PDL-1><PDX model><Patient derived xenograft><Plasma Membrane><Play><Polysaccharides><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Prosome><Protac><Proteasome><Proteasome Endopeptidase Complex><Protein Turnover><Proteins><Proteolysis targeting chimeric><Proteome><Proteosome><Pteroylglutamic Acid><Receptor Protein><Recycling><Regulatory Protein Degradation><Reporting><Role><Route><Series><Standardization><Structure><Surface Proteins><System><Techniques><Testing><Therapeutic><Time><Tissues><Toxic effect><Toxicities><Ubiquitilation><Ubiquitin><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Vitamin M><acquired immune system><anti-cancer immunotherapy><anti-cancer therapy><antibody assay><antibody based test><antibody conjugate><antibody test><anticancer immunotherapy><autophagy><cancer cell><cancer immunotherapy><cancer therapy><cancer type><cancer-directed therapy><carbohydrate binding protein><carbohydrate receptor><cartilage link protein><cell type><chimeras><design><designing><developmental><experience><experiment><experimental research><experimental study><experiments><extracellular><folate carrier><folate receptor><folate-binding protein><folate-methotrexate transporter><folic acid binding protein><folic acid receptor><head/neck cancer><hepatic body system><hepatic organ system><human disease><humanized mice><humanized mouse><immune check point inhibitor><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><inhibitor><innovate><innovation><innovative><interest><link protein><malignancy><malignant head and neck tumor><malignant neck tumor><membrane structure><methotrexate-binding protein><mouse model><multicatalytic endopeptidase complex><murine model><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><overexpress><overexpression><patient derived xenograft model><plasmalemma><programmed cell death ligand 1><programmed cell death protein ligand 1><protein bound carbohydrate><protein death-ligand 1><protein degradation><protein homeostasis><proteolysis targeting chimaera><proteolysis targeting chimera><proteostasis><public health relevance><receptor><receptor mediated endocytosis><recruit><social role><therapeutically effective><tumor><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase><vitamin Bc>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Guangyong Peng

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$396,205

FY 2026

Project Title

Targeting T Cell Senescence and Dysfunction for Anti-tumor Immunity

Grant Number:

5R01CA242188-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2020

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Current immunotherapy strategies, including immune checkpoint blockade therapy targeting CTLA-4 and/or PD1/PD-L1, have yielded promising results in certain types of cancer patients. However, the overall success rates of these strategies still vary from 15% to 35%, which sugg...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hiroyuki Inuzuka

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$395,509

FY 2026

Project Title

Targeting the SKP2 Axis for Anti-melanoma Therapy

Grant Number:

5R01CA291991-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/4/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Melanoma is one of the most aggressive skin cancers that develops from melanocytes. Although melanoma is less frequent than other types of skin cancer, it has a rapid growth rate and a tendency to spread quickly, leading to a high mortality rate and accounting for almost 75% of all skin can...

Research Terms

<20S Catalytic Proteasome><20S Core Proteasome><20S Proteasome><20S Proteosome><AGO Protein><APF-1><ATP-Dependent Proteolysis Factor 1><Accounting><Actinic Rays><Address><Archipelago Homologue><Archipelago Homologue Protein><Area><Assay><B-raf-1><BRAF><BRAF gene><Bioassay><Biological><Biological Assay><CDC4><CDK2/Cyclin A-Associated Protein p45><Cancers><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cessation of life><Complex><DNA mutation><Data><Data Bases><Databases><Death><Death Rate><Development><E3 Ligase><E3 Ubiquitin Ligase><Ectopic Expression><Exhibits><F-Box Protein SKP2><F-box and WD-40 domain protein 7><F-box protein FBW7><FBL1><FBW7><FBX30><FBXL1><FBXW7><FBXW7 Protein><FBXW7 gene><FLB1><FLJ11071><Frequencies><Gene Alteration><Gene Mutation><Genetic Change><Genetic defect><Genetic mutation><HMG-20><Hedgehog (Hh) signal transduction pathway><Heterograft><Heterologous Transplantation><High Mobility Protein 20><Immune><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Intracellular Communication and Signaling><MGC1366><Macropain><Macroxyproteinase><Malignant Melanoma><Malignant Neoplasms><Malignant Skin Neoplasm><Malignant Tumor><Mediating><Melanoma><Melanoma Cell><Melanoma Tumor><Melanoma patient><Metabolic Protein Degradation><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Molecular><Multicatalytic Proteinase><Mutation><Neoplasm Metastasis><Oncogenesis><Oncogenic><Outcome><PARK2><PARK2 gene><Parkinson disease 2 gene><Pathogenesis><Pathologic><Pathway interactions><Patients><Physiologic><Physiological><Play><Prognosis><Prognostic Marker><Prosome><Proteasome><Proteasome Endopeptidase Complex><Protein Turnover><Proteins><Proteosome><RAFB1><Receptor Protein><Regulation><Regulatory Protein Degradation><Research><Research Proposals><Ring Finger><Ring Finger Domain><Ring Finger Motif><Ring-Type Zinc Finger Domain><Risk Factors><Role><S-Phase Kinase-Associated Protein 2><SEL-10><SEL10><SKP2><SKP2 gene><Secondary Neoplasm><Secondary Tumor><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin Cancer><Skp2 Proteins><Strains Cell Lines><System><Therapeutic Intervention><Treatment outcome><Tumor Promotion><Tumor Subtype><Tumor Suppressor Proteins><Tumor growth in melanoma><UV light><UV radiation><UV rays><Ubiquitilation><Ubiquitin><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Ultraviolet Rays><Xenograft><Xenograft procedure><Xenotransplantation><anti-cancer immunotherapy><anticancer immunotherapy><assess effectiveness><biologic><biological signal transduction><cancer immunotherapy><cancer metastasis><cancer microenvironment><cancer type><clinical practice><combat><cultured cell line><data base><de-ubiquitinase><de-ubiquitinating enzyme><determine effectiveness><developmental><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><gene defect><genome mutation><genome scale><genome sequencing><genome-wide><genomewide><hedgehog signaling><hedgehog signaling pathway><hh signaling pathway><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><innovate><innovation><innovative><insight><intervention therapy><malignancy><malignant skin tumor><melanocyte><melanomagenesis><mortality rate><mouse model><multicatalytic endopeptidase complex><murine model><mutant><mutant allele><neoplasm/cancer><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><patient prognosis><patients suffering from melanoma><patients with melanoma><potential biological marker><potential biomarker><prognostic biomarker><prognostic indicator><protein degradation><rapid growth><receptor><response to therapy><response to treatment><screening><screenings><smoothened signaling pathway><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapeutic target><therapy response><translation strategy><translational approach><translational strategy><treatment response><treatment responsiveness><tumor cell metastasis><tumor growth><tumor microenvironment><tumor suppressor><tumorigenesis><ubiquination><ubiquitin conjugation><ubiquitin isopeptidase><ubiquitin-protein ligase><ubiquitin-specific isopeptidase><ultra violet light><ultra violet radiation><ultra violet rays><ultraviolet light><ultraviolet radiation><v-raf Murine Sarcoma Viral Oncogene Homolog B1><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lauren Averett Byers

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$387,250

FY 2026

Project Title

DNA damaging therapy and immune response in small cell lung cancer subtypes

Grant Number:

5R01CA207295-10

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2016

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Small cell lung cancer (SCLC) is a highly aggressive disease for which there remains a critical need for therapies that provide durable benefit and biomarkers to guide treatment selection. While immunotherapy provides clinical benefit for some patients, overall survival with current ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mercedes Rincon

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$377,999

FY 2026

Project Title

Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response

Grant Number:

5R01CA260909-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY CAR-T immunotherapy has great promise as a salvage regimen for patients who will no longer respond to conventional therapies. Five CAR-T cell therapies (four targeting CD19 on cancer cells) have been approved by FDA for treatment of relapsed and/or refractory (r/r) B-lineage malignancies, in...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jinqiang Zhang

TULANE UNIVERSITY OF LOUISIANA, NEW ORLEANS, LA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$373,292

FY 2026

Project Title

Investigating the Immunosuppressive Function of lncRNA CRNDE in Hepatic Tumorigenesis

Grant Number:

5R01CA291766-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Hepatocellular carcinoma (HCC), a malignancy with compromised immune responses in tumor-infiltrating lymphocytes (TILs), is an attractive target for immunotherapy. Studies have demonstrated that the inhibitory immune-checkpoint signaling attributes notably to TIL dysfunctio...

Research Terms

<(TNF)-α><Address><Antitumor Response><Binding><Biochemistry><Biological><Biological Chemistry><Blast Transformation><Blastogenesis><Cachectin><Calcium Modulating Ligand><Calcium-Modulating Cyclophilin Ligand><Cancer Cause><Cancer Etiology><Cancers><Carcinoma Cell><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell secretion><Cell to Cell Communication and Signaling><Cell-Cell Signaling><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cells><Cellular Cytotoxicity><Cellular Secretion><Cessation of life><Ciclosporin><Clinical><Co-Stimulator><Colorectal Neoplasms><Colorectal Tumors><Complex><Costimulator><CsA><Cyclophilin B-Binding Protein><Cyclosporin A><Cyclosporine><Cyclosporine A><Data><Death><Dephosphorylation><Development><Dysfunction><Effectiveness><Epidermal Thymocyte Activating Factor><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Event><Exhibits><FK 506><FK506><FKBP-70><Functional RNA><Functional disorder><Future><Gene Expression><Genes><Genetic><Goals><Granzyme><Hepatic><Hepatic Cancer><Hepatic Neoplasms><Hepatocarcinogenesis><Hepatocarcinoma><Hepatocarcinoma model><Hepatocellular Carcinoma><Hepatocellular cancer><Hepatoma><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IL-2><IL2 Protein><Immune Evasion><Immune Interferon><Immune Modulation Therapy><Immune mediated therapy><Immune response><Immunity><Immunologically Directed Therapy><Immunomodulation><Immunosuppressants><Immunosuppression><Immunosuppression Effect><Immunosuppressive Agents><Immunosuppressive Effect><Immunosuppressive drug><Immunosuppressive treatment><Immunotherapeutic agent><Immunotherapy><Impairment><Incidence><Infiltration><Inflammation Mediators><Innate Immune Response><Interferon Gamma><Interferon Type II><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intracellular Communication and Signaling><Large Bowel Tumor><Large Intestine Neoplasm><Large Intestine Tumor><Ligands><Liver><Liver Carcinogenesis><Liver Cells Carcinoma><Liver neoplasms><Lymphoblast Transformation><Lymphocyte Activation><Lymphocyte Cytotoxicity><Lymphocyte Mitogenic Factor><Lymphocyte Stimulation><Lymphocyte Transformation><Lymphocytotoxicity><Macrophage-Derived TNF><Malignant Cell><Malignant Epithelial Cell><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of liver><Mediating><Methods><Mice><Mice Mammals><Mitogenic Factor><Modern Man><Molecular><Molecular Biology Techniques><Molecular Interaction><Monocyte-Derived TNF><Murine><Mus><NF-AT><NF-AT proteins><NFAT proteins><NFAT-1><NFATC proteins><Noncoding RNA><Nontranslated RNA><Oncogenesis><Outcome><Pathway interactions><Patients><Physiopathology><Play><Population Decreases><Primary carcinoma of the liver cells><Production><Protein Dephosphorylation><Proteins><Receptor Protein><Regimen><Regulation><Research><Ribonucleoproteins><Role><Sandimmun><SangCya><Signal Transduction><Signal Transduction Systems><Signaling><Specific qualifier value><Specified><T cell growth factor><T-Cell Growth Factor><T-Cell Stimulating Factor><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Tacrolimus><Testing><Therapeutic><Thymocyte Stimulating Factor><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Promotion><Tumor-Derived><Tumor-Infiltrating Lymphocytes><United States><Untranslated RNA><anti-cancer immunotherapy><anti-tumor immune response><anti-tumor immunity><anti-tumor response><anticancer immunotherapy><antitumor immunity><biologic><biological signal transduction><calcineurin phosphatase><calcium-signal modulating cyclophilin ligand><cancer cell><cancer immunity><cancer immunotherapy><cancer progression><carcinogenesis in the liver><cell mediated cytotoxicity><check point blockade><checkpoint blockade><colorectal neoplasia><cyclophilin B><cypB gene product><cytoplasmic nuclear factor of activated T-cells><developmental><differential expression><differentially expressed><effective therapy><effective treatment><epigenetically><evidence base><expectation><extracellular vesicles><hepatic body system><hepatic carcinogenesis><hepatic neoplasia><hepatic neoplasm><hepatic organ system><hepatic tumor><hepatocellular carcinogenesis><hepatocellular carcinoma cancer model><hepatocellular carcinoma model><host response><immune check point><immune check point blockade><immune checkpoint><immune checkpoint blockade><immune drugs><immune evasive><immune modulation><immune modulatory therapies><immune modulatory treatment><immune regulation><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune suppression><immune suppressive activity><immune suppressive agent><immune suppressive function><immune suppressor><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-modulation treatment><immunecheckpoint><immuno therapy><immunologic reactivity control><immunologic therapeutics><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory><immunomodulatory biologics><immunomodulatory therapies><immunomodulatory treatment><immunoregulation><immunoregulatory><immunoregulatory therapy><immunoregulatory treatment><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunosuppressive substance><immunosuppressor><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><immunotherapy trials><in vivo><inflammatory environment><inflammatory mediator><inflammatory milieu><innovate><innovation><innovative><intercellular communication><lFN-Gamma><large bowel neoplasm><liver cancer><liver cancer model><liver cancer pathogenesis><liver carcinoma><liver malignancy><liver tumor><liver tumorigenesis><malignancy><malignant liver tumor><mortality><mouse model><murine model><neoplasm progression><neoplasm/cancer><neoplastic progression><neoral><new approaches><next generation><noncoding><novel><novel approaches><novel strategies><novel strategy><nuclear factors of activated T-cells><pathophysiology><pathway><patient variability><patient variation><ppiB gene product><receptor><response><sandimmune><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><therapeutic immunomodulation><therapeutic immunoregulation><transcription factor NF-AT><transcriptional differences><tumor><tumor growth><tumor progression><tumorigenesis><variability between patients><variation between patients>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rafet Basar

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$370,575

FY 2026

Project Title

TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer

Grant Number:

5R01CA288617-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/5/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY/ ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate of only ~12%. Therefore, there is a critical unmet need for new treatment options. Chimeric antigen receptor (CAR)-T cells have led to a paradigm shift in the treatment of some hematologic c...

Research Terms

<APAF-3><APAF3><Adoptive Transfer><Allogenic><Apaf-3 protein><Apoptosis-Related Cysteine Protease Caspase 9><Apoptosis-Related Cysteine Protease Gene Caspase 9><Apoptotic Protease Activating Factor 3><Apoptotic Protease Activating Factor 3 Gene><Apoptotic Protease MCH-6><Apoptotic Protease MCH-6 Gene><Autologous><B-Cell Lymphomas><Basal Transcription Factor><Basal transcription factor genes><Biopsy><CAR NK><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CASP-9><CASP9><CASP9 Protein><CASP9 gene><CD19><CD19 gene><Cancer Treatment><Cancers><Caspase-9 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Antigens><Cell Surface Glycoproteins><Cell Therapy><Cells><Clinic><Clinical><Clinical Research><Clinical Study><Cord Blood><Cryofixation><Cryopreservation><Cyclic AMP Response Element><Cytotoxic cell><Data><Dose><Effector Cell><Endowment><Event><Exhibits><FDA approved><Gene Deletion><Gene Modified><General Transcription Factor Gene><General Transcription Factors><Generations><GvHD><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Homologous Wasting Disease><ICE-LAP6><ICE-LAP6 Gene><ICE-LAP6 protein><ICE-Like Apoptotic Protease 6><ICE-Like Apoptotic Protease 6 Gene><IL-15><IL15><IL15 Protein><Immune Targeting><Immunological Surface Markers><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><Lactic acid><Lymphocytic Neoplasm><Lymphocytic Tumor><Lymphocytic and Plasma Cell Neoplasm><Lymphocytic and Plasma Cell Tumour><Lymphocytic and Plasmacytic Neoplasm><Lymphoid Cell><Lymphoid Tumor><Lymphoid and Plasma Cell Tumour><Lymphoid and Plasmacytic Neoplasm><Lymphoid and Plasmacytic Tumour><MCH6><MGC9721><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mch6 protein><Membrane Glycoproteins><Metabolic><Multiple Myeloma><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Normal Tissue><Normal tissue morphology><PDA model><PDAC Model><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Patients><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Plasma-Cell Myeloma><Population><Proliferating><Proteomics><Protocol><Protocols documentation><Publishing><Reporting><Research><Resistance><Retroviral Vector><Retrovirus Vector><Runt Disease><Safety><Secondary to><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Specificity><Surface Antigens><Surface Glycoproteins><Survival Rate><T cells for CAR><T-Cells><T-Lymphocyte><Testing><Time><Toxic effect><Toxicities><Transcription Factor Proto-Oncogene><Transcription factor genes><Translations><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Umbilical Cord Blood><aerobic glycolysis><anti-cancer therapy><biobank><biological signal transduction><biorepository><cAMP Response Element><cancer antigens><cancer microenvironment><cancer therapy><cancer-directed therapy><caspase-9><cell based intervention><cell mediated intervention><cell mediated therapies><cell transduction><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transduction><check point inhibition><checkpoint inhibition><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor engineered natural killer cell><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><chimeric antigen receptor natural killer cells><cold preservation><cold storage><cost><cytokine><effective therapy><effective treatment><engineered NK cell><engineered natural killer cell><fabrication cost><fetal cord blood><first in man><first-in-human><fitness><gene deletion mutation><gene modification><genetically engineered cells><genetically modified><genetically modified cells><graft versus host disease><graft vs host disease><graft vs. host disease><human study><immune check point><immune check point inhibition><immune checkpoint><immune checkpoint inhibition><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immunecheckpoint><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved outcome><in vitro Model><in vivo><innovate><innovation><innovative><intraperitoneal><lymphoid neoplasm><malignancy><manufacture><manufacturing cost><manufacturing process><metabolic fitness><mouse model><murine model><myeloma><myelomatosis><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cells expressing chimeric antigen receptors><natural killer cells with chimeric antigen receptors><natural killer cellular therapy><natural killer therapy><neoplasm/cancer><neoplastic cell><new approaches><next generation><novel><novel approaches><novel strategies><novel strategy><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><patients with pancreatic cancer><peripheral blood><pharmacologic><point of care><pre-clinical><preclinical><resistant><response><safety testing><success><therapeutic target><thymus derived lymphocyte><transcription factor><transcriptomics><transduced cells><translation><trophoblast><tumor><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><tumor-specific antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hind Rafei

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$370,575

FY 2026

Project Title

TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer

Grant Number:

5R01CA288617-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/5/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY/ ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate of only ~12%. Therefore, there is a critical unmet need for new treatment options. Chimeric antigen receptor (CAR)-T cells have led to a paradigm shift in the treatment of some hematologic c...

Research Terms

<APAF-3><APAF3><Adoptive Transfer><Allogenic><Apaf-3 protein><Apoptosis-Related Cysteine Protease Caspase 9><Apoptosis-Related Cysteine Protease Gene Caspase 9><Apoptotic Protease Activating Factor 3><Apoptotic Protease Activating Factor 3 Gene><Apoptotic Protease MCH-6><Apoptotic Protease MCH-6 Gene><Autologous><B-Cell Lymphomas><Basal Transcription Factor><Basal transcription factor genes><Biopsy><CAR NK><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CASP-9><CASP9><CASP9 Protein><CASP9 gene><CD19><CD19 gene><Cancer Treatment><Cancers><Caspase-9 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Antigens><Cell Surface Glycoproteins><Cell Therapy><Cells><Clinic><Clinical><Clinical Research><Clinical Study><Cord Blood><Cryofixation><Cryopreservation><Cyclic AMP Response Element><Cytotoxic cell><Data><Dose><Effector Cell><Endowment><Event><Exhibits><FDA approved><Gene Deletion><Gene Modified><General Transcription Factor Gene><General Transcription Factors><Generations><GvHD><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Homologous Wasting Disease><ICE-LAP6><ICE-LAP6 Gene><ICE-LAP6 protein><ICE-Like Apoptotic Protease 6><ICE-Like Apoptotic Protease 6 Gene><IL-15><IL15><IL15 Protein><Immune Targeting><Immunological Surface Markers><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><Lactic acid><Lymphocytic Neoplasm><Lymphocytic Tumor><Lymphocytic and Plasma Cell Neoplasm><Lymphocytic and Plasma Cell Tumour><Lymphocytic and Plasmacytic Neoplasm><Lymphoid Cell><Lymphoid Tumor><Lymphoid and Plasma Cell Tumour><Lymphoid and Plasmacytic Neoplasm><Lymphoid and Plasmacytic Tumour><MCH6><MGC9721><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mch6 protein><Membrane Glycoproteins><Metabolic><Multiple Myeloma><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Normal Tissue><Normal tissue morphology><PDA model><PDAC Model><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Patients><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Plasma-Cell Myeloma><Population><Proliferating><Proteomics><Protocol><Protocols documentation><Publishing><Reporting><Research><Resistance><Retroviral Vector><Retrovirus Vector><Runt Disease><Safety><Secondary to><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Specificity><Surface Antigens><Surface Glycoproteins><Survival Rate><T cells for CAR><T-Cells><T-Lymphocyte><Testing><Time><Toxic effect><Toxicities><Transcription Factor Proto-Oncogene><Transcription factor genes><Translations><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Umbilical Cord Blood><aerobic glycolysis><anti-cancer therapy><biobank><biological signal transduction><biorepository><cAMP Response Element><cancer antigens><cancer microenvironment><cancer therapy><cancer-directed therapy><caspase-9><cell based intervention><cell mediated intervention><cell mediated therapies><cell transduction><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transduction><check point inhibition><checkpoint inhibition><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor engineered natural killer cell><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><chimeric antigen receptor natural killer cells><cold preservation><cold storage><cost><cytokine><effective therapy><effective treatment><engineered NK cell><engineered natural killer cell><fabrication cost><fetal cord blood><first in man><first-in-human><fitness><gene deletion mutation><gene modification><genetically engineered cells><genetically modified><genetically modified cells><graft versus host disease><graft vs host disease><graft vs. host disease><human study><immune check point><immune check point inhibition><immune checkpoint><immune checkpoint inhibition><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immunecheckpoint><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved outcome><in vitro Model><in vivo><innovate><innovation><innovative><intraperitoneal><lymphoid neoplasm><malignancy><manufacture><manufacturing cost><manufacturing process><metabolic fitness><mouse model><murine model><myeloma><myelomatosis><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cells expressing chimeric antigen receptors><natural killer cells with chimeric antigen receptors><natural killer cellular therapy><natural killer therapy><neoplasm/cancer><neoplastic cell><new approaches><next generation><novel><novel approaches><novel strategies><novel strategy><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><patients with pancreatic cancer><peripheral blood><pharmacologic><point of care><pre-clinical><preclinical><resistant><response><safety testing><success><therapeutic target><thymus derived lymphocyte><transcription factor><transcriptomics><transduced cells><translation><trophoblast><tumor><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><tumor-specific antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Katy Rezvani

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$370,575

FY 2026

Project Title

TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer

Grant Number:

5R01CA288617-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/5/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY/ ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate of only ~12%. Therefore, there is a critical unmet need for new treatment options. Chimeric antigen receptor (CAR)-T cells have led to a paradigm shift in the treatment of some hematologic c...

Research Terms

<APAF-3><APAF3><Adoptive Transfer><Allogenic><Apaf-3 protein><Apoptosis-Related Cysteine Protease Caspase 9><Apoptosis-Related Cysteine Protease Gene Caspase 9><Apoptotic Protease Activating Factor 3><Apoptotic Protease Activating Factor 3 Gene><Apoptotic Protease MCH-6><Apoptotic Protease MCH-6 Gene><Autologous><B-Cell Lymphomas><Basal Transcription Factor><Basal transcription factor genes><Biopsy><CAR NK><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CASP-9><CASP9><CASP9 Protein><CASP9 gene><CD19><CD19 gene><Cancer Treatment><Cancers><Caspase-9 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Antigens><Cell Surface Glycoproteins><Cell Therapy><Cells><Clinic><Clinical><Clinical Research><Clinical Study><Cord Blood><Cryofixation><Cryopreservation><Cyclic AMP Response Element><Cytotoxic cell><Data><Dose><Effector Cell><Endowment><Event><Exhibits><FDA approved><Gene Deletion><Gene Modified><General Transcription Factor Gene><General Transcription Factors><Generations><GvHD><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Homologous Wasting Disease><ICE-LAP6><ICE-LAP6 Gene><ICE-LAP6 protein><ICE-Like Apoptotic Protease 6><ICE-Like Apoptotic Protease 6 Gene><IL-15><IL15><IL15 Protein><Immune Targeting><Immunological Surface Markers><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><Lactic acid><Lymphocytic Neoplasm><Lymphocytic Tumor><Lymphocytic and Plasma Cell Neoplasm><Lymphocytic and Plasma Cell Tumour><Lymphocytic and Plasmacytic Neoplasm><Lymphoid Cell><Lymphoid Tumor><Lymphoid and Plasma Cell Tumour><Lymphoid and Plasmacytic Neoplasm><Lymphoid and Plasmacytic Tumour><MCH6><MGC9721><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mch6 protein><Membrane Glycoproteins><Metabolic><Multiple Myeloma><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Normal Tissue><Normal tissue morphology><PDA model><PDAC Model><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Patients><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Plasma-Cell Myeloma><Population><Proliferating><Proteomics><Protocol><Protocols documentation><Publishing><Reporting><Research><Resistance><Retroviral Vector><Retrovirus Vector><Runt Disease><Safety><Secondary to><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Specificity><Surface Antigens><Surface Glycoproteins><Survival Rate><T cells for CAR><T-Cells><T-Lymphocyte><Testing><Time><Toxic effect><Toxicities><Transcription Factor Proto-Oncogene><Transcription factor genes><Translations><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Umbilical Cord Blood><aerobic glycolysis><anti-cancer therapy><biobank><biological signal transduction><biorepository><cAMP Response Element><cancer antigens><cancer microenvironment><cancer therapy><cancer-directed therapy><caspase-9><cell based intervention><cell mediated intervention><cell mediated therapies><cell transduction><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transduction><check point inhibition><checkpoint inhibition><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor engineered natural killer cell><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><chimeric antigen receptor natural killer cells><cold preservation><cold storage><cost><cytokine><effective therapy><effective treatment><engineered NK cell><engineered natural killer cell><fabrication cost><fetal cord blood><first in man><first-in-human><fitness><gene deletion mutation><gene modification><genetically engineered cells><genetically modified><genetically modified cells><graft versus host disease><graft vs host disease><graft vs. host disease><human study><immune check point><immune check point inhibition><immune checkpoint><immune checkpoint inhibition><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immunecheckpoint><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved outcome><in vitro Model><in vivo><innovate><innovation><innovative><intraperitoneal><lymphoid neoplasm><malignancy><manufacture><manufacturing cost><manufacturing process><metabolic fitness><mouse model><murine model><myeloma><myelomatosis><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cells expressing chimeric antigen receptors><natural killer cells with chimeric antigen receptors><natural killer cellular therapy><natural killer therapy><neoplasm/cancer><neoplastic cell><new approaches><next generation><novel><novel approaches><novel strategies><novel strategy><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><patients with pancreatic cancer><peripheral blood><pharmacologic><point of care><pre-clinical><preclinical><resistant><response><safety testing><success><therapeutic target><thymus derived lymphocyte><transcription factor><transcriptomics><transduced cells><translation><trophoblast><tumor><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><tumor-specific antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BRIDGET KEENAN

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 58/100

Training-friendly

Solid budget

Recent

Active award

$282,053

FY 2026

Project Title

Liver disease impact on myeloid cells driving immunotherapy resistance in hepatocellular carcinoma

Grant Number:

5K08CA290152-02

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary/Abstract Recent advances in the treatment of hepatocellular carcinoma (HCC) with immunotherapy have improved therapeutic options for patients living with this cancer; however, many patients still do not benefit, and response to immunotherapy regimens is complicated by underlying live...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yvonne Margaret Saenger

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Good lead · 56/100

Above-average budget

Very recent

Active award

Career award

$707,977

FY 2026

Project Title

Montefiore Einstein Clinical Oncology Training Program in the Bronx

Grant Number:

5K12CA279871-04

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The goal of Einstein/Montefiore Paul Calabresi Career Development Award for Clinical Oncology Research is to train the next generation of oncology scholars, with a special emphasis on conducting clinical and translational research. This will be achieved through a coordinated program of ment...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Amit K. Verma

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Good lead · 56/100

Above-average budget

Very recent

Active award

Career award

$707,977

FY 2026

Project Title

Montefiore Einstein Clinical Oncology Training Program in the Bronx

Grant Number:

5K12CA279871-04

Activity Code:

K12

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The goal of Einstein/Montefiore Paul Calabresi Career Development Award for Clinical Oncology Research is to train the next generation of oncology scholars, with a special emphasis on conducting clinical and translational research. This will be achieved through a coordinated program of ment...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Regina M Myers

CHILDREN'S HOSP OF PHILADELPHIA, PHILADELPHIA, PA

Good lead · 56/100

Training-friendly

Very recent

Active award

Career award

$181,074

FY 2026

Project Title

Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy

Grant Number:

5K08CA277013-04

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT This K08 Award encompasses a research and training plan to facilitate Dr. Regina Myers' transition to an independent clinical investigator. Dr. Myers is currently an Instructor of Pediatrics and a pediatric oncology and cell therapy physician at Children's Hospital of Philad...

Research Terms

<0-11 years old><21+ years old><Acute B-Lymphocytic Leukemia><Adult><Adult Human><Antigen Targeting><Award><B-ALL><B-Cell Acute Lymphocytic Leukemia><B-Cell Acute Lymphoblastic Leukemia><B-Cell Lymphoblastic Leukemia><B-Lymphocyte Antigen CD19><B-Lymphocyte Surface Antigen B4><B-cell ALL><B-cell precursor acute lymphoblastic leukemia><Biological Markers><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD19><CD19 Antigens><CD19 gene><CD19 molecule><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><Cell Therapy><Child><Child Youth><Childhood><Childhood Cancers><Children (0-21)><Children's Hospital><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Design><Cytotoxic agent><Cytotoxic drug><Data><Detectable Residual Disease><Differentiation Antigen CD19><Disease remission><Disease-Free Survival><Enrollment><Environment><Epidemiologic Methodology><Epidemiologic Methods><Epidemiologic Research><Epidemiologic research methodology><Epidemiologic research methods><Epidemiological Methods><Epidemiological Techniques><Event-Free Survival><Experimental Therapies><Failure><Foundations><Frequencies><Goals><HSC transplantation><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Immune><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Infrastructure><Instruction><International><Investigational Therapies><Investigational Treatments><K-Awards><K-Series Research Career Programs><Lead><Leu 12><Malignant Childhood Neoplasm><Malignant Childhood Tumor><Malignant Hematologic Neoplasm><Malignant Pediatric Neoplasm><Malignant Pediatric Tumor><Malignant childhood cancer><Mediating><Mentorship><Methods><Methods Epidemiology><Methods in epidemiology><Mice><Mice Mammals><Minimal Residual Disease><Murine><Mus><NGS Method><NGS system><Outcome><Outcomes Research><Patients><Pb element><Pediatric Hospitals><Pediatric Oncology><Pediatrics><Pennsylvania><Phase><Phase 1/2 Clinical Trial><Phase I Study><Phase I/II Clinical Trial><Philadelphia><Physicians><Pre-B-Cell Leukemia><Precursor B Lymphoblastic Leukemia><Predictive Value><Process Assessment><Prognosis><Proxy><Recommendation><Refractory><Relapse><Remission><Research><Research Career Program><Research Infrastructure><Research Resources><Residual Neoplasm><Residual Tumors><Resources><Safety><Scientist><T cells for CAR><Testing><Therapeutic><Time><Toxic effect><Toxicities><Training><Transplant Recipients><Universities><Variant><Variation><adult youth><adulthood><anti-cancer immunotherapy><anticancer immunotherapy><arm><bio-markers><biologic marker><biomarker><blood stem cell transplantation><cancer clinical trial><cancer immunotherapy><cancer in a child><cancer in children><career><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chemotherapy><child with cancer><childhood malignancy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical epidemiology><cohort><comparative effectiveness><comparative effectiveness study><compare effectiveness><conventional therapy><conventional treatment><data collected in real world><data pipeline><data resource><design><designing><early clinical trial><early phase clinical trial><effective therapy><effective treatment><efficacy outcomes><enroll><epidemiologic investigation><epidemiology research study><epidemiology study><epidemiology survey><evidence base><experience><experimental therapeutic agents><experimental therapeutics><heavy metal Pb><heavy metal lead><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor cell transplantation><high risk><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunotherapy clinical trials><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><innovate><innovation><innovative><instructor><investigate epidemiology><kids><leukemia><multidisciplinary><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><oncology clinical trial><patient prognosis><pediatric><pediatric cancer><pediatric malignancy><phase 1 study><phase 1 trial><phase I trial><programs><randomized, clinical trials><real world data><residual disease><response><safety outcomes><secondary analysis><specific biomarkers><study epidemiology><survey epidemiology><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transplant patient><treatment strategy><young adult><young adult age><young adulthood><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joyce Keshin Hwang

DUKE UNIVERSITY, DURHAM, NC

Good lead · 56/100

Training-friendly

Very recent

Active award

Career award

$106,164

FY 2026

Project Title

Modulation of HIV immune control by HLA-E-VL9 and HLA-E-VL9 binding antibodies

Grant Number:

1K99AI197913-01

Activity Code:

K99

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY. Introduction: HLA-E is a non-classical HLA class Ib molecule, which like classical HLA class Ia (HLA-A/B/C) presents intracellular virus-derived peptides. Unlike class Ia molecules, HLA-E is limited in polymorphisms and has an additional major role in presenting a conserved self pep...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lukasz Bugaj

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$498,878

FY 2026

Project Title

A molecular toolbox for thermal control of programmed cell death in animals

Grant Number:

5R01EB037456-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary/Abstract The objective of this proposal is to develop a molecular toolbox for non-invasive methods to kill cells in situ via specific cell death pathways using safe, penetrant, and tunable temperature stimuli. There is an urgent need for new technology that can engage specific forms of cell ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Samuel R Denmeade

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 52/100

Likely hiring

Solid budget

Active award

$495,606

FY 2026

Project Title

Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response

Grant Number:

5R01CA243184-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2021

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Bipolar androgen therapy (BAT) is a paradoxical approach for the treatment of castration-resistant prostate cancer (CRPC) whereby testosterone levels are rapidly cycled between supraphysiologic and castrate concentrations. Understanding how BAT works at the molecular and cellular levels might help i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sushant Krishna Kachhap

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 52/100

Likely hiring

Solid budget

Active award

$495,606

FY 2026

Project Title

Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response

Grant Number:

5R01CA243184-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2021

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Bipolar androgen therapy (BAT) is a paradoxical approach for the treatment of castration-resistant prostate cancer (CRPC) whereby testosterone levels are rapidly cycled between supraphysiologic and castrate concentrations. Understanding how BAT works at the molecular and cellular levels might help i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Pamela Rosato

DARTMOUTH COLLEGE, HANOVER, NH

Good lead · 52/100

Likely hiring

Solid budget

Active award

$494,877

FY 2026

Project Title

Therapeutically harnessing anti-viral resident memory T cells in solid tumors

Grant Number:

5R01CA269455-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Recent studies have revealed an abundance of resident memory T cells (TRM) specific for viral infections in a wide range of tumors, often outnumbering cancer-specific T cells. As these cells lack specificity to tumor antigens, they are spared from the hallmark exhaustion/dys...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Automobile Driving><B7-H1><Blood Tests><Body Tissues><Burkitt Herpesvirus><Burkitt Lymphoma Virus><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CMV><CMV infection><COVID-19 virus><COVID19 virus><Cancers><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Clinic><Clinical><CoV-2><CoV2><Complement><Complement Proteins><Cytomegalic Inclusion Disease><Cytomegalovirus><Cytomegalovirus Infections><Data><Detection><Development><Dysfunction><EB virus><EBV><EBV Infections><Environment><Epstein Barr Virus><Epstein-Barr Virus Infections><Epstein-Barr viral infections><Functional disorder><HCMV><HHV-4><HHV4><Hematologic Tests><Hematological Tests><Hematology Testing><Human><Human Herpesvirus 4><Immune><Immune Surveillance><Immune mediated therapy><Immunes><Immunochemical Immunologic><Immunologic><Immunologic Surveillance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapy><Inclusion Disease><Infection><Infectious Mononucleosis Virus><Inflammatory><Influenza A><Influenza A virus><Influenza Viruses Type A><Influenzavirus A><Innate Immunity><Knowledge><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Melanoma><Melanoma Tumor><Melanoma patient><Memory><Messenger RNA><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Murine><Mus><Native Immunity><Natural Immunity><Non-Specific Immunity><Nonspecific Immunity><Orthomyxovirus Type A><PD-L1><PD-L1 antibody><PDL-1><Patients><Peptides><Physiopathology><Population><Predisposition><Production><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Resistance><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Salivary Gland Virus Disease><Salivary Gland Viruses><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Slice><Solid Neoplasm><Solid Tumor><Specificity><Staining method><Stains><Subcellular Process><Susceptibility><System><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Tissues><Translations><Treatment Efficacy><Tumor Antigens><Tumor Cell><Tumor Immunity><Tumor growth in melanoma><Tumor-Associated Antigen><Type A Influenza><Vaccines><Viral><Viral Antigens><Viral Diseases><Virus><Virus Diseases><Work><Wuhan coronavirus><aPD-L1><aPD-L1 antibodies><adaptive immune response><adaptive immunity><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti programmed cell death ligand 1><anti programmed cell death protein ligand 1><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-cancer immunotherapy><anti-tumor immune therapy><anti-tumor immunity><anti-tumor immunotherapy><antiPD-L1><anticancer immunotherapy><antitumor immunity><cancer antigens><cancer immunity><cancer immunotherapy><cell killing><check point blockade><checkpoint blockade><clinical significance><clinical translation><clinically significant><clinically translatable><combinatorial><complementation><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytokine><cytomegalovirus group><cytotoxic><developmental><driving><exhaustion><flu infection><flu virus infection><hCoV19><human model><immune check point blockade><immune checkpoint blockade><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><in vivo><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza virus infection><innovate><innovation><innovative><intervention efficacy><mRNA><malignancy><melanoma cancer model><melanoma model><melanoma tumor model><model of human><mouse model><murine model><nCoV2><neoplasm immunotherapy><neoplasm/cancer><neoplastic cell><new approaches><novel><novel approaches><novel strategies><novel strategy><pathogen><pathophysiology><patients suffering from melanoma><patients with melanoma><programmed cell death ligand 1><programmed cell death protein ligand 1><protein death-ligand 1><recruit><resident memory T cell><resistant><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic T-cell platform><therapeutic efficacy><therapy efficacy><thymus derived lymphocyte><tissue resident memory T cell><translation><translational therapeutics><translational therapy><tumor><tumor growth><tumor immune therapy><tumor immunotherapy><tumor-specific antigen><viral infection><virus antigen><virus infection><virus-induced disease><αPD-L1><αPD-L1 antibodies><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Qing Yi

METHODIST HOSPITAL RESEARCH INSTITUTE, HOUSTON, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$489,857

FY 2026

Project Title

Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors

Grant Number:

5R01CA285209-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Adoptive cell transfer using tumor-specific T cells is a promising option for cancer treatment and the most powerful tumor-killing effector T cells are CD8+ type-1 cytotoxic T cells (Tc1). We have shown that IL-9- secreting CD8+ Tc9 cells mediate stronger and long-lasting antitumor e...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

George V Aslanidi

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 52/100

Likely hiring

Solid budget

Active award

$485,977

FY 2026

Project Title

Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.

Grant Number:

5R01CA285620-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/8/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Vaccination is a potent regulator of the immune system and much research is being conducted to understand how antigen-specific stimulation can be used to induce and redirect anti-tumor immunity. Our team develops a cancer immunotherapy program using novel AAV vectors to deli...

Research Terms

<(TNF)-α><5,6-dihydroxyindole-2-carboxylic acid oxidase><AAV vector><AAV-based vector><Achievement><Achievement Attainment><Active Immunization><Active vaccination><Address><Adeno-Associated Viruses><Adjuvant><Age><Animal Model><Animal Models and Related Studies><Antigen Presentation Pathway><Antigen Processing and Presentation><Antigen Targeting><Antigen-Presenting Cells><Antigens><Antineoplastic Vaccine><Assay><Basic Research><Basic Science><Bioassay><Biological Assay><Biomedical Engineering><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CMV><Cachectin><Cancer Treatment><Cancer Vaccines><Cancers><Canine Species><Canis familiaris><Capsid><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chemotactic Cytokines><Class I Antigens><Class I Major Histocompatibility Antigens><Clone Cells><Complex><Complex Class 1><Cresolase><Cross Presentation><Cutaneous Melanoma><Cytomegalovirus><DHI2C oxidase><DHICA oxidase><DNA Replication><DNA Synthesis><DNA biosynthesis><DNA cassette><Data><Dendritic Cells><Dependoparvovirus><Dependovirus><Development><Disease Progression><Dissection><Disseminated Malignant Neoplasm><Dogs><Dogs Mammals><Dopa Oxidase><Dopachrome isomerase><Dose><Dose Limiting><ELISA><Engineering><Environmental Exposure><Enzyme-Linked Immunosorbent Assay><Equilibrium><Expression Signature><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Functional impairment><GP100><Gene Expression Profile><Gene Therapy Vectors><Gene Transduction Agent><Gene Transduction Vectors><Genes><Genetic><Genetic Markers><Genotoxins><HCMV><Heterogeneity><Histocompatibility Antigens Class I><Homologous Chemotactic Cytokines><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><Immune><Immune Interferon><Immune Modulation Therapy><Immune Regulators><Immune mediated therapy><Immune response><Immune system><Immunes><Immunologic Stimulation><Immunological Stimulation><Immunologically Directed Therapy><Immunomodulators><Immunostimulation><Immunotherapy><Individual><Inflammatory Response><Injections><Intercrines><Interferon Gamma><Interferon Type II><Intracellular Communication and Signaling><Intramuscular><Kinetics><L-Serine><L-Threonine><L-Valine><LYT3><Lip and Oral Cavity Neoplasm><Lip and Oral Cavity Tumour><Local Therapy><Localized Therapy><ME20><MHC Class I Molecule><MHC Class I Protein><MHC class I antigen><Macrophage-Derived TNF><Major Histocompatibility Complex Class 1><Malignant Cutaneous Melanoma><Malignant Melanoma><Malignant Melanoma of Skin><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measures><Melanocyte Protein 17><Melanoma><Melanoma Skin><Melanoma Tumor><Metastasis><Metastasize><Metastatic Cancer><Metastatic Lesion><Metastatic Malignant Neoplasm><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Modeling><Modern Man><Modification><Molecular><Monocyte-Derived TNF><Monophenol Monooxygenase><Mouse Homolog of SILVER><Mouth Neoplasms><Mouth Tumor><Mucosa><Mucosal Tissue><Mucous Membrane><Mutagens><Neoplasm Metastasis><Neoplasm Vaccines><Nuclear Translocation><Oncologist><Operative Procedures><Operative Surgical Procedures><Oral><Oral Cavity Neoplasm><Oral Cavity Tumor><Oral Melanoma><Oral Neoplasms><Oral Tumor><PMEL gene><PMEL protein><PMEL17><Patients><Persons><Phenol Oxidase><Phenoloxidase><Population><Pre-Clinical Model><Preclinical Models><Premelanosomal Protein><Prevalence><Production><Proliferating><Property><Public Health><Recurrent Neoplasm><Recurrent tumor><Reporting><Research><Resistance><SILV gene><SILV protein><SIS cytokines><Safety><Salivary Gland Viruses><Secondary Neoplasm><Secondary Tumor><Serine><Serotyping><Signal Transduction><Signal Transduction Systems><Signaling><Site><Surface><Surgical><Surgical Interventions><Surgical Procedure><T-Cell Proliferation><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><TRP-2><Testing><Therapeutic><Threonine><Toxic effect><Toxicities><Treatment Failure><Treatment outcome><Tumor Antigens><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Vaccines><Tumor growth in melanoma><Tumor-Associated Antigen><Tyrosinase><Tyrosinase related protein-1><Tyrosinase-Related Protein-2><VAC-TX><Vaccination><Vaccine Therapy><Vaccines><Valine><Veiled Cells><Viral><Viral Genome><Virus><accessory cell><adaptive immune response><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><ages><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immunity><anti-tumor vaccine><anticancer immunotherapy><antigen processing><antitumor immunity><balance><balance function><bio-engineered><bio-engineers><bioengineering><biological engineering><biological signal transduction><cancer antigens><cancer immunity><cancer immunotherapy><cancer metastasis><cancer therapy><cancer-directed therapy><canine><chemoattractant cytokine><chemokine><chemotherapy><clinical relevance><clinically relevant><combinatorial><companion dog><cytokine><cytomegalovirus group><dermal melanoma><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><dihydroxyindole-carboxylic acid oxidase><domestic dog><dopachrome conversion factor><dopachrome oxidoreductase><dopachrome tautomerase><dosage><enhancer cassette><enzyme linked immunoassay><experiment><experimental research><experimental study><experiments><exposure to environmental agents><exposure to environmental factors><exposure to environmental stimuli><exposure to environmental substances><expression cassette><flow cytophotometry><gene biomarker><gene cassette><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic biomarker><genetic cassette><genotoxic agent><host response><immune modulators><immune modulatory therapies><immune modulatory treatment><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunogen><immunogenic><immunogenicity><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory biologics><immunomodulatory molecules><immunomodulatory therapies><immunomodulatory treatment><immunoregulator><immunoregulatory molecules><immunoregulatory therapy><immunoregulatory treatment><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><integration cassette><lFN-Gamma><malignancy><model of animal><monophenol oxidase><mucosal melanoma><multiplex assay><neoplasm recurrence><neoplasm/cancer><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><new vaccines><next generation><next generation vaccines><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><novel vaccines><oral neoplasia><pre-clinical><pre-clinical study><preclinical><preclinical study><programs><promoter><promoter cassette><promotor><reporter cassette><resistance cassette><resistant><response><selectable cassette><selection cassette><side effect><stop cassette><surgery><therapeutic agent development><therapeutic development><therapeutic immunomodulation><therapeutic immunoregulation><therapeutic vaccination><therapy failure><thymus derived lymphocyte><trafficking><transcription cassette><transcriptional cassette><transcriptional profile><transcriptional signature><transduction efficiency><transgene cassette><tumor><tumor cell metastasis><tumor diagnosis><tumor-specific antigen><tyrosinase-related TRP-1 protein><tyrosinase-related TRP1 protein><tyrosinase-related protein><vaccine development><vaccine for cancer><vaccine platform><vaccine strategy><vector><viral DNA><virus DNA><virus genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Antonella M Borgatti

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 52/100

Likely hiring

Solid budget

Active award

$485,977

FY 2026

Project Title

Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.

Grant Number:

5R01CA285620-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/8/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Vaccination is a potent regulator of the immune system and much research is being conducted to understand how antigen-specific stimulation can be used to induce and redirect anti-tumor immunity. Our team develops a cancer immunotherapy program using novel AAV vectors to deli...

Research Terms

<(TNF)-α><5,6-dihydroxyindole-2-carboxylic acid oxidase><AAV vector><AAV-based vector><Achievement><Achievement Attainment><Active Immunization><Active vaccination><Address><Adeno-Associated Viruses><Adjuvant><Age><Animal Model><Animal Models and Related Studies><Antigen Presentation Pathway><Antigen Processing and Presentation><Antigen Targeting><Antigen-Presenting Cells><Antigens><Antineoplastic Vaccine><Assay><Basic Research><Basic Science><Bioassay><Biological Assay><Biomedical Engineering><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CMV><Cachectin><Cancer Treatment><Cancer Vaccines><Cancers><Canine Species><Canis familiaris><Capsid><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chemotactic Cytokines><Class I Antigens><Class I Major Histocompatibility Antigens><Clone Cells><Complex><Complex Class 1><Cresolase><Cross Presentation><Cutaneous Melanoma><Cytomegalovirus><DHI2C oxidase><DHICA oxidase><DNA Replication><DNA Synthesis><DNA biosynthesis><DNA cassette><Data><Dendritic Cells><Dependoparvovirus><Dependovirus><Development><Disease Progression><Dissection><Disseminated Malignant Neoplasm><Dogs><Dogs Mammals><Dopa Oxidase><Dopachrome isomerase><Dose><Dose Limiting><ELISA><Engineering><Environmental Exposure><Enzyme-Linked Immunosorbent Assay><Equilibrium><Expression Signature><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Functional impairment><GP100><Gene Expression Profile><Gene Therapy Vectors><Gene Transduction Agent><Gene Transduction Vectors><Genes><Genetic><Genetic Markers><Genotoxins><HCMV><Heterogeneity><Histocompatibility Antigens Class I><Homologous Chemotactic Cytokines><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><Immune><Immune Interferon><Immune Modulation Therapy><Immune Regulators><Immune mediated therapy><Immune response><Immune system><Immunes><Immunologic Stimulation><Immunological Stimulation><Immunologically Directed Therapy><Immunomodulators><Immunostimulation><Immunotherapy><Individual><Inflammatory Response><Injections><Intercrines><Interferon Gamma><Interferon Type II><Intracellular Communication and Signaling><Intramuscular><Kinetics><L-Serine><L-Threonine><L-Valine><LYT3><Lip and Oral Cavity Neoplasm><Lip and Oral Cavity Tumour><Local Therapy><Localized Therapy><ME20><MHC Class I Molecule><MHC Class I Protein><MHC class I antigen><Macrophage-Derived TNF><Major Histocompatibility Complex Class 1><Malignant Cutaneous Melanoma><Malignant Melanoma><Malignant Melanoma of Skin><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measures><Melanocyte Protein 17><Melanoma><Melanoma Skin><Melanoma Tumor><Metastasis><Metastasize><Metastatic Cancer><Metastatic Lesion><Metastatic Malignant Neoplasm><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Modeling><Modern Man><Modification><Molecular><Monocyte-Derived TNF><Monophenol Monooxygenase><Mouse Homolog of SILVER><Mouth Neoplasms><Mouth Tumor><Mucosa><Mucosal Tissue><Mucous Membrane><Mutagens><Neoplasm Metastasis><Neoplasm Vaccines><Nuclear Translocation><Oncologist><Operative Procedures><Operative Surgical Procedures><Oral><Oral Cavity Neoplasm><Oral Cavity Tumor><Oral Melanoma><Oral Neoplasms><Oral Tumor><PMEL gene><PMEL protein><PMEL17><Patients><Persons><Phenol Oxidase><Phenoloxidase><Population><Pre-Clinical Model><Preclinical Models><Premelanosomal Protein><Prevalence><Production><Proliferating><Property><Public Health><Recurrent Neoplasm><Recurrent tumor><Reporting><Research><Resistance><SILV gene><SILV protein><SIS cytokines><Safety><Salivary Gland Viruses><Secondary Neoplasm><Secondary Tumor><Serine><Serotyping><Signal Transduction><Signal Transduction Systems><Signaling><Site><Surface><Surgical><Surgical Interventions><Surgical Procedure><T-Cell Proliferation><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><TRP-2><Testing><Therapeutic><Threonine><Toxic effect><Toxicities><Treatment Failure><Treatment outcome><Tumor Antigens><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Vaccines><Tumor growth in melanoma><Tumor-Associated Antigen><Tyrosinase><Tyrosinase related protein-1><Tyrosinase-Related Protein-2><VAC-TX><Vaccination><Vaccine Therapy><Vaccines><Valine><Veiled Cells><Viral><Viral Genome><Virus><accessory cell><adaptive immune response><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><ages><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immunity><anti-tumor vaccine><anticancer immunotherapy><antigen processing><antitumor immunity><balance><balance function><bio-engineered><bio-engineers><bioengineering><biological engineering><biological signal transduction><cancer antigens><cancer immunity><cancer immunotherapy><cancer metastasis><cancer therapy><cancer-directed therapy><canine><chemoattractant cytokine><chemokine><chemotherapy><clinical relevance><clinically relevant><combinatorial><companion dog><cytokine><cytomegalovirus group><dermal melanoma><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><dihydroxyindole-carboxylic acid oxidase><domestic dog><dopachrome conversion factor><dopachrome oxidoreductase><dopachrome tautomerase><dosage><enhancer cassette><enzyme linked immunoassay><experiment><experimental research><experimental study><experiments><exposure to environmental agents><exposure to environmental factors><exposure to environmental stimuli><exposure to environmental substances><expression cassette><flow cytophotometry><gene biomarker><gene cassette><gene expression biomarker><gene expression pattern><gene expression signature><gene marker><gene signature biomarker><genetic biomarker><genetic cassette><genotoxic agent><host response><immune modulators><immune modulatory therapies><immune modulatory treatment><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunogen><immunogenic><immunogenicity><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory biologics><immunomodulatory molecules><immunomodulatory therapies><immunomodulatory treatment><immunoregulator><immunoregulatory molecules><immunoregulatory therapy><immunoregulatory treatment><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><integration cassette><lFN-Gamma><malignancy><model of animal><monophenol oxidase><mucosal melanoma><multiplex assay><neoplasm recurrence><neoplasm/cancer><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><new vaccines><next generation><next generation vaccines><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><novel vaccines><oral neoplasia><pre-clinical><pre-clinical study><preclinical><preclinical study><programs><promoter><promoter cassette><promotor><reporter cassette><resistance cassette><resistant><response><selectable cassette><selection cassette><side effect><stop cassette><surgery><therapeutic agent development><therapeutic development><therapeutic immunomodulation><therapeutic immunoregulation><therapeutic vaccination><therapy failure><thymus derived lymphocyte><trafficking><transcription cassette><transcriptional cassette><transcriptional profile><transcriptional signature><transduction efficiency><transgene cassette><tumor><tumor cell metastasis><tumor diagnosis><tumor-specific antigen><tyrosinase-related TRP-1 protein><tyrosinase-related TRP1 protein><tyrosinase-related protein><vaccine development><vaccine for cancer><vaccine platform><vaccine strategy><vector><viral DNA><virus DNA><virus genome>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dana Casey

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$484,630

FY 2026

Project Title

Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer

Grant Number:

5R01CA274254-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/3/2023

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Our goal is to develop a novel approach to rationally incorporate radiotherapy (RT) to improve the outcome of neoadjuvant therapy in patients with lymph node positive, triple-negative breast cancer (TNBC). The mature results from the KEYNOTE-522 trial, which tested the addition of immune che...

Research Terms

<(TNF)-α><ACRIN><Adjuvant Chemotherapy><Adjuvant Drug Therapy><Adjuvant Therapy><American College of Radiology Imaging Network><Antibodies><Armpit><Axilla><Axillary><B-Cell Attracting Chemokine 1><B-Lymphocyte Chemoattractant><BCA1><BLC gene><BLC protein><Biological><Biological Markers><Biopsy Sample><Biopsy Specimen><Blood><Blood Reticuloendothelial System><Blood Sample><Blood Vessels><Blood specimen><Body Tissues><Breast><Breast Cancer><Breast Cancer Model><Breast Cancer Patient><Breast Neoplasms><Breast Tumor Patient><Breast Tumors><Breast tumor model><CCL5><CD183><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CKR-L2><CMKAR3><CXCL13><CXCL13 gene><CXCL9><CXCL9 gene><CXCR3><CXCR3 gene><Cachectin><Cancers><Catchment Area><Cell Communication and Signaling><Cell Signaling><Cell-Mediated Lympholytic Cells><Checkpoint inhibitor><Chemokine (C-C Motif) Ligand 5><Chemokine (C-X-C Motif) Receptor 3><Chemokine, CXC Motif, Ligand 13><Chemotactic Cytokines><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Clinical Data><Clinical Trials><Co-Stimulator><Combination Chemotherapy Regimen><Combination Drug Therapy><Combined Modality Therapy><Correlative Study><Costimulator><Cytolytic T-Cell><Cytometry><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><D17S136E><Data><Dendritic Cells><Detectable Residual Disease><Disease-Free Survival><Dose><Dose Fractionation><Drugs><ECOG><ERBB2><ERBB2 gene><Early treatment><Eastern Cooperative Oncology Group><Ectopic lymphoid organ><Ectopic lymphoid structure><Epidermal Thymocyte Activating Factor><Event-Free Survival><G Protein-Coupled Receptor 9><GPR9><Geography><Goals><HER -2><HER-2><HER2><HER2 Genes><HER2/neu><High Endothelial Venule><Homologous Chemotactic Cytokines><Human><Humig><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IL-2><IL2 Protein><IP10><IP10 Receptor><IP10-Mig receptor><IP10-R><Immune Interferon><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immune response><Immunity><Immuno-Chemotherapy><Immunochemotherapy><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In complete remission><Induction Therapy><Industry><Infiltration><Intercrines><Interferon Gamma><Interferon Type II><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intracellular Communication and Signaling><Keytruda><Knowledge><LYT3><Ligands><Lymphatic cell><Lymphocyte><Lymphocyte Mitogenic Factor><Lymphocytic><Lymphocytopenia><Lymphopenia><MGC17164><MIG Gene><Macrophage-Derived TNF><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Mammary Cancer><Mammary Neoplasms><Medication><Mig Receptor><Mig-R><MigR><Minimal Residual Disease><Mitogenic Factor><Modern Man><Molecular><Monocyte-Derived TNF><Multimodal Therapy><Multimodal Treatment><Myeloid Cells><NEOADJ><NEU Oncogene><NEU protein><Neoadjuvant><Neoadjuvant Therapy><Neoadjuvant Treatment><OKT3 antigen><Oncogene ErbB2><Operative Procedures><Operative Surgical Procedures><PD-1 antibody><PD-1 antibody therapy><PD-1 blockade><PD-1 therapy><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 blockade><Pathologic><Patient Selection><Patients><Pharmaceutical Preparations><Phase><Pilot Projects><Polychemotherapy><Population><Positive Lymph Node><Preclinical data><Protein Array><Publishing><Quimioterapia><RANTES><Radiation Dose><Radiation Dose Unit><Radiation therapy><Radiotherapeutics><Radiotherapy><Radiotherapy Dose Fractionation><Randomization trial><Randomized><Research Specimen><Residual Neoplasm><Residual Tumors><Resistance><Role><SCYA5><SCYB13><SCYB9><SIS cytokines><SIS delta><SIS-delta><SISd><SYS-TX><Signal Transduction><Signal Transduction Systems><Signaling><Specimen><Surgical><Surgical Interventions><Surgical Procedure><Systemic Therapy><T cell growth factor><T cell infiltration><T-Cell Growth Factor><T-Cell RANTES Protein><T-Cell Specific Protein p288><T-Cell Stimulating Factor><T-Cells><T-Lymphocyte><T3 Antigens><T3 Complex><T3 molecule><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TCP228><TKR1><TNBC><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Teff cell><Tertiary lymphoid structure><Testing><Thymocyte Stimulating Factor><Tissue Sample><Tissues><Tumor Cell><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Infiltrating Lymphocytes><Underarm><Veiled Cells><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><adjuvant treatment><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><anti-tumor immune response><anti-tumor immunity><antiPD-1><antitumor immunity><bio-markers><biologic><biologic marker><biological signal transduction><biomarker><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer chemotherapy><cancer immunity><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemo-immuno therapy><chemoattractant cytokine><chemoimmunotherapy><chemokine><chemotherapy><combination chemotherapy><combination pharmacotherapy><combination therapy><combined modality treatment><combined treatment><complete response><crg-10><cytokine><design><designing><drug/agent><early therapy><effector T cell><erbB-2 Genes><experience><herstatin><host response><immune cell infiltrate><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved><improved outcome><individuals with breast cancer><induction therapies><inhibitor drug><inhibitor therapeutic><inhibitor therapy><innovate><innovation><innovative><insight><killer T cell><lFN-Gamma><lymph cell><malignancy><malignant breast tumor><mammary cancer model><mammary tumor><mammary tumor model><multi-modal therapy><multi-modal treatment><multidisciplinary><neoplasm/cancer><neoplastic cell><neu Genes><new approaches><node positive><novel><novel approaches><novel strategies><novel strategy><patients with breast cancer><pembrolizumab><person with breast cancer><phase 2 study><phase 3 trial><phase II study><phase III trial><pilot study><preclinical findings><preclinical information><primary end point><primary endpoint><programmed cell death protein 1 therapy><radiation treatment><randomisation><randomization><randomized trial><randomized, clinical trials><randomly assigned><residual disease><resistant><responders and non-responders><responders from non-responders><responders or non-responders><responders versus non-responders><responders vs non-responders><responders/nonresponders><response><response to therapy><response to treatment><social role><standard of care><surgery><synergism><tertiary lymphoid organ><therapeutic response><therapy response><thymus derived lymphocyte><trafficking><treatment response><treatment responsiveness><treatment with radiation><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor immune microenvironment><tumor-immune system interactions><vascular><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dan Gabriel Duda

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$484,630

FY 2026

Project Title

Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer

Grant Number:

5R01CA274254-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/3/2023

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Our goal is to develop a novel approach to rationally incorporate radiotherapy (RT) to improve the outcome of neoadjuvant therapy in patients with lymph node positive, triple-negative breast cancer (TNBC). The mature results from the KEYNOTE-522 trial, which tested the addition of immune che...

Research Terms

<(TNF)-α><ACRIN><Adjuvant Chemotherapy><Adjuvant Drug Therapy><Adjuvant Therapy><American College of Radiology Imaging Network><Antibodies><Armpit><Axilla><Axillary><B-Cell Attracting Chemokine 1><B-Lymphocyte Chemoattractant><BCA1><BLC gene><BLC protein><Biological><Biological Markers><Biopsy Sample><Biopsy Specimen><Blood><Blood Reticuloendothelial System><Blood Sample><Blood Vessels><Blood specimen><Body Tissues><Breast><Breast Cancer><Breast Cancer Model><Breast Cancer Patient><Breast Neoplasms><Breast Tumor Patient><Breast Tumors><Breast tumor model><CCL5><CD183><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CKR-L2><CMKAR3><CXCL13><CXCL13 gene><CXCL9><CXCL9 gene><CXCR3><CXCR3 gene><Cachectin><Cancers><Catchment Area><Cell Communication and Signaling><Cell Signaling><Cell-Mediated Lympholytic Cells><Checkpoint inhibitor><Chemokine (C-C Motif) Ligand 5><Chemokine (C-X-C Motif) Receptor 3><Chemokine, CXC Motif, Ligand 13><Chemotactic Cytokines><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Clinical Data><Clinical Trials><Co-Stimulator><Combination Chemotherapy Regimen><Combination Drug Therapy><Combined Modality Therapy><Correlative Study><Costimulator><Cytolytic T-Cell><Cytometry><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><D17S136E><Data><Dendritic Cells><Detectable Residual Disease><Disease-Free Survival><Dose><Dose Fractionation><Drugs><ECOG><ERBB2><ERBB2 gene><Early treatment><Eastern Cooperative Oncology Group><Ectopic lymphoid organ><Ectopic lymphoid structure><Epidermal Thymocyte Activating Factor><Event-Free Survival><G Protein-Coupled Receptor 9><GPR9><Geography><Goals><HER -2><HER-2><HER2><HER2 Genes><HER2/neu><High Endothelial Venule><Homologous Chemotactic Cytokines><Human><Humig><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IL-2><IL2 Protein><IP10><IP10 Receptor><IP10-Mig receptor><IP10-R><Immune Interferon><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immune response><Immunity><Immuno-Chemotherapy><Immunochemotherapy><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In complete remission><Induction Therapy><Industry><Infiltration><Intercrines><Interferon Gamma><Interferon Type II><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intracellular Communication and Signaling><Keytruda><Knowledge><LYT3><Ligands><Lymphatic cell><Lymphocyte><Lymphocyte Mitogenic Factor><Lymphocytic><Lymphocytopenia><Lymphopenia><MGC17164><MIG Gene><Macrophage-Derived TNF><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Mammary Cancer><Mammary Neoplasms><Medication><Mig Receptor><Mig-R><MigR><Minimal Residual Disease><Mitogenic Factor><Modern Man><Molecular><Monocyte-Derived TNF><Multimodal Therapy><Multimodal Treatment><Myeloid Cells><NEOADJ><NEU Oncogene><NEU protein><Neoadjuvant><Neoadjuvant Therapy><Neoadjuvant Treatment><OKT3 antigen><Oncogene ErbB2><Operative Procedures><Operative Surgical Procedures><PD-1 antibody><PD-1 antibody therapy><PD-1 blockade><PD-1 therapy><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 blockade><Pathologic><Patient Selection><Patients><Pharmaceutical Preparations><Phase><Pilot Projects><Polychemotherapy><Population><Positive Lymph Node><Preclinical data><Protein Array><Publishing><Quimioterapia><RANTES><Radiation Dose><Radiation Dose Unit><Radiation therapy><Radiotherapeutics><Radiotherapy><Radiotherapy Dose Fractionation><Randomization trial><Randomized><Research Specimen><Residual Neoplasm><Residual Tumors><Resistance><Role><SCYA5><SCYB13><SCYB9><SIS cytokines><SIS delta><SIS-delta><SISd><SYS-TX><Signal Transduction><Signal Transduction Systems><Signaling><Specimen><Surgical><Surgical Interventions><Surgical Procedure><Systemic Therapy><T cell growth factor><T cell infiltration><T-Cell Growth Factor><T-Cell RANTES Protein><T-Cell Specific Protein p288><T-Cell Stimulating Factor><T-Cells><T-Lymphocyte><T3 Antigens><T3 Complex><T3 molecule><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TCP228><TKR1><TNBC><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Teff cell><Tertiary lymphoid structure><Testing><Thymocyte Stimulating Factor><Tissue Sample><Tissues><Tumor Cell><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Infiltrating Lymphocytes><Underarm><Veiled Cells><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><adjuvant treatment><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><anti-tumor immune response><anti-tumor immunity><antiPD-1><antitumor immunity><bio-markers><biologic><biologic marker><biological signal transduction><biomarker><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer chemotherapy><cancer immunity><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemo-immuno therapy><chemoattractant cytokine><chemoimmunotherapy><chemokine><chemotherapy><combination chemotherapy><combination pharmacotherapy><combination therapy><combined modality treatment><combined treatment><complete response><crg-10><cytokine><design><designing><drug/agent><early therapy><effector T cell><erbB-2 Genes><experience><herstatin><host response><immune cell infiltrate><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved><improved outcome><individuals with breast cancer><induction therapies><inhibitor drug><inhibitor therapeutic><inhibitor therapy><innovate><innovation><innovative><insight><killer T cell><lFN-Gamma><lymph cell><malignancy><malignant breast tumor><mammary cancer model><mammary tumor><mammary tumor model><multi-modal therapy><multi-modal treatment><multidisciplinary><neoplasm/cancer><neoplastic cell><neu Genes><new approaches><node positive><novel><novel approaches><novel strategies><novel strategy><patients with breast cancer><pembrolizumab><person with breast cancer><phase 2 study><phase 3 trial><phase II study><phase III trial><pilot study><preclinical findings><preclinical information><primary end point><primary endpoint><programmed cell death protein 1 therapy><radiation treatment><randomisation><randomization><randomized trial><randomized, clinical trials><randomly assigned><residual disease><resistant><responders and non-responders><responders from non-responders><responders or non-responders><responders versus non-responders><responders vs non-responders><responders/nonresponders><response><response to therapy><response to treatment><social role><standard of care><surgery><synergism><tertiary lymphoid organ><therapeutic response><therapy response><thymus derived lymphocyte><trafficking><treatment response><treatment responsiveness><treatment with radiation><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor immune microenvironment><tumor-immune system interactions><vascular><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gaorav P. Gupta

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$484,630

FY 2026

Project Title

Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer

Grant Number:

5R01CA274254-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/3/2023

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Our goal is to develop a novel approach to rationally incorporate radiotherapy (RT) to improve the outcome of neoadjuvant therapy in patients with lymph node positive, triple-negative breast cancer (TNBC). The mature results from the KEYNOTE-522 trial, which tested the addition of immune che...

Research Terms

<(TNF)-α><ACRIN><Adjuvant Chemotherapy><Adjuvant Drug Therapy><Adjuvant Therapy><American College of Radiology Imaging Network><Antibodies><Armpit><Axilla><Axillary><B-Cell Attracting Chemokine 1><B-Lymphocyte Chemoattractant><BCA1><BLC gene><BLC protein><Biological><Biological Markers><Biopsy Sample><Biopsy Specimen><Blood><Blood Reticuloendothelial System><Blood Sample><Blood Vessels><Blood specimen><Body Tissues><Breast><Breast Cancer><Breast Cancer Model><Breast Cancer Patient><Breast Neoplasms><Breast Tumor Patient><Breast Tumors><Breast tumor model><CCL5><CD183><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CKR-L2><CMKAR3><CXCL13><CXCL13 gene><CXCL9><CXCL9 gene><CXCR3><CXCR3 gene><Cachectin><Cancers><Catchment Area><Cell Communication and Signaling><Cell Signaling><Cell-Mediated Lympholytic Cells><Checkpoint inhibitor><Chemokine (C-C Motif) Ligand 5><Chemokine (C-X-C Motif) Receptor 3><Chemokine, CXC Motif, Ligand 13><Chemotactic Cytokines><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Clinical Data><Clinical Trials><Co-Stimulator><Combination Chemotherapy Regimen><Combination Drug Therapy><Combined Modality Therapy><Correlative Study><Costimulator><Cytolytic T-Cell><Cytometry><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><D17S136E><Data><Dendritic Cells><Detectable Residual Disease><Disease-Free Survival><Dose><Dose Fractionation><Drugs><ECOG><ERBB2><ERBB2 gene><Early treatment><Eastern Cooperative Oncology Group><Ectopic lymphoid organ><Ectopic lymphoid structure><Epidermal Thymocyte Activating Factor><Event-Free Survival><G Protein-Coupled Receptor 9><GPR9><Geography><Goals><HER -2><HER-2><HER2><HER2 Genes><HER2/neu><High Endothelial Venule><Homologous Chemotactic Cytokines><Human><Humig><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IL-2><IL2 Protein><IP10><IP10 Receptor><IP10-Mig receptor><IP10-R><Immune Interferon><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immune response><Immunity><Immuno-Chemotherapy><Immunochemotherapy><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In complete remission><Induction Therapy><Industry><Infiltration><Intercrines><Interferon Gamma><Interferon Type II><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intracellular Communication and Signaling><Keytruda><Knowledge><LYT3><Ligands><Lymphatic cell><Lymphocyte><Lymphocyte Mitogenic Factor><Lymphocytic><Lymphocytopenia><Lymphopenia><MGC17164><MIG Gene><Macrophage-Derived TNF><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Mammary Cancer><Mammary Neoplasms><Medication><Mig Receptor><Mig-R><MigR><Minimal Residual Disease><Mitogenic Factor><Modern Man><Molecular><Monocyte-Derived TNF><Multimodal Therapy><Multimodal Treatment><Myeloid Cells><NEOADJ><NEU Oncogene><NEU protein><Neoadjuvant><Neoadjuvant Therapy><Neoadjuvant Treatment><OKT3 antigen><Oncogene ErbB2><Operative Procedures><Operative Surgical Procedures><PD-1 antibody><PD-1 antibody therapy><PD-1 blockade><PD-1 therapy><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 blockade><Pathologic><Patient Selection><Patients><Pharmaceutical Preparations><Phase><Pilot Projects><Polychemotherapy><Population><Positive Lymph Node><Preclinical data><Protein Array><Publishing><Quimioterapia><RANTES><Radiation Dose><Radiation Dose Unit><Radiation therapy><Radiotherapeutics><Radiotherapy><Radiotherapy Dose Fractionation><Randomization trial><Randomized><Research Specimen><Residual Neoplasm><Residual Tumors><Resistance><Role><SCYA5><SCYB13><SCYB9><SIS cytokines><SIS delta><SIS-delta><SISd><SYS-TX><Signal Transduction><Signal Transduction Systems><Signaling><Specimen><Surgical><Surgical Interventions><Surgical Procedure><Systemic Therapy><T cell growth factor><T cell infiltration><T-Cell Growth Factor><T-Cell RANTES Protein><T-Cell Specific Protein p288><T-Cell Stimulating Factor><T-Cells><T-Lymphocyte><T3 Antigens><T3 Complex><T3 molecule><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TCP228><TKR1><TNBC><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Teff cell><Tertiary lymphoid structure><Testing><Thymocyte Stimulating Factor><Tissue Sample><Tissues><Tumor Cell><Tumor Immunity><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Infiltrating Lymphocytes><Underarm><Veiled Cells><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><adjuvant treatment><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><anti-tumor immune response><anti-tumor immunity><antiPD-1><antitumor immunity><bio-markers><biologic><biologic marker><biological signal transduction><biomarker><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer chemotherapy><cancer immunity><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemo-immuno therapy><chemoattractant cytokine><chemoimmunotherapy><chemokine><chemotherapy><combination chemotherapy><combination pharmacotherapy><combination therapy><combined modality treatment><combined treatment><complete response><crg-10><cytokine><design><designing><drug/agent><early therapy><effector T cell><erbB-2 Genes><experience><herstatin><host response><immune cell infiltrate><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><improved><improved outcome><individuals with breast cancer><induction therapies><inhibitor drug><inhibitor therapeutic><inhibitor therapy><innovate><innovation><innovative><insight><killer T cell><lFN-Gamma><lymph cell><malignancy><malignant breast tumor><mammary cancer model><mammary tumor><mammary tumor model><multi-modal therapy><multi-modal treatment><multidisciplinary><neoplasm/cancer><neoplastic cell><neu Genes><new approaches><node positive><novel><novel approaches><novel strategies><novel strategy><patients with breast cancer><pembrolizumab><person with breast cancer><phase 2 study><phase 3 trial><phase II study><phase III trial><pilot study><preclinical findings><preclinical information><primary end point><primary endpoint><programmed cell death protein 1 therapy><radiation treatment><randomisation><randomization><randomized trial><randomized, clinical trials><randomly assigned><residual disease><resistant><responders and non-responders><responders from non-responders><responders or non-responders><responders versus non-responders><responders vs non-responders><responders/nonresponders><response><response to therapy><response to treatment><social role><standard of care><surgery><synergism><tertiary lymphoid organ><therapeutic response><therapy response><thymus derived lymphocyte><trafficking><treatment response><treatment responsiveness><treatment with radiation><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor immune microenvironment><tumor-immune system interactions><vascular><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mary Helen Barcellos-Hoff

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$483,213

FY 2026

Project Title

Investigating the Genesis of Tumor Immune Microenvironment (TIME) as a function of Inflammation

Grant Number:

5R01CA270332-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT The type and pattern of immune cell infiltrate in breast cancer is of growing clinical importance as they associate with response to therapy and are the specific target of immunotherapy. `Cold' cancers that lack infiltrating T cells exhibit pronounced transforming growth factor β (TGFβ) act...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

NAHID F MIVECHI

AUGUSTA UNIVERSITY, AUGUSTA, GA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$462,585

FY 2026

Project Title

Role of heat shock transcription factors (HSFs) in hematological malignancies

Grant Number:

5R01CA276933-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/15/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Among the human hematological malignancies, acute leukemia types including acute myeloid leukemia (AML) accounts for 4% of all cancer deaths worldwide and 6% of cancer in the US population. AML is the second most common type of diagnosed leukemia in pediatric and adult populations but most ...

Research Terms

<21+ years old><AML - Acute Myeloid Leukemia><Ablation><Accounting><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Acute leukemia><Adoptive Transfer><Adult><Adult Human><Antigens><Applications Grants><Attenuated><Automobile Driving><Basal Transcription Factor><Basal transcription factor genes><Bioenergetics><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancer Genes><Cancer Patient><Cancer Treatment><Cancer-Promoting Gene><Cancers><Cell Body><Cell Communication and Signaling><Cell Mediated Immunology><Cell Signaling><Cell-Mediated Immunity><Cells><Cellular Immunity><Cessation of life><Chemoresistance><Childhood><Chimera Protein><Chimeric Proteins><Clinical><Clinical Trials><Collaborations><DNA Alteration><DNA Sequence Alteration><DNA mutation><Death><Development><Diagnosis><Disease remission><Drug resistance><Dysfunction><Effector Cell><Elderly><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Experimental Designs><Functional disorder><Fusion Protein><GC MS><GCMS><Gas-Liquid-Mass Spectrometry Chromatography><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generations><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Grant Proposals><Heat Shock><Heat-Shock Reaction><Heat-Shock Response><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Human><Human Engineering><Immune><Immune Surveillance><Immune mediated therapy><Immunes><Immunity><Immunologic Surveillance><Immunologically Directed Therapy><Immunosurveillance><Immunotherapeutic agent><Immunotherapy><Intermediary Metabolism><Intracellular Communication and Signaling><LC/MS><Leukemic Cell><Malignant><Malignant - descriptor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Fragmentographies><Mass Fragmentography><Mass-Gas Chromatography Spectrometry><Mass-Gas Chromatography Spectrum Analysis><Mediating><Memory><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Modern Man><Modernization><Molecular><Murine><Mus><Mutation><Myeloid Disease><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><Oncogenes><Oncogenesis><Oncogenic><Outcome><Pathogenesis><Pathway interactions><Patients><Physiology><Physiopathology><Population><Prognosis><Proteins><Proteome><RNA Expression><Recurrence><Recurrent><Refractory><Regulation><Relapse><Remission><Remission Induction><Research><Resistance><Role><Sampling><Sequence Alteration><Signal Transduction><Signal Transduction Systems><Signaling><Stem Cell like><Stress><Study models><Survival Rate><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell receptor based immunotherapy><T cell receptor cellular immunotherapy><T cell receptor engineered therapy><T cell receptor immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Receptor Therapy><T-Cell Receptor Treatment><T-Cell Receptor based Therapy><T-Cell Receptor based Treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><T8 Cells><T8 Lymphocytes><TCR T cell immunotherapy><TCR T cell therapy><TCR Therapy><TCR based T cell immunotherapy><TCR based Therapy><TCR based immune therapy><TCR based immunotherapy><TCR based treatment><TCR immunotherapy><Testing><Therapeutic><Therapeutic Intervention><Toxic effect><Toxicities><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Tumor Immunity><Tumor Promotion><acute granulocytic leukemia><acute myeloid leukemia><adaptive immunity><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><adulthood><advanced age><anti-cancer therapy><anti-tumor immune response><anti-tumor immunity><antitumor immunity><attenuate><attenuates><biological signal transduction><blood cancer><cancer cell><cancer immunity><cancer of blood><cancer of the blood><cancer regression><cancer therapy><cancer type><cancer-directed therapy><cell transformation><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><chromatin modification><clinical efficacy><clinical significance><clinically significant><developmental><driving><drug resistant><epigenetic regulation><epigenetically><exhaustion><experiment><experimental research><experimental study><experiments><fitness><gene signatures><genetic signature><genome mutation><genomic alteration><genotoxicity><geriatric><heat shock transcription factor><hemopoietic><immune drugs><immune modulatory intervention><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunointervention><immunologic therapeutics><immunological intervention><immunotherapeutics><immunotherapy agent><improved><individual patient><intervention therapy><ion trap mass spectrometry><leukemia><leukemia relapse><leukemia treatment><leukemic therapy><liquid chromatography mass spectrometry><long-term memory><malignancy><mass fragmentometry><metabolic profile><metabolism measurement><metabolomics><metabonomics><mouse model><murine model><myeloproliferative neoplasm><neoplasm/cancer><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><oncogene addiction><pathophysiology><pathway><pediatric><pre-clinical study><preclinical study><prevent><preventing><progenitor><progenitor capacity><progenitor cell like><progenitor-like><programs><protein folding><recurrent leukemia><resistance to Drug><resistant><resistant to Drug><senior citizen><social role><stem><stem cell characteristics><stem-like><stemness><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic T-cell platform><therapeutic target><therapeutically effective><thymus derived lymphocyte><transcription factor><transformed cells><translational goal><translational mission><treatment strategy><tumor><tumorigenesis>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dimitrios Moskofidis

AUGUSTA UNIVERSITY, AUGUSTA, GA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$462,585

FY 2026

Project Title

Role of heat shock transcription factors (HSFs) in hematological malignancies

Grant Number:

5R01CA276933-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/15/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Among the human hematological malignancies, acute leukemia types including acute myeloid leukemia (AML) accounts for 4% of all cancer deaths worldwide and 6% of cancer in the US population. AML is the second most common type of diagnosed leukemia in pediatric and adult populations but most ...

Research Terms

<21+ years old><AML - Acute Myeloid Leukemia><Ablation><Accounting><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Acute leukemia><Adoptive Transfer><Adult><Adult Human><Antigens><Applications Grants><Attenuated><Automobile Driving><Basal Transcription Factor><Basal transcription factor genes><Bioenergetics><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancer Genes><Cancer Patient><Cancer Treatment><Cancer-Promoting Gene><Cancers><Cell Body><Cell Communication and Signaling><Cell Mediated Immunology><Cell Signaling><Cell-Mediated Immunity><Cells><Cellular Immunity><Cessation of life><Chemoresistance><Childhood><Chimera Protein><Chimeric Proteins><Clinical><Clinical Trials><Collaborations><DNA Alteration><DNA Sequence Alteration><DNA mutation><Death><Development><Diagnosis><Disease remission><Drug resistance><Dysfunction><Effector Cell><Elderly><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Experimental Designs><Functional disorder><Fusion Protein><GC MS><GCMS><Gas-Liquid-Mass Spectrometry Chromatography><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generations><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Grant Proposals><Heat Shock><Heat-Shock Reaction><Heat-Shock Response><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Human><Human Engineering><Immune><Immune Surveillance><Immune mediated therapy><Immunes><Immunity><Immunologic Surveillance><Immunologically Directed Therapy><Immunosurveillance><Immunotherapeutic agent><Immunotherapy><Intermediary Metabolism><Intracellular Communication and Signaling><LC/MS><Leukemic Cell><Malignant><Malignant - descriptor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Fragmentographies><Mass Fragmentography><Mass-Gas Chromatography Spectrometry><Mass-Gas Chromatography Spectrum Analysis><Mediating><Memory><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Modern Man><Modernization><Molecular><Murine><Mus><Mutation><Myeloid Disease><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><Oncogenes><Oncogenesis><Oncogenic><Outcome><Pathogenesis><Pathway interactions><Patients><Physiology><Physiopathology><Population><Prognosis><Proteins><Proteome><RNA Expression><Recurrence><Recurrent><Refractory><Regulation><Relapse><Remission><Remission Induction><Research><Resistance><Role><Sampling><Sequence Alteration><Signal Transduction><Signal Transduction Systems><Signaling><Stem Cell like><Stress><Study models><Survival Rate><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell receptor based immunotherapy><T cell receptor cellular immunotherapy><T cell receptor engineered therapy><T cell receptor immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Receptor Therapy><T-Cell Receptor Treatment><T-Cell Receptor based Therapy><T-Cell Receptor based Treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><T8 Cells><T8 Lymphocytes><TCR T cell immunotherapy><TCR T cell therapy><TCR Therapy><TCR based T cell immunotherapy><TCR based Therapy><TCR based immune therapy><TCR based immunotherapy><TCR based treatment><TCR immunotherapy><Testing><Therapeutic><Therapeutic Intervention><Toxic effect><Toxicities><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Tumor Immunity><Tumor Promotion><acute granulocytic leukemia><acute myeloid leukemia><adaptive immunity><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><adulthood><advanced age><anti-cancer therapy><anti-tumor immune response><anti-tumor immunity><antitumor immunity><attenuate><attenuates><biological signal transduction><blood cancer><cancer cell><cancer immunity><cancer of blood><cancer of the blood><cancer regression><cancer therapy><cancer type><cancer-directed therapy><cell transformation><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><chromatin modification><clinical efficacy><clinical significance><clinically significant><developmental><driving><drug resistant><epigenetic regulation><epigenetically><exhaustion><experiment><experimental research><experimental study><experiments><fitness><gene signatures><genetic signature><genome mutation><genomic alteration><genotoxicity><geriatric><heat shock transcription factor><hemopoietic><immune drugs><immune modulatory intervention><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunointervention><immunologic therapeutics><immunological intervention><immunotherapeutics><immunotherapy agent><improved><individual patient><intervention therapy><ion trap mass spectrometry><leukemia><leukemia relapse><leukemia treatment><leukemic therapy><liquid chromatography mass spectrometry><long-term memory><malignancy><mass fragmentometry><metabolic profile><metabolism measurement><metabolomics><metabonomics><mouse model><murine model><myeloproliferative neoplasm><neoplasm/cancer><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><oncogene addiction><pathophysiology><pathway><pediatric><pre-clinical study><preclinical study><prevent><preventing><progenitor><progenitor capacity><progenitor cell like><progenitor-like><programs><protein folding><recurrent leukemia><resistance to Drug><resistant><resistant to Drug><senior citizen><social role><stem><stem cell characteristics><stem-like><stemness><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic T-cell platform><therapeutic target><therapeutically effective><thymus derived lymphocyte><transcription factor><transformed cells><translational goal><translational mission><treatment strategy><tumor><tumorigenesis>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

STEPHEN C JAMESON

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 52/100

Likely hiring

Solid budget

Active award

$449,257

FY 2026

Project Title

T Cell Homeostasis

Grant Number:

5R01AI038903-30

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/1996

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary The durability of diverse forms of T cell memory is critical for effective immunity against various pathogens, and can be harnessed for cancer immunotherapy. Yet the signals that maintain T cell memory, and preserves the identity of distinct memory subsets, are incompletely understood. In pa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHARLES H. SPRUCK

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, LA JOLLA, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$446,063

FY 2026

Project Title

Targeting the FBXO44/SUV39H1 Pathway in Cancer

Grant Number:

5R01CA267103-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/10/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Repetitive elements (REs) compose ~45% of the human genome and are normally transcriptionally silenced, although the mechanism has remained elusive. Through a high-content RNAi screen, we identified FBXO44 as an essential repressor of REs in cancer cells. FBXO44 bound repressive H3K9...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mansoor M. Amiji

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$442,422

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James E Egan

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$442,422

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edward J Kim

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$442,422

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gerardo Guillermo Mackenzie

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$442,422

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuri Bunimovich

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$437,595

FY 2026

Project Title

The Role of Schwann Cells in the Progression of Melanoma

Grant Number:

5R01CA266529-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Clinical and experimental evidence demonstrate that cancer progression depends on the interactions of malignant cells with other elements of the tumor microenvironment (TME). Functions of cancer-associated fibroblasts, endothelial cells, tumor-infiltrating immune cells and other stro...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Guangyong Peng

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 52/100

Likely hiring

Solid budget

Active award

$420,182

FY 2026

Project Title

Metabolic Control of Innate and Adaptive Immunity in Breast Cancer

Grant Number:

5R01CA237149-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/11/2020

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immunotherapy is a promising approach for treating patients with advanced breast cancer. However, immunosuppressive microenvironments induced by regulatory T cells (Treg) present a major barrier to successful anti-tumor immunotherapy. Defining the suppressive mechanisms used...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuxuan Phoenix Miao

UNIVERSITY OF CHICAGO, CHICAGO, IL

Good lead · 52/100

Likely hiring

Solid budget

Active award

$407,298

FY 2026

Project Title

Dissecting the Sox2-orchestrated transcriptional network that governs immune resistance in tumor initiating cells

Grant Number:

5R01CA285786-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY The treatments for various squamous cell carcinomas (SCCs), such as SCCs of the head and neck, have been revolutionized by the development of immunotherapies. However, even though many treated patients can evoke robust initial responses, most SCC patients often experience rapid tumor...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ZHENG-RONG LU

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 52/100

Likely hiring

Solid budget

Active award

$405,116

FY 2026

Project Title

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy

Grant Number:

5R01CA235152-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/12/2018

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The goal of this project is to develop smart targeted lipid ECO/siRNA nanoparticles (ELNP) to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat triple-negative breast cancer (TNBC). Metastasis and drug resistance are the main causes for the high mortality rates of women dia...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

William Schiemann

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 52/100

Likely hiring

Solid budget

Active award

$405,116

FY 2026

Project Title

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy

Grant Number:

5R01CA235152-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/12/2018

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The goal of this project is to develop smart targeted lipid ECO/siRNA nanoparticles (ELNP) to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat triple-negative breast cancer (TNBC). Metastasis and drug resistance are the main causes for the high mortality rates of women dia...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jinming Gao

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$399,271

FY 2026

Project Title

Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy

Grant Number:

5R01CA289258-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Interleukin-2 (IL-2) is an immunostimulatory cytokine that plays a central role in antitumor immunity, particularly in the activation and proliferation of T cells and natural killer (NK) cells for tumor eradication. Proleukin® is the first FDA approved immunotherapy drug with curable respo...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gang Huang

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$399,271

FY 2026

Project Title

Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy

Grant Number:

5R01CA289258-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Interleukin-2 (IL-2) is an immunostimulatory cytokine that plays a central role in antitumor immunity, particularly in the activation and proliferation of T cells and natural killer (NK) cells for tumor eradication. Proleukin® is the first FDA approved immunotherapy drug with curable respo...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Marina Sokolsky-Papkov

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$388,750

FY 2026

Project Title

Nanoformulated small molecule immunotherapy for SHH medulloblastoma

Grant Number:

5R01NS125073-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Nanoformulated small molecule immunotherapy for SHH medulloblastoma M. Sokolsky-Papkov, (PI) This project focuses on improving therapy of medulloblastomas. Despite aggressive and highly toxic multi-modality therapy, 30% of the children diagnosed with medulloblastoma will still die from recurrent dis...

Research Terms

<0-11 years old><1-Phosphatidylinositol 3-Kinase><AKT><Adjuvant><Affect><Agonist><Akt protein><Anti-Cancer Agents><Antibodies><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Bladder Cancer><Blood - brain barrier anatomy><Blood-Brain Barrier><Body Tissues><CD152><CD152 Antigen><CD152 Gene><CDK4><CDK4 gene><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Drug><Cancer Treatment><Cancers><Cell Body><Cell Division Kinase 4><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Survival><Cell Viability><Cells><Cellular Proliferation><Child><Child Youth><Childhood Malignant Brain Tumor><Children (0-21)><Circulation><Clinical><Cognitive deficits><Combined Modality Therapy><Cyclin-Dependent Kinase 4><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Data><Development><Diagnosis><Disease Progression><Drugs><Environment><Exposure to><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Formulation><GEM model><GEMM model><Genetically Engineered Mouse><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioma><Hemato-Encephalic Barrier><Immune><Immune mediated therapy><Immune response><Immune system><Immunes><Immunologically Directed Therapy><Immunotherapy><Impairment><Implant><In Vitro><Infiltration><Left><Macrophage><Malignant Bladder Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant neoplasm of urinary bladder><Medication><Medulloblastoma><Melanoma patient><Mice><Mice Mammals><Micelles><Modality><Modeling><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Mφ><Neoplasms><Neoplastic Disease Chemotherapeutic Agents><Neuroglial Neoplasm><Neuroglial Tumor><Operative Procedures><Operative Surgical Procedures><Outcome><P105-RB><PD 1><PD-1><PD1><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><PP110><PSK-J3><Pathway interactions><Patients><Pediatric Malignant Brain Tumor><Penetration><Pharmaceutical Preparations><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Physiologic><Physiological><Play><Polymers><Population><Protein Kinase B><Proto-Oncogene Proteins c-akt><PtdIns 3-Kinase><RAC-PK protein><Radiation therapy><Radiotherapeutics><Radiotherapy><Rb Gene Product><Rb Protein><Rb1 Gene Product><Recurrence><Recurrent><Recurrent Neoplasm><Recurrent disease><Recurrent tumor><Relapsed Disease><Reporting><Retinoblastoma Associated Protein><Retinoblastoma Protein><Risk><Role><SHH><SHH gene><Sonic Hedgehog><Surgical><Surgical Interventions><Surgical Procedure><Survivors><T cell infiltration><T-Cells><T-Lymphocyte><TLR7><TLR7 gene><Therapeutic><Therapeutic Effect><Time><Tissues><Toll-Like Receptor 7><Toxic effect><Toxicities><Treatment outcome><Tumor Cell><Tumor Promotion><Tumor Tissue><Tumor-Specific Treatment Agents><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Vaccines><aggressive therapy><aggressive treatment><alternative treatment><anti-cancer drug><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immune response><anticancer immunotherapy><blood-brain tumor barrier><blood-tumor barrier><bloodbrain barrier><bloodbrain tumor barrier><brain tissue><c-akt protein><cancer clinical trial><cancer immunotherapy><cancer microenvironment><cancer therapy><cancer-directed therapy><chemotherapy><childhood brain cancer><cognitive defects><combination therapy><combined modality treatment><combined treatment><cytokine><cytotoxic T-lymphocyte antigen 4><developmental><drug/agent><flow cytophotometry><genetically engineered mouse model><genetically engineered murine model><glial-derived tumor><global gene expression><global transcription profile><host response><immune check point><immune checkpoint><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunological status><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><inhibitor><innovate><innovation><innovative><interest><kids><mTOR Inhibitor><malignancy><motor deficit><mouse model><multi-modal therapy><multi-modal treatment><murine model><nano><nano particle><nano-sized particle><nanoparticle><nanosized particle><neoplasia><neoplasm recurrence><neoplasm/cancer><neoplastic cell><neoplastic growth><neuroglia neoplasm><neuroglia tumor><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncology clinical trial><pRB><pathway><patients suffering from melanoma><patients with melanoma><pediatric brain cancer><polymer><polymeric><programmed cell death 1><programmed cell death protein 1><programmed death 1><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><radiation treatment><related to A and C-protein><resiquimod><response><sle2><social role><surgery><synergism><systemic lupus erythematosus susceptibility 2><targeted agent><therapeutic outcome><therapy outcome><thymus derived lymphocyte><timeline><transcriptome><treatment effect><treatment strategy><treatment with radiation><tumor><tumor growth><tumor microenvironment><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Khalid S. Salaita

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$381,260

FY 2026

Project Title

Mechano-ID for tagging immune cells

Grant Number:

5R01AI172452-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract The long-term goal of this proposal is to develop new tools to study how T cells defend against pathogens and eradicate cancerous cells within our bodies. ~106-108 unique T cell clones circulate in the adult human body seeking evidence of foreign peptide fragments on the su...

Research Terms

<21+ years old><Adaptive Immune System><Address><Adult><Adult Human><Affinity><Amino Acids><Antigens><Area><Assay><Autoimmune Diseases><Beds><Binding><Binding Sites><Bioassay><Biological Assay><Biomechanics><Biotin><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><Cancerous><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell surface><Cells><Cellular Mechanotransduction><Cellular biology><Clone Cells><Combining Site><Complex><DNA><DNA Hybridization Probes><DNA Probes><Data><Deoxyribonucleic Acid><Eligibility><Eligibility Determination><Enzyme Gene><Enzymes><Event><FDA approved><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Genotype><Geometry><Goals><Hemi-Myeloperoxidase><High Throughput Assay><Histocompatibility Complex><Histocompatibility Complices><Human><Human Figure><Human body><Immobilization><Immune><Immune response><Immunes><Immunology><Intracellular Communication and Signaling><Label><Ligands><Ligase><Ligase Gene><Link><MHC Receptor><Major Histocompatibility Complex><Major Histocompatibility Complex Receptor><Major Histocompatibility Complices><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Maps><Measures><Mechanical Signal Transduction><Mechanics><Mechanosensory Transduction><Methods><Modeling><Modern Man><Molecular><Molecular Interaction><Mutate><Myeloperoxidase><Nucleic Acid Probes><Nucleic Acids><Oligo><Oligonucleotides><Outcome><Ovalbumin><Pathway interactions><Peptide Fragments><Peptide Library><Peptides><Peroxidases><Phenotype><Population><Process><Proteins><Proteomics><Protocol Screening><Radial><Radius><Reaction><Reactive Site><Reagent><Receptor Activation><Receptor Protein><Receptor Signaling><Research><Scanning><Screening procedure><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spectroscopy><Spectrum Analyses><Spectrum Analysis><Surface><Synthetases><T cells for CAR><T-Cell Activation><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><Techniques><Technology><Testing><Transcend><Transmission><Virus><Vitamin H><Work><acquired immune system><activate T cells><adulthood><aminoacid><anti-cancer immunotherapy><anticancer immunotherapy><antigen-specific T cells><autoimmune condition><autoimmune disorder><autoimmunity disease><biological signal transduction><biomechanical><cancer cell><cancer immunotherapy><cell biology><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><coenzyme R><design><designing><engineered T cells><engineered immune system><experience><experiment><experimental research><experimental study><experiments><fighting><flow cytophotometry><genetically engineered T-cells><high throughput screening><host response><immune engineering><immune system response><immune-based cancer therapies><immunoengineering><immunogen><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><innovate><innovation><innovative><interest><malignancy><mechanic><mechanical><mechanical force><mechanosensing><mechanotransduction><meter><molecular mechanics><mutant><nanometer><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm/cancer><nucleic acid stability><oligos><orthopedic freezing><particle><pathogen><pathway><peptide aminoacid sequence><peptide sequence><phenol ion><phenoxy ion><phenoxy radical><phenoxyl radical><protein aminoacid sequence><protein complex><protein protein interaction><public health relevance><receptor><receptor binding><receptor bound><recruit><screening><screening tools><screenings><single molecule><thymus derived lymphocyte><tool><transgenic T- cells><transmission process><virtual>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jianmei Wu Leavenworth

UNIVERSITY OF ALABAMA AT BIRMINGHAM, BIRMINGHAM, AL

Good lead · 52/100

Likely hiring

Solid budget

Active award

$377,166

FY 2026

Project Title

Follicular Regulatory T-cells Promote Cancer

Grant Number:

5R01CA276190-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Efforts to amplify the body’s immune system against cancer has faced a barrier due to the body’s own immunosuppressive tumor-promoting mechanisms, as commonly present for many cancers. We are dissecting these shared mechanisms by focusing on specific immunosuppressive cells in the tu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jing Chen

UNIVERSITY OF CHICAGO, CHICAGO, IL

Good lead · 52/100

Likely hiring

Solid budget

Active award

$375,150

FY 2026

Project Title

Dietary trans-vaccenic acid enhances anti-tumor immunity

Grant Number:

5R01CA276568-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/7/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract: Despite extensive studies on relationships between diets and cancer risk, or many “balanced” nutrition therapies with hope to keep cancer patients healthy and strong for treatment and recovery, little is known about how dietary substances influence cancer. Our recent work s...

Research Terms

<21+ years old><3'5'-cyclic ester of AMP><3-ethoxy-1,1-dihydroxy-2-butanone><3-ethoxy-2-oxobutyraldehyde><Acetoacetates><Acids><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adult><Adult Human><Agonist><Antibodies><Apoptosis><Apoptosis Pathway><Athymic Mice><Athymic Nude Mouse><Attenuated><B-raf-1><B7-H1><BRAF><BRAF gene><Binding><Binding Proteins><Blood><Blood Reticuloendothelial System><Breast Cancer Cell><Breast Milk><Breastmilk><Butter><CD274><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CRE Binding Protein><CREB Protein><Cancer Patient><Cancer Treatment><Cancers><Cell Communication and Signaling><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Signaling><Cell Survival><Cell Viability><Cellular Proliferation><Checkpoint inhibitor><Chemicals><Chondroitin Sulfates><Clinical><Colon Cancer><Colon Carcinoma><Cyclic AMP><Cyclic AMP Response Element-Binding Protein><Cyclic AMP Responsive Element Binding Protein><Cyclic AMP-Dependent Protein Kinases><Cyclic AMP-Responsive DNA-Binding Protein><Cyclicity><DNA seq><DNA sequencing><DNAseq><Dairy Products><Data><Diet><Dietary Proteins><E0771><EO771><Eating><Elements><Enhancers><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><FFAR2><FFAR2 gene><Food Intake><Foundations><Fructus Hippophae><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GPCR><GPR43><Gene Transcription><Genetic Transcription><Heterograft><Heterologous Transplantation><Hippophae><Human><Human Milk><Human Mother's Milk><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Intracellular Communication and Signaling><KO mice><Ketone Bodies><Knock-out Mice><Knockout Mice><LLC1><Lewis lung carcinoma cell><Libraries><Ligand Binding Protein><Ligand Binding Protein Gene><Link><Lipids><MC-38><MC38><Malignant Melanoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mammary Gland Milk><Melanoma><Mice><Mice Mammals><Milk><Modern Man><Molecular Interaction><Mother's Milk><Murine><Mus><NGS Method><NGS system><Nude Mice><Null Mouse><Nutrient><Nutrition Therapy><Oils><Outcome><PD 1><PD-1><PD-1/PD-L1><PD-1/PDL1><PD-L1><PD1><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL-1><PKA><Pathway interactions><Periodicity><Population><Programmed Cell Death><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein Binding><Protein Kinase A><RAFB1><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recovery><Research Activity><Rhythmicity><Sea Buckthorn><Short-Chain Fatty Acids><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><Single-Stranded DNA><Stereoisomer><Structure><T-Cell Activation><T-Cell Proliferation><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Testing><Trans Fatty Acids><Transcription><Tumor Immunity><Tumor-Infiltrating Lymphocytes><Volatile Fatty Acids><Work><Xenograft><Xenograft procedure><Xenotransplantation><activate T cells><adenosine 3'5' monophosphate><adulthood><anti-cancer therapy><anti-tumor immunity><antitumor immunity><attenuate><attenuates><biological signal transduction><bound protein><breast tumor cell><cAMP><cAMP Response Element-Binding Protein><cAMP Responsive Element Binding Protein><cAMP-Dependent Protein Kinases><cancer immunity><cancer in the colon><cancer infiltrating T cells><cancer initiation><cancer risk><cancer therapy><cancer-directed therapy><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemotherapy><design><designing><diet and cancer><diet supplement><dietary><dietary supplements><diets><epigenetically><exhaustion><extracellular><free fatty acid receptor 2><global gene expression><global transcription profile><host response><hydrogen sulfate Chondroitin><hypoimmunity><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune deficiency><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunodeficiency><immunodeficient mouse model><immunogenic><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><insight><interest><kethocal><kethoxal><lung cancer cell><malignancy><maternal milk><meter><multidisciplinary><neoplasm/cancer><next gen sequencing><next generation sequencing><nextgen sequencing><novel><nutritional supplement><pathway><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><response><response to therapy><response to treatment><sle2><ssDNA><systemic lupus erythematosus susceptibility 2><therapeutic response><therapy response><thymus derived lymphocyte><transcriptome><transcriptome sequencing><transcriptomic sequencing><treatment response><treatment responsiveness><tumor><tumor growth><tumor infiltrating T cells><v-raf Murine Sarcoma Viral Oncogene Homolog B1><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aimee S Payne

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Good lead · 52/100

Likely hiring

Solid budget

Active award

$373,611

FY 2026

Project Title

Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris

Grant Number:

5R01AR082675-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project summary: Chimeric antigen receptor T (CART) cells have transformed the cancer therapy paradigm by genetically engineering a patient's own T cells to specifically kill cells expressing the targeted antigen, such as CD19 for B cell malignancies. CART cell proliferation and formation of memory...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joshua Mark Brockman

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 52/100

Likely hiring

Solid budget

Active award

$372,100

FY 2026

Project Title

Measuring and Programming Piconewton Receptor Forces for Synthetic Mechanobiology

Grant Number:

5R35GM157007-02

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary: Mechanical forces are critical in diverse biological processes, including coagulation, cancer metastasis, embryonic development, and immune function. Individual receptors exert forces at the piconewton scale, one trillionth the force required to lift an apple. Our lab seeks to devel...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sunila Pradeep

MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI

Good lead · 52/100

Likely hiring

Solid budget

Active award

$364,532

FY 2026

Project Title

Role of exosomal SPHK1 in ovarian cancer progression

Grant Number:

5R01CA258433-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Immunotherapies, including those that involve immune checkpoint inhibitors against programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1), have revolutionized cancer treatment. However, in stark contrast to other malignancies such as melanoma or renal cell cancer, immunother...

Research Terms

<4-Sphingenine><Antibodies><Autologous><B7-H1><Biologic Models><Biological Markers><Biological Models><Blood Sample><Blood specimen><CD274><Cancer Model><Cancer Patient><Cancer Treatment><CancerModel><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell model><Cell-Mediated Lympholytic Cells><Cells><Cellular model><Checkpoint inhibitor><Communication><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Data><Development><Dysfunction><E2F Transcription Factor 1><E2F transcription factor 1 protein><E2F transcription factors><E2F-1><E2F-1 protein><E2F1><E2F1 gene><E2F1 protein><Environment><Event><Functional disorder><Gene Transcription><Generalized Growth><Genetic Transcription><Goals><Grawitz Tumor><Growth><Homolog of Yeast Vacuolar Protein Sorting 23><Hypernephroid Carcinoma><Hypernephroma><Immune><Immune Evasion><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunologically Directed Therapy><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Intracellular Communication and Signaling><Kinases><Laboratories><Lipids><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Tumor><Malignant Tumor of the Ovary><Malignant neoplasm of ovary><Mediating><Melanoma Cell><Model System><Modeling><Molecular><Nephroid Carcinoma><Non-Polyadenylated RNA><Outcome><Ovarian Tumor><Ovary Cancer><Ovary Neoplasms><Ovary Tumor><PBR3><PD 1><PD-1><PD-L1><PD1><PDL-1><PDX model><PRB-Binding Protein E2F-1><Pathway interactions><Patient derived xenograft><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Play><Population><Production><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proliferating><Protein Phosphorylation><Proteins><RBAP-1><RBBP-3><RBBP3><RBP3><RNA><RNA Expression><RNA Gene Products><Renal Adenocarcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Research Proposals><Retinoblastoma Binding Protein 3><Retinoblastoma-Associated Protein 1><Ribonucleic Acid><Role><SPHK1 enzyme><Sampling><Serous><Signal Transduction><Signal Transduction Systems><Signaling><Sphingosine><T-Cells><T-Lymphocyte><TSG101><TSG101 gene><Testing><Therapeutic><Tissue Growth><Transcription><Transphosphorylases><Tumor Cell><Tumor Promotion><VPS23><Work><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><bio-markers><biologic marker><biological signal transduction><biomarker><cancer cell><cancer immunotherapy><cancer microenvironment><cancer progression><cancer therapy><cancer-directed therapy><developmental><exhaustion><exosome><extracellular><extracellular vesicles><host response><immune check point inhibitor><immune evasive><immune microenvironment><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><in vivo><inhibitor><kidney adenocarcinoma><killer T cell><malignancy><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><novel><ontogeny><ovarian cancer><ovarian neoplasm><pathophysiology><pathway><patient derived xenograft model><pharmacologic><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><response><sle2><social role><sphingosine 1-phosphate><sphingosine kinase-1><success><synergism><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><transcription factor E2F1><treatment strategy><tumor><tumor growth><tumor immune microenvironment><tumor microenvironment><tumor progression><tumor susceptibility gene 101><tumor-immune system interactions>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anna Huttenlocher

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 52/100

Likely hiring

Solid budget

Active award

$362,722

FY 2026

Project Title

Adhesive regulation during cell migration

Grant Number:

5R01CA085862-25

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/10/2000

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Cell migration is important in normal development, wound healing and cancer. The long-term goal of this work is to study cell migration in the context of cancer. The most motile, and understudied, population of cells in the tumor microenvironment (TME) are neutrophils, which are primary eff...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuwen Zhu

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 52/100

Likely hiring

Solid budget

Active award

$355,706

FY 2026

Project Title

The CD93 pathway and melanoma therapy

Grant Number:

5R01CA258302-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/3/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immune checkpoint blocker therapy has recently greatly improved survival of patients with late- stage melanoma. However, about 2/3 of patients do not benefit from this therapy. One of main hurdles is that many melanoma tissues lack effector CD8+ T cells. The immature and dys...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Fekadu Kassie

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 52/100

Likely hiring

Solid budget

Active award

$352,275

FY 2026

Project Title

Targeting tumor cell mitochondria for the prevention and treatment of lung cancer

Grant Number:

5R01CA285608-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Lung cancer is the leading cause of cancer-related mortality in the United States and adenocarcinoma (ADC) is the most common histological type of lung cancer. Kras mutations occur in 20–40% of lung ADCs and, among Kras-mutant lung tumors (K tumors), concurrent mutations of Kras and the tumor suppre...

Research Terms

<3-D><3-Dimensional><3D><4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol><4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone><A/J Mouse><A549><Acetylcysteine><Acetylin><Active Oxygen><Adenocarcinoma><Affect><Airbron><Anti-Oncogenes><Anti-diabetic Agents><Anti-diabetic Drugs><Antioncogenes><Antioxidants><Apopain><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Caspase 3><Apoptotic><Assay><Attenuated><Bioassay><Biological Assay><Biological Markers><Broncholysin><Brunac><CASP-3><CASP3><CASP3 gene><CD44><CD44 gene><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CPP-32><CPP32><CPP32 protein><CPP32B><CPP32beta><Cancer Cause><Cancer Causing Agents><Cancer Etiology><Cancer Patient><Cancer Suppressor Genes><Carcinogens><Cell Body><Cell Communication and Signaling><Cell Death Induction><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Signaling><Cells><Cellular Proliferation><Cessation of life><Clinical Trials><Complex><Cysteine Protease CPP32><Cysteine Protease CPP32 Gene><Cytosol><DNA Methylation><DNA mutation><Data><Death><Diabetes Mellitus><Dimethylbiguanidine><Dimethylguanylguanidine><Dose><Drugs><Emerogenes><Exhibits><Fabrol><Ferricytochrome c><Ferrocytochrome c><Fluatox><Fluimucetin><Fluimucil><Fluprowit><Future><Generations><Genes><Genetic Change><Genetic defect><Genetic mutation><Goals><Growth Agents><Growth Factor><Growth Substances><Histologic><Histologically><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><Immune><Immune Interferon><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Infiltration><Interferon Gamma><Interferon Type II><Intracellular Communication and Signaling><LKB1><LKB1/STK11 Gene><Lesion><LoxP-flanked allele><Lung><Lung Adenocarcinoma><Lung Neoplasms><Lung Respiratory System><Lung Tumor><MDU3><Malignant><Malignant - descriptor><Malignant Adenoma><Malignant Cell><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medication><Mercapturic Acid><Metabolic stress><Metformin><Methylation><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Muco Sanigen><Mucocedyl><Mucolator><Mucolyticum><Mucomyst><Mucosolvin><Mucret><Murine><Mus><Mutation><N,N-dimethyl-imidodicarbonimidic diamide><N-Acetylcysteine><NAC Zambon><NNAL><NNK><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Neo-Fluimucil><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncogens><Oxidation-Reduction><Oxidative Stress><Oxygen Consumption><Oxygen Radicals><PARP Cleavage Protease><PARP Cleavage Protease Gene><Parvolex><Pgp1><Pharmaceutical Preparations><Phosphorylation><Population Study><Prevention><Pro-Oxidants><Programmed Cell Death><Protein Phosphorylation><Proteins><Proteins Growth Factors><Pulmonary Cancer><Pulmonary Neoplasms><Pulmonary malignant Neoplasm><Reactive Oxygen Species><Recessive Oncogenes><Redox><Resistance><Respaire><Risk Reduction><SCA-1><SCA-1 Gene><SREBP Cleavage Activity 1><SREBP Cleavage Activity 1 Gene><STK11><STK11 gene><Safety><Signal Transduction><Signal Transduction Systems><Signaling><Stress><System><T8 Cells><T8 Lymphocytes><Therapeutic><Tixair><Tobacco smoke><Tumor Cell><Tumor Suppressing Genes><Tumor Suppressor Genes><United States><Yama><Yama protein><analog><anti-diabetic><anti-tumor effect><antitumor effect><attenuate><attenuates><bio-markers><biologic marker><biological signal transduction><biomarker><cancer cell><cancer progenitor><cancer progenitor cells><cancer stem cell><cancer stem like cell><caspase-3><check point blockade><checkpoint blockade><cysteine protease P32><cytochrome c><determine efficacy><diabetes><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><evaluate efficacy><examine efficacy><floxed><floxed allele><genome mutation><immune check point blockade><immune checkpoint blockade><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><lFN-Gamma><liver kinase B1><loss of function><loss of function mutation><lung cancer><malignant progenitor><malignant stem cell><mitochondrial><mortality><mouse model><murine model><mutant><neoplastic><neoplastic cell><novel><oncogenic agent><oncogenic progenitor><oncogenic stem cells><oncosuppressor gene><overexpress><overexpression><oxidation reduction reaction><oxidative DNA damage><population research study><population survey><population-based study><population-level study><prevent><preventing><progenitor cell markers><progenitor like cancer cell><progenitor markers><progenitor stem cell markers><pulmonary><recruit><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><resistant><risk-reducing><safety assessment><self-renew><self-renewal><stem cell biomarkers><stem cell markers><stem like cancer cell><three dimensional><tumor><tumor immune microenvironment><tumor-immune system interactions>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jayanth Panyam

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$349,778

FY 2026

Project Title

TLR7/8 agonist design and delivery for effective anticancer immune response

Grant Number:

5R01CA260825-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/8/2021

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Agonists of toll like receptors (TLRs) are promising anticancer vaccine adjuvants because of their ability to induce proinflammatory cytokines necessary to generate a robust immune response. However, currently available TLR agonists suffer from a number of limitations including self-regulatory immun...

Research Terms

<Ab-dependent cellular cytotoxicity><Activated Natural Killer Cell><Agonist><Aldara><Antibodies><Antigens><Antineoplastic Vaccine><Applications Grants><Assay><BCG immunotherapy><BCG therapy><BCG treatment><Bacillus Calmette Guérin immunotherapy><Bacillus Calmette Guérin therapy><Bacillus Calmette-Guerin Immunotherapy><Bacillus Calmette-Guerin Therapy><Basal Cell Epithelioma><Basal cell carcinoma><Basiloma><Bioassay><Biological Assay><Bladder Cancer><Breast Cancer><Breast Cancer Model><Breast tumor model><CSIF><CSIF-10><Cancer Vaccines><Cancers><Cell Body><Cell surface><Cell-Mediated Lympholytic Cells><Cells><Characteristics><Charge><Chemosensitization><Chemosensitization/Potentiation><Combined Modality Therapy><Common Rat Strains><Cytokine Synthesis Inhibitory Factor><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Cytotoxic cell><Dendritic Cells><Drug Combinations><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drug Precursors><EGF Receptor><EGFR><ELISA><ERBB Protein><ERBB2><ERBB2 gene><Encapsulated><Endosomes><Enzyme-Linked Immunosorbent Assay><Epidermal Growth Factor Receptor><Epidermal Growth Factor Receptor Kinase><Epidermal Growth Factor Receptor Protein-Tyrosine Kinase><Epidermal Growth Factor-Urogastrone Receptors><Equilibrium><FDA approved><Formulation><Grant Proposals><HER -2><HER-2><HER1><HER2><HER2 Genes><HER2/neu><HPV caused cancer><HPV driven cancers><HPV induced cancer><HPV malignancy><HPV+ cancer><HPV-Related Malignancy><HPV-associated cancer><HPV-associated malignancy><HPV-related cancer><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Human><Human Papilloma Virus-Related Malignancy><Human Papilloma Virus-Related Malignant Neoplasm><Human Papilloma Virus-associated cancer><Human Papilloma Virus-associated malignancy><Human Papilloma Virus-related cancer><Human papillomavirus cancer><Human papillomavirus induced cancer><Human papillomavirus malignancy><Human papillomavirus-Related Malignancy><Human papillomavirus-Related Malignant Neoplasm><IL-10><IL10><IL10A><Imiquimod><Immune><Immune response><Immunes><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Inducer Cells><Inducer T-Lymphocytes><Infiltration><Inflammatory><Injections><Interleukin 10 Precursor><Interleukin-10><Investigation><K lymphocyte><Lead><Ligands><Lipid A><Malignant Bladder Neoplasm><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant neoplasm of urinary bladder><Mediating><Modeling><Modern Man><Modification><Multimodal Therapy><Multimodal Treatment><Myeloid-derived suppressor cells><NEU Oncogene><NEU protein><NK Cells><NK T cell><NKT cell><Natural Killer Cells><Natural Killer T cell><Needles><Neoplasm Vaccines><Oncogene ErbB2><Ovalbumin><PBMC><Particle Size><Pb element><Peripheral Blood Mononuclear Cell><Pharmacokinetics><Potentiation><Pro-Drugs><Prodrugs><Property><Rat><Rats Mammals><Rattus><Receptosomes><Regulatory T-Lymphocyte><Rodent Ulcer><Safety><Series><Site><Specificity><Structure><Surface><System><T cell response><T-Cells><T-Lymphocyte><TGF-alpha Receptor><TKR1><TLR protein><TLR7><TLR7 gene><Techniques><Toll-Like Receptor 7><Toll-Like Receptor Family Gene><Toll-like receptors><Transforming Growth Factor alpha Receptor><Treg><Tumor Immunity><Tumor Vaccines><Upregulation><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Urogastrone Receptor><Vaccination><Vaccine Adjuvant><Vaccines><Veiled Cells><Viscosity><analog><anti-cancer><anti-cancer immunotherapy><anti-tumor immunity><anti-tumor vaccine><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><anticancer immunotherapy><antigen-specific T cells><antitumor immunity><balance><balance function><basal cell carcinoma of skin><c-erbB-1><c-erbB-1 Protein><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer immunity><cancer immunotherapy><cancer type><combination therapy><combined modality treatment><combined treatment><cytokine><cytotoxic><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><design><designing><draining lymph node><drug discovery><enzyme linked immunoassay><erbB-1><erbB-1 Proto-Oncogene Protein><erbB-2 Genes><erbBl><heavy metal Pb><heavy metal lead><herstatin><host response><human papillomavirus associated malignancy><human papillomavirus caused cancer><human papillomavirus driven cancers><human papillomavirus-associated cancer><human papillomavirus-related cancer><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune-based cancer therapies><immunogen><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive myeloid cells><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><immunotoxicity><improved><intravesical BCG><killer T cell><malignancy><malignant breast tumor><mammary cancer model><mammary tumor model><multi-modal therapy><multi-modal treatment><myeloid suppressor cells><myeloid-derived suppressive cells><nano particle><nano particle delivery><nano vaccine><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><nanovaccine><natural killer T lymphocyte><neoplasm/cancer><neu Genes><novel><proto-oncogene protein c-erbB-1><regional lymph node><regulatory T-cells><response><suppressive myeloid cells><systemic toxicity><thymus derived lymphocyte><toxic reaction in immunology><trafficking><tumor><vaccine for cancer>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gregory L Beatty

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$347,344

FY 2026

Project Title

Targeting the liver for immunotherapy in pancreatic cancer

Grant Number:

5R01CA197916-10

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2016

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Immunotherapy has shown the capacity to improve outcomes for some patients across a wide-range of malignancies. However, many patients still do not achieve clinical benefit and in particular, patients with liver metastases demonstrate poor responsiveness to immunotherapy. Emerging ev...

Research Terms

<Acute-Phase Proteins><Acute-Phase Reactants><Address><Amyloid><Amyloid Substance><Antigens><Applications Grants><Autoregulation><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Biology><Blood Serum><CD8><CD8B><CD8B1><CD8B1 gene><Cancer Induction><Cancers><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Cellular biology><Clinical><Data><Dendritic Cells><Deposit><Deposition><Development><Environment><Exposure to><Extracellular Matrix Proteins><Funding><GI cancers><GI malignancies><GI tract cancers><Gastrointestinal Cancer><Gastrointestinal Tract Cancer><Genetic><Grant><Grant Proposals><HPGF><Hepatic Cells><Hepatic Neoplasm Secondary><Hepatic Parenchymal Cell><Hepatic Stellate Cell><Hepatic metastasis><Hepatocyte><Hepatocyte-Stimulating Factor><Homeostasis><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune Evasion><Immune Surveillance><Immune mediated therapy><Immune reaction><Immunobiology><Immunochemical Immunologic><Immunologic><Immunologic Surveillance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunophysiology><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunosurveillance><Immunotherapy><Impairment><Infiltration><Interleukin-6><Ito Cell><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><KRAS(G12D)><KRASG12D><Knowledge><Kupffer Cells><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><LYT3><Liver><Liver Cells><Liver secondaries><Liver secondary cancer><MGI-2><Macrophage><Malignant Cell><Malignant Gastrointestinal Neoplasm><Malignant Melanoma><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of gastrointestinal tract><Malignant neoplasm of lung><Malignant neoplasm of pancreas><Melanoma><Metastatic Neoplasm to the Liver><Metastatic Tumor to the Liver><Metastatic malignant neoplasm to liver><Mice><Mice Mammals><Modeling><Molecular><Murine><Mus><Myeloid Cells><Myeloid Differentiation-Inducing Protein><Mφ><Neutrophil Infiltration><Neutrophil Recruitment><Neutrophilic Infiltrate><Non-Malignant><Organ><Outcome><PDA model><PDAC Model><Pancreas><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Patients><Physiological Homeostasis><Plasmacytoma Growth Factor><Play><Portal Vein><Portal vein structure><Primary Neoplasm><Primary Tumor><Process><Productivity><Proteins><Pulmonary Cancer><Pulmonary malignant Neoplasm><Reproducibility><Resistance><Retrospective Studies><Role><STAT3><STAT3 gene><Serum><Shapes><Signal Pathway><Soil><Stellate Sinusoidal Macrophage><Stromal Cells><Subcellular Process><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell infiltration><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Teff cell><Therapeutic><Tumor Escape><Tumor Immune Escape><Variant><Variation><Veiled Cells><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti-cancer immunotherapy><anticancer immunotherapy><cancer cell><cancer evasion><cancer immune escape><cancer immune evasion><cancer immunotherapy><cancer microenvironment><carcinogenesis><cell biology><check point blockade><checkpoint blockade><clinical relevance><clinically relevant><design><designing><developmental><effector T cell><gastrointestinal malignancies><hepatic body system><hepatic inflammation><hepatic organ system><human cancer mouse model><human disease><human tissue><immune check point blockade><immune checkpoint blockade><immune evasive><immune microenvironment><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunogenicity><immunologic reactivity control><immunomodulatory><immunoreaction><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><improved outcome><inflamed liver><interferon beta 2><liver inflammation><liver macrophage><liver metastases><lung cancer><malignancy><malignant liver neoplasm, specified as secondary><metastasis in the liver><metastasis to the liver><metastasize to the liver><metastatic cancer to liver><metastatic liver><metastatic liver neoplasm><mouse model><murine model><neoplasm/cancer><new approaches><nonmalignant><novel><novel approaches><novel strategies><novel strategy><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><patients with pancreatic cancer><peripheral tolerance><resistant><retrospective research study><retrospective survey><secondary liver malignancy><secondary malignant liver neoplasm><social role><systemic inflammation><systemic inflammatory response><therapeutic T-cell platform><thymus derived lymphocyte><tool><trafficking><tumor><tumor evasion><tumor immune evasion><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Paula T Hammond

MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$318,532

FY 2026

Project Title

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles

Grant Number:

5R01CA235375-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2019

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

An immunosuppressive or immune excluded tumor microenvironment (TME) plays a key role in limiting the response of many tumor types to immunotherapy. One attractive strategy to accomplish increased lymphocyte infiltration in tumors is the use of cytokines, which can directly impact multiple immune pa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Darrell J Irvine

MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$318,532

FY 2026

Project Title

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles

Grant Number:

5R01CA235375-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2019

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

An immunosuppressive or immune excluded tumor microenvironment (TME) plays a key role in limiting the response of many tumor types to immunotherapy. One attractive strategy to accomplish increased lymphocyte infiltration in tumors is the use of cytokines, which can directly impact multiple immune pa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia Ingrid Moreno

UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, CORAL GABLES, FL

Good lead · 48/100

Above-average budget

Very recent

Active award

$985,114

FY 2026

Project Title

Symptomatic Toxicities & Quality of Life among Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer.

Grant Number:

5R37CA288566-02

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Immunotherapy has revolutionized cancer treatment and has become the fourth pillar of cancer care alongside surgery, radiation, and chemotherapy. Immune checkpoint inhibitors work by binding to proteins in order to enable the immune system to recognize and attack cancer cells. Although checkpoint in...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christina Vadala Angeles

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 48/100

Above-average budget

Very recent

Active award

$660,808

FY 2026

Project Title

Durability of memory T cell responses in melanoma

Grant Number:

1R37CA292078-01A1

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Melanoma is the most lethal type of skin cancer. About 50% of patients with metastatic melanoma have a meaningful response to treatment with immunotherapy, of which some develop a durable response. Many patients with the best response to immunotherapy develop immunotherapy-i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher Austin Klebanoff

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Good lead · 48/100

Above-average budget

Very recent

Active award

$538,178

FY 2026

Project Title

Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.

Grant Number:

4R37CA259177-06

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT - There are no changes. Immunotherapy induces durable remissions in a subset of patients with highly mutated cancers. However, most cancers are modestly mutated and fail to respond to current immunotherapy treatments. This is especially true for malignancies caused by activa...

Research Terms

<1-Phosphatidylinositol 3-Kinase><Adoptive Cellular Immunotherapy><Adoptive Immunotherapy><Affinity><Alleles><Allelomorphs><Antibodies><Antibody Therapy><Antigens><Autoantigens><Autologous Antigens><Avidity><Binding><Bioinformatics><Biometrics><Biometry><Biophysics><Biostatistics><Blood Sample><Blood specimen><Breast Cancer><Cancer Cause><Cancer Etiology><Cancer Genes><Cancer Patient><Cancer-Promoting Gene><Cancers><Carcinoma><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cessation of life><Clone Cells><Colon><Complement><Complement Proteins><Complex><DNA Alteration><DNA Sequence Alteration><DNA Therapy><DNA mutation><Data><Death><Disease remission><Disseminated Malignant Neoplasm><Endocrine Therapy><Endometrium><Epithelial cancer><Exhibits><Frequencies><Gene Transfer><Gene Transfer Clinical><Generalized Growth><Genetic Alteration><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genomic approach><Genotype><Growth><HL-A Antigens><HLA Antigens><Heterogeneity><Hormonal Therapy><Human><Human Leukocyte Antigens><Immune><Immune Monitoring><Immune mediated therapy><Immune response><Immunes><Immunochemical Immunologic><Immunogenomics><Immunologic><Immunologic Monitoring><Immunological><Immunological Monitoring><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomonitoring><Immunotherapy><Individual><Kinetics><Knowledge><Leukocyte Antigens><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Breast Neoplasm><Malignant Cell><Malignant Epithelial Neoplasms><Malignant Epithelial Tumors><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Mediating><Memory><Metastasis><Metastasize><Metastatic Cancer><Metastatic Lesion><Metastatic Malignant Neoplasm><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Modern Man><Molecular><Molecular Interaction><Mutate><Mutation><Neoplasm Metastasis><Oncogenes><PD 1><PD-1><PD1><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Pathway interactions><Patients><Peptides><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Population><Pre-Clinical Model><Preclinical Models><Privatization><Process><Property><Proteins><PtdIns 3-Kinase><Reagent><Remission><Resistance><Secondary Neoplasm><Secondary Tumor><Self-Antigens><Sequence Alteration><Single Crystal Diffraction><Somatic Mutation><Structure><T cell response><T-Cell Antigen Receptors><T-Cell Development><T-Cell Ontogeny><T-Cell Receptor><T-Cell Receptor Genes><T-Cells><T-Lymphocyte><T-Lymphocyte Development><TcR Genes><Testing><Time><Tissue Growth><Toxic effect><Toxicities><Transforming Genes><Tumor Antigens><Tumor-Associated Antigen><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><Uterine lining><Viral><Viral Antigens><Work><X Ray Crystallographies><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray/Neutron Crystallography><Xray Crystallography><adoptive cell immunotherapy><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antigen-specific T cells><biophysical foundation><biophysical principles><biophysical sciences><cancer antigens><cancer cell><cancer immunology><cancer metastasis><chemotherapy><complementation><conventional therapy><conventional treatment><cost efficient><curative intervention><curative therapeutic><curative therapy><curative treatments><engineered T cells><epithelial carcinoma><exhaustion><fitness><gain of function mutation><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetically engineered T-cells><genome mutation><genome sequencing><genomic alteration><genomic effort><genomic strategy><genomic therapy><hormone therapy><host response><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-genomic treatment><immuno therapy><immuno-gene therapy><immunogen><immunogene therapy><immunogenic><immunogenicity><immunoresponse><individual patient><inhibitor><innovate><innovation><innovative><malignancy><malignant breast tumor><multidisciplinary><mutant><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm immunology><neoplasm/cancer><new approaches><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel approaches><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><pathway><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><personalized immunotherapy><precision immunotherapy><programmed cell death 1><programmed cell death protein 1><programmed death 1><resistant><response><sle2><somatic variant><structural biology><systemic lupus erythematosus susceptibility 2><therapeutic target><thymus derived lymphocyte><transgenic T- cells><translation strategy><translational approach><translational strategy><tumor><tumor cell metastasis><tumor immunology><tumor-specific antigen><virus antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Marco Ruella

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 48/100

Above-average budget

Very recent

Active award

$527,525

FY 2026

Project Title

MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER

Grant Number:

5R37CA262362-05

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/12/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Adoptive T-cell immunotherapies and, in particular, chimeric antigen receptor T cells (CART) generated unprecedented responses in patients with highly refractory CD19+ B cell malignancies. However, only a limited number of patients treated with anti-CD19 CART will experience prolonge...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jared H. Rowe

DANA-FARBER CANCER INST, BOSTON, MA

Good lead · 48/100

Training-friendly

Recent

Active award

Career award

$165,240

FY 2026

Project Title

Identifying metabolic regulation of T cells during early childhood development

Grant Number:

5K08HD109453-03

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Similar to the mature immune system in adults, the developing immune system in children must protect the host from infections and cancer while preventing autoimmunity. Immune system function undergoes changes during early organism development. Therefore, in order to develop ...

Research Terms

<0-11 years old><21+ years old><Adult><Adult Human><Age><Alanine><Autoimmune Status><Autoimmunity><Biology><Body Tissues><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancer Biology><Cancer Model><Cancer Treatment><CancerModel><Cancers><Cause of Death><Cell Body><Cell Function><Cell Physiology><Cell Process><Cell Protection><Cells><Cellular Function><Cellular Immunology><Cellular Metabolic Process><Cellular Physiology><Cellular Process><Cellular biology><Child><Child Health><Child Youth><Childhood><Childhood Cancers><Childhood Neoplasm><Childhood Tumor><Children (0-21)><Complex><Cytoprotection><Development><Developmental Process><Disease><Disorder><Disparities><Disparity><Equilibrium><Foundations><Goals><Hostility><IMiD><Immune><Immune mediated therapy><Immune modulatory therapeutic><Immune response><Immune system><Immunes><Immunochemical Immunologic><Immunocompetent><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapy><Impairment><In Situ><Individual><Infection><Intermediary Metabolism><Knowledge><Life><Malignant Childhood Neoplasm><Malignant Childhood Tumor><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pediatric Neoplasm><Malignant Pediatric Tumor><Malignant Tumor><Malignant childhood cancer><Metabolic><Metabolic Control><Metabolic Pathway><Metabolic Processes><Metabolism><Mice><Mice Mammals><Murine><Mus><Neonatal><Neuroblastoma><Nutrient><Organism><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Pediatric Neoplasm><Pediatric Tumor><Physiologic><Physiological><Pre-Clinical Model><Preclinical Models><Process><Proliferating><Property><Pyruvate><Pyruvate Metabolism><Pyruvate Metabolism Pathway><Regulation><Research><Role><Subcellular Process><Supplementation><Systems Biology><Systems Development><T cell regulation><T-Cell Activation><T-Cell Development><T-Cell Ontogeny><T-Cells><T-Lymphocyte><T-Lymphocyte Development><T8 Cells><T8 Lymphocytes><Therapeutic><Thymus><Thymus Gland><Thymus Proper><Thymus Reticuloendothelial System><Tissues><Treatment-related toxicity><Tumor Cell><Tumor Escape><Tumor Immune Escape><Tumor Immunity><Tumor-Derived><Tumor-Infiltrating Lymphocytes><Vulnerable Populations><activate T cells><adulthood><ages><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immunity><anticancer immunotherapy><antitumor immunity><balance><balance function><cancer evasion><cancer immune escape><cancer immune evasion><cancer immunity><cancer immunotherapy><cancer in a child><cancer in children><cancer microenvironment><cancer therapy><cancer-directed therapy><cell biology><cell metabolism><cellular metabaolism><child patients><child with cancer><childhood malignancy><clinical relevance><clinically relevant><critical period><customized therapy><customized treatment><cytoprotective><developmental><early childhood><host response><immune competent><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulatory agents><immune modulatory drugs><immune system function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunomodulating agents><immunomodulating drugs><immunomodulator agent><immunomodulator drug><immunomodulator medication><immunomodulator prodrug><immunomodulator therapeutic><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><inhibitor><innovate><innovation><innovative><juvenile animal><kids><living system><malignancy><metabolism measurement><metabolomics><metabonomics><neoplasm/cancer><neoplastic cell><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><pathway><patient oriented outcomes><patient specific therapies><patient specific treatment><pediatric><pediatric cancer><pediatric malignancy><pediatric patients><prevent><preventing><resistance mechanism><resistant mechanism><response><social role><tailored medical treatment><tailored therapy><tailored treatment><therapeutic toxicity><therapy associated toxicity><therapy related toxicity><therapy toxicity><thymus derived lymphocyte><transcriptomics><treatment toxicity><treatment-associated toxicity><tumor><tumor evasion><tumor immune evasion><tumor microenvironment><tumors in children><unique treatment><vulnerable group><vulnerable individual><vulnerable people><young animal><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jesus Jimenez

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 48/100

Training-friendly

Recent

Active award

Career award

$162,705

FY 2026

Project Title

CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease

Grant Number:

5K08HL163518-03

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary/Abstract (30 lines) Immunotherapy has revolutionized cancer treatment and is a cornerstone of standard clinical practice and ongoing clinical trials. However, some immunotherapies including immune checkpoint inhibitors (ICIs) impart adverse cardiac events ranging from arrhythmias to ...

Research Terms

<(TNF)-α><Acceleration><Address><Agonist><AngII><Angiotensin II><Antibodies><Antigen Presentation><Antigen-Presenting Cells><Arrhythmia><Assay><B-Cells><B-Lymphocytes><B-cell><Bioassay><Bioinformatics><Biological Assay><Body Tissues><Bp50><C-C Chemokines><CC Chemokines><CD154 Antigens><CD40><CD40 Ligand><CD40-L><CDW40><CITE sequencing><CITE-seq><CITEseq><CTLA-4 blockade><CTLA4 blockade><Cachectin><Cancer Model><Cancer Patient><Cancer Treatment><CancerModel><Cancers><Cardiac><Cardiac Arrhythmia><Cardiomyopathies><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Caring><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Proteins><Cells><Cellular Indexing of Transcriptomes and Epitopes by Sequencing><Characteristics><Checkpoint inhibitor><Chemokine Receptor Gene><Chemotactic Cytokines><Clinical><Clinical Trials><Competence><Data><Dendritic Cells><Development><Development Plans><Doctor of Philosophy><Eligibility><Eligibility Determination><Evaluation><Event><Fatality rate><Fellowship><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Gene Expression><Genetic><Goals><Grant><HIGM1><Heart><Heart Arrhythmias><Heart Injuries><Heart Vascular><Homologous Chemotactic Cytokines><IFN-Gamma><IFN-Gamma Receptor><IFN-g><IFN-γ><IFN-γ Receptor><IFNG><IFNγ><IMD3><Immune><Immune Interferon><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunologically Directed Therapy><Immunology><Immunotherapy><Impairment><Infiltration><Inflammation><Inflammatory><Inflammatory Response><Infusion><Infusion procedures><Injections><Injury><Integral Membrane Protein><Intercrines><Interferon Gamma><Interferon Gamma Receptor Complex><Interferon Type II><Internal Medicine><Intracellular Communication and Signaling><Intrinsic Membrane Protein><KO mice><Knock-out Mice><Knockout Mice><LV remodeling><Left Ventricular Remodeling><Ligands><Lineage Tracing><MGC9013><Macrophage><Macrophage Activation><Macrophage-Derived TNF><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Manuscripts><Mediating><Mediator><Mentors><Mentorship><Mice><Mice Mammals><Monocyte-Derived TNF><Murine><Mus><Myocardial><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><Myocarditis><Mφ><Null Mouse><Oncology><Oncology Cancer><Outcome><PD 1><PD-1><PD-1 inhibitors><PD-L1 blockade><PD1><PD1 inhibitors><PDL1 blockade><Patients><Ph.D.><PhD><Phenotype><Phenylephrine><Physicians><Postdoc><Postdoctoral Fellow><Preparation><Principal Investigator><Production><Protocol Screening><Receptor Protein><Research><Research Associate><Role><SIS cytokines><Scientist><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Single cell seq><T cell response><T memory cell><T-B Cell Activating Molecule><T-Cell Activation><T-Cell Subsets><T-Cell gp39 Antigen><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><TNF><TNF A><TNF Alpha><TNF gene><TNF-Related Activation Protein><TNF-α><TNFA><TNFRSF5><TNFRSF5 gene><TNFα><Technical Expertise><Testing><Tissues><Training><Transmembrane Protein><Transmembrane Protein Gene><Tumor Necrosis Factor><Tumor Necrosis Factor Ligand Superfamily Member 5><Tumor Necrosis Factor Receptor Superfamily Member 5 Gene><Tumor Necrosis Factor-alpha><Veiled Cells><Writing><accessory cell><activate T cells><anti programmed cell death protein 1 inhibitor><anti-PD-1 inhibitors><anti-PD-L1 blockade><anti-PD1 inhibitors><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><autoimmune check point><autoimmune checkpoint><autoimmunity check point><autoimmunity checkpoint><beta-Chemokines><biological signal transduction><cancer immunotherapy><cancer therapy><cancer-directed therapy><cardiac inflammation><cardiac injury><cardiovascular disorder><career development><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cellular indexing of transcriptomes and epitopes by single cell sequencing><cellular lineage mapping><cellular lineage tracking><chemoattractant cytokine><chemokine><chemokine receptor><circulatory system><clinical practice><clinical training><conditional knock-out><conditional knockout><cytokine><cytotoxic><developmental><flow cytophotometry><host response><immune check point><immune check point inhibitor><immune checkpoint><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><improved><infusions><inhibitor drug><inhibitor therapeutic><inhibitor therapy><injuries><injury to the myocardium><innovate><innovation><innovative><insight><lFN-Gamma><left ventricle remodeling><malignancy><member><memory T lymphocyte><myocardial injury><myocardium disease><myocardium disorder><neoplasm/cancer><p50><post-doc><post-doctoral><post-doctoral trainee><preparations><programmed cell death 1><programmed cell death protein 1><programmed death 1><programs><protein expression><receptor><recruit><research associates><response><single cell next generation sequencing><single cell sequencing><skills><sle2><social role><systemic lupus erythematosus susceptibility 2><targeted cancer therapy><technical skills><thymus derived lymphocyte><tumor><β-Chemokines>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Longwei Liu

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Good lead · 48/100

Training-friendly

Recent

Active award

Career award

$151,548

FY 2026

Project Title

Development of single fluorophore biosensors for multiplex imaging of CAR T Signaling

Grant Number:

5K01EB035649-03

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary The complexity and dynamics of protein kinases and epigenetic modifications in cellular processes necessitate the development of precise biosensors for live imaging. This proposal aims to develop single-FP-based, high- performance, ultrasensitive biosensors through directed evolution...

Research Terms

<70 kDa zeta-associated protein><ATP-protein phosphotransferase><Achievement><Achievement Attainment><Address><Affect><Area><Behavior><Benchmarking><Best Practice Analysis><Bioinformatics><Biosensor><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><Cancer Treatment><Cancers><Cell Body><Cell Communication and Signaling><Cell Function><Cell Line><Cell Physiology><Cell Process><Cell Signaling><Cell model><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular model><Chromatin><Color><Development><Directed Molecular Evolution><Disease><Disorder><EPH- and ELK-Related Tyrosine Kinase><EPH-and ELK-Related Kinase><Engineering><Environment><Ephrin Type-A Receptor 8><Ephrin Type-A Receptor 8 Precursor><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Evolution><FRET><Fluorescence Resonance Energy Transfer><Focused Ultrasound><Förster Resonance Energy Transfer><Genes><Genetics-Mutagenesis><High Throughput Assay><Histones><Image><Immune><Immunes><In Situ><In Vitro><Intracellular Communication and Signaling><Kinase Family Gene><Kinases><Kinetics><Link><Lymphocyte-Specific Protein-Tyrosine Kinase><Lymphocyte-Specific p56LCK Tyrosine Protein Kinase><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mammalian Cell><Measures><Mentors><Methods><Modification><Molecular><Monitor><Mutagenesis><Mutagenesis Molecular Biology><NGS Method><NGS system><Pattern><Performance><Phenotype><Phosphotransferase Gene><Phosphotransferases><Play><Protein Dynamics><Protein Kinase><Protein Tyrosine Kinase><Protein Tyrosine Kinase EEK><Protein Tyrosine Kinase Zap70><Protein Tyrosine Kinase p56(lck)><Protein-Serine Kinase><Protein-Serine-Threonine Kinases><Protein-Threonine Kinase><Proto-Oncogene Protein c-lck><Proto-Oncogene Protein lck><Proto-Oncogene Tyrosine-Protein Kinase LCK><Rejuvenation><Research><Rest><SRK><Serine Kinase><Serine-Threonine Kinases><Serine/Threonine Protein Kinase Gene><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Specificity><Strains Cell Lines><Subcellular Process><Syk-related tyrosine kinase><System><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell regulation><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Activation><T-Cell Specific Protein Tyrosine Kinase><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Therapeutic><Threonine Kinase><Transphosphorylases><Tyrosine Kinase><Tyrosine-Protein Kinase Receptor EEK><Tyrosine-Specific Protein Kinase><Tyrosylprotein Kinase><Visualization><Work><ZAP-70><ZAP-70 Gene><ZAP-70 Kinase><ZAP-70 protein><ZAP70><Zeta-Chain Associated Protein Kinase><activate T cells><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><benchmark><biological sensor><biological signal transduction><cancer cell><cancer immunotherapy><cancer therapy><cancer-directed therapy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cultured cell line><design><designing><detection sensitivity><developmental><directed evolution><engineered immune system><epigenetic biomarker><epigenetic marker><epigenetically><epigenome><exhaust><exhaustion><fluorophore><functional restoration><glycogen synthase a kinase><high throughput screening><hydroxyalkyl protein kinase><hydroxyaryl protein kinase><image-based method><imaging><imaging method><imaging modality><imaging platform><immune engineering><immune-based cancer therapies><immunoengineering><immunotherapy for cancer><immunotherapy of cancer><improved><inhibitor><innovative technologies><insight><knock-down><knockdown><knockout gene><lck Kinase><live cell image><live cell imaging><live cellular image><live cellular imaging><malignancy><multiplexed imaging><neoplasm/cancer><next gen sequencing><next generation sequencing><nextgen sequencing><novel><p56 lck><phosphorylase b kinase kinase><prevent><preventing><prototype><response><restore function><restore functionality><restore lost function><sensor><side effect><spatial and temporal><spatial temporal><spatiotemporal><success><technology platform><technology system><therapeutic T-cell platform><thymus derived lymphocyte><tool><tumor><tyrosyl protein kinase>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mary-Keara Boss

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Good lead · 48/100

Training-friendly

Recent

Active award

Career award

$94,413

FY 2026

Project Title

Impact of lymph node sparing on the anti-tumor response for head and neck cancer treated with radiation and immunotherapy

Grant Number:

5K01OD031809-05

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Abstract As a board-certified veterinary radiation oncologist and radiobiologist, I am committed to, and excited for, a career in translational cancer research as a physician scientist. My long-term career goal is to develop into an independent veterinary clinician scientist, proficient in designing...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mansoor M. Amiji

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100

Likely hiring

Recent

Active award

$86,583

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James E Egan

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100

Likely hiring

Recent

Active award

$86,583

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edward J Kim

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100

Likely hiring

Recent

Active award

$86,583

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gerardo Guillermo Mackenzie

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100

Likely hiring

Recent

Active award

$86,583

FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Paarth Bhupendra Dodhiawala

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 48/100

Training-friendly

Very recent

Active award

$47,827

FY 2026

Project Title

Targeting oncogenic KRAS to sensitize pancreatic cancer to NK cell immunotherapy

Grant Number:

1F30CA301797-01A1

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/9/2026

End Date:

4/8/2030

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 13% that is refractory to immunotherapies. Combination with targeted therapy is a potential approach for overcoming resistance and sensitizing tumors. To this end, recently developed ...

Research Terms

<3-D><3-Dimensional><3D><ABCD-3><Ab-dependent cellular cytotoxicity><Activated Natural Killer Cell><Antigens><Assay><B7-H3><B7H3><Binding><Bioassay><Biological Assay><Biomedical Engineering><C-K-RAS><C3Xkine><CCL20><CCL20 gene><CD16><CD16B><CD276><CD276 gene><CD56><CRISPR><CRISPR/Cas system><CX3CL1><CX3CL1 gene><CXC3><CXC3C><CXCL1><CXCL1 gene><Cancer Genes><Cancer Patient><Cancer-Promoting Gene><Cancers><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Function><Cell Interaction><Cell Locomotion><Cell Migration><Cell Migration Assay><Cell Movement><Cell Physiology><Cell Process><Cell Signaling><Cell Therapy><Cell-to-Cell Interaction><Cells><Cellular Function><Cellular Migration><Cellular Motility><Cellular Physiology><Cellular Process><Chemokine, CC Motif, Ligand 20><Chemotactic Cytokines><Chemotaxis><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Co-culture><Cocultivation><Coculture><Coculture Techniques><Collagen><Colon Adenocarcinoma><Colonic Adenocarcinoma><Combination immunotherapy><Combined Modality Therapy><Cytolysis><Cytotoxic cell><DNA mutation><Data><Data Set><Disease Progression><Edodekin Alfa><Engineering><Exodus 1><FCGR3B><FCGR3B gene><Fc Receptor III-1><Fc gamma IIIb receptor><Fc-Gamma RIII-Beta><Fc-Gamma RIIIB><FcRIIIB><Fibrosis><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Future><GRO1><GROA><Generalized Growth><Genetic Change><Genetic defect><Genetic mutation><Growth><Histology><Homing><Homologous Chemotactic Cytokines><Human><IL-12><IL-15><IL12><IL15><IL15 Protein><IgG Fc Receptor IIIB><Immune><Immune mediated therapy><Immunes><Immunocompetent><Immunologically Directed Therapy><Immunology><Immunooncology><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Infiltration><Inflammatory><Intercrines><Interleukin-12><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KRAS><KRAS driven oncogenesis><KRAS oncogenesis><KRAS-driven tumorigenesis><KRAS-mediated tumorigenesis><KRAS2><KRAS2 gene><Ki-RAS><Knock-out><Knockout><LARC><Ligands><Low Affinity IgG Fc Receptor IIIB><Low Affinity Immunoglobulin Gamma Fc Region Receptor III-B><Lung Adenocarcinoma><Lysis><Lytotoxicity><MGC9721><MGSA><MIP3A><Macrophage Inflammatory Protein 3-Alpha><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mediating><Mice><Mice Mammals><Migration Assay><Modeling><Modern Man><Molecular Interaction><Motility><Multimodal Therapy><Multimodal Treatment><Multiplexed Ion Beam Imaging><Murine><Mus><Mutate><Mutation><NCAM><NCAM1><NCAM1 gene><NK Cell Activation><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><NKSF><Natural Killer Cell Activation><Natural Killer Cell Immunotherapy><Natural Killer Cell Stimulatory Factor><Natural Killer Cells><Oncogene K-Ras><Oncogene Products><Oncogene Proteins><Oncogenes><Oncology><Oncology Cancer><Oncoproteins><Organoids><Outcome><PDA model><PDAC Model><PDAC cancer cell><PDAC cell><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pansy><Pathway interactions><Patients><Physicians><Production><Proliferating><Proteins><Proteomics><Publishing><Quantitative Microscopy><RASK2><RNA Seq><RNA sequencing><RNAseq><Receptor Protein><Refractory><Regulation><Research Specimen><Resistance><SCYA20><SCYB1><SCYD1><SIS cytokines><Scientist><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Slice><Spatial Distribution><Specificity><Specimen><Subcellular Process><Survival Rate><TCGA><Testing><The Cancer Genome Atlas><Tissue Growth><Training><Transforming Genes><TriKE><Tumor Antigens><Tumor Burden><Tumor Cell><Tumor Load><Tumor Promotion><Tumor-Associated Antigen><Upregulation><Viola><Violet><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><arm><bio-engineered><bio-engineers><bioengineering><biological engineering><biological signal transduction><cancer antigens><cancer immunology><cancer microenvironment><cancer type><career><cell based intervention><cell killing><cell mediated intervention><cell mediated therapies><cell motility><cell type><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chemoattractant cytokine><chemokine><combination therapy><combinatorial immunotherapy><combined modality treatment><combined treatment><cytokine><cytotoxic><cytotoxicity><data modeling><dual immunotherapy><flow cytophotometry><gene signatures><genetic signature><genome mutation><immune competent><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-oncology><immuno oncology><immuno therapy><immunogen><immunology oncology><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vitro Assay><in vivo><inhibitor><malignancy><migration><model of data><model the data><modeling of the data><mouse model><multi-modal therapy><multi-modal treatment><multidisciplinary><multiomics><multiphoton excitation microscopy><multiphoton microscopy><multiple omics><murine model><mutant><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cellular therapy><natural killer therapy><neoplasm immunology><neoplasm/cancer><neoplastic cell><novel><oncogenic KRAS><oncoimmunology><ontogeny><overexpress><overexpression><pancreatic ductal adenocarcinoma cell><pancreatic ductal adenocarcinoma model><pancreatic malignancy><panomics><pathway><pre-clinical><preclinical><programs><receptor><recruit><resistant><response><response to therapy><response to treatment><skills><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy response><three dimensional><transcriptome sequencing><transcriptomic sequencing><transcriptomics><treatment response><treatment responsiveness><trispecific killer cell engager><trispecific killer engager><trispecific natural killer engager><tumor><tumor growth><tumor immunology><tumor microenvironment><tumor-specific antigen><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Blake Sells

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 48/100

Training-friendly

Very recent

Active award

$36,622

FY 2026

Project Title

Dissecting how activated immunity reshapes the stromal TME of pancreatic ductal adenocarcinoma

Grant Number:

5F30CA298121-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2029

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary / Abstract Immunotherapy has been shown to be effective in several cancer types leading to enhancement in long-term survival in subsets of patients. However, there are no proven effective immunotherapeutic approaches for pancreatic ductal adenocarcinoma (PDAC)1. There are many reaso...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Suman Paul

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Exploratory lead · 42/100

Training-friendly

Active award

Career award

$216,810

FY 2026

Project Title

TCR Targeting Antibodies for the Treatment of T cell Cancers

Grant Number:

5K08CA270403-05

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/8/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary Antibody-mediated targeted immunotherapies are highly effective in killing cancer cells. T cell leukemias and lymphomas, collectively known as T cell cancers, affect ~100,000 patients worldwide each year. Relapsed T cell cancers respond poorly to aggressive chemotherapy with a 5-yea...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Theodore Scott Nowicki

UNIVERSITY OF CALIFORNIA LOS ANGELES, LOS ANGELES, CA

Exploratory lead · 40/100

Above-average budget

Recent

Active award

$647,632

FY 2026

Project Title

TNF-alpha-"armed" TCR vectors to enhance adoptive cell therapy for solid tumors

Grant Number:

5R37CA289813-02

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/11/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Cancer immunotherapy with T-cells expressing a transgenic T-cell receptor (TCR) or chimeric antigen receptor (CAR) can generate dramatic clinical responses in a variety of solid tumors. However, a significant number of patients do not respond to therapy. We have previously s...

Research Terms

<(TNF)-α><Activities of Daily Living><Activities of everyday life><Adoptive Cell Transfers><Antigens><Assay><Bioassay><Biologic Factor><Biological Assay><Biological Factors><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CTAG><CTAG1><CTAG1 gene><CTAG1B><CTAG1B Gene><Cachectin><Cachectin Receptors><Cancer Treatment><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Therapy><Cell secretion><Cells><Cellular Secretion><Cellular biology><Cellular immunotherapy><Chronic><Clinical><Cytometry><Data><ESO1><Expression Signature><Future Generations><Gene Expression><Gene Expression Profile><HPV 16><HPV-16><HPV16><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Heterograft><Heterologous Transplantation><Human papilloma virus type 16><Human papillomavirus 16><Human papillomavirus type 16><Immune infiltrates><Immune mediated therapy><Immunoglobulin Enhancer-Binding Protein><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Impairment><In Vitro><Incidence><Inducer Cells><Inducer T-Lymphocytes><Inferior><Intracellular Communication and Signaling><Knock-out><Knockout><LAGE2B><Lentiviral Vector><Lentivirus Vector><MHC Receptor><Macrophage-Derived TNF><Major Histocompatibility Complex Receptor><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mediating><Mice><Mice Mammals><Monocyte-Derived TNF><Murine><Mus><NF-kB><NF-kappa B><NF-kappaB><NFKB><NY-ESO-1><Nature><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Patients><Phenotype><Proteomics><Recurrent disease><Relapsed Disease><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell differentiation><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell infiltration><T cell receptor based immunotherapy><T cell receptor cellular immunotherapy><T cell receptor engineered therapy><T cell receptor immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Antigen Receptors><T-Cell Receptor><T-Cell Receptor Therapy><T-Cell Receptor Treatment><T-Cell Receptor based Therapy><T-Cell Receptor based Treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><TCR T cell immunotherapy><TCR T cell therapy><TCR Therapy><TCR based T cell immunotherapy><TCR based Therapy><TCR based immune therapy><TCR based immunotherapy><TCR based treatment><TCR immunotherapy><TNF><TNF A><TNF Alpha><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNF gene><TNF-α><TNFA><TNFR><TNFα><Testing><Time><Toxic effect><Toxicities><Toxicology><Transcription Factor NF-kB><Transgenic Organisms><Translations><Treatment Failure><Tumor Antigens><Tumor Cell><Tumor Necrosis Factor><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Associated Antigen><Tumor-Infiltrating Lymphocytes><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><adoptive cell therapy><adoptive cellular therapy><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><biological signal transduction><cancer antigens><cancer immunotherapy><cancer infiltrating T cells><cancer microenvironment><cancer therapy><cancer type><cancer-directed therapy><cell based intervention><cell biology><cell killing><cell mediated intervention><cell mediated therapies><cell-based immunotherapy><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cytokine><daily living function><daily living functionality><design><designing><digital><engineered T cells><experiment><experimental research><experimental study><experiments><functional ability><functional capacity><gene expression pattern><gene expression signature><genetically engineered T-cells><human papilloma virus 16><humanized mice><humanized mouse><immune cell infiltrate><immune cell therapy><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><improved><in vitro Assay><in vitro activity><in vivo><innovate><innovation><innovative><kappa B Enhancer Binding Protein><mouse model><murine model><neoplastic cell><next generation><novel><nuclear factor kappa beta><phospho-proteomics><phosphoproteomics><responders and non-responders><responders from non-responders><responders or non-responders><responders versus non-responders><responders vs non-responders><responders/nonresponders><response><response to therapy><response to treatment><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><systemic toxicity><therapeutic T-cell platform><therapeutic response><therapy failure><therapy response><thymus derived lymphocyte><transcriptional profile><transcriptional signature><transgenic><transgenic T- cells><translation><translational therapeutics><translational therapy><treatment response><treatment responsiveness><tumor><tumor growth><tumor infiltrating T cells><tumor microenvironment><tumor-specific antigen><type 16 Human papilloma virus><type 16 Human papillomavirus><vector><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mary Philip

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Exploratory lead · 40/100

Above-average budget

Recent

Active award

$556,308

FY 2026

Project Title

TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction

Grant Number:

5R37CA263614-05

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY T cells have the potential to recognize and eliminate cancer cells. However, most often cancers progress in spite of the tumor-specific T cells present within tumors. While current immunotherapies such as immune checkpoint blockade can bring about long-lasting remissions in some pati...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JING LI

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$408,829

FY 2026

Project Title

Immunosuppression mediated by regulatory CD8+ T cells in lung cancers

Grant Number:

1R21CA301104-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2026

End Date:

2/29/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Lung cancer is a common and deadly malignancy, accounting for the highest number of cancer-related deaths worldwide. It is divided into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Despite groundbreaking advancements in cancer treatment using immune ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hua Zhang

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$408,829

FY 2026

Project Title

Immunosuppression mediated by regulatory CD8+ T cells in lung cancers

Grant Number:

1R21CA301104-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/13/2026

End Date:

2/29/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Lung cancer is a common and deadly malignancy, accounting for the highest number of cancer-related deaths worldwide. It is divided into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Despite groundbreaking advancements in cancer treatment using immune ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ju Fang Chang

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$399,829

FY 2026

Project Title

Rational Design of Next-Generation Engineered T Cells for Enhanced Cancer Immunotherapy

Grant Number:

1R21CA307944-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY A major challenge for engineered T cells to combat cancer is their limited persistence. The goal of this project is to enhance the persistence of T cells by harnessing 4-1BB using structure-informed protein design. As a co- stimulatory molecule, 4-1BB improves T cell long-term immune...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edward Bo-yi Chuong

UNIVERSITY OF COLORADO, Boulder, CO

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$385,333

FY 2026

Project Title

Splicing-mediated dysregulation of interferon signaling in cancer

Grant Number:

1R21CA309375-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/19/2026

End Date:

2/28/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Our DNA contains many enigmatic elements called transposons, which are genetic parasites that make up over half of our genetic material. In healthy cells, these elements are usually silenced, but they can become active in cancer cells. In our study, we explore a unique process called...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sungjune Kim

MAYO CLINIC JACKSONVILLE, JACKSONVILLE, FL

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$357,994

FY 2026

Project Title

Role of Sirt2 in T Cell Metabolism - Extension

Grant Number:

4R37CA248298-07

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/29/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Metabolism is a key driver of T cell functions, and the switch from oxidative-phosphorylation to aerobic glycolysis is a hallmark of T cell activation. Unfortunately, tumor reactive T cells often display a compromised metabolic status due to metabolic competition with cancer cells wi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Noah Chen

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$55,114

FY 2026

Project Title

Improving bacterial cancer therapeutics

Grant Number:

5F30CA287792-03

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/1/2024

End Date:

2/28/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY (ABSTRACT) Bacterial cancer therapy has existed since Dr. William Coley employed deliberate bacterial infection of tumors over a century ago in the first known example of cancer immunotherapy. Bacteria are genetically tractable self-replicating therapeutics which can be tuned to del...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zachary Hudson Walsh

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$52,068

FY 2026

Project Title

Dissecting the impact of genomic variants on hallmarks of T cell anti-tumor activity

Grant Number:

5F30CA298572-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/7/2025

End Date:

3/6/2029

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT While a fraction of patients with melanomas and leukemias experience durable response to T cell- based therapies, including adoptive transfer of tumor infiltrating lymphocytes (TILs) and chimeric antigen receptor T (CAR-T) cells, respectively, a majority do not. Emerging stu...

Research Terms

<1-Phosphatidylinositol 3-Kinase><1H-Purin-6-amine><AKT><Address><Adenine><Adoptive Transfer><Akt protein><Antigenic Determinants><Antigens><Area><Assay><Autoimmune Status><Autoimmunity><Binding><Binding Determinants><Bioassay><Biological Assay><CALNA><CALNA1><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD19><CD19 gene><CD58><CD58 gene><CNA-Alpha><CRISPR><CRISPR/Cas system><CTAG><CTAG1><CTAG1 gene><CTAG1B><CTAG1B Gene><Calcineurin><Calcineurin A><Calcineurin A Alpha><Calcineurin A1><Calcium-Dependent Activator Protein><Calcium-Dependent Regulator><Calmodulin><Cancers><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cell Therapy><Cellular Function><Cellular Physiology><Cellular Process><Cellular biology><Cellular immunotherapy><Closure by Ligation><Clustered Regularly Interspaced Short Palindromic Repeats><Co-Immunoprecipitations><Coupling><Cytosine><Deamination><Disease><Disorder><ESO1><Engineering><Environment><Epitopes><Event><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Future><Gene variant><Genes><Goals><Heterograft><Heterologous Transplantation><Human><Immune Evasion><Immune mediated therapy><Immunoblotting><Immunologically Directed Therapy><Immunotherapeutic agent><Immunotherapy><In Vitro><In vivo analysis><Individual><Infiltration><Inflammatory><Intracellular Communication and Signaling><Intracellular Second Messenger><Intrinsic factor><L-Serine><LAGE2B><LFA-3><LFA3 Gene><Ligation><Lymphocyte Function-Associated Antigen 3 Gene><MHC Receptor><MSK2 Gene><Major Histocompatibility Complex Receptor><Malignant Cell><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mediating><Medical center><Melanoma><Melanoma Cell><Melanoma patient><Mentors><Methods><Mice><Mice Mammals><Mill Hill-2 Viral Oncogene Homolog><Modeling><Modern Man><Molecular Interaction><Murine><Mus><NY-ESO-1><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><PIP2><PP2B><PPP2B><PPP3CA><PPP3CA gene><Phenotype><Phosphatidylinositol 3-Kinase><Phosphatidylinositol 4,5-Biphosphate><Phosphatidylinositol 4,5-Diphosphate><Phosphatidylinositol-3-OH Kinase><Phosphatidylinositol-4,5-Bisphosphate><Phosphodiesterase Activating Factor><Phosphodiesterase Protein Activator><Phosphoinositide 3-Hydroxykinase><Physicians><Preclinical data><Production><Proliferating><Protein Kinase B><Protein Phasphatase 2B Catalytic Subunit Alpha Isoform><Protein Phosphatase 3 Catalytic Subunit Alpha Isoform><Protein Phosphatase-2B><Protein-Serine Kinase><Protein-Serine-Threonine Kinases><Protein-Threonine Kinase><Proto-Oncogene Proteins c-akt><PtIns 4,5-P2><PtdIns 3-Kinase><PtdInsP2><RAC-PK protein><RAF-1><RAF1><RAF1 gene><Receptor Protein><Research><Resistance><Scientist><Second Messenger Systems><Second Messengers><Series><Serine><Serine Kinase><Serine-Threonine Kinases><Serine/Threonine Protein Kinase Gene><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Single Base Polymorphism><Single Nucleotide Polymorphism><Site><Stem Cell like><Subcellular Process><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Testing><Threonine Kinase><Tumor Cell><Tumor-Infiltrating Lymphocytes><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><Universities><Variant><Variation><Vitamin B4><Western Blotting><Western Immunoblotting><Work><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><allelic variant><base><base editing><base editor><bases><biological signal transduction><c-akt protein><cancer cell><cancer type><career><cell based intervention><cell biology><cell killing><cell mediated intervention><cell mediated therapies><cell-based immunotherapy><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical relevance><clinically relevant><combinatorial><cytokine><efficacy study><engineered T cells><experience><flow cytophotometry><genetic variant><genetically engineered T-cells><genomic variant><humanized mice><humanized mouse><immune cell therapy><immune drugs><immune evasive><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunotherapeutics><immunotherapy agent><improved><in vivo><in vivo Model><in vivo evaluation><in vivo testing><leukemia><malignancy><melanoma cancer model><melanoma model><melanoma tumor model><neoplasm/cancer><neoplastic cell><novel><patients suffering from melanoma><patients with melanoma><preclinical findings><preclinical information><predict responsiveness><predicting response><progenitor capacity><progenitor cell like><progenitor-like><protein blotting><protein protein interaction><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><receptor><related to A and C-protein><resistance to therapy><resistant><resistant to therapy><response><screening><screenings><signal transduction second messengers><single nucleotide variant><stem cell characteristics><stem-like><stemness><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic T-cell platform><therapeutic resistance><therapy resistant><thymus derived lymphocyte><transgenic T- cells><treatment resistance><tumor><v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew Arvedson

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$42,633

FY 2026

Project Title

Elucidating the Role of AIRE and Tumor Associated Aire-expressing Cells in Tumor Growth and Immune Evasion

Grant Number:

5F31CA288017-03

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/30/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Autoimmune Regulator gene (AIRE) prevents autoimmunity by promoting thymic deletion of self-reactive T cells. While most studied in the thymus, AIRE is also expressed in secondary lymphoid organs, where it is thought to contribute to peripheral tolerance through interaction ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nouran Saied Abdelfattah

MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MA

Exploratory lead · 38/100

Very recent

Active award

Career award

$94,921

FY 2026

Project Title

Cellular engineering to improve the efficacy and specificity of targeted immunotherapy

Grant Number:

5K00CA264312-05

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2021

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Adoptive cell therapy (ACT) is a promising therapeutic approach for the treatment of cancer. However, the initial success of ACT has been limited to chimeric antigen receptor (CAR)-T cell therapies for hematological malignancies. Applying this cell therapy to solid tumors i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Saad Nadeem

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 34/100

Above-average budget

Active award

$674,010

FY 2026

Project Title

Reproducible and Accurate PD-L1 Immunohistochemistry Biomarker Quantification Using Virtual Multiplex Immunofluorescence Restaining

Grant Number:

5R37CA295658-02

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Groundbreaking immunotherapy (IO) drugs offer durable response and improved survival in cancer patients who previously had limited treatment options. The semi-quantitative assessment of PD-L1 protein expression on tumor and/or immune cells (lymphocytes, macrophage) by a certified pat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jordan Scott Orange

CHILDREN'S HOSP OF PHILADELPHIA, PHILADELPHIA, PA

Exploratory lead · 34/100

Above-average budget

Active award

$546,512

FY 2026

Project Title

Directing Function at the Natural Killer Cell Secretory Immunological Synapse

Grant Number:

7R37AI067946-17

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2005

End Date:

10/31/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Cytotoxic lymphocytes, including Natural Killer (NK) cells, are at the forefront of a therapeutic revolution in which the power of the cytotoxic cell is harnessed to kill tumor or virus-infected cells in patients with otherwise hopeless medical diagnoses. For nearly two decades, our ...

Research Terms

<3-D><3-Dimensional><3D><Actins><Assay><Bioassay><Biologic Models><Biological><Biological Assay><Biological Models><Body Tissues><CRISPR library><CRISPR-based library><CRISPR/Cas9 library><Cancer Treatment><Cancerous><Cancers><Candidate Disease Gene><Candidate Gene><Cannot see a future><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Degranulation><Cell Function><Cell Interaction><Cell Line><Cell Physiology><Cell Process><Cell Signaling><Cell Therapy><Cell secretion><Cell-to-Cell Interaction><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Secretion><Cellular biology><Cellular immunotherapy><Charge><Clinical><Clinical Treatment><Clustered Regularly Interspaced Short Palindromic Repeats library><Complex><Custom><Cytoplasmic Granules><Cytotoxic cell><DNA mutation><Data><Dependence><Diagnosis><Disease><Disorder><Dynein><Dynein ATPase><Dynein Adenosine Triphosphatase><Dynein Adenosinetriphosphatase><Effectiveness><Environment><Feeling hopeless><Feels there is no future><Future><Genes><Genetic Change><Genetic Screening><Genetic defect><Genetic mutation><Goals><Human><Hydrogels><Immune><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Individual><Intracellular Communication and Signaling><Investigation><K lymphocyte><Laboratories><Learning><Libraries><Loss of hope for the future><Lymphatic cell><Lymphocyte><Lymphocytic><Lytic><Lytotoxicity><MTOC><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Maps><Mechanics><Mediating><Medical><Methods><Microtubule-Organizing Center><Model System><Modeling><Modern Man><Motor><Movement><Mutation><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Negative about the future><No hope for the future><Organelles><Pathogenicity><Pathologic><Patients><Physiologic><Physiological><Position><Positioning Attribute><Process><Proliferating><Proteins><Publications><Radial><Radius><Research Resources><Resistance><Resolution><Resources><Scientific Publication><Secretory Cell><Series><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Subcellular Process><Surface><Synapses><Synaptic><System><Testing><Therapeutic><Time><Tissues><Tumor Cell><Tumor Promotion><Virus><Work><anti-cancer therapy><biologic><biological signal transduction><body movement><cancer cell><cancer therapy><cancer-directed therapy><cell based intervention><cell biology><cell killing><cell mediated intervention><cell mediated therapies><cell-based immunotherapy><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><clinical intervention><clinical therapy><cultured cell line><customs><cytotoxic><cytotoxicity><design><designing><exhaustion><experiment><experimental research><experimental study><experiments><genome mutation><granule><hopelessness><human disease><immune cell therapy><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunological synapse><improved><inhibitor><insight><interest><live cell image><live cell imaging><live cellular image><live cellular imaging><lymph cell><lymphocyte pore-forming protein><malignancy><mechanic><mechanical><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cellular therapy><natural killer therapy><neoplasm/cancer><neoplastic cell><novel><perforin><prevent><preventing><programs><resistant><resolutions><synapse><synapse function><synaptic function><three dimensional><tool><trial regimen><trial treatment><tumor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eugene Pietzak

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 34/100

Above-average budget

Active award

$514,185

FY 2026

Project Title

Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer

Grant Number:

5R37CA276946-04

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer PI: Eugene Pietzak, MD SUMMARY Our overall goal is to develop therapies that selectively target molecular alterations responsible for progression of bladder cancers from non-invasive to the often-lethal muscle-i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brett I Bell

ALBERT EINSTEIN COLLEGE OF MEDICINE, BRONX, NY

Exploratory lead · 34/100

Training-friendly

Active award

$55,114

FY 2026

Project Title

Anti-Complement Immunotherapy for Pancreatic Cancer

Grant Number:

5F30CA278322-03

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2026

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY / ABSTRACT Pancreatic Ductal Adenocarcinoma (PDAC) is an almost uniformly lethal disease, with an overall survival under 10%. Despite therapeutic advances in all arenas of cancer treatment, including immunotherapy, overall survival has not significantly improved in PDAC, representing...

Research Terms

<18-FDG><18F- FDG><18FDG><2 Fluoro 2 deoxy D glucose><2-Fluoro-2-deoxyglucose><Alternative Therapies><Alternative intervention><Anaphylatoxins><Animals><Area><Assay><Bioassay><Biological Assay><Blood Serum><Bone Marrow><Bone Marrow Reticuloendothelial System><C 5b-9><C3 a><C3AR><C3AR1><C3AR1 gene><C3a><C3b><C5 a><C5a><C5b-9><CAT scan><CT X Ray><CT Xray><CT imaging><CT scan><Cancer Cause><Cancer Etiology><Cancer Treatment><Cancers><Carbon ion><Cell Body><Cell Communication and Signaling><Cell Membrane Alteration><Cell Signaling><Cell model><Cells><Cellular model><Cessation of life><Co-culture><Cocultivation><Coculture><Coculture Techniques><Complement><Complement 3a><Complement 3b><Complement 5a><Complement Activation><Complement C3a><Complement C3b><Complement C5a><Complement Complex C5b-9><Complement Membrane Attack Complex><Complement Proteins><Complement Receptor><Computed Tomography><Curative Surgery><Cytolytic Terminal Complement Complex><DNA mutation><Data><Death><Dendritic Cells><Dendritic cell activation><Deposit><Deposition><Development><Disease><Disorder><Effector Cell><Exclusion><Fibroblasts><Fibrosis><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Generalized Growth><Generations><Genetic Change><Genetic defect><Genetic mutation><Goals><Growth><H+ element><Histologic><Histologic Grade><Histologically><Histology><Histopathologic Grade><Human><Hydrogen Ions><IVIS SpectrumCT><IVIS imaging><IVIS optical imaging><IVIS spectral imaging><IVIS spectrum><IVIS system><Immune><Immune Modulation Therapy><Immune Regulators><Immune Tolerance><Immune infiltrates><Immune mediated therapy><Immunes><Immunoblotting><Immunochemical Immunologic><Immunofluorescence><Immunofluorescence Immunologic><Immunologic><Immunologic Tolerance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulators><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapeutic agent><Immunotherapy><Impairment><Implant><In Vitro><Infiltration><Intracellular Communication and Signaling><Irradiated tumor><KO mice><KRAS(G12D)><KRASG12D><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Linear Energy Transfer><LoxP-flanked allele><Macrophage><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mannan-Binding Lectin><Mannan-Binding Protein><Mannose Binding Lectin><Mannose-Binding Protein><Mannose-Specific Lectin><Measures><Mediating><Membrane Attack Complex><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mice><Mice Mammals><Modality><Modeling><Modern Man><Murine><Mus><Mutation><Mφ><Neoplasm Metastasis><Null Mouse><Oncogenesis><PDA model><PDAC Model><PET/CT><PET/CT scan><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pathway interactions><Patients><Phagocytes><Phagocytic Cell><Photons><Population><Production><Proliferating><Protons><Radiation><Radiation therapy><Radiotherapeutics><Radiotherapy><Receptor Protein><Recombinant C5a><Regulatory T-Lymphocyte><Reporting><Research><Roentgen Rays><Role><Secondary Neoplasm><Secondary Tumor><Serum><Signal Transduction><Signal Transduction Systems><Signaling><Sirius Red F3B><Source><Staining method><Stains><Survival Rate><T-Cells><T-Lymphocyte><Tamoxifen><Terminal Complement Complex><Testing><Therapeutic><Tissue Growth><Tomodensitometry><Treatment Efficacy><Treg><Tumor Cell><Tumor Immunity><Tumor Promotion><Unresectable><Veiled Cells><Western Blotting><Western Immunoblotting><X-Radiation><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><X-Ray Radiation><X-ray><Xray><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><amebocyte><anti-cancer therapy><anti-tumor immunity><antitumor immunity><biological signal transduction><cancer immunity><cancer metastasis><cancer microenvironment><cancer therapy><cancer-directed therapy><catscan><complement deficiency><complement pathway><complement pathway regulation><complement system><complementation><computed axial tomography><computer tomography><computerized axial tomography><computerized tomography><develop therapy><developmental><flow cytophotometry><floxed><floxed allele><fluorodeoxyglucose><genome mutation><immune cell infiltrate><immune drugs><immune modulators><immune modulatory therapies><immune modulatory treatment><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune suppression><immune suppressive activity><immune suppressive function><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunologic therapeutics><immunological paralysis><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory biologics><immunomodulatory molecules><immunomodulatory therapies><immunomodulatory treatment><immunoregulator><immunoregulatory molecules><immunoregulatory therapy><immunoregulatory treatment><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapeutics><immunotherapy agent><improved><in vivo imaging system><inhibitor><insight><intervention development><intervention efficacy><irradiation><knock-down><knockdown><malignancy><migration><mouse model><murine model><neoplasm/cancer><neoplastic cell><neutralizing antibody><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><non-contrast CT><noncontrast CT><noncontrast computed tomography><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic carcinogenesis><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic oncogenesis><pancreatic tumor model><pancreatic tumorigenesis><pathway><picrosirius red><positron emission computed tomography><protein blotting><proton therapy><radiation treatment><receptor><receptor expression><regulatory T-cells><response><restraint><scRNA sequencing><scRNA-seq><shRNA><short hairpin RNA><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sirius red F 3B><social role><therapeutic efficacy><therapeutic immunomodulation><therapeutic immunoregulation><therapy development><therapy efficacy><thymus derived lymphocyte><translational study><translational therapeutics><translational therapy><treatment development><treatment with radiation><tumor><tumor cell metastasis><tumor growth><tumor microenvironment><tumorigenesis>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Stefani Spranger

MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MA

Exploratory lead · 32/100

Solid budget

Recent

Active award

$460,938

FY 2026

Project Title

Understanding the induction of T cell dysfunction in the context of lung cancer

Grant Number:

5R37CA273819-04

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/14/2023

End Date:

2/29/2028

Project Abstract

Project Summary Cancer immunotherapy, foremost checkpoint blockade therapy (CBT), has revolutionized the landscape of cancer treatment. However, to date only a minority of cancer patients is experiencing a long-term clinical benefit, while the majority of patients does not respond or progresses upon...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laurent Gapin

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 32/100

Solid budget

Recent

Active award

$429,000

FY 2026

Project Title

Development and Characterization of the MAIT-Boost Knock-In (MBKI) Mouse to Investigate MAIT Cell Biology and Cancer Immunotherapy

Grant Number:

1R21AI195296-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2026

End Date:

1/31/2028

Project Abstract

Project Summary This research project seeks to develop and characterize a novel mouse model to address the limitations of current systems for studying mucosal-associated invariant T (MAIT) cells. MAIT cells are a conserved subset of T lymphocytes that bridge innate and adaptive immunity by recognizi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jennifer L Matsuda

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 32/100

Solid budget

Recent

Active award

$429,000

FY 2026

Project Title

Development and Characterization of the MAIT-Boost Knock-In (MBKI) Mouse to Investigate MAIT Cell Biology and Cancer Immunotherapy

Grant Number:

1R21AI195296-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2026

End Date:

1/31/2028

Project Abstract

Project Summary This research project seeks to develop and characterize a novel mouse model to address the limitations of current systems for studying mucosal-associated invariant T (MAIT) cells. MAIT cells are a conserved subset of T lymphocytes that bridge innate and adaptive immunity by recognizi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hyun Jung Kim

CLEVELAND CLINIC LERNER COM-CWRU, CLEVELAND, OH

Exploratory lead · 32/100

Solid budget

Recent

Active award

$400,890

FY 2026

Project Title

Microbiome-Mediated Tumor Immunomodulation in a Pathomimetic Colorectal Cancer Chip

Grant Number:

5R33CA286797-02

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2028

Project Abstract

ABSTRACT Immune checkpoint inhibitors (ICI) have demonstrated notable efficacy in various cancers, yet the majority of colorectal cancer (CRC) patients with mismatch repair-proficient (MMR-p) and microsatellite-stable (MSS) tumors do not respond to ICI-based immunotherapy. Recent research suggests t...

Research Terms

<3-D><3-D Imaging><3-Dimensional><3D><3D imaging><B7-H1><Bifidobacterium><CD152><CD152 Antigen><CD152 Gene><CD274><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancers><Cell Body><Cell-Mediated Lympholytic Cells><Cells><Characteristics><Checkpoint inhibitor><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><Colon><Colorectal Cancer><Colorectal Neoplasms><Colorectal Tumors><Complex><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic T-Lymphocytes><Data Bases><Databases><Defecation><Demographic Impact><Demography><ELISA><Enzyme-Linked Immunosorbent Assay><Epithelial Cells><Epithelium><Ethnic Group><Ethnic People><Ethnic Population><Ethnic individual><Ethnicity People><Ethnicity Population><Exploratory/Developmental Grant><Female><Fusobacterium><GI microbiome><GI microbiota><Gastrointestinal microbiota><Genetic><Germ-Free><Goals><Image><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunofluorescence><Immunofluorescence Immunologic><Immunologically Directed Therapy><Immunomodulation><Immunotherapeutic agent><Immunotherapy><In Situ Hybridization><Intratumoral heterogeneity><Investigation><Knowledge><Large Bowel Tumor><Large Intestine Neoplasm><Large Intestine Tumor><Malignant Neoplasms><Malignant Tumor><Mediating><Microbe><Microbial Taxonomy><Microsatellite Markers><Microsatellite Repeats><Microsatellites><Mismatch Repair><Molecular><Molecular Analysis><Non-Polyadenylated RNA><Normal Tissue><Normal tissue morphology><O element><O2 element><Organoids><Outcome><Oxygen><PD 1><PD-1><PD-L1><PD1><PDL-1><Pathologic><Patients><Phenotype><Physiology><Post-Replication Mismatch Repair><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proteins><R21 Mechanism><R21 Program><RNA><RNA Gene Products><RNA Seq><RNA sequencing><RNAseq><Racial Group><Reproducibility><Research><Ribonucleic Acid><Running><Solid Neoplasm><Solid Tumor><Sphaerophorus><Technology><Testing><Therapeutic><Three-Dimensional Imaging><Validation><Vascularization><Visual><Visualization><analyze microbiome><anti-cancer><anti-cancer immunotherapy><anti-cancer therapeutic><anti-tumor drug><anticancer immunotherapy><bowel movement><cancer immunotherapy><cancer microenvironment><chip model><chip system><colon cancer patients><colorectal cancer patients><colorectal neoplasia><cytotoxic T-lymphocyte antigen 4><data base><digestive tract microbiome><enteric microbial community><enteric microbiome><enteric microbiota><enzyme linked immunoassay><ethnic subgroup><ethnicity group><exploratory developmental study><fecal microbial community><fecal microbial transplantation><fecal microbiome transplantation><fecal microbiota><fecal microbiota transplant><fecal microbiota transplantation><fecal transplant><fecal transplantation><fluid flow><gastrointestinal microbial flora><gastrointestinal microbiome><global gene expression><global transcription profile><gut community><gut flora><gut microbe community><gut microbial community><gut microbial composition><gut microbial consortia><gut microbiome><gut microbiota><gut microbiotic><gut microflora><gut-associated microbiome><heterogeneity in tumors><host microbiome><imaging><immune cell infiltrate><immune check point><immune check point inhibitor><immune checkpoint><immune clearance><immune drugs><immune elimination><immune modulation><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenicity><immunologic reactivity control><immunologic therapeutics><immunomodulatory><immunoregulation><immunoregulatory><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in situ Hybridization Genetics><in situ Hybridization Staining Method><innovate><innovation><innovative><intestinal biome><intestinal epithelium><intestinal flora><intestinal microbiome><intestinal microbiota><intestinal microflora><intestinal tract microflora><intra-tumoral heterogeneity><intratumor heterogeneity><killer T cell><large bowel neoplasm><male><malignancy><microbial><microbial signature><microbiome><microbiome analysis><microphysiologic model><microphysiologic platform><microphysiologic system><microphysiology model><microphysiology platform><microphysiology system><molecular phenotype><neoplasm/cancer><new technology><novel technologies><on a chip><on chip><patient profile><pre-clinical><prebiotics><preclinical><probiotic supplement><probiotic supplementation><profiles in patients><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><prophylactic><protein death-ligand 1><racial population><racial subgroup><response><sle2><socio-demographics><sociodemographics><supplementation with probiotics><systemic lupus erythematosus susceptibility 2><technology platform><technology system><therapeutic outcome><therapy outcome><three dimensional><transcriptome><transcriptome sequencing><transcriptomic sequencing><transcriptomics><translational impact><tumor><tumor eradication><tumor heterogeneity><tumor microbiome><tumor microbiota><tumor microenvironment><tumor-associated microbiome><tumor-associated microbiota><validations><♀><♂>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rahul Anil Sheth

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Exploratory lead · 32/100

Solid budget

Recent

Active award

$395,807

FY 2026

Project Title

An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma

Grant Number:

5R37CA269622-04

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Project Abstract

ABSTRACT Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related deaths in the US. Immunotherapy is a promising new treatment approach for HCC, but there are numerous barriers to immunotherapy in HCC. Local intratumoral injection of immunotherapies is a logical solution to over...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ping-Ching Hsu

UNIV OF ARKANSAS FOR MED SCIS, LITTLE ROCK, AR

Exploratory lead · 32/100

Solid budget

Recent

Active award

$384,492

FY 2026

Project Title

Arkansas Rural Community Health-Healthy Environmental Research (ARCH-HER) Study

Grant Number:

5R24ES037082-02

Activity Code:

R24

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/19/2024

End Date:

11/30/2029

Project Abstract

Residents in Arkansas (AR) face high risks in generational exposure to pesticides and fertilizers from agricultural production; heavy metals such as arsenic found in the soil, water, air; and aromatic hydrocarbons (benzene, benzo[a]pyrene) from frequent burning of trash, crop and timber residues, an...

Research Terms

<3,4-Benzopyrene><3,4-Benzpyrene><Active Follow-up><Adult females><Adult women><Agriculture><Air><Area><Arkansas><Aromatic Hydrocarbons><Arsenic><Benzene><Benzo(a)pyrene><Benzol><Benzole><Blood><Blood Reticuloendothelial System><Breast Cancer><Cancer Cause><Cancer Etiology><Cancer Treatment><Cancers><Cell Body><Cells><Cellular Immune Function><Chemicals><Collaborations><Communities><Community Health><County><Cyclohexatriene><Data><Data Bases><Databases><Daughter><Development><Enrollment><Ensure><Environmental Exposure><Environmental Health><Environmental Health Science><Environmental Protection Agency><Epidemiology><Exposure Assessment><Exposure to><Face><Females in adulthood><Fertilizers><Future><Generations><Genetic><Geological Survey><Geology Survey><Goals><Health><Heavy Metals><High temperature of physical object><Hydrogen Oxide><Immune><Immunes><Incidence><Individual><Information Dissemination><Infrastructure><Institution><Insurance><Intervention><Investments><Link><Maintenance><Malignant Breast Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediator><Medical><Medical Records><Mothers><Onset of illness><Outcome><Participant><Pesticides><Population><Predisposition><Production><Recontacts><Reporting><Research><Research Institute><Research Resources><Resources><Risk><Rural><Rural Community><Rural Population><Rural group><Rural people><Saliva><Sampling><Science><Soil><Susceptibility><Translational Research><Translational Science><United States Environmental Protection Agency><Universities><Urine><Water><Woman><Women in adulthood><active followup><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><arsenics><bio-informatics pipeline><bioinformatics pipeline><cancer diagnosis><cancer immunotherapy><cancer registry><cancer therapy><cancer-directed therapy><cohort><cohort investigation><cohort research><community health study><community-based health><cooking><dashboard><data base><data management><data sharing><deprivation><developmental><disease onset><disorder onset><dissemination of results><early onset><enroll><epidemiologic><epidemiological><exposure analysis><exposure evaluation><exposure measurement><exposure profiling><exposure survey><exposure to environmental agents><exposure to environmental factors><exposure to environmental stimuli><exposure to environmental substances><faces><facial><follow up><follow-up><followed up><followup><geological applications><geological characterization><geology characterization><high risk><high temperature><immune function><immune-based cancer therapies><immunotherapy for cancer><immunotherapy of cancer><indexing><investigate cohort><malignancy><malignant breast tumor><methylome><modifiable lifestyle factors><neoplasm registry><neoplasm/cancer><predict responsiveness><predicting response><recruit><research study><response to therapy><response to treatment><rural individual><study cohort><survey cohort><therapeutic response><therapy response><translation research><translational investigation><treatment response><treatment responsiveness>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Georg Seelig

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Exploratory lead · 32/100

Solid budget

Recent

Active award

$379,994

FY 2026

Project Title

Sequence optimization for mRNA cancer therapy

Grant Number:

5R33CA286947-02

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/29/2028

Project Abstract

SUMMARY mRNA technology is in the public spotlight thanks to its role in fighting the COVID-19 pandemic, and it is also rapidly transforming cancer therapeutics development through application areas such as immunotherapy. This wave of mRNA therapeutics is the result of decades of work on many fronts...

Research Terms

<3' Untranslated Regions><3'UTR><5' Untranslated Regions><5'UTR><Acceleration><Algorithm Design><Algorithmic Design><Algorithmic Engineering><Area><Assay><Bioassay><Biological Assay><Body Tissues><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 years><Cancer Treatment><Cancers><Cell Line><CellLine><Chemicals><Code><Coding System><Codon><Codon Nucleotides><Communicable Diseases><Complex><Data><Drug Kinetics><Engineering><Future><G+C Compositions><G+C Content><GC Composition><GC Content><Genes><Globin><Guanine + Cytosine Composition><Guanine + Cytosine Content><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Infectious Diseases><Infectious Disorder><Learning><Length><Location><Machine Learning><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measurement><Measures><Messenger RNA><MicroRNAs><Modeling><Modification><Nucleosides><Pharmacokinetics><Production><Proteins><RNA-Binding Proteins><Regulation><Regulatory Element><Reporter><Research><Ribosomes><Role><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Site><Specific qualifier value><Specificity><Specified><Strains Cell Lines><Technology><Testing><Therapeutic><Tissues><Training><Transcript><Translations><UTRs><Untranslated Regions><Vaccines><Variant><Variation><Work><adversarial neural network><algorithm engineering><algorithmic composition><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><cancer immunotherapy><cancer therapy><cancer-directed therapy><cell type><clinical applicability><clinical application><computer based prediction><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><cultured cell line><data to train><dataset to train><design><designing><develop therapy><fighting><fitness><generative adversarial network><generative neural network><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogenicity><immunotherapy for cancer><immunotherapy of cancer><improved><in silico><innovate><innovation><innovative><interest><intervention design><intervention development><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA Leader Sequences><mRNA Stability><mRNA Translation><machine based learning><malignancy><miRNA><multi-task><multitask><neoplasm/cancer><p-Globin><predictive modeling><protein expression><recurrent neural network><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><social role><therapeutic agent development><therapeutic development><therapy design><therapy development><timeline><training data><translation><treatment design><treatment development><tumor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laurent Gapin

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 30/100

Very recent

Active award

$234,000

FY 2026

Project Title

Dissecting the Transcriptional Control of Human MAIT Cell Identity and Function by PLZF and Helios

Grant Number:

1R21AI199335-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/23/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary This project aims to uncover the transcriptional and metabolic mechanisms that govern the identity, function, and therapeutic potential of mucosal-associated invariant T (MAIT) cells, a non-MHC-restricted, innate-like T cell subset with growing relevance in cancer and infectious dise...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KYLE GABRIEL DANIELS

STANFORD UNIVERSITY, STANFORD, CA

Exploratory lead · 30/100

Very recent

Active award

$192,500

FY 2026

Project Title

Combinatorial engineering of a three-cell synthetic immunotherapy system

Grant Number:

5R21EB037367-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract: T cells, natural killer (NK) cells, and macrophages engineered to express chimeric antigen receptors (CARs) have shown promise as therapies for cancers, autoimmune diseases, heart disease, aging, and chronic viral infections. Current therapies use these CAR immune cells in ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xiaopei Huang

OHIO STATE UNIVERSITY, Columbus, OH

Exploratory lead · 30/100

Very recent

Active award

$184,492

FY 2026

Project Title

Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung Cancer

Grant Number:

5R21CA299786-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The prognosis for patients with metastatic non-small cell lung cancer (NSCLC) remains poor despite recent progress in immune checkpoint blockade therapy. A better understanding of mechanisms for lung cancer immune evasion within the tumor microenvironment (TME) will allow for the rat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dwight H. Owen

OHIO STATE UNIVERSITY, Columbus, OH

Exploratory lead · 30/100

Very recent

Active award

$184,492

FY 2026

Project Title

Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung Cancer

Grant Number:

5R21CA299786-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The prognosis for patients with metastatic non-small cell lung cancer (NSCLC) remains poor despite recent progress in immune checkpoint blockade therapy. A better understanding of mechanisms for lung cancer immune evasion within the tumor microenvironment (TME) will allow for the rat...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven W. Dow

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 30/100

Very recent

Active award

$179,988

FY 2026

Project Title

Novel Immunotherapy Targeting Local and Systemic Immunity for Treatment of Ocular Surface Squamous Neoplasia

Grant Number:

5R21CA289152-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Ocular surface squamous neoplasia (OSSN) is a progressive ocular cancer that lacks approved treatments and is increasing in prevalence globally. We have developed a new liposomal-TLR agonist immunotherapy (LTAC) that in a novel equine spontaneous OSSN model effectively induces OSSN r...

Research Terms

<5-FU><5-Fluracil><5FU><Accounting><Address><Adverse effects><After Care><After-Treatment><Aftercare><Agonist><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigens><Assay><B-Cells><B-Lymphocytes><B-cell><Bioassay><Biological Assay><Biopsy><Blindness><Blood Sample><Blood specimen><CDDP><Cancers><Cell Body><Cell Line><Cell Mediated Immunology><Cell secretion><Cell-Mediated Immunity><CellLine><Cells><Cellular Assay><Cellular Immunity><Cellular Secretion><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinical><Complex><Cornea><Corneal Injury><Cysplatyna><Cytotoxic cell><Dichlorodiammineplatinum><Disease remission><Domestic Horse><Epithelial Cells><Equine><Equine Species><Equus caballus><Equus przewalskii><Exposure to ultraviolet radiation><Eyelid structure><Eyelids><FDA approved><Fluoro Uracil><Fluorouracil><Fluoruracil><Fluouracil><Generalized Growth><Growth><Horses><Human><IFN><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><Immune><Immune Interferon><Immune mediated therapy><Immune response><Immunes><Immunity><Immunochemical Immunologic><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><Injections><Innate Immunity><Interferon Gamma><Interferon Type II><Interferons><K lymphocyte><Lesion><Liposomal><Liposomes><Malignant Neoplasms><Malignant Tumor><Mediating><Mitomycin C><Modeling><Modern Man><NK Cells><Native Immunity><Natural Immunity><Natural Killer Cells><Neoplasms><Non-Specific Immunity><Nonspecific Immunity><Palpebra><Pathway interactions><Patients><Peyrone's Chloride><Peyrone's Salt><Platinum Diamminodichloride><Prevalence><Proliferating><Public Health><Recurrence><Recurrent><Remission><Reporting><Resistance><Resolution><Risk><Role><Safety><Sampling><Strains Cell Lines><Swab><T cell response><T-Cells><T-Lymphocyte><TLR3><TLR3 gene><Testing><Tissue Growth><Toll-Like Receptor 3><Topical Drug Administration><Topical application><Tumor Immunity><Tumor Tissue><UV Radiation Exposure><UV exposure><Ultraviolet Radiation Related Exposure><Ultraviolet radiation exposure><Work><adaptive immunity><anti-tumor immune response><anti-tumor immunity><antibody assay><antibody based test><antibody test><antigen-specific T cells><antitumor immunity><apply topically><cancer immunity><cell assay><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><conjunctiva><corneal><corneal epithelial><corneal epithelium><corneal wound><cultured cell line><cytokine><cytotoxic><deliver topically><host response><immune drugs><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><insight><lFN-Gamma><malignancy><model of animal><neoplasia><neoplasm/cancer><neoplastic growth><new approaches><novel><novel approaches><novel strategies><novel strategy><ocular surface><ocular surface squamous neoplasia><off-label><ontogeny><pathway><post treatment><prevent><preventing><resistant><resolutions><response><side effect><social role><thymus derived lymphocyte><topical administration><topical delivery><topical drug application><topical drug delivery><topical instillation><topical treatment><transcriptomics><treat topically><tumor><ultraviolet exposure><ultraviolet light exposure><vision loss><visual loss>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xiao Han

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Exploratory lead · 30/100

Recent

Active award

Career award

$101,322

FY 2026

Project Title

Unravel Tumor-Intrinsic and Age-Associated Mechanisms of Immune Evasion

Grant Number:

4K00CA284292-03

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/12/2023

End Date:

11/30/2029

Project Abstract

While most ovarian cancer (OvCa) patients initially respond to surgery and chemotherapy, over 80% of these patients eventually develop recurrent tumors, most commonly in the peritoneal cavity. These recurrent tumors exhibit resistance to chemotherapy and often show poor responses to immunotherapy, w...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SeyedehFatemeh Razavipour

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Exploratory lead · 30/100

Recent

Active award

Career award

$98,928

FY 2026

Project Title

Enhancing Anti-Tumor Immunity against Glioblastoma through Neoantigen-Specific T Cells and Myeloid Checkpoint Blockade

Grant Number:

4K00CA284295-03

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/17/2023

End Date:

11/30/2029

Project Abstract

Glioblastoma multiforme (GBM) is the most aggressive and incurable brain cancer, with a median survival under 1.5 years. Unlike many other solid tumors, GBM shows little or no benefit from immune checkpoint blockade targeting PD1 or CTLA4, underscoring the urgent need for innovative immunotherapeuti...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard Tobin

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 26/100

Solid budget

Active award

$356,850

FY 2026

Project Title

MAIT cell: microbiome crosstalk in antitumor immunity

Grant Number:

5R37CA279604-03

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2023

End Date:

11/30/2028

Project Abstract

PROJECT SUMMARY The composition of microorganisms that inhabit the gut, known as the gut microbiome, has been strongly associated with the pathogenesis of several diseases including cancer, diabetes, and multiple sclerosis. Notably, several high-profile studies have reported that the composition of ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Shengqing Gu

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Exploratory lead · 24/100

Active award

Career award

$192,240

FY 2026

Project Title

Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics

Grant Number:

5K22CA279077-03

Activity Code:

K22

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2026

Project Abstract

PROJECT SUMMARY Shenqqing (Stan) Gu, Ph.D., is an experimental-computational biologist whose career goal is to develop personalized strategies for optimal combination immunotherapy to cure cancer. Titled “Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics”, the proposed research...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hua Zhang

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 24/100

Active award

Career award

$189,756

FY 2026

Project Title

Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumor

Grant Number:

5K22CA276357-03

Activity Code:

K22

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/21/2023

End Date:

11/30/2026

Project Abstract

Summary: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. KRAS is the most frequently mutated oncogene in lung adenocarcinoma, the most common subtype of NSCLC. Approximately 30% of patients with lung adenocarcinoma harbor KRAS mutations, with G12C and G12V ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Melissa Berrien Elliott

SAINT LOUIS UNIVERSITY, SAINT LOUIS, MO

Exploratory lead · 24/100

Active award

Career award

$186,030

FY 2026

Project Title

Elucidating Mechanisms of CAR ML NK cell biology to treat cancer and infection

Grant Number:

5K22CA279495-03

Activity Code:

K22

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2027

Project Abstract

PROJECT SUMMARY Candidate: During my training, I have been highly motivated to understand how cytotoxic lymphocytes can be used as an adoptive therapy and how immune cells are regulated during immunotherapy. I have served as first, co-, and corresponding author on numerous high-impact original resea...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christian Gabriel FIGUEROA-ESPADA

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 24/100

Active award

Career award

$104,765

FY 2026

Project Title

Engineering Biomaterials to Modulate the Tumor Immune Microenvironment

Grant Number:

5K00CA284294-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2028

Project Abstract

Cancer remains a significant global health challenge, with an anticipated 611,240 deaths in 2024. Substantial strides in cancer research have enhanced our understanding of the mechanisms underlying its development, progression, and spread. While current treatments such as surgery, radiation, chemoth...

Research Terms

<3-D><3-Dimensional><3D><Acceleration><Address><Assay><Automobile Driving><Bioassay><Biocompatible Materials><Bioinformatics><Biological Assay><Biomaterials><Breast><Breast Cancer><CD34><CD34 gene><Cancer Biology><Cancer Treatment><Cancers><Cause of Death><Cell Body><Cell Communication><Cell Growth in Number><Cell Interaction><Cell Line><Cell Multiplication><Cell Proliferation><Cell-to-Cell Interaction><CellLine><Cells><Cellular Proliferation><Cessation of life><Co-culture><Cocultivation><Coculture><Coculture Techniques><Complement><Complement Proteins><DNA mutation><Data><Death><Development><Differential Gene Expression><Drug Delivery><Drug Delivery Systems><Drug resistance><Drugs><Dysfunction><Effectiveness><Engineering><Event><Expression Signature><Functional disorder><Funding><Future><Gene Expression><Gene Expression Profile><Generalized Growth><Genetic Change><Genetic defect><Genetic mutation><Germinoblastic Sarcoma><Germinoblastoma><Goals><Grips><Growth><HPCA1><Heterogeneity><Human><Immune><Immune infiltrates><Immune mediated therapy><Immune system><Immunes><Immunologically Directed Therapy><Immunotherapy><In Vitro><Laboratory Research><Ligands><Liquid substance><Literature><Lung><Lung Respiratory System><Lymphoma><MSKCC><Malignant Breast Neoplasm><Malignant Cell><Malignant Lymphoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Malignant neoplasm of prostate><Malignant prostatic tumor><Medication><Memorial Sloan-Kettering Cancer Center><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Profiling><Multiple Myeloma><Murine><Mus><Mutation><NIH><National Institutes of Health><Natural regeneration><Non-Polyadenylated RNA><Operative Procedures><Operative Surgical Procedures><Outcome><Patients><Pennsylvania><Pharmaceutical Preparations><Physiopathology><Plasma-Cell Myeloma><Process><Prostate><Prostate CA><Prostate Cancer><Prostate Gland><Prostate malignancy><Prostatic Gland><Pulmonary Cancer><Pulmonary malignant Neoplasm><RNA><RNA Gene Products><Radiation><Receptor Protein><Regeneration><Relapse><Reporting><Research><Resistance><Resistance development><Resistant development><Rest><Reticulolymphosarcoma><Ribonucleic Acid><Solid><Strains Cell Lines><Surgical><Surgical Interventions><Surgical Procedure><System><Therapeutic Effect><Therapeutic Uses><Time><Tissue Engineering><Tissue Growth><Tissue-Specific Differential Gene Expression><Tissue-Specific Gene Expression><Training><Treatment Efficacy><Treatment outcome><United States National Institutes of Health><Universities><Validation><analytical tool><anti-cancer><anti-cancer research><anti-cancer therapy><anti-cancer treatment><bioengineered tissue><biological material><cancer cell><cancer heterogeneity><cancer microenvironment><cancer progression><cancer research><cancer therapy><cancer type><cancer-directed therapy><cell regeneration><cell type><cellular regeneration><chemotherapy><clinical relevance><clinically relevant><complementation><cultured cell line><determine efficacy><developing resistance><developmental><dosage><driving><drug discovery><drug efficacy><drug resistant><drug sensitivity><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><engineered tissue><evaluate efficacy><examine efficacy><fluid><gene expression pattern><gene expression signature><genome mutation><global gene expression><global health><global transcription profile><grasp><high dimensionality><high-throughput drug screening><immune cell infiltrate><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><individualized cancer therapy><ineffective therapies><ineffective treatment><insight><intervention efficacy><liquid><lung cancer><malignancy><malignant breast tumor><molecular profile><molecular signature><mortality><myeloma><myelomatosis><nanosystems><neoplasm progression><neoplasm/cancer><neoplastic progression><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><ontogeny><pathophysiology><personalization of treatment><personalized cancer therapy><personalized cancer treatment><personalized medicine><personalized therapy><personalized treatment><physical model><programs><receptor><regenerate><regeneration potential><regenerative potential><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><response><scATAC sequencing><scATAC-seq><single cell ATAC-seq><single cell ATAC-sequencing><single cell Assay for Transposase Accessible Chromatin sequencing><single cell sequencing assay for transposase accessible chromatin><single cell technology><single-cell Assay for Transposase-Accessible Chromatin with sequencing><single-cell assay for transposase-accessible chromatin using sequencing><single-cell assay for transposase-accessible chromatin-seq><surgery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic resistance><therapeutic target><therapy efficacy><therapy resistant><three dimensional><transcriptional profile><transcriptional signature><transcriptome><treatment resistance><treatment strategy><tumor><tumor growth><tumor immune microenvironment><tumor microenvironment><tumor progression><tumor-immune system interactions><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Amanda Johnson

DANA-FARBER CANCER INST, BOSTON, MA

Exploratory lead · 24/100

Active award

Career award

$103,126

FY 2026

Project Title

Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma

Grant Number:

5K00CA284254-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/7/2025

End Date:

1/31/2029

Project Abstract

Glioblastoma (GBM) is the most common and aggressive form of brain cancer in adults with a dismal prognosis and limited therapeutic options. Despite significant advancements in the field, cancer immunotherapy is relatively ineffective in many solid tumors, including GBM. Several factors contribute t...

Research Terms

<21+ years old><Adult><Adult Human><Architecture><Area><Attenuated><Bioinformatics><Blocking Antibodies><Body Tissues><Brain Cancer><CRE Recombinase><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cancers><Candidate Disease Gene><Candidate Gene><Cas nuclease technology><Cell Body><Cell Communication><Cell Function><Cell Interaction><Cell Isolation><Cell Mediated Immunology><Cell Physiology><Cell Process><Cell Segregation><Cell Separation><Cell Separation Technology><Cell-Mediated Immunity><Cell-to-Cell Interaction><Cells><Cellular Function><Cellular Immunity><Cellular Physiology><Cellular Process><Checkpoint inhibitor><Classification><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Co-culture><Cocultivation><Coculture><Coculture Techniques><Complex><Development><Dissociation><Dysfunction><Engineering / Architecture><Enterobacteria phage P1 Cre recombinase><Exclusion><Failure><Functional disorder><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Inactivation><Gene Silencing><Gene Transcription><Genes><Genetic><Genetic Screening><Genetic Transcription><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioblastoma><Glioma><Goals><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Guide RNA><Heterogeneity><Human><Imaging technology><Immune><Immune Evasion><Immune Regulators><Immune checkpoint inhibitor><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunomodulators><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Implant><In Vitro><In vivo analysis><Individual><Investigation><Label><Libraries><Lymphatic cell><Lymphocyte><Lymphocytic><Malignant><Malignant - descriptor><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Brain><Malignant neoplasm of brain><Mediating><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Molecular><Molecular Target><Murine><Mus><Myeloid Cells><Necrosis><Necrotic><Neuroglial Neoplasm><Neuroglial Tumor><Pathway interactions><Patients><Phenotype><Physiopathology><Prevalence><Prognosis><Proteins><Proteomics><RNA Expression><Repression><Research><Research Specimen><Resolution><Single cell seq><Slice><Solid Neoplasm><Solid Tumor><Specimen><Structure><Subcellular Process><System><Systematics><T cell infiltration><T cell response><T-Cells><T-Lymphocyte><Techniques><Technology><Testing><Therapeutic><Therapeutically Targetable><Tissues><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Tumor Cell><Tumor-infiltrating immune cells><Validation><Visualization><Work><adulthood><analyze gene expression><anti-cancer immunotherapy><anti-tumor immune response><anticancer immunotherapy><attenuate><attenuates><bacteriophage P1 recombinase Cre><cancer immunotherapy><cancer microenvironment><cell sorting><cell type><clinical translation><clinically translatable><cytotoxic><determine efficacy><developmental><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experiment><experimental research><experimental study><experiments><gRNA><gene editing platform><gene editing system><gene editing technology><gene editing tools><gene expression analysis><gene expression assay><gene manipulation><gene-editing toolkit><genetic manipulation><genetically manipulate><genetically perturb><glial-derived tumor><glioblastoma multiforme><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point inhibitor><immune evasive><immune microenvironment><immune modulators><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunomodulatory molecules><immunoregulator><immunoregulatory molecules><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive response><immunosuppressive tumor microenvironment><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><in vivo evaluation><in vivo testing><indexing><infiltration of tumors by immune cells><inhibitor><insight><intratumoral immune cell><intratumoral immune infiltrate><lymph cell><malignancy><molecular phenotype><mouse model><murine model><neoplasm/cancer><neoplastic cell><neuroglia neoplasm><neuroglia tumor><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathophysiology><pathway><pre-clinical><pre-clinical efficacy><preclinical><preclinical efficacy><preservation><programs><resolutions><scRNA sequencing><scRNA-seq><screening><screenings><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell next generation sequencing><single cell sequencing><single cell transcriptomic profiling><single-cell RNA sequencing><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial multiomics><spatial omics><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatial tri-omics><spatially resolved transcriptomics><spatio transcriptomics><spongioblastoma multiforme><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic evaluation><therapeutic target><therapeutic testing><thymus derived lymphocyte><transcriptional profiling><transcriptional silencing><transcriptomics><tumor><tumor immune cell><tumor immune infiltrate><tumor immune microenvironment><tumor infiltration of immune cells><tumor microenvironment><tumor-immune system interactions><validation studies><validations><virtual>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

NOAH GREENWALD

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 24/100

Active award

Career award

$97,686

FY 2026

Project Title

USING DEEP MUTATIONAL SCANNING TO CHARACTERIZE TUMOR-IMMUNE INTERACTIONS

Grant Number:

5K00CA264307-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2028

Project Abstract

Cancer immunotherapy is a new treatment modality that has revolutionized cancer care, providing benefits to many patients who previously had untreatable disease. However, we still do not fully understand how this breakthrough treatment works at a molecular level. Deep mutational scanning (OMS) is a ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kelsey R Monson

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Exploratory lead · 24/100

Active award

Career award

$97,551

FY 2026

Project Title

Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer

Grant Number:

5K00CA274650-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2028

Project Abstract

The advent of immunotherapies (IO) such as immune checkpoint inhibitors (ICI) heralded a significant improvement in cancer patient survival, but the mechanisms underlying treatment response are still opaque. The level of tumor-infiltrating lymphocytes (TILs) has been suggested as one potential ICI r...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuesong Hu

HARVARD UNIVERSITY, CAMBRIDGE, MA

Exploratory lead · 24/100

Active award

Career award

$91,945

FY 2026

Project Title

Mechanically active artificial antigen presenting cells for cancer immunotherapy

Grant Number:

5K00CA274690-05

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/1/2022

End Date:

12/31/2027

Project Abstract

PROJECT SUMMARY In the adaptive immune response, cytotoxic T lymphocyte (CTL) continuously “crawl” seeking evidence of foreign peptide fragments on the surface of other cells. Once the T cell encounters a target cell with foreign or mutant peptides, then it is activated unleashing a potent immune re...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ivan Susin Pires

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Exploratory lead · 24/100

Active award

Career award

$89,145

FY 2026

Project Title

Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies

Grant Number:

5K00CA274651-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2028

Project Abstract

Gene therapy has had an exciting last decade with many novel FDA approved therapies reaching the clinic. These treatments have not only been fruitful in cancer treatment, but also for genetic diseases and, more recently, in COVID-19 vaccines. Unlike macromolecules or small molecules, nucleic acids (...

Research Terms

<2019-nCoV vaccine><4T1><ASO therapeutics><ASO therapy><ASO treatment><Address><Antigen-Presenting Cells><Antisense Oligonucleotide Therapy><B-Cell Activation><B-Cells><B-Lymphocytes><B-cell><B16F10><Blood Serum><Body Tissues><Breast><COVID-19 vaccine><CT-26><CT26><Cancer Model><Cancer Treatment><Cancer cell line><CancerModel><Cancers><Cell Body><Cell Line><CellLine><Cells><Characteristics><Charge><Circulation><Clinic><Clinical><Colon><DNA><DNA Therapy><Data Set><Dendritic Cells><Deoxyribonucleic Acid><Dependence><Development><Engineering><Enzyme Gene><Enzymes><Evaluation><FDA approved><FRET><Face><Fluorescence Resonance Energy Transfer><Formulation><Foundations><Förster Resonance Energy Transfer><Gene Delivery><Gene Inactivation><Gene Silencing><Gene Transcription><Gene Transfer Clinical><Genes><Genetic Diseases><Genetic Intervention><Genetic Transcription><Goals><Human><Immune><Immune Modulation Therapy><Immune Targeting><Immune mediated therapy><Immune response><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Subtyping><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunophenotyping><Immunotherapeutic agent><Immunotherapy><In Vitro><In vivo analysis><Libraries><Lipids><Lung><Lung Respiratory System><Macrophage><Malignant Melanoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Melanoma><Messenger RNA><Mice><Mice Mammals><Modern Man><Murine><Mus><Myeloid Cells><Mφ><Nanotechnology><Non-Polyadenylated RNA><Nucleic Acids><Pathway interactions><Patients><Play><Post-Transcriptional Gene Silencing><Production><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Interference><RNA Silencing><RNAi><Ribonucleic Acid><Role><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Sampling><Sequence-Specific Posttranscriptional Gene Silencing><Serum><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Short interfering RNA><Solid><Strains Cell Lines><T-Cells><T-Lymphocyte><TCGA><The Cancer Genome Atlas><Therapeutic><Therapeutic Agents><Tissues><Transcription><Transfection><Translating><Translations><Treatment Efficacy><Tumor Immunity><Validation><Veiled Cells><accessory cell><activated B cells><anti-cancer immunotherapy><anti-cancer therapy><anti-sense oligonucleotide drug><anti-sense oligonucleotide therapy><anti-sense oligonucleotide treatment><anti-sense therapy><anti-tumor effect><anti-tumor immune response><anti-tumor immunity><anticancer immunotherapy><antisense drug><antisense oligonucleotide therapeutic><antisense therapeutics><antisense therapy><antitumor effect><antitumor immunity><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><cancer immunity><cancer immunotherapy><cancer therapy><cancer-directed therapy><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><cultured cell line><cytokine><cytokine based immunotherapy><cytokine based therapy><cytokine immunotherapy><cytokine therapy><cytokine treatment><delivery vector><delivery vehicle><design><designing><developmental><effective therapy><effective treatment><experiment><experimental research><experimental study><experiments><faces><facial><gene repair therapy><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic therapy><genomic therapy><host response><immune drugs><immune microenvironment><immune modulation><immune modulatory therapies><immune modulatory treatment><immune regulation><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunologic reactivity control><immunologic therapeutics><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory><immunomodulatory biologics><immunomodulatory therapies><immunomodulatory treatment><immunoregulation><immunoregulatory><immunoregulatory therapy><immunoregulatory treatment><immunoresponse><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><in vivo evaluation><in vivo testing><insight><intervention efficacy><lipid based nanoparticle><lipid nanoparticle><mRNA><macromolecule><malignancy><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano tech><nano technology><nano-sized particle><nano-technological><nanoparticle><nanosized particle><nanotech><nanotechnological><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><nucleic acid delivery><pathway><programs><rational design><response><siRNA><social role><subcutaneous><subdermal><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic immunomodulation><therapeutic immunoregulation><therapy efficacy><thymus derived lymphocyte><transcriptional silencing><translation><tumor><tumor growth><tumor immune microenvironment><tumor-immune system interactions><uptake><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine strategy><vaccines preventing COVID><vaccines to prevent COVID><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Santiago Correa

COLUMBIA UNIV NEW YORK MORNINGSIDE, NEW YORK, NY

Exploratory lead · 22/100

Recent

Active award

$219,981

FY 2026

Project Title

Lymph node inspired hydrogels for immune cell reprogramming

Grant Number:

5R21EB034818-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

1/31/2028

Project Abstract

Summary Abstract This proposal combines the fields of DNA origami, colloids, and supramolecular hydrogels to develop biomimetic scaffolds to transform the way we engineer T cells for cellular immunotherapy. Cell therapies have broad biomedical potential, spanning application areas as diverse as canc...

Research Terms

<3-D><3-Dimensional><3D><Address><Animals><Antigen-Presenting Cells><Antigens><Area><Assay><Autoantigens><Autoimmune Diseases><Autologous Antigens><Bioassay><Biochemical><Biocompatible Materials><Biological Assay><Biological Mimetics><Biomaterials><Biomimetics><Biopolymers><Body Tissues><Cancer Treatment><Cancers><Cardiovascular Diseases><Cell Body><Cell Communication and Signaling><Cell Locomotion><Cell Migration><Cell Movement><Cell Reprogramming><Cell Signaling><Cell Therapy><Cell-Extracellular Matrix><Cells><Cellular Migration><Cellular Motility><Cellular immunotherapy><Chemistry><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><Colloids><Complex><Cues><DNA><DNA Integration><Dancing><Deoxyribonucleic Acid><Disease><Disorder><ECM><Engineering><Environment><Extracellular Matrix><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Funding><Gene Delivery><Goals><Histocompatibility Complex><Histocompatibility Complices><Human><Hydrogels><Immune><Immunes><Immunoassay><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunology><Immunomodulation><Immunosuppressed Host><Individual><Injectable><Intracellular Communication and Signaling><Lead><Length><Life><Ligands><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Major Histocompatibility Complex><Major Histocompatibility Complices><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mechanics><Medical><Methods><Modern Man><Molecular><Nanostructures><Nucleic Acids><Organism><Patients><Pattern><Pb element><Peptides><Phenotype><Position><Positioning Attribute><Procedures><Process><Production><Research><Self-Antigens><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Structure><Surface><Synapses><Synaptic><System><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Activation><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Technical Expertise><Technology><Teen><Teenagers><Time><Tissues><Training><Tumor Expansion><Tumor-Infiltrating Lymphocytes><Viral Diseases><Virus Diseases><Work><accessory cell><activate T cells><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><anti-cancer therapy><antigen-specific T cells><autoimmune condition><autoimmune disorder><autoimmunity disease><biological material><biological signal transduction><cancer therapy><cancer-directed therapy><cardiovascular disorder><cell based intervention><cell mediated intervention><cell mediated therapies><cell motility><cell-based immunotherapy><cell-based therapeutic><cell-based therapy><cellular reprogramming><cellular therapeutic><cellular therapy><cost><cytokine><design><designing><engineered T cells><experience><fitness><flow cytophotometry><genetically engineered T-cells><heavy metal Pb><heavy metal lead><immune cell therapy><immune modulation><immune regulation><immunogen><immunologic reactivity control><immunological synapse><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressed patient><improved><in vivo><innovate><innovation><innovative><living system><lymph gland><lymph nodes><lymphnodes><malignancy><manufacture><mechanic><mechanical><mimicry><molecular imaging><molecule imaging><nano><nano medicinal><nano medicine><nano meter scale><nano meter sized><nano-sized structures><nano-structures><nanofabricate><nanofabrication><nanomedicinal><nanomedicine><nanometer scale><nanometer sized><nanoscale><neoplasm/cancer><particle><pre-clinical><preclinical><programs><prototype><recruit><scaffold><scaffolding><self assembly><success><synapse><technical skills><technology platform><technology system><teen years><teenage><therapeutic T-cell platform><three dimensional><thymus derived lymphocyte><tissue culture><tool><transgenic T- cells><tumor><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nathan G. Salomonis

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Exploratory lead · 22/100

Recent

Active award

$187,584

FY 2026

Project Title

Pancancer discovery and exploration of shared splicing neoantigens

Grant Number:

5R21CA300922-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Project Abstract

PROJECT SUMMARY Cellular and immunotherapies are increasingly emerging as front-line treatments in clinical oncology. However, current immune checkpoint blockade therapies improve outcome in only a subset of patients for a few cancers. While immunotherapy is typically reserved for cancer patients wi...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><AI system><Adult><Adult Human><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Antibodies><Antigen Presentation><Antigenic Determinants><Antigens><Antineoplastic Vaccine><Antisense Agent><Antisense Oligonucleotides><Artificial Intelligence><Atlases><Binding><Binding Determinants><Body Tissues><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><Cancer Biology><Cancer Induction><Cancer Patient><Cancer Treatment><Cancer Vaccines><Cancers><Cell Death><Cell surface><Chemoresistance><Childhood Cancers><Clinical><Clinical Oncology><Clinical Treatment Moab><Collection><Communities><Computer Reasoning><DNA mutation><Data><Data Bases><Databases><Detection><Development><Epitopes><Eukaryota><Eukaryote><Event><Failure><Future><Gene Expression><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genomics><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Immune mediated therapy><Immune response><Immunologically Directed Therapy><Immunologist><Immunology><Immunotherapeutic agent><Immunotherapy><Infrastructure><Integral Membrane Protein><Internet><Intratumoral heterogeneity><Intrinsic Membrane Protein><Intuition><Investigators><Isoforms><Length><Link><Machine Intelligence><Malignant><Malignant - descriptor><Malignant Cell><Malignant Childhood Neoplasm><Malignant Childhood Tumor><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pediatric Neoplasm><Malignant Pediatric Tumor><Malignant Tumor><Malignant childhood cancer><Mediator><Membrane><Messenger RNA><Metadata><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Molecular><Molecular Interaction><Monoclonal Antibodies><Mutation><Neoplasm Metastasis><Neoplasm Vaccines><Oncogenic><Patient Selection><Patients><Peptides><Post-Transcriptional Control><Post-Transcriptional Regulation><Precancerous Cells><Premalignant Cell><Production><Protein Isoforms><Proteins><Proteomics><RNA Splicing><RNA-Binding Proteins><Recurrence><Recurrent><Regulation><Repression><Research><Research Personnel><Researchers><Role><Secondary Neoplasm><Secondary Tumor><Solid><Source><Specificity><Splicing><Survival Analyses><Survival Analysis><T cells for CAR><Technology><Tissues><Transcript><Translational Research><Translational Science><Transmembrane Protein><Transmembrane Protein Gene><Treatment outcome><Tumor Vaccines><Vaccines><Validation><Viral Diseases><Virus Diseases><Visualization><WWW><Work><adulthood><anti-cancer therapy><anti-tumor vaccine><antisense oligo><cancer cell><cancer in a child><cancer in children><cancer metastasis><cancer microenvironment><cancer progression><cancer therapy><cancer-directed therapy><carcinogenesis><check point blockade><checkpoint blockade><chemoresistant><chemotherapy resistance><chemotherapy resistant><child with cancer><childhood malignancy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical predictors><clinical significance><clinical subtypes><clinically significant><comparative><computational studies><computer studies><data base><design><designing><developmental><disease subgroups><disease subtype><disorder subtype><experiment><experimental research><experimental study><experiments><genome mutation><heterogeneity in tumors><host response><immune check point blockade><immune checkpoint blockade><immune drugs><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunogenic><immunogenicity><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><improved outcome><innovate><innovation><innovative><internet based platform><internet platform><internet portal><intra-tumoral heterogeneity><intratumor heterogeneity><intuitive><knowledgebase><long read seq><long-read sequencing><long-read transcript sequencing><mAbs><mRNA><malignancy><membrane structure><meta data><monoclonal Abs><necrocytosis><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm progression><neoplasm/cancer><neoplastic progression><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><on-line portal><online portal><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><pediatric cancer><pediatric malignancy><post-transcriptional gene regulation><protein structure><protein structures><proteins structure><proteogenomics><social role><targeted cancer therapy><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><three dimensional><tool><translation research><translational investigation><translational medicine><tumor cell metastasis><tumor heterogeneity><tumor microenvironment><tumor progression><vaccine for cancer><validations><viral infection><virus infection><virus-induced disease><web><web based platform><web based system><web enabled platform><web platform><web portal><web-based portal><world wide web>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

TERRY L. SHEPPARD

KEYSTONE SYMPOSIA, SILVERTHORNE, CO

Exploratory lead · 22/100

Recent

Active award

$5,000

FY 2026

Project Title

Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations

Grant Number:

1R13CA310704-01

Activity Code:

R13

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/3/2026

End Date:

2/28/2027

Project Abstract

Abstract Support is requested for a Keystone Symposia conference entitled “Cancer Immunotherapy: Basic Mechanism Informing Clinical Applications & Combinations” organized by Drs. Jennifer Guerriero, Thomas Marron, Ira Mellman and Solange Peters, with scientific programming input from Keystone Sympos...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ALEXANDER S. KRUPNICK

BALTIMORE VA MEDICAL CENTER, BALTIMORE, MD

Exploratory lead · 22/100

Recent

Active award

$0

FY 2026

Project Title

Mechanisms of Immunosurveillance for Lung Cancer-the Role of CD8+ T Cells in Tumor Tolerance Induction

Grant Number:

5I01BX002299-09

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

1/1/2014

End Date:

9/30/2026

Project Abstract

Lung cancer remains the major cancer-related cause of death in the Western World and intense efforts are directed toward the development of immunotherapy for the treatment of this disease. While immunotherapy targeting cytotoxic T (CD8+ T) lymphocytes has been successful in several malignancies, suc...

Research Terms

<(TNF)-α><Acceleration><Adjuvant><Affect><Alimentary Canal><Animal Model><Animal Models and Related Studies><Armed Forces Personnel><Award><B7-H1><Belief><Blood><Blood Reticuloendothelial System><Body Tissues><CD274><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cachectin><Cancer Biology><Cancer Causing Agents><Cancer Patient><Cancers><Carcinogens><Cause of Death><Cell Body><Cell Line><CellLine><Cells><Clinical><Clinical Trials><Consumption><Cytotoxic cell><Data><Development><Digestive Tract><Disease><Disorder><Down-Regulation><Environment><Failure><GI Tract><Gastrointestinal Tract><Gastrointestinal tract structure><Gene Inactivation><Gene Silencing><Gene Transcription><General Population><General Public><Generalized Growth><Genetic Transcription><Graft Rejection><Grafting Procedure><Growth><HIP8><HYPD><Human><IFN><Immune Surveillance><Immune Tolerance><Immune mediated therapy><Immune response><Immune system><Immunochemical Immunologic><Immunologic><Immunologic Surveillance><Immunologic Tolerance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunosurveillance><Immunotherapy><Interferons><K lymphocyte><LLC1><LYT3><Laboratories><Lewis lung carcinoma cell><Lung><Lung Grafting><Lung Respiratory System><Lung Transplantation><Lymphatic cell><Lymphocyte><Lymphocytic><Lymphoid><Lytotoxicity><MAGE-3><MAGE-3 Gene><MAGE3><MAGEA3><MAGEA3 gene><Macrophage-Derived TNF><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Malignant neoplasm of prostate><Malignant prostatic tumor><Mediating><Mediator><Melanoma><Melanoma Antigen Family A3 Gene><Melanoma Antigen, Family A, 3, Gene><Memory><Mice><Mice Mammals><Military><Military Personnel><Modeling><Modern Man><Monocyte-Derived TNF><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><NK Cells><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Natural Killer Cells><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Oncogens><Organ><Organ Transplantation><Organ Transplants><PD-L1><PDL-1><Patients><Peptides><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phenotype><Play><Population><Preclinical data><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Prostate CA><Prostate Cancer><Prostate malignancy><Protocol><Protocols documentation><Pulmonary Cancer><Pulmonary Graft><Pulmonary Transplant><Pulmonary Transplantation><Pulmonary malignant Neoplasm><RNA Expression><Role><Series><Skin><Solid Neoplasm><Solid Tumor><Strains Cell Lines><T cell differentiation><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Techniques><Testing><Tissue Growth><Tissues><Transcription><Transplant Rejection><Transplantation><Transplantation Rejection><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><United States><Vaccination><Veterans><Western World><Work><alimentary tract><amino acid metabolism><animal data><anti-cancer immunotherapy><anticancer immunotherapy><base><bases><cancer immunotherapy><cancer microenvironment><clinical applicability><clinical application><compound repositioning><compound repurposing><cultured cell line><cytokine><cytotoxic><cytotoxicity><developmental><digestive canal><drug repositioning><drug repurposing><high risk><host response><immune modulation><immune regulation><immune system response><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunological paralysis><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunotherapy for cancer><immunotherapy of cancer><immunotherapy trials><improved><lung cancer><lung transplant><lymph cell><malignancy><military population><military veteran><model of animal><mouse model><murine model><neoplasm/cancer><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic uses for existing drugs><new therapy approaches><new treatment approach><new treatment strategy><new use of drug><new uses for an approved drug><new uses for existing drugs><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><oncogenic agent><ontogeny><organ allograft><organ graft><organ xenograft><overexpress><overexpression><pharmaceutical><pharmacological repurposing><pre-clinical><preclinical><preclinical findings><preclinical information><programmed cell death ligand 1><programmed cell death protein ligand 1><protein death-ligand 1><rational design><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><resident memory T cell><response><social role><success><synapse formation><synaptogenesis><therapeutic repositioning><therapeutic repurposing><thymus derived lymphocyte><tissue resident memory T cell><transcriptional silencing><transplant><tumor><tumor growth><tumor microenvironment><veteran population>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Valerie Phoebe O'Brien

PURDUE UNIVERSITY, WEST LAFAYETTE, IN

Exploratory lead · 16/100

Active award

$249,000

FY 2026

Project Title

Investigating gastric inflammation and preneoplastic progression driven by Helicobacter pylori infection

Grant Number:

5R00CA263036-05

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/7/2022

End Date:

12/31/2026

Project Abstract

Project Summary Many cancers are attributed to chronic inflammation, which can cause mutations and activate oncogenic signaling pathways. An important example is gastric cancer, the fourth-leading cause of cancer death worldwide. At least 80% of gastric cancer cases are attributed to stomach infecti...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JUSTIN L SONNENBURG

STANFORD UNIVERSITY, STANFORD, CA

Exploratory lead · 16/100

Active award

$215,985

FY 2026

Project Title

Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer

Grant Number:

5R21CA290426-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2026

Project Abstract

PROJECT SUMMARY Cancer immunotherapy has been one of the great recent breakthroughs in cancer treatment options. Antibodies that antagonize immune-inhibitory receptors, a therapy type known as immune checkpoint blockade (ICB), show great promise and further improvements in response rates and durabil...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Pietro Genovese

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

Exploratory lead · 16/100

Active award

$208,038

FY 2026

Project Title

Advanced Genetic Engineering to Unravel Tumor-Specific B Cell Responses

Grant Number:

5R21CA296527-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2026

Project Abstract

RESEARCH SUMMARY B cells are among the most abundant tumor-infiltrating immune cells, and their presence in several solid tumors is associated with a more favorable prognosis. Yet, investigations on the role of B cells in cancer have so far yielded contradicting results, with some studies indicating...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Imene Hamaidi

MAYO CLINIC JACKSONVILLE, JACKSONVILLE, FL

Exploratory lead · 16/100

Active award

$182,909

FY 2026

Project Title

Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6

Grant Number:

5R21CA288808-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2026

Project Abstract

PROJECT SUMMARY Cancer immunotherapy represents a major paradigm shift in cancer care. Despite such breakthrough, most cancer patients remain refractory to these therapies. Metabolism is a key driver of T cell functions, and the metabolic switch from oxidative phosphorylation to aerobic glycolysis i...

Research Terms

<2-Phospho-D-Glycerate Hydrolase><2-Phospho-D-glycerate hydro-lyase><Acetylation><Address><Antigens><Antitumor Response><Assay><Autologous><Basal Transcription Factor><Basal transcription factor genes><Beds><Bioassay><Biological Assay><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cell Function><Cell Nucleus><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Immune Function><Cellular Metabolic Process><Cellular Physiology><Cellular Process><Cellular biology><ChIP assay><Chromatin><Clinical Trials><Consensus><D-Glucose><Data><Deacetylase><Dextrose><Disabling><Endowment><Enzyme Gene><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Family member><Financial Hardship><Gene Down-Regulation><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genetic Transcription><Glucose><HDAC><HDAC Proteins><HDAC4><HDAC4 gene><HDACA><Health Care Systems><Histone Deacetylase><Histone Deacetylase 4><Histone Deacetylase A><Histone Deacetylation><Histones><Human><Immune><Immune Targeting><Immune mediated therapy><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><Impairment><In Vitro><Infiltration><Inflammation><Intermediary Metabolism><Knowledge><Link><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Melanoma Tumor><Metabolic><Metabolic Processes><Metabolic stress><Metabolism><Mice><Mice Mammals><Modern Man><Murine><Mus><Myelogenous><Myeloid><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Nuclear Protein><Nucleus><Nutrient><Oxidative Phosphorylation><Oxidative Phosphorylation Pathway><PDX model><Pathway interactions><Patient derived xenograft><Patients><Phosphopyruvate Hydratase><Pre-Clinical Model><Preclinical Models><Promoter Regions><Promotor Regions><Proteins><Public Health><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recombinant DNA Technology><Refractory><Regulation><Reporting><Repression><Research Design><Resistance><Role><Silent Mating Type Information Regulator 2-like Proteins><Sir2-like Proteins><Sirtuins><Study Type><Subcellular Process><T cell regulation><T cell response><T-Cell Activation><T-Cells><T-Lymphocyte><Teff cell><Testing><Therapeutic><Transcription><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription factor genes><Transposase><Tumor Cell><Tumor Escape><Tumor Immune Escape><Tumor Immunity><Tumor growth in melanoma><Tumor-Infiltrating Lymphocytes><Upregulation><Work><activate T cells><aerobic glycolysis><anti-cancer immunotherapy><anti-cancer therapy><anti-tumor immune response><anti-tumor immunity><anti-tumor response><anticancer immunotherapy><antitumor immunity><c myc><c-myc Genes><cancer care><cancer cell><cancer evasion><cancer immune escape><cancer immune evasion><cancer immunity><cancer immunotherapy><cancer microenvironment><cancer therapy><cancer-directed therapy><cell biology><cell mediated immune response><cell metabolism><cellular metabaolism><chromatin immunoprecipitation><chromatin remodeling><clinical applicability><clinical application><cmyc><combat><economic hardship><economic strain><effector T cell><enolase><epigenetic regulation><epigenetically><exhaustion><fighting><financial adversity><financial burden><financial distress><financial insecurity><financial instability><financial strain><financial stress><financial worry><gene repression><genetic promoter element><genetic promoter sequence><genetically engineered><host response><immune check point><immune checkpoint><immune drugs><immune function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogen><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><malignancy><metabolic fitness><mouse model><murine model><neoplasm/cancer><neoplastic cell><novel><pathway><patient derived xenograft model><phosphoglycerate dehydratase><phosphoglycerate hydro lyase><programs><promoter sequence><resistant><response><restraint><social role><study design><thymus derived lymphocyte><transcription factor><transcriptome sequencing><transcriptomic sequencing><translational applications><translational opportunities><translational potential><tumor><tumor evasion><tumor immune evasion><tumor microenvironment><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anant Madabhushi

VETERANS HEALTH ADMINISTRATION, Decatur, GA

Exploratory lead · 10/100

Active award

$0

FY 2026

Project Title

BLRD Research Career Scientist Award Application

Grant Number:

5IK6BX006185-04

Activity Code:

IK6

Mechanism:

Other

Agency:

VA

Start Date:

10/1/2022

End Date:

9/30/2027

Project Abstract

Project Summary/Abstract Dr Madabhushi has emerged as a pioneer in the development and application of novel and interpretable Artificial Intelligence (AI) algorithms for disease diagnosis, prognosis and prediction of treatment response for a variety of diseases including several cancers, cardiovascu...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JOSEPH C LIAO

VETERANS ADMIN PALO ALTO HEALTH CARE SYS, PALO ALTO, CA

Exploratory lead · 10/100

Active award

$0

FY 2026

Project Title

BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Leveraging Artificial Neural Networks to Enhance Detection of Carcinoma in situ

Grant Number:

5I01BX005598-05

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2021

End Date:

9/30/2026

Project Abstract

PROJECT SUMMARY ABSTRACT Herein, a group of collaborative merit review applications (CMA) aim to advance the precision management of bladder cancer (BCa), especially focused on the early stage initiation of urothelium as a model of dynamic epithelial changes in response to smoking and deployment-rel...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Principal Investigator Finder

Search Principal Investigators

Search Results

Opportunity Digest

MICHAEL A TEITELL

Project Title

Project Abstract

Research Terms

Judy Lieberman

Project Title

Project Abstract

Research Terms

Hao Wu

Project Title

Project Abstract

Research Terms

David E. Avigan

Project Title

Project Abstract

Research Terms

Jacalyn Rosenblatt

Project Title

Project Abstract

Research Terms

Goutam Chakraborty

Project Title

Project Abstract

Research Terms

Nagavarakishore Pillarsetty

Project Title

Project Abstract

Research Terms

Vladimir Ponomarev

Project Title

Project Abstract

Research Terms

ALBERT FOLCH

Project Title

Project Abstract

Research Terms

Tyler J. Curiel

Project Title

Project Abstract

Research Terms

YANFEN HU

Project Title

Project Abstract

Research Terms

Rong Li

Project Title

Project Abstract

Research Terms

Phuoc T. Tran

Project Title

Project Abstract

Research Terms

Andrew B. Sharabi

Project Title

Project Abstract

Research Terms

Francesco Marangoni

Project Title

Project Abstract

Research Terms

Janghee Woo

Project Title

Project Abstract

Research Terms

Keiran Smalley

Project Title

Project Abstract

Research Terms

Weizhou Zhang

Project Title

Project Abstract

Research Terms

Guangrong Zheng

Project Title

Project Abstract

Research Terms